Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1996

Comparative Pharmacologic Studies on Synthetic and
Recombinant Inhibitors of Thrombin
Demetra D. Callas
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Callas, Demetra D., "Comparative Pharmacologic Studies on Synthetic and Recombinant Inhibitors of
Thrombin" (1996). Dissertations. 3406.
https://ecommons.luc.edu/luc_diss/3406

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1996 Demetra D. Callas

LOYOLA UNIVERSITY CHICAGO

COMPARATIVE PHARMACOLOGIC STUDIES ON SYNTHETIC AND
RECOMBINANT INHIBITORS OF THROMBIN

VOLUME I
(CHAPTERS I, II, III, IV)

A DISSERTATION SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

DEPARTMENT OF PHARMACOLOGY AND
EXPERIMENTAL THERAPEUTICS

BY
DEMETRA D. CALLAS

CHICAGO, ILLINOIS
MAY 1996

LOYOLA UNIVERSITY MEDICAL CENTER LIBRARY

Copyright by Demetra D. Callas, 1996
All rights reserved.

ii

ACKNOWLEDGEMENTS

I would like to take this opportunity to thank all of those who helped me and
supported me throughout my graduate studies. I will always be grateful to my mentor,
Dr. Jawed Fareed, for his guidance and support during the past six years. Dr. Fareed
has not been only a source of scientific knowledge for me, but has also taught me many
other aspects that are important and contribute to the survival of a scientist in our days
and for these I will always be thankful.
I thank the members of my dissertation committee, Dr. Sandor Bajusz, Dr.
Edward W. Bermes Jr., Dr. Joseph R. Davis, Dr. Yale Nemerson and Dr. Loek Van de
Kar, for their contributions, suggestions and critical evaluation of various parts of this
dissertation and for their efforts in evaluating overall this body of work. I also thank Dr.
Umberto Cornelli for his critical and insightful comments on this manuscript.
I express my sincere appreciation to my colleagues at the Hemostasis Research
Laboratories for teaching me many of the techniques used in these studies: Peter Bacher,
Mike Koza, Debra Hoppensteadt, Dr. Ahmad Ahsan and Dr. Omer Iqbal.

I also

appreciate the assistance received by Dr. Tom Herndon, Scott Asselmeyer and Dr.
Kaiding Fu. I thank our secretary, Ms. Elayne Grzeda, for her help and for always
being cheerful and encouraging. I thank my classmate, colleague and friend Walter Jeske
for his suggestions and his attentive ears, since the beginning of our graduate careers.

iii

I thank Dr. Jeanine Walenga for her insights, comments, suggestions and support
with many of the projects and in manuscript preparation. I thank Peter Molnar and Dan
Murphy for their invaluable assistance with the computer-related work and slide
preparation. I thank Ms. Debra Arendziak for expediting and facilitating some of my
work in the department of Pathology. I am thankful to Dr. Volker Eschenfelder, Dr.
John Fenton II, Dr. Bill Drohan and Dr. Richard Schwarz for their generous
contributions and suggestions.

Last, but not least, I am most thankful to Dr. Klaus

Breddin, Ms. Dietrich and Dr. Wolfram Raake for teaching me, guiding me and helping
me establish the rat laser-induced thrombosis model, with utmost patience and sincere
interest.
Most of all, I would like to acknowledge and thank my parents and my brothers
for their infinite love, moral support, trust and confidence they have in me and for never
failing to make me smile through difficult times.

IV

DEDICATION
To my parents

TABLE OF CONTENTS
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . m
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xvii
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xxii
LIST OF STANDARD ABBREVIATIONS . . . . . . . . . . . . . . . . . . . . . . xxviii
LIST OF NON-STANDARD ABBREVIATIONS . . . . . . . . . . . . . . . . . . . xxxii

VOLUME I
Chapter
I.

PURPOSE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

II. REVIEW OF LITERATURE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
A. Overview of Hemostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
B. Role of Serine Proteases in the Regulation of Coagulation, Fibrinolytic,
Kallikrein and Complement Pathways. . . . . . . . . . . . . . . . . . . . . . 12
1.

Biochemical Characteristics of Serine Proteases . . . . . . . . . . . . . . 17

2.

Role of Serine Proteases and Cofactors in the Hemostatic and Hemorrhagic
Processes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
a. High Molecular Weight Kininogen (HMWK) . . . . . . . . . . . . . 22
b. Prekallikrein . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
c. Factor XII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
d. Factor XI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
e. Factor IX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
f. Factor VIII/von Willebrand Factor Complex . . . . . . . . . . . . . 26
g. Tissue Factor (TF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
h. Factor VII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
i. Factor X . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
J. Factor XIII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
k. Plasmin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
1. Tissue Type Plasminogen Activator (tPA) . . . . . . . . . . . . . . . 31
m. Urokinase Type Plasminogen Activator (uPA) . . . . . . . . . . . . 32

3.

Regulation of Serine Proteases by Serpins . . . . . . . . . . . . . . . . . . 32
v

a.
b.
c.
d.
e.
f.
g.
h.

Antithrombin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Heparin Cofactor II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Tissue Factor Pathway Inhibitor (TFPI) . . . . . . . . . . . . . . . . 35
Protein C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Protein S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Factor V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
a 2 Plasmin Inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Plasminogen Activator Inhibitors . . . . . . . . . . . . . . . . . . . . . 38

C. Thrombin: Structure, Function, Physiologic, Pathologic and Pharmacologic
Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
1.

Biology of Thrombin Formation and Structure of the Thrombin
Molecule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

2.

Molecular Variants of Thrombin . . . . . . . . . . . . . . . . . . . . . . . 43

3.

Thrombin Standardization

4.

Physiologic Regulation of Thrombin Formation . . . . . . . . . . . . . . 44

5.

Cellular Interactions of Thrombin . . . . . . . . . . . . . . . . . . . . . . . 45

6.

Thrombin Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

. . . . . . . . . . . . . . . . . . . . . . . . . . . 43

D. Pharmacologic Control of Thrombin's Action . . . . . . . . . . . . . . . . . . 46

1.

Inhibition of Thrombin Receptors . . . . . . . . . . . . . . . . . . . . . . . 47

2.

Inhibition of Cellular Processes Mediated by Thrombin . . . . . . . . . 47

3.

Inhibition of Thrombin Generation . . . . . . . . . . . . . . . . . . . . . . 48

4.

Inhibition of Formed Thrombin . . . . . . . . . . . . . . . . . . . . . . . . 53

E. Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
1.

Inhibitors of Plasma Origin . . . . . . . . . . . . . . . . . . . . . . . . . . 55

2.

Synthetic Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
a. Compounds Restricted to the Specificity Pocket of the Catalytic Domain
of Thrombin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
b. Compounds Extending Unidirectionally Beyond the Specificity Pocket
of the Catalytic Site of Thrombin . . . . . . . . . . . . . . . . . . . . 58
Vl

c. Compounds Extending Bidirectionally Beyond the Specificity Pocket of
the Catalytic Domain of Thrombin . . . . . . . . . . . . . . . . . . . 59
3.

Peptide Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
a. Aldehyde Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
b. Chloromethyl Ketone Derivatives . . . . . . . . . . . . . . . . . . . . 64
c. Nitrile Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
d. Boronic acid Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . 66
e. Other Peptide Analogues . . . . . . . . . . . . . . . . . . . . . . . . . 68

4.

Recombinant Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . . 69
a. Aptamers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
b. Hirudin and its Variants . . . . . . . . . . . . . . . . . . . . . . . . . . 69

5.

Thrombin Inhibitors not Directed Against its Catalytic Site . . . . . . . 72

6.

Chimeric Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . 73

7.

Thrombin Directed Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . 75

F. Clinical Applications of Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . 76
1.

Antithrombin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

2.

Argatroban . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

3.

Efegatran

4.

Inogatran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80

5.

Napsagatran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80

6.

Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80

7.

Hirulog . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

G. Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
H. Synopsis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
III. MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
A. Synthesis and Characterization of Serine Protease Inhibitors . . . . . . . . . . 93

Vll

B. Analytical Profile of Peptide Thrombin Inhibitors . . . . . . . . . . . . . . . . 96
1.

D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H Purity
Determination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

2.

Ac-(D)Phe-Pro-boroArg-OH Purity Determination . . . . . . . . . . . . 98

C. Analytical Profile of the Unfractionated Heparin . . . . . . . . . . . . . . . . . 98
D. Biochemical Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
1.

Thrombin Titration Assay

. . . . . . . . . . . . . . . . . . . . . . . . . . . 99

2.

Thrombin Time (TT) in a Fibrinogen Based System . . . . . . . . . . 101

3.

Antithrombin Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
a. Preparation of Normal Human Plasma (NHP) . . . . . . . . . . . .
b. Antithrombin Amidolytic Assay with NHP . . . . . . . . . . . . . .
c. Preparation of Normal Rabbit Plasma (NRP) . . . . . . . . . . . .
d. Antithrombin Amidolytic Assay with NRP . . . . . . . . . . . . . .

4.

Anti-Xa Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
a. Anti-Xa Amidolytic Assay with NHP . . . . . . . . . . . . . . . . . 106
b. Anti-Xa Amidolytic Assay with NRP . . . . . . . . . . . . . . . . . 106

5.

Inhibitory Actions of Various Thrombin Inhibitors on Specific Serine
Proteases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
a. Inhibition of Chymotrypsin . . . . . . . . . . . . . . . . . . . . . . . 108
b. Inhibition of Trypsin . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
c. Inhibition of Activated Protein C (APC) . . . . . . . . . . . . . . . 109
d. Inhibition of Glandular Kallikrein . . . . . . . . . . . . . . . . . . . 109
e. Inhibition of Tissue Plasminogen Activator (tPA) . . . . . . . . . 109
f. Inhibition of Urokinase . . . . . . . . . . . . . . . . . . . . . . . . . 110
g. Inhibition of Plasmin . . . . . . . . . . . . . . . . . . . . . . . . . . . 110

6.

Inhibition of Plasminogenolysis . . . . . . . . . . . . . . . . . . . . . . . 110
a. Pure Plasminogen System . . . . . . . . . . . . . . . . . . . . . . . . 111
b. NHP System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112

7.

Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient Human
Plasma by Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . 113
a. Inhibition of Extrinsic Thrombin Generation . . . . . . . . . . . . . 114
b. Inhibition Extrinsic Factor Xa Generation . . . . . . . . . . . . . . 114

Vlll

102
103
103
104
105

8.

Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient Human
Plasma by Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . 114
a. Inhibition of Intrinsic Thrombin Generation . . . . . . . . . . . . . 115
b. Inhibition of Intrinsic Factor Xa Generation . . . . . . . . . . . . . 116

9.

Inhibition of KONYNE® Based Systems by Thrombin Inhibitors ... 116
a. Inhibition of Thrombin Generation from KONYNE® . . . . . . . 117
b. Inhibition of Factor Xa Generation from KONYNE® . . . . . . . 117

10.

Inhibition of FEIBA® Based Systems by Thrombin Inhibitors . . . . . 118
a. Inhibition of Thrombin Generation from FEIBA® . . . . . . . . . 119
b. Inhibition of Factor Xa Generation from FEIBA ® . . . . . . . . . 119

E. Anticoagulant Effects of Thrombin Inhibitors in NHP . . . . . . . . . . . . 119
1.

Prothrombin Time (PT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120

2.

Activated Partial Thromboplastin Time (APTT) . . . . . . . . . . . . . 120

3.

Thrombin Time (TT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121

4.

Ecarin Clotting Time (ECT) . . . . . . . . . . . . . . . . . . . . . . . . . 121

5.

Heptest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122

F. Anticoagulant Effects of Thrombin Inhibitors in Normal Human Whole
Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
1.

Activated Clotting Time (ACT) . . . . . . . . . . . . . . . . . . . . . . . 123

2.

Thrombelastographic Analysis . . . . . . . . . . . . . . . . . . . . . . . . 124

G. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Plasma
(NRP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
H. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole
Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the Rabbit Stasis

Thrombosis Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
1.

Standardization of the Rabbit Stasis Thrombosis Model . . . . . . . . 126
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 128
ix

2.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . .
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . .
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . .

I.V.
129
129
129

3.

Duration of Antithrombotic Effects of Thrombin Inhibitors After I. V.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 130
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 130

4.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . . 131
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 131

5.

Duration of Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 132
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 132

J. Antithrombotic Effects of Thrombin Inhibitors as Studied in the Rat Model of
Laser-Induced Thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
K. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the Rabbit Ear
Bleeding Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134

1.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After I. V.
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . . 135

2.

Duration of Hemorrhagic Effects of Thrombin Inhibitors After I.V.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 136

3.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After S.C.
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . . 136

4.

Duration Hemorrhagic Effects of Thrombin Inhibitors After S.C.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 137

L. Effects of Thrombin Inhibitors on Blood Pressure After I.V. Administration to

Rabbits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
M. Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
IV. RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
x

A. Analytical Profile of Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . 142
1.

Stability and Homogeneity of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and
Boc-D-Phe-Pro-Arg-H . . . . . . . . . . . . . . . . . . . . . . . . . . . 142

2.

Ac-(D)Phe-Pro-boroArg-OH Purity Determination . . . . . . . . . . . 146

B. Analytical Profile of the Unfractionated Heparin . . . . . . . . . . . . . . . . 148

C. Biochemical Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
1.

Thrombin Titration Assay

. . . . . . . . . . . . . . . . . . . . . . . . . . 151

2.

Thrombin Time (TT) in a Fibrinogen Based System . . . . . . . . . . 154

3.

Antithrombin Effects of Thrombin Inhibitors . . . . . . . . . . . . . . . 157
a. Antithrombin Amidolytic Assay with NHP . . . . . . . . . . . . . . 157
b. Antithrombin Amidolytic Assay with NRP . . . . . . . . . . . . . . 159

4.

Anti-Xa Effects of Thrombin Inhibitors . . . . . . . . . . . . . . . . . . 160
a. Anti-Xa Amidolytic Assay with NHP . . . . . . . . . . . . . . . . . 160
b. Anti-Xa Amidolytic Assay with NRP . . . . . . . . . . . . . . . . . 163

5.

Inhibitory Actions of Various Thrombin Inhibitors on Specific Serine
Proteases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
a. Inhibition of Chymotrypsin . . . . . . . . . . . . . . . . . . . . . . . 163
b. Inhibition of Trypsin . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
c. Inhibition of Activated Protein C (APC) . . . . . . . . . . . . . . . 166
d. Inhibition of Glandular Kallikrein . . . . . . . . . . . . . . . . . . . 168
e. Inhibition of Tissue Plasminogen Activator (tPA) . . . . . . . . . 169
f. Inhibition of Urokinase . . . . . . . . . . . . . . . . . . . . . . . . . 169
g. Inhibition of Plasmin . . . . . . . . . . . . . . . . . . . . . . . . . . . 171

6.

Inhibition of Plasminogenolysis . . . . . . . . . . . . . . . . . . . . . . . 171
a. Pure Plasminogen System . . . . . . . . . . . . . . . . . . . . . . . . 173
b. NHP System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176

7.

Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient Human
Plasma by Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . 178
a. Inhibition of Extrinsic Thrombin Generation . . . . . . . . . . . . . 179
b. Inhibition Extrinsic Factor Xa Generation . . . . . . . . . . . . . . 182

8.

Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient Human
Plasma by Thrombin Inhibitors . . . . . . . . . . . . . . . . . . . . . . 182
Xl

a. Inhibition of Intrinsic Thrombin Generation
b. Inhibition of Intrinsic Factor Xa Generation

183
183

9.

Inhibition of KONYNE® Based Systems by Thrombin Inhibitors ... 185
a. Inhibition of Thrombin Generation from KONYNE® . . . . . . . 185
b. Inhibition of Factor Xa Generation from KONYNE® . . . . . . . 188

10.

Inhibition of FEIBA® Based Systems by Thrombin Inhibitors . . . . . 188
a. Inhibition of Thrombin Generation from FEIBA® . . . . . . . . . 190
b. Inhibition of Factor Xa Generation from FEIBA® . . . . . . . . . 190

D. Anticoagulant Effects of Thrombin Inhibitors in NHP . . . . . . . . . . . . 191
1.

Prothrombin Time (PT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191

2.

Activated Partial Thromboplastin Time (APTT) . . . . . . . . . . . . . 194

3.

Thrombin Time (TT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

4.

Ecarin Clotting Time (ECT) . . . . . . . . . . . . . . . . . . . . . . . . . 195

5.

Heptest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197

E. Anticoagulant Effects of Thrombin Inhibitors in Normal Human Whole
Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
1.

Activated Clotting Time (ACT) . . . . . . . . . . . . . . . . . . . . . . . 199

2.

Thrombelastographic Analysis (TEG)

. . . . . . . . . . . . . . . . . . . 199

F. Anticoagulant Effects of Thrombin Inhibitors in NRP

. . . . . . . . . . . . 201

1.

Prothrombin Time (PT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203

2.

Activated Partial Thromboplastin Time (APTT) . . . . . . . . . . . . . 203

3.

Thrombin Time (TT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205

4.

Heptest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205

G. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole
Blood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206

1.

Activated Clotting Time (ACT) . . . . . . . . . . . . . . . . . . . . . . . 206
xii

2.

Thrombelastographic Analysis (TEG)

. . . . . . . . . . . . . . . . . . . 208

H. Antithrombotic Effects of Thrombin Inhibitors as Studied in the Rabbit Stasis
Thrombosis Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
1.

Standardization of the Rabbit Stasis Thrombosis Model . . . . . . . . 209
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 210

2.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After I.V.
Administration at a Fixed Time Point . . . . . . . . . . . . . . . . . . 215
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 217

3.

Duration of Antithrombotic Effects of Thrombin Inhibitors After I. V.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 222
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 224

4.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration at a Fixed Time Point . . . . . . . . . . . . . . . . . . 228
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 228
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 230

5.

Duration of Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 235
a. Clot Score Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
b. Ex Vivo Analyses of Plasma and Whole Blood Samples . . . . . . 238

I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the Rat Model of
Laser-Induced Thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . 243
J. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the Rabbit Ear
Bleeding Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246

1.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After I. V.
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . . 246

2.

Duration of Hemorrhagic Effects of Thrombin Inhibitors After I.V.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 249

3.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After S.C.
Administration at Fixed Time Points . . . . . . . . . . . . . . . . . . . 249

Xlll

4.

Duration of Hemorrhagic Effects of Thrombin Inhibitors After S.C.
Administration at a Fixed Dose . . . . . . . . . . . . . . . . . . . . . . 252

K. Effects of Thrombin Inhibitors on Blood Pressure After I.V. Administration in
Rabbits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255
VOLUME II
V.

DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 257
A. Molecular and Structural Characterization of heparin and antithrombin

agen~2

B. Relative Antithrombin Potencies of Thrombin Inhibitors . . . . . . . . . . . 263

C. Antithrombin and Anti-Xa Activities of Thrombin Inhibitors in Plasmatic
Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 267
D. Antiprotease Spectrum of Various Thrombin Inhibitors . . . . . . . . . . . . 271
E. Inhibitory Actions of Thrombin Inhibitors in Protease Generating Systems 275
1.

Extrinsic Activation Systems . . . . . . . . . . . . . . . . . . . . . . . . . 276

2.

Intrinsic Activation Systems . . . . . . . . . . . . . . . . . . . . . . . . . 279

3.

Plasminogenolysis Systems . . . . . . . . . . . . . . . . . . . . . . . . . . 280

F. Global Anticoagulant Effects of Thrombin Inhibitors: PT, APTT, ACT and
TEG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 281
G. Specific Measurements of Antithrombin Actions: TT and ECT . . . . . . . 283
H. Comparative Antithrombotic Actions of Various Thrombin Inhibitors ... 285
1.

Standardization of r-TF as a Thrombogenic Trigger in the Rabbit Stasis
Thrombosis Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286

2.

Comparative Antithrombotic Actions of Thrombin Inhibitors . . . . . 292
a. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After
I. V. Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . 292
b. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After
S.C. Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . 295
c. Time-Dependance of Antithrombotic Effects of Thrombin Inhibitors
After I. V. Administration . . . . . . . . . . . . . . . . . . . . . . . 298
XIV

d.

Time-Dependance of Antithrombotic Effects of Thrombin Inhibitors
After S.C. Administration . . . . . . . . . . . . . . . . . . . . . . . 299

I. Comparative Hemorrhagic Profile of Thrombin Inhibitors . . . . . . . . . . 303
1.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After I.V.
Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 303

2.

Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors After S.C.
Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 305

3.

Time-Hemorrhagic Effects of Thrombin Inhibitors After I.V. and S.C.
Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306

J. Integration of Data on Antithrombotic and Hemorrhagic Effects of Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 306
K. Rat Laser-Induced Thrombosis Model . . . . . . . . . . . . . . . . . . . . . . 309

L. Species Dependence of Antithrombotic and Anticoagulant Effects of Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
M. Integration of in vitro Studies with Observed Pharmacologic Actions of Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
N. Significance of Studies in Understanding the Pharmacology of Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316
0. Developmental Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
VI.

SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335
A. In Vitro Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 335

B. In Vivo Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339
VII.

CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 342

APPENDIX I.

PRODUCT SPECIFICATION SHEETS

. . . . . . . . . . . . . . 344

APPENDIX II.

BLOOD DONATION CONSENT FORM . . . . . . . . . . . . . 349

APPENDIX III. LETTERS OF PERMISSION . . . . . . . . . . . . . . . . . . . . . 352

xv

APPENDIX IV. DATA TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355
REFERENCES
VITA

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 490

DISSERTATION APPROVAL SHEET . . . . . . . . . . . . . . . . . . . . . . . . . . 494

XVI

LIST OF FIGURES
Figure

Page

1.

The coagulation and fibrinolytic system

2.

Three dimensional model of human a-thrombin . . . . . . . . . . . . . . . . . 40

3.

Primary structures of natural hirudin variants 1, 2 and 3 and aprotinin . . . 54

4.

Chemical structures of thrombin inhibitors . . . . . . . . . . . . . . . . . . . . 60

5.

Analytical profile of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-PhePro-Arg-H, as detected at 214 nm . . . . . . . . . . . . . . . . . . . . . 143

6.

Analytical profile of Ac-(D)Phe-Pro-boroArg-OH, as detected at 214 nm

7.

Analytical profile of unfractionated porcine mucosal heparin . . . . . . . . 149

8.

Concentration dependent inhibition of the amidolytic activity of thrombin by
antithrombin agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153

9.

Concentration dependent prolongation of the fibrinogen-based TT by various
agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156

10.

Concentration dependent inhibition of the amidolytic activity of thrombin by
various agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158

11.

Concentration dependent inhibition of the amidolytic activity of factor Xa by
various agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162

12.

Concentration dependent inhibition of the amidolytic activity of chymotrypsin by
various agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165

13.

Concentration dependent inhibition of the amidolytic activity of trypsin by
thrombin inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165

14.

Concentration dependent inhibition of the amidolytic activity of APC by various
agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
xvii

.. 14

147

15.

Concentration dependent inhibition of the amidolytic activity of kallikrein by
thrombin inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167

16.

Concentration dependent inhibition of the amidolytic activity of t-PA by
antithrombin agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170

17.

Concentration dependent inhibition of the amidolytic activity of urokinase by
various agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170

18.

Concentration dependent inhibition of the amidolytic activity of plasmin by
thrombin inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172

19.

Concentration dependent inhibition of the process of plasminogenolysis by
antithrombin agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174

20.

Concentration dependent inhibition of process of plasminogenolysis by
antithrombin agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177

21.

Concentration-dependent inhibition of the extrinsic activation of coagulation, by
antithrombin agents, in the fibrinogen-deficient system . . . . . . . . 181

22.

Concentration dependent inhibition of the intrinsic activation of coagulation, by
antithrombin agents, in the fibrinogen-deficient system . . . . . . . . 184

23.

Concentration-dependent inhibition of the extrinsic activation of coagulation in
the KONYNE® system, by antithrombin agents . . . . . . . . . . . . 186

24.

Concentration-dependent inhibition of the extrinsic activation of coagulation in
the FEIBA® system, by antithrombin agents . . . . . . . . . . . . . . . 189

25.

Comparative anticoagulant effects of antithrombin agents, after supplementation
to NHP, as studied in the PT . . . . . . . . . . . . . . . . . . . . . . . . 193

26.

Comparative anticoagulant effects of various agents, after supplementation to
NHP, as studied in the APTT . . . . . . . . . . . . . . . . . . . . . . . 193

27.

Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to NHP, as studied in the TT . . . . . . . . . . . . . . . . . . . . . . . 196

28.

Comparative anticoagulant effects of antithrombin agents, after supplementation
to NHP, as studied in the ECT . . . . . . . . . . . . . . . . . . . . . . 196

29.

Comparative anticoagulant effects of various agents, after supplementation to
NHP, as studied in the Heptest . . . . . . . . . . . . . . . . . . . . . . 198
XVlll

30.

Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal human whole blood, as detected in the ACT assay . . . . 200

31.

Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal human whole blood, as studied in the TEG assay . . . . . 200

32.

Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal rabbit plasma, as studied in the global clotting tests . . . 204

33.

Comparative anticoagulant effects of various agents, after supplementation to
normal rabbit whole blood, as studied in the ACT assay . . . . . . . 207

34.

Comparative anticoagulant effects of various agents, after supplementation to
normal rabbit whole blood, as studied in the TEG assay . . . . . . . 207

35.

Dose-dependent thrombotic effects of r-TF as studied in the rabbit model of
jugular vein stasis thrombosis . . . . . . . . . . . . . . . . . . . . . . . 211

36.

Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit
model of jugular vein stasis thrombosis, utilizing the ACT assay .. 213

37.

Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit
model of jugular vein stasis thrombosis, utilizing the TEG assay .. 213

38.

Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit
model of jugular vein stasis thrombosis . . . . . . . . . . . . . . . . . 214

39.

Comparative dose-dependent antithrombotic effects of various agents as studied
in the rabbit model of jugular vein stasis thrombosis . . . . . . . . . 216

40.

Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218

41.

Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218

42.

Dose-dependent ex vivo anticoagulant effects of antithrombin agents after I. V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220

43.

Time dependance of antithrombotic effects of various agents in the rabbit model
of jugular vein stasis thrombosis . . . . . . . . . . . . . . . . . . . . . . 223
XIX

44.

Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I.V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

45.

Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225

46.

Time-dependent ex vivo anticoagulant effects of antithrombin agents after I.V.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

47.

Comparative dose-dependent antithrombotic effects of various agents as studied
in the rabbit model of jugular vein stasis thrombosis . . . . . . . . . 229

48.

Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232

49.

Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232

50.

Dose-dependent ex vivo anticoagulant effects of antithrombin agents after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234

51.

Time dependance of antithrombotic effects of various agents in the rabbit model
of jugular vein stasis thrombosis . . . . . . . . . . . . . . . . . . . . . . 237

52.

Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239

53.

Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239

54.

Time-dependent ex vivo anticoagulant effects of antithrombin agents after S.C.
injection as studied in the rabbit model of jugular vein stasis
thrombosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241

55.

Comparative dose-dependent antithrombotic effects of various agents as studied
in the rat laser-induced thrombosis model . . . . . . . . . . . . . . . . 244

xx

56.

Comparative dose-dependent hemorrhagic effects of thrombin inhibitors as
studied in the rabbit ear bleeding model . . . . . . . . . . . . . . . . . 247

57.

Time dependance of hemorrhagic effects of antithrombin agents in the rabbit ear
bleeding model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 250

58.

Comparative dose-dependent hemorrhagic effects of various agents as studied in
the rabbit ear bleeding model . . . . . . . . . . . . . . . . . . . . . . . 251

59.

Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit ear
bleeding model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254
Intra-arterial blood pressure monitoring of rabbits during in vivo investigation
with rTF and antithrombotic agents . . . . . . . . . . . . . . .
256

60.

61.

Sites of Actions of Thrombin Inhibitors . . . . . . . . . . .

XXl

330

LIST OF TABLES
Table

Page

1.

Characteristics of Procoagulant and Pro-fibrinolytic Proteins . . . . . . . . . 19

2.

Characteristics of Inhibitors of Procoagulant and Pro-fibrinolytic Proteins . 34

3.

Integration of various peaks eluted during the analysis of D-Phe-Pro-ArgH · H2S04 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 144

4.

Integration of various peaks eluted during the analysis of D-MePhe-Pro-ArgH · H2S04 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 145

5.

Integration of various peaks during the analysis of Boc-D-Phe-Pro-ArgH · V2H 2S04 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 146

6.

Integration of various peaks during the analysis of Ac-(D)Phe-Pro-boroArgOH ·HCl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148

7.

Molecular Weight Distribution of Unfractionated Heparin . . . . . . . . . . 150

8.

Specific Activities of Various Thrombin Inhibitors as Assessed by Utilizing an
Amidolytic Assay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152

8a-f

Antithrombin Activity of Antithrombin Agents, as Studied in the Thrombin
Titration Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 356-361

9.

Antithrombin potencies of thrombin inhibitors as determined in fibrinogen
clotting systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155

9a-d.

10 U TT of Various Thrombin Inhibitors in the Human Fibrinogen Based
System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362-363

9e-h.

10 U Ca++TT of Various Thrombin Inhibitors in the Human Fibrinogen Based
System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 364-365

10.

Antithrombin potencies of thrombin inhibitors as determined in amidolytic
systems in NHP and NRP . . . . . . . . . . . . . . . . . . . . . . . . . . 159
xxn

lOa-d.

Inhibition of the Amidolytic Activity of Thrombin by Various Agents in
NHP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366-367

lOe.

Inhibition of the Amidolytic Activity of Thrombin by Various Agents in
NHP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368

11.

Anti-factor Xa potencies of thrombin inhibitors as determined in amidolytic
systems in NHP or NRP . . . . . . . . . . . . . . . . . . . . . . . . . . 161

1la-b.

Inhibition of the Amidolytic Activity of Factor Xa by Various Agents in
NHP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369

1lc.

Inhibition of the Amidolytic Activity of Thrombin by Various Agents in
NRP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 370

12.

Inhibition of serine proteases by thrombin inhibitors as determined in
biochemically defined amidolytic systems . . . . . . . . . . . . . . . . 164

12a.

Inhibition of the Amidolytic Activity of Chymotrypsin by Various
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371

12b.

Inhibition of the Amidolytic Activity of Trypsin by Thrombin Inhibitors . 372

12c.

Inhibition of the Amidolytic Activity of APC by Thrombin Inhibitors . . . 373

12d-e.

Inhibition of the Amidolytic Activity of Glandular Kallikrein by Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 374

12f.

Inhibition of the Amidolytic Activity oft-PA by Thrombin Inhibitors ... 375

12g.

Inhibition of the Amidolytic Activity of Urokinase by Thrombin Inhibitors 376

12h-i.

Inhibition of the Amidolytic Activity of Plasmin by Thrombin Inhibitors . 377

13.

Inhibition of plasminogenolysis by thrombin inhibitors as determined in
biochemically defined and NHP amidolytic systems . . . . . . . . . . 175

13a-c.

Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen Lysed
by Streptokinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 378

13d-f.

Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen Lysed
by t-PA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 379

13g-i.

Inhibition of Plasminogenolysis by Thrombin Inhibitors:
xxm

NHP-Derived

Plasminogen Lysed by Streptokinase . . . . . . . . . . . . . . . . . . . 380
13j-l.

Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived
Plasminogen Lysed by t-PA . . . . . . . . . . . . . . . . . . . . . . . . 381

14.

Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as
determined in fibrinogen-deficient amidolytic systems . . . . . . . . . 180

14a-e.

Inhibition of Thrombin Generation After Extrinsic Stimulation of FibrinogenDeficient Human Plasma . . . . . . . . . . . . . . . . . . . . . . . 382-385

14f-j.

Inhibition of Factor Xa Generation After Extrinsic Stimulation of FibrinogenDeficient Human Plasma . . . . . . . . . . . . . . . . . . . . . . . 386-390

14k-o.

Inhibition of Thrombin Generation After Intrinsic Stimulation of FibrinogenDeficient Human Plasma . . . . . . . . . . . . . . . . . . . . . . . 390-393

14p-t.

Inhibition of Factor Xa Generation After Intrinsic Stimulation of FibrinogenDeficient Human Plasma . . . . . . . . . . . . . . . . . . . . . . . 394-397

15.

Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as
determined in FEIBA® and KONYNE amidolytic systems . . . . . . 187

15a-c.

Inhibition of Thrombin Generation from KONYNE® by Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 398-399

15d-f.

Inhibition of Factor Xa Generation from KONYNE® by Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399-400

15g-i.

Inhibition of Thrombin Generation from FEIBA® by Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401-402

15j-l.

Inhibition of Factor Xa Generation from FEIBA® by Thrombin
Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402-403

16.

Comparative anticoagulant effects of thrombin inhibitors in NHP . . . . . 192

16a-c.

Comparative anticoagulant effects of thrombin inhibitors in the NHP based PT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 404-406

16d-f.

Comparative anticoagulant effects of thrombin inhibitors in the NHP based APTT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 407-409

16g-i.

Comparative anticoagulant effects of thrombin inhibitors in the NHP based TT
XXlV

assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 410-412
16j-k.

Comparative anticoagulant effects of thrombin inhibitors in the NHP based ECT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 413-414

161-n.

Comparative anticoagulant effects of thrombin inhibitors in the NHP based
Heptest assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415-417

160.

Comparative anticoagulant effects of thrombin inhibitors after supplementation
into normal human whole blood, in the ACT assay . . . . . . . . . . 418

16p.

Comparative anticoagulant effects of thrombin inhibitors after supplementation
into normal human whole blood, in the TEG assay . . . . . . . . . . 419

17.

Comparative anticoagulant effects of thrombin inhibitors in NRP

17a.

Comparative anticoagulant effects of thrombin inhibitors in the NRP based PT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 420

17b.

Comparative anticoagulant effects of thrombin inhibitors in the NRP based APTT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421

17c.

Comparative anticoagulant effects of thrombin inhibitors in the NRP based TT
assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 422

17d.

Comparative anticoagulant effects of thrombin inhibitors in the NRP based
Heptest assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423

17e.

Comparative anticoagulant effects of thrombin inhibitors after supplementation
into normal whole rabbit blood, as assessed by the ACT assay . . . 424

17f.

Comparative anticoagulant effects of thrombin inhibitors after supplementation
into normal whole rabbit blood, as assessed by the TEG assay
424

18.

Standardization of the rabbit model of jugular vein stasis thrombosis

19.

Comparative antithrombotic potencies of thrombin inhibitors after I. V. injection
as determined in the rabbit model of jugular vein stasis thrombosis 217

19a-d.

. . . . . 202

210

Comparative dose-dependent antithrombotic effects of thrombin inhibitors as
studied in the rabbit model of jugular vein stasis thrombosis, after I. V.
injection, 5 min prior to r-TF injection, after 10 and 20 min
stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 425-426

xxv

19e.

Time dependance of antithrombotic effects of thrombin inhibitors in the rabbit
model of jugular vein stasis thrombosis, after I.V. injection and 10 minutes
stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427

19f.

Time dependance of antithrombotic effects of thrombin inhibitors in the rabbit
model of jugular vein stasis thrombosis, after I. V. injection and 20 minutes
stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427

20.

Comparative antithrombotic potencies of thrombin inhibitors after S.C. injection,
as determined in the rabbit model of jugular vein stasis thrombosis 230

20a-d.

Comparative dose-dependent antithrombotic effects of thrombin inhibitors as
studied in the rabbit model of jugular vein stasis thrombosis, after S.C.
injection, 45 min prior to r-TF injection and after 10 and 20 min
stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 428-429

20e.

Time dependance of antithrombotic effects of thrombin inhibitors in the rabbit
model of jugular vein stasis thrombosis, after S.C. injection and 10
minutes stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430

20f.

Time dependance of antithrombotic effects of thrombin inhibitors in the rabbit
model of jugular vein stasis thrombosis, after S.C. injection and 20
minutes stasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 430

21.

Comparative antithrombotic potencies of thrombin inhibitors, as determined in
the rat model of laser-induced thrombosis in isolated mesenterial
arterioles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245

21a-d.

Comparative dose-dependent antithrombotic effects of thrombin inhibitors as
studied in the rat model of laser induced thrombosis, after I. V. injection,
5 min prior to initiation of the laser injuries . . . . . . . . . . . 431-432

22.

Comparative hemorrhagic potencies of thrombin inhibitors after I.V. injection,
as determined in the rabbit model of ear bleeding . . . . . . . . . . . 248

22a-d.

Comparative dose-dependent hemorrhagic effects of thrombin inhibitors as
studied in the rabbit ear bleeding model, after I. V. injection, 5 and 20 min
prior to initiation of the bleeding procedure . . . . . . . . . . . . 433-434

22e.

Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit ear
bleeding model, after I. V. injection . . . . . . . . . . . . . . . . . . . . 435

23.

Comparative hemorrhagic potencies of thrombin inhibitors after S.C. injection,
as determined in the rabbit model of ear bleeding . . . . . . . . . . . 253
xxvi

23a-d.

Comparative dose-dependent hemorrhagic effects of thrombin inhibitors as
studied in the rabbit ear bleeding model, after S.C. injection, 45 and 60
min prior to initiation of the bleeding procedure . . . . . . . . . 436-437

23e.

Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit ear
bleeding model after S.C. injection . . . . . . . . . . . . . . . . . . . . 438

24.

Comparative properties of heparin and thrombin inhibitors . . . . . . . . . 258

25.

Classification of thrombin inhibitors based on their pharmacologic actions 319

26.

Classification of thrombin inhibitors based on their serine protease inhibitory
spectrum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320

27.

Comparative rank order of potencies of various antithrombin agents in various
biochemical assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322

28.

Comparative rank order of potencies of various antithrombin agents in in vitro
anticoagulant assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 323

29.

Comparative rank order of potencies of various antithrombin agents in in vivo
pharmacologic models . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324

30.

Developmental Status of Site-Directed Thrombin Inhibitors . . . . . . . . . 327

xxvii

LIST OF STAND ARD ABBREVIATIONS

µg

microgram

µm

micrometer

µM

micromoles/liter

µmol

micromoles

A

angstrom

Arg

arginine

Asp

aspartate

Boe

t-buty loxycarbony1

ca++

calcium

CaCl2

calcium chloride

cAMP

cyclic adenosine monophopsphate

cGMP

cyclic guanosine monophosphate

cm

centimeter

dL

deciliter

DNA

deoxyribonucleic acid

EDTA

ethylene diamine tetraacetic acid

fmol

femtomoles

g

gram

xxvm

g

acceleration of gravity (9.8 m/s 2)

Glu

glutamine

Gly

glycine

GPC

gas permeation chromatography

H2 0

water

His

histidine

HPLC

high pressure liquid chromatography

I.V.

intravenous

Ile

isoleucine

kcat

catalytic rate constant

kd

dissociation rate constant

kg

kilogram

Ki

inhibition constant

Km

Michaelis constant

L

liter

Lys

lysine

M

moles/liter

M.W.

molecular weight

mg

milligram

ml

milliliter

ml

milliliter

mm

millimeter

XXlX

mM

millimoles/liter

mmol

millimoles

mol

moles

mV

millivolt

mW

milliwatt

N

nitrogen

Na2S04

sodium sulfate

-NHS03

aminosulfate

nm

nanometer

nM

nanomoles/liter

nmol

nano moles

NMR

nuclear magnetic resonance

NO

nitric oxide

-OH

hydroxyl

-0503

sulfate

pg

picogram

Phe

phenylalanine

pM

picomoles/liter

pmol

picomoles

pNA

para nitroaniline

Pro

proline

RBC

red blood cell

xxx

RI

refractive index

RNA

ribonucleic acid

S.C.

subcutaneous

S.E.M. (SEM)

standard error of mean

SD

standard deviation

Ser

serme

Tris

tris(hydroxymethyl)aminomethane

t1h

biologcal half life

u

unit

USP

United States Pharmacopeia

UV

ultraviolet

Val

valine

WBC

white blood cell

®

registered trademark

TM

trademark

oc

degree Celsius

xxxi

LIST OF NON-STANDARD ABBREVIATIONS

a angle

the angle defined by the center line transversing the length of the
TEG graph and the tangent from the initial point of divergence and
the first inflection point of the tracing
change in absorbance at 405 nm

5-HT

5-hydroxytryptamine

5U TT

5 unit thrombin time

Ac

acetyl

ACT

activated clotting time

AMI

acute myocardial infarction

ANOVA

analysis of variance

Anti-Ila

antithrombin

Anti-Xa

anti-factor Xa

APC

activated protein C

APTT

activated partial thromboplastin time

AT-III

antithrombin III

ATU

antithrombin unit

BBP

blood bank plasma
dose producing bleeding of 2 · 109 RBC/L

b.i.d.

twice daily

xxxn

activated fragment of complement 3a
activated fragment of complement 5a
calcium thrombin time
CPDA-1

mixture of 26.3 g/L trisodium citrate, 3.27 g/L citric acid, 31.9
g/L dextrose, 2.22 g/L monobasic sodium phosphate, and 0.275
g/L adenine

CT100

concentration resulting in prolongation of clotting time to 100 sec

cu

casein unit

DIC

disseminated intravascular coagulation

DVT

deep venous thrombosis

E.C.

enzyme commission

EACA

E-aminocaproic acid (Amicar®)
effective dose producing 50 3 of maximal effect

EGF

epidermal growth factor

ELISA

enzyme-linked immunoabsorbance assay

EPI

extrinsic pathway inhibitor (same as LACI and TFPI)
prothrombin fragments 1 +2 assay

FEIBA®

factor eight inhibitor bypass activator (prothrombin complex
containing factors II, VII, VIIa, IX and X)

Gla

-y-carboxyglutamic acid residue domain

GP lb

glycoprotein lb

GPIIb/IIIa

glycoprotein IIb/IIIa

HC-II

heparin cofactor II

HIT

heparin induced thrombocytopenia
xxxiii

HMWK

high molecular weight kininogen

HV

hirudin variant

I.D. (ID)

internal diameter
inhibitory concentration, producing 50 3 inhibition of maximal
effect

Ila

thrombin

k value

the difference between the rand rk values of a TEG recording

IU

International Unit

KIU

kallikrein inactivator unit

KONYNE®

prothrombin complex consisting of factors II, VII, IX and X

LACI

lipoprotein associated coagulation inhibitor (same as EPI and TFPI)

LDL

low density lipoprotein

LMW

low molecular weight

LMWH

low molecular weight heparin

Me

methyl

mm

minutes

msec

millisecond

N-terminal

amino-terminal

NHP

normal human plasma

NIH

National Institutes of Health

nkat

nanocatalytic unit

NRP

normal rabbit plasma

O.D.

optical density
xxxiv

PAF

platelet activating factor

PAI-1

plasminogen activator inhibitor 1

PAI-2

plasminogen activator inhibitor 2

PAI-3

plasminogen activator inhibitor 3

PCI

protein C inhibitor

PDGF

platelet derived growth factor

PF3

platelet factor 3

PF4

platelet factor 4

PI

phosphatidyl inositol

PMH

porcine mucosa! heparin

PPACK

D-Phe-Pro-ArgCH2 Cl

PPP

platelet poor plasma

proUK

pro-urokinase

PRP

platelet rich plasma

PT

prothrombin time

r value

the length from the beginning of the TEG recording until the point
where the graph reaches a 2 mm divergence

r-hirudin

recombinant hirudin

rHV

recombinant hirudin variant

RIA

radio immunoassay

rk value

the length from the beginning of the thrombelastogram until the
point where the graph reaches a 2 cm divergence

rTF

recombinant tissue factor

xx xv

sc-uPA

single chain urokinase type plasminogen activator

sec

second

serpm

serine protease inhibitor

tc-uPA

two chain urokinase type plasminogen activator

TEG

thrombelastogram

TF

tissue factor

TFPI

tissue factor pathway inhibitor (same as EPI and LACI)

t.i.d.

three times daily

TNF

tumor necrosis factor

tPA

tissue type plasminogen activator

TT

thrombin time

TXB 2

thromboxane B2

uPA

urokinase type plasminogen activator

vWF

von Willebrand Factor

XXXVl

CHAPTER I
PURPOSE

Thrombin is known to play a key role in the development of various thrombotic
conditions,

such as

stroke,

myocardial infarction,

pulmonary embolism and

hypercoagulable states. Therefore it is the primary biochemical and pharmacologic target
for developing newer antithrombotic drugs.

One of the hypotheses underlying this

approach is that sole inhibition of thrombin at blood and vascular sites is sufficient for
the control of thrombogenesis and cellular activation processes. The purpose of this
dissertation is to examine the hypothesis that inhibition of thrombin alone is sufficient for
the control of thrombogenesis. This central question is addressed by determining the
relative inhibitory effects of recombinant hirudin, a monospecific inhibitor of thrombin,
along with the synthetic serine protease inhibitors (serpins) D-MePhe-Pro-Arg-H, Ac(D)Phe-Pro-boroArg-OH, argatroban and unfractionated heparin in the control of
thrombogenesis. While the thrombin inhibitors included in this investigation represent
varying degrees of specificities and potencies towards thrombin, heparin represents a
poly-functional drug with mupltiple sites of action involving both the plasmatic proteases
and cellular targets. Biochemical and pharmacologic models based on defined in vivo
and in vitro experimental systems are used to investigate the comparative effects of each
of these agents. This dissertation also provides supportive data on the relative role of
non-specific serine protease inhibition in the mediation of the antithrombotic actions of
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the newly developed thrombin specific peptide inhibitors.
Several antithrombin agents with different mechanisms of action are studied in
terms of their specificity for inhibiting thrombin and related serine proteases such as
factor Xa, activated protein C, plasminogen activator, plasmin and kallikrein.

It is

widely accepted that hirudin exhibits its antithrombotic action by solely inactivating
thrombin. On the other hand, heparin which also is an effective antithrombotic agent
exhibits a more complex mechanism of action through endogenous serpins such as
antithrombin or heparin cofactor II (HC-11), to inactivate serine proteases. The synthetic
peptides and peptidomimetic inhibitors used in this study are reported to be potent
inhibitors of thrombin but are not monospecific for thrombin. Tripeptide inhibitors sitedirected towards the catalytic region of thrombin vary in their specificity and potency for
thrombin inhibition, which is largely dependent on their structure.

The thrombin

inhibitors chosen for this study provide structurally defined tools with different serpin
profile which may be useful in identifying the activation processes which lead to a
thrombogenic event. The relative efficacy of each one of these inhibitors in valid animal
models of venous as well as arterial thrombosis provides a clear indication as to whether
or not sole inhibition of thrombin is the most effective method to prevent
thrombogenesis.
Many of these agents are in various phases of clinical development. However,
a comparative account of their biochemical and pharmacological actions has not been
available until now. Several studies indicate that these agents are not only different from
heparin but marked differences among these inhibitors in terms of their mechanisms of
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action and pharmacologic properties are predictable.

Since each of the thrombin

inhibitors exhibit a specific structural and biochemical profile, this investigation
represents valuable information on the structure activity relationship for these agents.
Furthermore, a direct comparison with heparin also provides additional insight into the
role of endogenous macromolecular ligands and receptors in the mediation of the
pharmacologic actions of the newly developed synthetic and recombinant agents.
Except for heparin, all of the agents included in this study are homogeneous,
structurally characterized peptides or peptidomimetics, whose pharmacologic actions can
be expressed in terms of molarity in relation to their interactions with endogenous
enzymes, ligands and other sites. Thus, the anticoagulant and anti-protease actions of
these agents can be quantified and compared in defined terms. A direct comparison of
these data with heparin also provides new information on the mechanisms of mediation
of the actions of these antithrombin agents.
The comparative anticoagulant profile of these agents does not correlate with their

in vivo antithrombotic actions. Furthermore, the global clotting tests do not provide
information on the precise site of action of anticoagulants but rather provide an indication
of a general area of the protease cascade where inhibitory activities may take place.
One of the novel features of this investigation is the development and utilization
of defined in vitro protease generation systems, which allow for the assessment of the
relative importance of inhibition of specific factors in the coagulation cascade in defined
and plasma based matrices. Furthermore, the studies on the inhibition of thrombin as
well as its generation from specific precursors along with the studies on the broader
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inhibitory spectrum of these agents on other purified proteases such as plasmin, activated
protein C and kallikrein, adds to the understanding of the mechanisms of mediation of
both the anticoagulant and antithrombotic actions of these agents.
Another important purpose of this research was to demonstrate the impact of the
non-specific inhibition of regulatory serine proteases. While the amidolytic assays for
the direct inhibition of many of the serine proteases and the generation of plasmin assays
have been employed in isolated studies, a comparative investigation of these in a uniform
manner has not been reported before. Furthermore, in this investigation all comparisons
are made in a manner where the inhibitor levels as well as the enzymes (preformed or
generated) can be directly compared at molar levels. Such a comparison can be used to
project the relative impact of these thrombin inhibitors in the modulation of coagulation,
fibrinolysis and kallikrein system.
Protease generation assays using in vitro plasmatic systems also provide a useful
approach to characterize the multiple sites at which these thrombin inhibitors act. In the
fibrinogen deficient human plasmatic systems, where thrombin is generated by activation
of either the intrinsic or the extrinsic pathway, the difference in the pharmacologic
actions of these antithrombin agents can be determined. These methods provide insights
to the overall mode of actions of the thrombin inhibitors in a diluted plasma matrix where
feedback modulatory actions of thrombin can be simultaneously studied.
Defined non-plasmatic protease generation systems have also been used to trigger
the generation of thrombin is provided by extrinsic activation of prothrombin complexes
(FEIBA® and KONYNE®), to determine the role of other plasmatic proteins in the

5
mediation of the anticoagulant effects of the thrombin inhibitors. Agents such as heparin,
which require endogenous cofactors for the mediation of their inhibitory activities do not
prevent the generation of thrombin or inhibit thrombin in these systems, whereas agents
not specific for thrombin and possessing other serine protease inhibitory actions, are
more effective in these assays.
To measure the relative in vivo antithrombotic actions of heparin, hirudin, Ac(D) Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H, pharmacologic models of acute
thrombosis are utilized.

In the rabbit jugular vein stasis thrombosis model, the

effectiveness of these agents in preventing clot formation is assessed in terms of potency,
efficacy and duration of antithrombotic actions. However, the physiology of venous
thrombosis differs from that of arterial thrombosis, thus, inhibition of thrombin and its
generation and/or inhibition of other serine proteases may be of different importance in
each model. Therefore, the antithrombotic actions of these agents are also studied in a
rat laser-induced arterial thrombosis model. The results from these two models are
useful in understanding not only the relative importance of direct thrombin inhibition as
compared to the inhibition of thrombin generation and/or other serine proteases, but also
the role of the proteases inhibited in the venous system as compared to the arterial
system.
Since trace amounts of thrombin are required for the hemostatic function of
platelets, thrombin inhibitors may also compromise this hemostatic process. At relatively
higher dosage, indiscriminate inhibition of all effects of thrombin may lead to bleeding.
Thus, the studies on the rabbit ear blood loss model can provide useful data on the
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relative bleeding effects of these agents. Based on these observations, some projections
on the role of platelets in the mediation of the thrombotic events and their modulation by
thrombin inhibitors can also be made.
The animal model of venous thrombosis also allows for ex vivo analyses of blood
samples so that a comparison of the pharmacodynamic actions (anticoagulant and
antiprotease) with the antithrombotic effects of each antithrombin agent can be made.
This is important in the understanding of the additional mechanisms of action for each
agent. Additional correlations between the ex vivo antithrombin or related anticoagulant
actions with the observed hemorrhagic actions in a rabbit model of ear blood loss
provides data on the endogenous interactions of these agents resulting in bleeding effects.
Thus, a safety/efficacy index can be developed for each of the agents studied.
Another important feature of this investigation is the utilization of recombinant
tissue factor (rTF) in the in vitro biochemical assays and the in vivo rabbit venous
thrombosis studies. The thrombogenic environment developed by using this trigger is
rather defined and the role of heparin and antithrombin agents can be readily assessed
in the rTF mediated thrombogenesis. The use of rTF in the stasis thrombosis model is
more defined than the existing models using mixtures of enzymes or human serum. The
tissue factor used in this investigation is produced by recombinant technology and is
molecularly characterized and packaged in phospholipids. In the in vivo thrombogenic
studies, it acts as a strong extrinsic pathway activator that leads to thrombogenic events.
Thus, the data generated on rTF in both the biochemical and pharmacologic studies
represent more defined information on the control of thrombogenesis with the new
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antithrombin agents.
The experimental approaches included in this dissertation are designed to
differentiate the pharmacological profile of antithrombin agents as a class from those of
heparin.

Furthermore, these studies also provide crucial data on the significant

differences which exist amongst these agents. In addition, this dissertation also addresses
the question of standardization, relative role of thrombin inhibitors in the mediation of
antithrombotic actions and some of the non-thrombin mediated modulatory actions of
these agents, such as their effects on the fibrinolytic network and activated protein C
modulated regulatory processes.
The experimental methods included in this dissertation represent optimal and
pharmacologically defined systems to obtain valid data in a systematic fashion on the
biologic actions of these antithrombin agents of different origins. It is expected that the
reported data in this dissertation will serve as a systematic approach for the valid
pharmacologic investigation of newer antithrombin agents.

CHAPTER II
REVIEW OF LITERATURE

A. Overview of Hemostasis
Unicellular organisms derive their nutrients by simple physiochemical process
and/or by phagocytotic process. However, more complex multicellular organisms require
more complex mechanisms of essential nutrient delivery to their cells. The vasculature
in mammals serves as a conduit via which nutrients reach individual cells. Evolution has
shaped the vascular physiology with mechanisms to take corrective measures to cope with
the disruptive events. Blood is a non-Newtonian fluid which flows through the vessels
to provide oxygen and nutrients and regulate the vascular integrity. While the process
of hemostasis (arrest of bleeding) will prevent blood loss, the fibrinolytic process
facilitates the dissolution of clot as the healing process progresses, allowing the
restoration of blood flow.

Despite all of the mechanisms which serve to regulate

hemostasis, uncontrolled activation of this process leads to a range of disorders, including
both the thrombotic and hemorrhagic disorders.
It is now becoming clear that the role of the endothelial cell monolayer is rather

important in the regulation of hemostasis and extends beyond providing a nonthrombogenic surface for the continuous flow of blood. The products of the vascular
cells are essential in regulating various physiologic processes. Receptors expressed on
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the surface of these endothelial cells regulate many of their hemostatic functions. Cell
surface interactions on the endothelium and on other blood-borne cells control a multitude
of natural processes, among these is the localized production and control of thrombin,
the key enzyme in clot formation. The importance of these components is evident when
there is a defect in one of these which can lead to a wide range of clinical disorders
ranging from thrombosis and atherosclerosis to neurological disease, inflammatory and
immune disorders, microangiopathy and vasculitis.
Focusing on the processes that regulate the flow of blood, while the recognition
of the role of fibers has been noted since the time of Plato, the specifics of blood clotting
started to become unravelled in the beginning of the 19th century (Bloom et al. 1994).
By 1964, enough was known about specific coagulation proteins to develop the
"waterfall" or "cascade" coagulation model (Macfarlane 1964), in which activation of one
zymogen leads sequentially to the activation of another, until thrombin is generated to
mediate the conversion of liquid fibrinogen to solid fibrin clots.

Since then, an

exponential increase in the knowledge of about these proteins has led to several
modifications of the original simplified scheme to develop increasingly more complex
networks. It has also become clear that these processes are not independent of other
cellular components and that there is a constant interaction with many different cell types
mediating equally diverse physiologic responses (Loscalzo and Schafer 1994).
The pathophysiology of thrombotic events is multicomponent and involves blood,
vascular system and target sites. Vascular injury results in the localized alterations of
the vessels and subsequent platelet activation. Activated cells mediate several direct or
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signal transduction mediated processes resulting in the activation of platelets. Cellular
activation also results in the release of various mediators which amplify vascular spasm
and the coagulation process.

Thus, anaphylatoxins (C3a and C5a), superoxide,

leukotrienes (LTC4), thromboxane B2 (TxB 2), serotonin, platelet factor 3 (PF3), platelet
factor 4 (PF4), platelet activating factor (PAF), endothelin-1 and numerous cytokines
play a role in the overall pathophysiology of the thrombotic process. Drugs that target
various sites of the activation process can be developed to control thrombotic events.
Because of the coupled pathophysiology, a single drug may not be able to target these
sites to produce therapeutic actions.

Furthermore, many of these mediators produce

localized actions at cellular and subcellular levels. The feedback amplification process
also plays an important role in the pathology of these disorders. This understanding has
led to the concept of polytherapy in the management of thrombotic disorders.
Venous insufficiency, blood plasma related disorders, fibrinolytic deficit and an
imbalance of regulatory proteins result in the activation of the hemostatic process. Postsurgical trauma, inflammation and sepsis also lead to the activation of the hemostatic
process leading to venous thrombosis. The primary process in venous thrombosis is the
generation of thrombin. Thus, drugs targeting coagulation protease activation are useful
in the treatment of venous disorders (Fareed 1992). However, platelet and cellular
activation contribute significantly to arterial thrombotic events, and therefore, drugs
targeting those sites are important in the management of arterial thrombosis and
microangiopathic disorders.
The newer developments in antithrombotic drugs are significant. Many advanced
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techniques to develop anti thrombotic drugs are used at the present time. Advances in
biotechnology and separation techniques have also contributed to the development of
newer antithrombotic drugs (Fareed et al. 1988-1992). These drugs may prove to have
a better efficacy in the control of thrombogenesis and its treatment. Drugs and devices
which have been or are being developed based on newer concepts and range from heparin
related drugs and antiplatelet agents to endothelial lining and viscosity modulators.
Antithrombotic drugs represent a wide spectrum of natural, synthetic, semisynthetic and biotechnology produced agents with marked differences in chemical
composition, physicochemical properties, biochemical actions and pharmacologic effects.
The use of physical means to treat thrombotic disorders, and advanced means of drug
delivery, add to the expanding nature of this area.
The endogenous actions of the antithrombotic drugs are remarkably complex. It
is no longer valid to assume that an antithrombotic drug must produce an anticoagulant
action in blood as the conventional heparin and oral anticoagulants.

Many of these

drugs, such as platelet inhibitors, do not produce any alteration of blood clotting
parameters, yet they are effective therapeutic agents because of their interactions with the
various elements of the vasculature and other blood components. Another perspective
is that several of these agents require endogenous transformation to become active
products. Therefore, it becomes important to rely on the pharmacodynamic actions of
these agents rather than on their in vitro characteristics to assess potency or efficacy of
the product.

Hematologic modulation plays a key role in the mediation of the

antithrombotic actions of these drugs involving red cells, white cells, platelets and blood
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proteins. This is particularly true for the case of trauma induced thrombotic disorders
where multiple processes are involved in thrombogenesis.

B. Role of Serine Proteases i.n the Regulation of Coagulation,
Fibrinolytic, Kallikrein and Complement Pathways

Blood is a complex liquid tissue that serves as an interface between its own cells
and those of the organ systems which it perfuses to mediate many vital physiologic
processes, one of which is prevention of excessive bleeding following trauma, a process
which is usually referred to as hemostasis. A crucial component of hemostasis is the
coagulation system. Upon activation, this system results in clotting of liquid blood. The
processes involved in the activation of the coagulation system are enzymatic in nature and
are mostly mediated through a series of coagulation factors (proteins) and cofactors
whose activities are enhanced by ca++ and phospholipids.

The activation of the

coagulation system leads to formation of a key active coagulation factor, thrombin.
Thrombin is essential in converting liquid fibrinogen to fibrin clots which are deposited
in platelet plugs to arrest bleeding. In addition, thrombin plays a key role in many other
physiologic and pathologic processes.
Thrombin is generated in the blood through two separate enzymatic pathways
(Ratnoff et al. 1964, Macfarlane et al. 1964). In the intrinsic pathway, components
intrinsic to whole blood (circulating in blood) are involved through contact activation,
in the reactions leading to thrombin generation. In the extrinsic pathway, components
extrinsic to whole blood (not normally in contact with whole blood) are generated or
activated to initiate a cascade of events leading to thrombin formation. These pathways
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coalesce at the level of activation of a common enzyme, factor Xa, which activates
prothrombin leading to thrombin formation. An integrated version of the coagulation,
fibrinolytic and kallikrein systems is illustrated in Fig 1.
All of the enzymes involved in blood coagulation normally circulate in inactive
proenzyme forms as zymogens. When a zymogen is activated to an enzyme, this enzyme
further activates another zymogen to its active enzymatic state, thus propagating the
coagulation cascade. The activated form of the zymogen is denoted with a lower case
"a" following the name of the zymogen.
The extrinsic pathway is initiated physiologically when membrane surface bound
tissue factor (TF), on tissues outside the circulatory system, comes in contact and forms
a complex with blood born factor VIIa through trauma (Bloom et al. 1994). In the
presence of Ca++ this complex is able to directly activate factor X to factor Xa, also
shown in Fig.1. Beside the activation of coagulation, this complex is also involved in
cellular activation at various sites.
The kallikrein-kinin system is a system of protease interactions in the blood,
whose major physiological function is to produce bradykinin and other low molecular
weight kinins. The effects of these peptides on the circulatory system include increased
vascular permeability, vasodilation of smaller blood vessels, pain, smooth muscle
contraction and synthesis and enhancement of prostaglandins (Bloom et al. 1994). This
system also interacts with both the coagulation system and the fibrinolytic system in a
complex manner. The kallikrein-kinin system can be stimulated by a variety of factors
such as tissue damage, allergic reactions, viral infections and inflammatory processes that
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Fig. 1. The coagulation and fibrinolytic system. The interactions and feedback amplifications within the coagulation system
are depicted, as are its interactions with the fibrinolytic system. - - - indicates inhibition by the major endogenous serpins. '.j;'.
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lead to plasmatic generation of bradykinin (via proteolytic action of plasma kallikrein on
high molecular weight kininogen or HMWK) and direct activation of the complement
system (kallikrein can directly activate CS) (Bloom et al. 1994). Of relevant interest is
the generation of plasma kallikrein, which is generated through the proteolytic action of
factor XIIa on prekallikrein, as depicted in Fig. I. Factor XIIa is generated from factor
XII upon interaction with negatively charged surfaces or collagen as with tissue damage
and is accelerated by HMWK. The generated kallikrein, with HMWK as a catalyst, can
then further catalyze the activation of factor XII to factor XIIa. Thus, the kallikreinkinin system is linked to the intrinsic activation pathway via kallikrein and factor XII
(Loscalzo et al. 1994).
The intrinsic pathway is initiated physiologically by disruption of the vessel wall
inner lining and exposure of connective tissue elements which provide the negatively
charged surface necessary for the activation of factor XII by kallikrein and HMWK
(Loscalzo et al. 1994), as seen in Fig. I. Factor XIIa in turn activates factor XI to factor
XIa in the presence of Ca++ and HMWK. Kallikrein, factors XII and XI and HMWK
comprise the group of contact factors. Factor XIa converts factor IX to factor IXa in the
presence of ca++. Factor IXa binds to a membrane surface bound cofactor, factor VIIIa,
to form the tenase complex, which activates factor X to factor Xa.
The extrinsic and intrinsic pathways are not completely independent up to the
point of formation of factor Xa and interact at different levels during feedback processes.
For example, factor XIIa from the intrinsic pathway is also capable of activating factor
VII to VIIa in the extrinsic pathway and factor VIIa is capable of converting factor IX
to IXa in the intrinsic pathway. Furthermore, factor IXa from the intrinsic pathway is
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capable of activating factor V in the extrinsic pathway. Thus, enzymatic activations are
complex and feedback controls are abundant.
The activation of the two pathways leads to formation of factor Xa which is a
component of the common pathway. Factor Xa binds to membrane bound factor Va in
the presence of Ca++ to form the prothrombinase complex.

This complex converts

prothrombin to thrombin which converts fibrinogen to fibrin clot.

In addition to

prothrombin activation, factor Xa also mediates the activation of factor VII in the
extrinsic pathway, cofactor VIII in the intrinsic pathway and cofactor V in common
pathway.

The function of thrombin in the coagulation cascade is not restricted to

conversion of fibrinogen to fibrin, but also includes further activation of cofactors V and
VIII (as does factor Xa), as well as activation of factors XI and XIII. The common
pathway ends in stabilization of the formed fibrin by factor XIIIa mediated cross-linking
of the fibrin strands.
The coagulation system is controlled at various levels by four major physiological
inhibitors, also shown in Fig. 1: antithrombin, heparin cofactor II (HC-II), tissue factor
pathway inhibitor (TFPI) and activated protein C (APC). Antithrombin mediates its
anticoagulant effects by inhibiting thrombin and factor Xa and to a lesser extent factors
XIIa, Xla, IXa and kallikrein. HC-II directly inhibits only thrombin, while TFPI forms
an inactive complex with TF and factor Xa. The inhibitory mechanism of APC is more
complex in that while this enzyme is activated by thrombin and it degrades cofactors
VIIIa and Va (which are necessary for factor X and prothrombin activation), it requires
two cofactors for its anticoagulant activities: protein S and factor V (which it degrades
in the activated form). Thus, activation of coagulation and formation of thrombin also
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triggers its inactivation.
The fibrinolytic system, balances the coagulation system by ultimately resulting
in fibrin clot dissolution. The two systems regulate and balance each other intricately
and offset towards one or the other system leads to thrombosis or bleeding respectively.
The enzymes involved in fibrinolysis, similar to the ones involved in coagulation,
also circulate in their inactive forms under normal physiological conditions.

In an

oversimplified scheme, shown in Fig.1, fibrinolysis is initiated with the formation of
fibrin clots where plasminogen and thrombin become entrapped. Plasminogen binds to
fibrin weakly but activators such as tissue plasminogen activator and urokinase, which
also diffuse into the clot, accelerate the binding of plasminogen to fibrin and mediate its
activation to plasmin (Bloom et al. 1994). Plasmin then can degrade fibrin to fibrin
degradation products. The interaction of the kallikrein -kinin system with the fibrinolytic
system is at the level of urokinase, where kallikrein can directly activate single chain prourokinase to the two chain urokinase (Bloom et al. 1994), also depicted in Fig. 1.

1. Biochemical Characteristics of Serine Proteases

All of the blood coagulation factors and enzymes involved in fibrinolysis belong
to the family of serine proteases with the following exceptions: tissue factor, factors V
and VIII and HMWK which function as cofactors, factor XIII which is a transamidase
and fibrinogen which is a non-enzymatic glycoprotein. The blood coagulation serine
proteases share some common features in terms of their structure and mode of action.
All are synthesized in the liver, except for Von Willebrand factor (vWF), initially with
a signal peptide which allows for their translocation to the endoplasmic reticulum, where
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this peptide is cleaved (Loscalzo et al. 1994). Some of the characteristics of serine
proteases involved in coagulation are summarized in Table 1.
The catalytic domain of all blood clotting enzymes is highly homologous to that
of trypsin (Furie et al. 1982). This domain is composed of a specific site for recognition
of macromolecular substrates referred to as the specificity pocket and an active site
referred to as the catalytic triad, which serves for the conversion of inactive zymogens
to active enzymes via cleavage of specific bonds. The blood clotting enzymes are trypsinlike enzymes, meaning that they recognize and cleave peptide bonds involving arginine.
They are also serine proteases. meaning that their active site in the catalytic domain is
composed of a specific catalytic triad: serine, aspartate and histidine (Stroud et al. 1974).
Other common features shared among blood coagulation enzymes are epidermal
growth factor (EGF) domains which consist of 3 disulfide bonds in a characteristic
covalent structure (Gregory 1977). Factors VII, IX, X, XII, protein C and protein S,
as well as tPA and pro-urokinase (proUK) from the fibrinolytic system, all have at least
1 EGF domain. These structures may mediate the binding of factor IX to endothelial
cells (Ryan et al. 1989). Another structure shared among many blood proteins is the
Kringle domain, also composed of 3 disulfide bonds in a characteristic covalent structure
but involving double the amount of amino acids involved in EGF domains and with a
different three dimensional structure. This type of domain is thought to be important in
protein complex formation (Parket al. 1986). Among the blood proteins possessing such
a structure are prothrombin (Magnusson et al. 1973), factor XII (Cool et al. 1987),
plasminogen (Malinowski 1984), pro-urokinase (Holmes et al. 1985) and tissue- type
plasminogen activator (Ny et al. 1984).

Table 1 -- Characteristics of Procoagulant and Pro-fibrinolytic Proteins
Proenzyme
Enzyme
MW
Plasma Level Natural Substrates
Commission #
85,000
0.6µM
Factor XII, sc-uPA, C5
Kallikrein
3.4.21.34
0.7 µM
120,000
HMWK

3.4.21.6

80,000
160,000
45,000
166,000
50,000
37,000
48,000

0.4 µM
0.025 µM
0.09 µM
0.3pM
0.01 µM
OµM
0.17 µM

3.4.21.5

180,000
36,000

0.03 µM
2µM

Fibrinogen
Factor XIIIa

2.3.2.13

340,000
150,000

6-12 µM
0.03 µM

Plasmin
tPA
uPA

3.4.21.7
3.4.21.68
3.4.21.73

92,000
68,000
33,000

2µM
70 pM
150 pM

Factor
Factor
Factor
Factor
Factor
Tissue
Factor

XIIa
Xla
IXa
VIIIa
VIIa
Factor
Xa

Factor Va
Thrombin

3.4.21.38
3.4.21.27
3.4.21.22
3.4.21.21

Prekallikrein, factors VII and XI, C 1
Factors XII XI and IX
Factors X, VII and VIIIa
Factors X, IX and VII
Prothrombin, factors XII, X, VIII, V
and VIIIa, protein C
Fibrinogen, factors V, VII, VIII, XI
and XIII, protein C

Enzyme Type
Serine protease
Cofactor for prekallikrein,
kallikrein and factor XI
Serine protease
Serine protease
Serine protease
Cofactor for factor IXa
Serine protease
Cofactor for TF
Serine protease
Cofactor for factor Xa
Serine protease

Non-enzymatic glycoprotein
Fibrin, a 2plasmin inhibitor, fibronectin, Transglutaminase
von Willebrand factor, vitronectin,
actin, myosin, lipoprotein(a)
Fibrin, plasminogen
Serine protease
Plasminogen
Serine protease
Plasminogen
Serine protease

The proenzyme forms of these proteases have the same MW as the active enzymes, with the following exceptions: factor XI (MW
of 55,000), factor VIII and factor V (MW of 330,000), factor X (MW of 59,000), prothrombin (MW of 72,000), factor XIII (MW
of 320,000) and sc-uPA (MW of 54,000). Loscalzo and Schafer 1994, Bloom et al. 1994, High and Roberts 1995.
.........
\0
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Prothrombin, factors VII, IX, X, and the inhibitory proteins, namely protein C
and protein S require vitamin K for their synthesis (Stenflo et al. 1974, Nelsestuen et al.
1974). These are the vitamin K-dependent proteins and the requirement for vitamin K
stems from a characteristic string of 10-12 glutamic acid residues of these proteins in the
first 45 amino acids of their amino termini. Vitamin K is required for the carboxylation
of these residues to form dicarboxylic acid side chains ('Y-carboxyglutamic acid residues
or Gla domains) which are necessary for binding ca++ and assembly on membrane
surfaces in the presence of these ions. The carboxylation of these residues is catalyzed
by a membrane bound hepatic microsomal '}'-Carboxylase in the presence of reduced
vitamin K, as a post-translational step in the synthesis of these proteins.

2. Role of Serine Proteases and Cofactors in the
Hemostatic and Hemorrhagic Processes
Certain defects in the coagulation and fibrinolytic systems as well as other causes
can lead to development of thrombosis.

The pathophysiology of thrombosis in the

arterial system is quite different from that in the venous system and it is important that
they are recognized and understood for effective differential clinical management.
Arterial thrombosis is frequently associated with atherosclerosis (Davies et al.
1985). Thrombosis is initiated by disruption of atherosclerotic plaques which exposes
the subendothelium to the blood (Falk et al. 1983, Fuster et al. 1988, Davies et al. 1984,
1985).

This leads to activation of platelets and their aggregation, followed by

stabilization of this platelet aggregate by fibrin generated from the activation of the
coagulation cascade (Davies et al. 1986).

Therefore, the plug formed at the site of

atherosclerotic lesioning is a platelet-rich clot. This clot may remain attached to the site
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of injury and may grow to completely obstruct the blood vessel. Thrombogenic factors
involved in this kind of thrombosis are damage to the vessel wall exposure of TF and
connective tissue elements with subsequent activation of coagulation.

Treatment of

arterial thrombotic disorders include antiplatelet agents (to prevent further activation of
platelets which are the building block of arterial thrombi), anticoagulants (to inhibit the
coagulation cascade, highly controversial but with positive results -Resnekov et al. 1989,
Theroux et al. 1988) and thrombolytic therapy (to accelerate fibrinolysis, Cairns et al.
1989). When these non-invasive treatments fail to re-open an occluded vessel, invasive
procedures are employed such as endarterectomy, embolectomy, arterial bypass surgery
and angioplasty. More recently, to stabilize the vessels non-thrombogenic supporting
devices such as stents are also used.
There is always a low basal level (subclinical) of coagulation activation produced
even in normal subjects (Conway et al. 1987) but the activated coagulation factors are
normally cleared by flowing blood, or controlled by plasma inhibitors and inhibitors on
the surface of endothelial cells (Esmon et al. 1987). When blood coagulation exceeds
the anticoagulant system and the fibrinolytic system, thrombosis occurs, most frequently
in the large venous sinuses of the calf and in the deep vein valve cusps of the calf. The
thrombi formed in such locations are composed primarily of fibrin and red cells (no
platelets) (Frieman 1987). The thrombogenic factors involved are activation of blood
coagulation, venous stasis and vessel wall

damage.~.~~~!!y:ation ofbleed·-eoagulation
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occur as a result of disseminated malignant disease (Gordon et al. 1975) or even infusion
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of activated factor concentrates (Kingdon et al. 1979). Venous stasis (impediment in
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venous return) can be the result of immobility, increased venous pressure, venous
dilation, venous obstruction or increased blood viscosity (Leonard 1987). Vessel wall
damage may occur after surgical procedures or after trauma and results in the expression
of tissue factor activity which leads to activation of coagulation and thrombus formation.
Pharmacological treatment of venous thrombosis consists of thrombolytic and
anticoagulant therapy. The most common preventable cause of death in a hospital setting
is venous thromboembolism (Salzman et al, 1987), where a venous thrombus breaks off
to produce satellites which lodge in pulmonary vessels causing a variety of pathologic
effects which may lead to death if untreated. Prophylaxis of venous thromboembolism
consists of anticoagulants in conjunction with intermittent leg compression.
A hypercoagulable state can arise not only from the above clinical disorders, but
may also be a result of an inherited thrombotic disorder. These inherited disorders may
be deficiencies in protein C or protein S, antithrombin, plasminogen and fibrinogen.
Taking a closer look at the coagulation enzymes, it is evident that activation of certain
enzymes has a stronger impact than that of others. This point is illustrated best when
comparing the coagulation disorders arising from deficiencies or disorders in various
blood coagulation factors.

a. High Molecular Weight Kininogen (HMWK)
In the coagulation cascade, HMWK functions as a cofactor for prekallikrein,
kallikrein and factor XI. Prekallikrein and factor XI circulate in the blood as complexes
with HMWK (which mediates surface binding) while the presence of HMWK catalyzes
the activation of factor XII by kallikrein. Apart from its role in the coagulation cascade,

23
HMWK is also the precursor to the vasoactive peptide bradykinin, which results from
the proteolytic action of kallikrein on HMWK.

Deficiency in HMWK is a rare

autosomal recessive deficiency and the individuals characterized with this disorder do not
suffer from bleeding complications, despite markedly prolonged coagulation tests
(Cheung et al, 1993, Hayashi et al, 1990). No association between HMWK deficiency
and hypertension has been made.

b. Prekallikrein
Prekallikrein circulates in the blood as a complex with HMWK and is activated
to kallikrein by the action of factor XIIa (Bloom et al. 1994). Kallikrein then, in the
presence of HMWK further activates factor XII.

In addition, kallikrein also

proteolytically releases bradykinin from HMWK, directly activates C5 in the complement
system and activates pro-urokinase to urokinase in the fibrinolytic system.

Thus,

deficiency in this factor may be expected to be precipitate disorders associated with all
of these systems. However, individuals diagnosed with this deficiency appear to have
no bleeding diatheses, even though the APTT is prolonged, and although intrinsic
fibrinolytic activity is reduced, the association with thromboembolic complications is
questionable (Wuillemin et al. 1993, Hess et al. 1991, Castaman et al. 1990, Bouma et
al. 1986, Sollo and Sallem, 1985).

This deficiency is transmitted in an autosomal

recessive manner.

c. Factor XII
Factor XII is activated by kallikrein (Meier et al. 1977, Griffin et al. 1978,
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Fujikawa et al. 1980) and this conversion of factor XII to factor XIIa is accelerated by
HMWK and negatively charged surfaces or collagen (Ratnoff et al. 1966, Wilner et al.
1968). Factor XIIa functions to convert factor XI to factor Xla and prekallikrein to
kallikrein. In addition, factor XIIa can directly stimulate the complement system, by
activating C 1. As with deficiencies in HMWK or prekallikrein, deficiency in this factor
(Ratnoff et al. 1955) may be discovered in preoperative evaluations and is not associated
with a bleeding history nor with excess bleeding during surgical procedures. Factor XI's
coagulant function is not impaired even if its physiological activator (factor XIIa) is
absent. Patients lacking factor XII also have low plasminogen activity which, however,
is not associated with defective fibrinolysis.

d. Factor XI
Factor XI circulates in blood as a complex with HMWK, as does prekallikrein.
Factor Xla (resulting from the action of factor XIIa on factor XI, described above)
functions to catalyze the activation of factor IX to factor IXa (Bloom et al. 1994).
Deficiency in factor XI (Rosenthal et al. 1953) is inherited and is due to abnormalities
in the gene of this factor which may lead to heterozygote, compound heterozygote or
homozygote patients. Bleeding complications arise only after trauma and the severity of
these episodes varies proportionally with the deficiency in the factor.

However, low

levels of factor XI are not always associated with bleeding and this may be due to platelet
membrane factor XI-like activity or the interaction with factor VIia in the extrinsic
pathway which can also activate factor IX.

25

e. Factor IX
Factor IX is activated by either factor Xia (Fujikawa et al. 1974, DiScipio et al.
1978, Davie et al. 1987) or factor VIia/tissue factor complex (Osterud et al. 1977),
always in the presence of Ca++ while it is in solution (in contrast to the other vitamin
K dependent clotting factors which have to be bound to be activated). Both factors IX
and IXa bind on platelet surfaces or the surface of endothelial cells. This binding to cell
surfaces is enhanced by factors V, VIII and X and renders factor IXa about 3 times more
active than in solution. The activation of factor IX is slow compared to the rest of the
coagulation steps, which signifies its importance in the control of the coagulation
cascade. At the site of injury, factor IX is slowly activated which leads to inefficient
activation of factor X on cell surfaces. This activated factor Xa then leads to activation
of factor VII/tissue factor complex which then can further activate both factors IX and
X leading to "burst" of coagulant activity (Warn-Cramer et al. 1986).
Deficiency in factor IX is sex-linked recessive and may arise from defects in its
gene on chromosome X, such as point mutations, gene deletions, missense mutations and
gene insertions, and are the cause of the bleeding disorder termed Hemophilia B and
Christmas disease. Hemophilia B (Mandel et al. 1988) can also result from production
of normal levels of factor IX but defective post-translational factor IX protein processing
that may affect the ')'-carboxylation, EGF domain and function, zymogen activation,
substrate recognition and enzyme activity (Green et al. 1989). Hemophilia B patients
suffer from excessive bleeding in the form of easy bruising and frequent hematomas that
often spread after a few days and may become life-threatening.

Current treatment
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approaches include factor IX concentrates, fresh-frozen plasma or supernatant from
cryoprecipitates.

f. Factor VIII/von Willebrand Factor Complex
Although factor VIII is a cofactor and not a serine protease, it deserves attention
since deficiencies in this protein lead to Hemophilia A. The circulating form of this
cofactor is inactive and it is activated to factor Villa by thrombin or factor Xa (Pittman
et al. 1988). Factor VIII is an unstable protein when free in solution and it circulates as
a stable complex with von Willebrand factor (vWF), a completely different protein under
separate genetic control (Kaufman et al. 1988, Weiss et al. 1977, Brinkhaus et al. 1985,
Koedam et al. 1989). The two proteins have different physiologic functions as well:
vWF is essential for platelet adhesion to subendothelium, whereas factor VIila serves as
a cofactor for factor IXa to activate factor X. Whereas phospholipid surfaces serve to
anchor and concentrate factors IXa and X (enzyme and substrate respectively) factor
Villa binds to both previous factors, increasing the forward rate of catalysis of factor X
to Xa by factor IXa. Factor Villa is thus able to accelerate the activation of factor X by
factor IXa by 10,000 in the presence of Ca++ and phospholipids.
Hemophilia A is sex linked and is due to defects of the factor VIII gene located
on the X chromosome, such as deletions, insertions, base mutations, transitions and point
mutations (White et al. 1989, Antonarakis et al. 1988, Vehar et al. 1989, Gitschier et al.
1989). The bleeding abnormalities associated with factor VIII deficiency include joint
and muscle hemorrhages that lead to disabling long-term events, easy bruising and
prolonged post-operational bleeding. The platelet function is normal and therefore there
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is no excessive bleeding from minor cuts. Current clinical treatment strategies include
immobilization, compression, E-aminocaproic acid (EACA) which is an anti-fibrinolytic
agent and in more severe cases factor VIII or factor IX concentrates.

g. Tissue Factor
Tissue factor (TF) is a 30,000 integral membrane glycoprotein that serves as a
cofactor and is required for the activation of factor VII (Broze et al. 1985, Guha et al.
1986, Bach et al. 1986, Nemerson 1988). In addition to catalyzing the activation of
factor VII, TF also enhances the catalytic activity of factor VIia (Andree and Nemerson,
1995), since factor VIia alone has negligible coagulant activity. The crystal structure of
the TF /factor VIia has been recently reported (Banner et al. 1996).

While TF is

expressed on the surface of a variety of cell types, non of these cells are normally in
contact with blood. Basal coagulation levels are due to circulating factor VIia, which
corresponds to about 1 % of the total factor VII antigen. However, since blood is not
physiologically exposed to TF and free factor VIia has minimal activity, only low level
of coagulation is normally in effect and is readily counteracted by endogenous inhibitors
and the basal fibrinolytic system.
Other functions of TF are currently unknown, however various cells are believed
to have TF receptors.

Many of the post-surgical and post-interventional thrombotic

events are due to the release of TF. Increased levels of TF are associated with several
pathologic conditions such as cancer, sepsis and inflammation (Bloom et al. 1994).
Cellular necrosis also results in an increase of TF as the cells in the traumatized area lyse
and release endogenous cell surface-bound TF.

TF has been mapped by using
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immunohistochemical methods in various tissues, such as the brain, kidney, spleen, liver,
skin, gut, vessels, adrenal glands and peripheral nerves (Feleck et al. 1990). TF is
produced constitutively by cells that are normally separated from blood by the vascular
endothelium. It is present in the subendothelial sites and is only exposed after endothelial
damage.

TF is also produced in response to a host of stimuli, including endotoxin,

complement C5a, immune complexes, interleukin-I and tumor necrosis factor (Fleck et
al. 1990) in a variety of cells. In addition, TF is also generated under some pathological
conditions by monocytes, some tumor cells, foam cells of atherosclerotic lesions, smooth
muscle cells and their mesenchymal derivatives (Koyama et al. 1994, Takahashi et al.
1994, Adamson et al. 1994, Carty et al. 1990, Marmur et al. 1993, Muller et al. 1993,
Callander et al. 1992, Lockwood et al. 1991). No deficiencies in this factor have been
reported.

h. Factor VII
After factor VII has complexed with TF, it is most rapidly activated by factor Xa,
although factors Vila (auto-activation), IXa, Xlla and thrombin also activate this factor.
Factor Vlla/TF complex then activates factor X directly or via activation of factor IX to
IXa (Radcliffe et al. 1973, Jesty et al. 1974). A small amount of generated factor Xa
serves as feedback loop to activate factor VII to Vila, resulting in amplification of
extrinsically generated thrombin. Deficiency in factor VII is a rare autosomal recessive
disorder and results from point mutations or partial gene deletions and can lead to worse
bleeding than deficiency in factor IX (Ragni et al. 1981, Briet et al. 1987, Bernardi et
al. 1994, Chaing et al. 1994).

The clinical symptoms are variable and poorly
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understood, ranging from none (Ohiwa et al. 1994) to cerebral hemorrhage (Papa et al.
1994) to thromboembolism Martini et 1992, Mitropoulos et al. 1992).

Factor VII

deficiency is the only deficiency that results in prolongation of the PT with a normal
APTT. Therapy of factor VII deficient patients consists of factor IX concentrate or
plasma supplementation.

I.

Factor X
Factor X is a Ca++ dependent protein that interacts with acidic phospholipids.

Factor X and factor Xa bind to endothelial cells and are endocytosed. While factor Xa
is degraded by lysosomes, factor X reappears on the cell surface. The activation of
factor X to factor Xa is the point where the intrinsic and extrinsic pathways of
coagulation join, since it is activated by either factor VIIa/TF complex or by factor
IXa/factor VIIIa complex. Factor V is a cofactor necessary for the catalytic activity of
factor Xa and is activated to factor Va by thrombin. Factor Xa can then form a complex
with factor Va to form the prothrombinase complex, and this complex catalyzes the
conversion of prothrombin to active thrombin, which then in turn converts fibrinogen to
fibrin.
The concentration of factor V in plasma is lower than that of factor X (Nesheim
et al. 1981, Miletich et al. 1981) and without TF available (as under normal conditions)
only the VIIIa/IXa complex can catalyze the activation of factor X (Drake et al. 1989).
Thus, as in the PT assay, the supplementation of large exogenous TF, after complexation
with the basal factor VIIa, causes a direct activation of factor X that is then able to
saturate all of the available factor V. The generated factor Xa can then further catalyze
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the activation of factor VII, thus resulting in an amplified loop of the extrinsic pathway
of coagulation, leading to generation of massive amounts of thrombin with the end result
of formation of thrombi.
Factor X deficiency (Hougie et al. 1956) is an autosomal recessive trait resulting
from 4 point mutations to its gene (Watzke et al. 1990, Reddy et al. 1989). Treatment
regimens include fresh-frozen plasma or factor IX concentrate supplementation.

j. Factor XIII

Factor XIII is a transglutaminase that, once activated by thrombin to factor XIIIa,
it cross links fibrin

~trands,

thus making them more stable and less susceptible to

proteolytic digestion by plasmin. Factor XIII deficiency is a rare autosomal recessive
disorder that results in bleeding diathesis and delayed hemorrhages in soft tissues after
a primary plug is successfully formed. About fourteen different mutations have been
reported and most of them are due to point mutations (Mikkola et al. 1996).

k. Plasmin
Just as thrombin is the key enzyme in the coagulation cascade, plasmin is the key
enzyme in the fibrinolytic system.

Plasmin results from the two-step activation of

plasminogen, upon the action of plasmin and plasminogen activators (tissue type
plasminogen activator and urokinase type plasminogen activator). The activators cleave
the Arg561 -Val 562 bond which on the plasminogen molecule converts it Glu-plasmin (a less
active form of plasmin) and on the Lys-plasminogen molecule converts it to fully active
plasmin.

Plasmin cleaves the Lys77 -Lys78 bond, which on the plasminogen molecule
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converts it to Lys-plasminogen and on Glu-plasmin converts it to fully active plasmin.
Plasmin then acts on both fibrin and fibrinogen to produce degradation products, which
is the mechanism by which plasmin mediates clot dissolution (Bloom et al. 1994).
Genetic variations in the plasminogen molecule are present in the normal population and
they are not associated with pathologic states.

However, mutation resulting in

dysfunctional plasminogen, associated with thromboembolic complications, have been
isolated in Japanese populations and in one European Jewish patient (Robbins 1992).

I. Tissue Type Plasminogen Activator (tPA)

tPA is a serine, protease of the fibrinolytic system (Pennica et al. 1983). tPA is
a relatively insignificant enzyme when not bound to fibrin, but after binding to fibrin it
is able to activate plasminogen to plasmin (Hoylaerts et al. 1982). Plasmin (also a serine
protease) then can degrade fibrin, thus exposing new tPA binding sites on the underlying
fibrin (Higgins et al. 1987). In addition to binding to fibrin, tPA also binds to receptors
on endothelial cells as does plasminogen which may provide focal points for plasmin
generation.

An association between the contact system and the stimulation of the

fibrinolytic system is made at this point: bradykinin, resulting from the action of
kallikrein on HMWK, directly stimulates the release of tPA from endothelial cells
(Tranquille et al. 1989), so that when intrinsic activation of the coagulation cascade
occurs, the fibrinolytic system is also activated.

Furthermore, thrombin is the most

potent inducer of secretion of tissue-type plasminogen activator (tPA) from endothelial
cells (Mosher 1990).
Although no reports on mutant tPA production have been made, reduced tPA

32
production or decreased release of tPA may contribute to thrombosis in about 10-20 %
of patients with deep vein thrombosis who have an inadequate fibrinolytic response
(Juhan-Vague et al. 1987). However, there is little evidence to support this hypothesis
and the current thinking is that reduction of available tPA is mostly due to increased
complexation with plasminogen activator inhibitors, secondary to increase in plasminogen
activator inhibitors.

m. Urokinase Type Plasminogen Activator (uPA)
Single-chain urokinase type plasminogen activator (sc-uPA) acts on plasminogen
to convert it to plasmin-Lijnen et al, 1987). Plasmin then converts sc-uPA to a two chain
derivative (tc-uPA, Lijnen et al. 1987). This tc-uPA further cleaves plasminogen to
plasmin. The difference between tc-uPA and sc-uPA is that the former accelerates the
conversion of plasminogen to plasmin without being specific towards fibrin while sc-uPA
is specific towards fibrin (Lijnen et al. 1986). An additional association between the
contact system and the fibrinolytic system is made at this level: kallikrein can directly
mediate the conversion of sc-uPA to tc-UPA, so that intrinsic activation of coagulation
also precipitates fibrinolytic activation (Bloom et al. 1994).

3. Regulation of Serine Proteases by Serpins

Blood coagulation is controlled by many physiologic inhibitors, called serpins
(serine Q.rotease inhibitors). Among these are protein C and protein S, antithrombin
(antithrombin-III), Heparin Cofactor II, C1inactivator (C 1esterase inhibitor), a 2plasmin
inhibitor (a 2antiplasmin), a 1proteinase inhibitor (a 1antitrypsin) and a 2macroglobulin.
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Some of the characteristics of these inhibitors are listed in Table 2.

Acquired and

congenital deficiency of these factors predisposes to thrombotic or bleeding diseases.

a. Antithrombin
Thrombin is inactivated by a class of serpins called antithrombins. The most
significant of these inhibitors is antithrombin (also referred to as antithrombin III) which
inactivates heparin bound thrombin faster than free thrombin (Pomerantz and Owen 1978,
Griffith 1982, Nesheim 1983). The activity of antithrombin is catalyzed by the presence
of heparin which acts as a cofactor by binding to antithrombin to form a non-covalent
ternary complex.

Ad~itional

actions of antithrombin include inhibition of factors IXa,

Xa, Xla, XIIa, kallikrein and plasmin.
I

Deficiency in antithrombin, congenital heterozygous or acquired, leads to
thrombotic episodes when the hemostatic system is stressed. Hereditary deficiencies of
antithrombin include quantitative and qualitative abnormalities and their classification is
controversial at present, although many of them have been molecularly analyzed and over
50 point mutations have been reported (Lane et al. 1993). Treatment of patients with

thromboembolic disorders due to deficiency in antithrombin consists of replacing the
levels with antithrombin concentrates and heparin.

b. Heparin Cofactor II
Thrombin is also inactivated by heparin cofactor II (HC-II). HC-II is present in
plasma at concentrations approximately half of antithrombin.

HC-II has a similar

mechanism of action to that of antithrombin in that its action is catalyzed in the presence

Table 2 -- Characteristics of Inhibitors of Procoagulant and Pro-fibrinolytic Proteins
MW

Plasma Level

Natural Targets

Antithrombin

58,000

2.6µM

Thrombin, factors IXa, Xa, Xia and Xlla, kallikrein, plasmin

HC-11

66,000

0.09 µM

Thrombin

TFPI

33,000

3.5 nM

Factor Vlla/TF and factor Xa

APC

62,000

0.08 µM

Factor Va and VIiia, PAI-1 (enzyme commission# 3.4.21.69)

Factor V

330,000

0.03 µM

cofactor for APC

Protein S

75,000

0.33 µM

cofactor for APC, factor Va, factor Xa

a 2plasmin inhibitor

65,000

0.6-1.2 µM

Plasmin, thrombin, kallikrein, tPA, uPA, trypsin, chymotrypsin

PAI-1

52,000

0.4 µM

APC, tPA, uPA

PAl-2

47,000

<0.001 µM

uPA, tPA, plasmin

PCI

57,000

0.06-0.12 µM

Thrombin, factors Xa and Xia, kallikrein, trypsin, tPA, uPA, APC

PN-1

50,000

0

Thrombin, factor Xa, trypsin, kallikrein, tPA, uPA, plasmin

a 2macroglobulin

845,000

22-50 µM

Thrombin, factor Xa, kallikrein, plasmin, tPA, trypsin, elastase,
collagenase, cathepsin C, APC

a 1proteinase

104,000

13-31 µM

Thrombin, kallikrein, factors Xa, Xia, trypsin, plasmin, elastase,
cathepsin G, APC

725,000

0.25 µM

Factor Xia, complement system

inhibitor

cl inactivator

Loscalzo and Schafer 1994, Bloom et al. 1994, High and Roberts 1995.2
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of heparin (Blinder et al. 1988). The physiologic role of antithrombin and HC-II differ
in that HC-II is a specific inhibitor of thrombin without reacting with other serine
proteases, while in contrast to antithrombin, it can slowly inactivate chymotrypsin-like
proteases (Parker et al. 1985, Church et al. 1985). Only two deficiencies of this cofactor
have been molecularly analyzed, HCII Oslo (Blinder et al. 1989) which is asymptomatic
and HCII Awaji (Kondo et al. 1996) which is associated with coronary artery disease
(Matsuo et al. 1992).

c. Tissue Factor Pathway Inhibitor
Tissue factor pathway inhibitor (TFPI) , also known as extrinsic pathway inhibitor
(EPI) or lipoprotein associated coagulation inhibitor (LACI), is present in plasma in
different molecular forms which are primarily determined by its association with
circulating lipoproteins. TFPI is a Kunitz-type protease inhibitor (Wun et al. 1988,
Girard et al. 1989). One domain of this protease binds to the factor VIIa/TF complex
while another binds to factor Xa, thus blocking both the extrinsic pathway leading to
thrombin formation and the amplification of the same pathway by factor Xa (Broze et al.
1988, Hjort et al. 1957). Therefore, while antithrombin controls the final stage of
coagulation, TFPI regulates the activation of coagulation (Abildgaard 1995). TFPI is
present in the plasma at ng/ml concentrations (Warr et al, 1989).

The vascular

endothelium secretes TFPI in culture (Broze et al. 1987, Warr et al. 1989) but the stimuli
that lead to release or increase in plasma TFPI are not well defined and neither is their
mechanism of action. It is known that intravenous and subcutaneous heparin as well as
low molecular weight heparins, acidic glycosaminoglycans and their synthetic analogues,
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cause the release of TFPI bound to the luminal surface of the vascular endothelium
(Sandset et al. 1988, Fareed et al. 1994, Hoppensteadt et al. 1995, Samama et al. 1994,
Jeske et al. 1995). Recently, there has been a proposal of a heparin-recognition site on
the TFPI molecule, but further studies are needed to support this model (Harenberg et
al. 1995).

d. Protein C
Protein C and protein S are vitamin K dependent proteins produced in the liver.
Protein C is slowly activated by free thrombin to activated protein C (APC), but when
thrombin is bound to its endothelial receptor, thrombomodulin, the activation of protein

<2 is catalyzed (Esmon et al. 1989). The function of APC is to inactivate factors Va and
VIiia (the two cofactors of the coagulation system) via proteolysis. Factor Va bound to
factor Xa is protected from protein Ca inactivation, as is factor VIiia bound to factor IXa
(Walker et al. 1987, Bertina et al. 1984, Rick et al. 1988). However, when factor Va
is bound to the endothelial surface it catalyzes the activation of protein C (Maruyama et
al. 1984).
Another function of APC is to complex with plasminogen activator inhibitor 3
(PAl-3), also referred to as protein C inhibitor (PCI), which renders both proteins
inactive (De Fouw et al. 1987). While PAl-3 is the major APC inhibitor, plasminogen
activator inhibitor 1 (P Al-1) also inhibits APC.

Other inactivators of APC include

a 2macroglobulin and a 1proteinase inhibitor (a 1antitrypsin).

Acquired and congenital deficiencies of APC have been reported to cause
thrombotic syndromes such as DVT, microangiopathy and necrosis due to a deficit of
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protein C or its production (Griffin et al. 1981, Broekmans et al. 1983). At least 55
different mutations of protein C have been discovered and they are transmitted as
autosomal dominant traits (Gandrille et al. 1995). These mutations result in variable
degrees of plasma protein C levels and the individuals with these mutations may be
asymptomatic or they may develop thrombotic episodes such as purpura fulminans, skin
necrosis and disseminated intravascular coagulation (Gandrille et al. 1995).

e. Protein S
APC is potentiated by protein S, which is a cofactor synthesized and secreted in
the liver and endothelial cells.

In addition, protein S is capable of independently

inactivating factor Va (Heeb et al. 1993) and factor VIIIa (Heeb et al. 1994). Its activity
is regulated by the C4b-binding protein, which forms an inactive complex with proteins
S. Familial protein S deficiency is associated with recurrent venous thrombosis (Comp
and Esmon, 1984, Schwartz et al. 1984) and with arterial thrombosis (Girolami et al.
1989, Allaart et al. 1990).

f. Factor V
Another essential cofactor for the activity of APC is factor V in its native
proenzyme form. Thus, while the active form of factor V serves as a cofactor for factor
Xa to mediate procoagulant activities, factor V is a cofactor for APC that mediates the
inactivation of factor Va (and VIIIa). More recently, a new syndrome known as APC
resistance has been identified and is claimed to be the most common cause of inherited
venous thrombosis (Svensson and Dahlback 1994). Most of the individuals exhibiting
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APC resistance possess a point mutation of factor V represented by a substitution of
Arg 506 with Gln (Factor V Leiden). In contrast to the normal factor V molecule, the
mutant form does not retain its regulatory function as a cofactor in the mediation of
APC's effects in the inactivation of factor Va and factor VIIIa. In addition, the mutant
form of factor V is activatable by thrombin to factor Va and it retains its procoagulant
activity as a cofactor for factor Xa. Furthermore, the mutant form of factor Va is nonsusceptible to the digestive action of APC. Another recently characterized factor V
mutation resulting in factor V deficiency has been characterized, in which a missense
mutation of Ala221 -to-Val occurs (Factor VNew Brunswick, Murray et al. 1995).

g,___g_2Plasmin Inhibitor

Free plasmin is rapidly inactivated by a 2plasmin inhibitor (or a 2antiplasmin),
another serpin (Collen et al. 1986, Wiman et al. 1978). When plasmin is bound to
fibrin, the binding sites for a 2plasmin inhibitor on plasmin are occupied so that
inactivation is slow (Wiman et al. 1978).

a 2plasmin inhibitor also inhibits tPA.

Aprotinin is a synthetic inactivator of plasmin, approved in 1995 by the U.S. FDA for
clinical usage during cardiac bypass surgery.
Additional plasmin inhibitors include plasminogen activator inhibitor 1, protease
nexin 1, a 2macroglobulin, a 1proteinase inhibitor and C1inactivator.
h. Plasminogen Activator Inhibitors
Plasminogen activator inhibitor 1 (PAI-1) is the primary inhibitor of tPA and uPA
in plasma (Lawrence et al. 1989, Pannekoek et al. 1986, Kruithof et al. 1984). In
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addition, PAI-1 inhibits plasmin, thrombin and APC. The major source of PAI-1 is
vascular smooth muscle cells and it is also released from activated platelet ex granules.
In endotoxemia and other pathological disorders endothelial cells are the major site of
PAI-1 synthesis.
Plasminogen activator inhibitor 2 (PAI-2), or placental PAI, is produced by the
placenta and is significantly increased during pregnancy. PAI-2 inhibits tc-uPA and tPA,
but the physiological function of this inhibitor is unknown.
Plasminogen activator inhibitor 3 (PAI-3) or protein C inhibitor (PCI), is
synthesized in the liver and inactivates several serine proteases including APC, kallikrein,
thrombin, factors Xa and Xla, uPA and tPA. PCI is the major inhibitor of APC.

C. Thrombin: Structure, Function, Physiologic,
Pathologic and Pharmacologic Mechanisms
1. Biology of Thrombin Formation and Structure of the Thrombin Molecule

Negatively charged phospholipids such as on the surface of activated platelets promote
factor activation leading to thrombin formation. More specifically, thrombin is formed
by the proteolytic cleavage of prothrombin by the prothrombinase complex, which is the
complex of factor Xa, Va, ca++ and phospholipids, that cleaves prothrombin twice
(Suttie et al. 1977). It is the amino terminal prothrombin fragment that results in active
ex

thrombin (Magnusson et al. 1975) and in contrast to most activated serine proteases,

thrombin loses most of its activation peptide which forms the small A chain of the
molecule (Dodt et al. 1990). A diagrammatic representation of the tertiary conformation
of the thrombin molecule (Fenton et al. 1988) is depicted in Fig. 2.
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CHO

FIBRINOPEPTIDE
GROOVE

'-----APOLAR BINDING SITE

Fig. 2. Three dimensional model of human a-thrombin (Fenton 1988). Among other
important structural features, the proteolytic cleavage sites fi and "Y (autoproteolytic
digestion or trypsin), E (elastase), ~ (chymotrypsin or cathepsin G) are depicted near the
anion-binding site.
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a thrombin is different from the other serine proteases in its mode of proteolytic

action: this protein possesses three important exosites adjacent to its catalytic site which
serve to align protein substrates and inhibitors optimally. The human thrombin molecule
is composed of two chains, A (36 residues) and B (259 residues), linked together by a
single disulfide bridge. The function of the A chain remains unknown although it may
be implicated in conformational stability of the protein. From crystallographic (Bode et
al. 1989) and computer-generated models (Fenton et al. 1986, Bing et al. 1981, Furie
et al. 1982) of the thrombin molecule, the structure and nature of the molecule has been
characterized. The B chain of thrombin assumes a round conformation with a substrate
groove resembling a deep narrow canyon. The catalytic site of thrombin, composed of
the catalytic triad His-57, Asp-102, Ser-195, lies in the center of the global mass, in the
groove. When fibrinogen fits into this groove and it is cleaved at the catalytic site of
thrombin, the right half of the groove is occupied by fibrin (fibrin groove, carboxy
terminus of fibrinogen) while the left half is occupied by the fibrinopeptide
(fibrinopeptide groove, amino terminus of fibrinogen). The interior of the groove is
composed of apolar residues and lined on the exterior with charged groups (Fenton
1986).

The region above the catalytic site is also very hydrophobic.

The site of

fibrinopeptide groove next to the catalytic site is notably hydrophobic and forms the
apolar binding site of thrombin (Berliner et al. 1977, Sonder et al. 1984).

On the

opposite site of the catalytic site across from the apolar binding site is the anion binding
exosite I, which is composed of a long peptide segment rich in arginines and lysines
(Fenton et al. 1986). This cluster of positively charged residues is involved in fibrinogen
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recognition and hirudin complexation (Fenton et al. 1988). ex thrombin possesses another
anion binding exosite II which seems to play a synergistic role with the anion binding
exosite I in the binding of heparin (Church et al. 1989). This second anion binding
exosite is located above the catalytic groove. Thrombin also has a single carbohydrate
attachment for carboxylation but no known function has been yet attributed to this moiety
(Horne et al. 1984).

Another domain of ambiguous importance is the Arg-Gly-Asp

sequence which may be involved in thrombin receptor recognition under certain
circumstances.
Differences between the bovine and the human thrombin molecule are distinct in
structure and lead to functional differences. The structural differences were delineated
with electron spin resonance and fluorescence studies (Nienaber and Berliner, 1991).
These studies revealed that the active site region of the bovine molecule is more apolar
but more accessible.

Furthermore, a hydrophobic insertion loop penetrates and thus

obstructs the human thrombin active site. This is not observed with the bovine molecule
and this difference accounts for the inability of aprotinin to inhibit the human form but
not the bovine variant. Deletion of this insertion loop in the human thrombin resulted
in the mutant des-PPW thrombin, which remains a specific serine protease but is
sensitive to aprotinin, indicating that other structural factors are also involved in the
narrow specificity of thrombin (Le Bonniec et al. 1993). The apolar binding site on the
human and bovine ex thrombin molecules also differs, as does the 'Y cleavage site that
converts human ex thrombin to 'Y thrombin (Nienaber and Berliner, 1991). In the bovine

ex thrombin, the 'Y cleavage site does not exist and therefore 'Y bovine thrombin cannot
be formed (Fenton and Bing, 1986).
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2. Molecular Variants of Thrombin
Human a thrombin degrades either auto-proteolytically (slowly) or via the action
of trypsin (rapidly) to 6 and then to 'Y thrombin with loss of its clotting activity (Fenton
et al. 1977, a and b). The cleavage sites for formation of both thrombins lie in the anion
binding exosite I (fibrinogen recognition site, Fenton 1986, Fenton 1988). Since trypsin
does not normally circulate in the bloodstream and since autoproteolytic cleavage is slow,
these forms of thrombin (6 and 'Y) are not found in vivo (Fenton and Bing, 1986). Since
bovine thrombin lacks the 'Y cleavage site, only 6 bovine thrombin can be formed (Fenton
and Bing, 1986). Leukocyte elastase and cathepsin G cleave human a thrombin at sites
before the 'Y site to yield

E

and

r thrombin respectively (Brower et al. 1987' Brezniak et

I

al. 1990).

The elastase-mediated conversion is enhanced by heparin and occurs at

physiologically relevant concentrations, so that E form may occur in vivo to mediate nonclotting thrombin activities (Fenton and Bing, 1986). !: thrombin retains about 85 % of
the a thrombin clotting activity (Brezniak et al. 1990).

Except for !: thrombin, the

previous forms that result from the a form after proteolytic cleavage, have no clotting
activity but retain high amidolytic and esterolytic activities (Fenton and Bing, 1986).

3. Thrombin Standardization
Highly purified preparations of human a thrombin are prepared by the same
procedure (Fenton et al. 1977) and supplied from the same source around the world for
standardization purposes.

However, the first standardization of human thrombin was

attempted in 1942 (Seegers and Smith, 1942), with the definition of the Iowa Unit as the
amount of thrombin that clots 1 ml of standardized fibrinogen solution (bovine plasma

44
based) in 15 sec at 28°C. The Division of Biologics Control, National Institutes of
Health, U.S. Public Health Service issued specifications for commercial thrombin
preparations in 1946, attempting to define the NIH unit equal to the Iowa unit. The two
units are not equal and 1 NIH unit equals about 1.25 Iowa units. Both of these units are
based on the clotting activity of thrombin. The NIH standard thrombin is also referred
to as the US standard. In 1975, the Expert Committee on Biological Standardization of
the World Health Organisation established an International Standard for thrombin, which
is used to define the thrombin International Unit (IU, Gaffney and Edgell, 1995).
Another International Standard for thrombin was established in 1991. Although the IU
was originally defined to approximate the NIH unit, 1 NIH unit equals 1.15 IU (Gaffney
and Edgell, 1995). Currently, both units are used in the literature and the reagent and
pharmaceutical grade products are standardized in terms of NIH units.

4. Physiologic Regulation of Thrombin Formation

Thrombin has a unique mechanism of regulation of its generation from
prothrombin. As mentioned above, thrombin is generated from prothrombin by the
double proteolytic activity of factor Xa in the prothrombinase complex. The activated
thrombin can then activate factors V and VIII to amplify its generation to a burst of
coagulant activity (Mosesson et al. 1990 a, b). These steps are the targets of the natural
antithrombins (antithrombin and HC-II). Thrombin down-regulates its own activity by
binding to thrombomodulin, which results in loss of thrombin's ability to convert
fibrinogen to fibrin. Furthermore, thrombomodulin bound thrombin activates protein C,
which then can degrade factors V and VIII with protein S as a cofactor, thus blocking
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the generation of thrombin (Esmon et al. 1987).

5. Cellular Interactions of Thrombin

In addition to proteolytic activities, thrombin exhibits several non-enzymatic or
hormonal activities.

Thrombin activates platelets and other factors to promote

hemostasis. In vitro, thrombin addition to platelets causes phosphatidyl inositol (Pl)
hydrolysis, eicosanoid formation, protein phosphorylation, increase in cytosolic free
ca++, change in their shape, granule secretion and fibrinogen receptor expression.
Thrombin also suppresses cAMP synthesis and has other effects as well, such as on
endothelial

cells

(stimulation of PGl2

formation,

proliferation,

angiogenesis,

neovascularization), fibroblasts (production of cAMP, proliferation, chemotaxis), and
vascular smooth muscle cells, all of which may be implicated in platelet activation, for
example PGI 2 inhibits platelet activation by stimulating cAMP synthesis. Other hormonal
activities of thrombin include monocyte (Bar-Shavit et al. 1983) and neutrophil
chemotaxis and aggregation (Bizios et al. 1984), mitogenesis in certain macrophage-like
cells (Bar-Shavit et al. 1983), albumin transport across endothelial cell monolayers
(Malik et al. 1986) and inhibition of neurite outgrowth (Gurwitz et al. 1988, Hawkins
et al. 1986).

6. Thrombin Receptors

Thrombin activates a variety of receptors. It interacts with a specific high affinity
receptor on platelets to cleave the amino terminus thus exposing a tethered ligand which
activates the receptor (Vu et al. 1991). This receptor is linked to an inhibitory G protein
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and activation of it results to inhibition of adenylate cyclase and decrease in cAMP
(Seiler et al. 1992). The same receptor also regulates the Na+/H+ exchange in platelets
during stimulation with thrombin. This receptor is thought to be linked through another
G protein to phospholipase A2 which may be the main source of arachidonate production
(Siess et al 1984, Silk et al. 1989, Kajiyama et al. 1989). Thrombin also interacts with
a lower affinity receptor on the platelets, but this one is thought to be linked through a
G protein to phospholipase C and protein kinase C (McGowan et al. 1986). Activation
of this receptor could be the source of the thrombin-induced elevations in cytoplasmic
Ca++ levels.
Cultured fibroblasts also have a high affinity thrombin receptor, activation of
I

which leads to increase in cAMP (Carney et al. 1978, 1984, 1992), which is identical
to the high affinity receptor found on platelets. The same thrombin receptor is also
expressed by endothelial cells, smooth muscle cells and lymphocytes (Brass 1995).
Thrombomodulin is the thrombin specific receptor found on endothelial cells (Awbrey
et al. 1979). This receptor recognizes the fibrinogen recognition site on thrombin which
is independent of its catalytic site (Hofsteenge et al. 1986). There appear to be over 1
million low affinity receptors with a kd of about 30 nM, on the endothelial cells (Isaacs
et al. 1981, Bauer et al. 1983).

D. Pharmacologic Control of Thrombin's Action.

Understanding the mechanisms through which thrombin mediates its various
activities, as well as knowing the structural requirements for these actions, provides the
basis of the strategies for the modulation of thrombin's action. Thrombin mediated
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effects can thus be controlled at four different levels: (1) blockade of the thrombin
receptors, (2) physiological antagonism of the effects mediated by thrombin, (3)
inhibition of the generation of thrombin and (4) direct inhibition of formed thrombin.

1. Inhibition of Thrombin Receptors
Thrombin has multiple receptors in a variety of tissues. Some of these receptors
have been characterized and studied extensively, but most remain insufficiently
characterized.

The obvious thrombin receptor targets is the newly cloned thrombin

receptor found on platelets and endothelial cells (Vu et al, 1991). Effective antagonists
of the cloned thrombin receptor are currently under investigation. Aplysillin A (1,4-DPhe-1,3-butadiene disulfate ester) is a compound isolated from a deep water sponge, with
a reported IC 50 for binding to the thrombin receptor of 20 µM (Gulavita et al. 1995).
Another thrombin receptor inhibitor, Cl86-65 (3-mercapto-propionyl-Phe-Cha-Cha-ArgLys-Pro-Asn-Asp-Lys-amide), has been recently reported to be effective in inhibiting
vascular smooth muscle relaxation and platelet aggregation, phospolipase A2 and the
Na+/H+ exchange, all mediated through the thrombinreceptor (Tesfamariam 1994, Seilet
et al. 1995). A phage selection technique has also resulted in the isolation of a thrombin
receptor inhibitor that was effective in antagonizing platelet aggregation, serotonin release
and tyrosine phosphorylation (Doorbar and Winter 1994). The clinical potential of these
thrombin receptor inhibitors is unknown.

2. Inhibition of Cellular Processes Mediated by Thrombin
Targeting of the cellular processes mediated by thrombin provide an alternative
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mode of pharmacological control of the actions of thrombin.

This approach is

complicated by the fact that thrombin mediates a spectrum of cellular processes ranging
from platelet activation to stimulation of proliferation of various cell types. An agent
that has such effects and is being used clinically is defibrotide. The exact modes of
action and the full pharmacologic potential of this agent is currently being explored
(Ulutin et al. 1988).

This agent is different from the usual antithrombotic and

anticoagulants in that it is a functional antagonist of thrombogenesis and not necessarily
a direct antithrombin.

This approach of pharmacological management of thrombin

becomes even more complicated when considering the effects of thrombin on platelets
and whether thrombin is the main activator of platelets or other activators play an equally
I

important role.

If thrombin is indeed the most important activator of platelets as

suggested by Badimon et al. (1990), then single thrombin targeting would be an efficient
method for controlling arterial thrombosis (in which platelet activation is the key event).
However, this has not been proven and management of platelet activation with antiplatelet
agents such as cyclooxygenase inhibitors are still widely used with success. On the other
hand, Cadroy et al. (1989) have indicated with their work that thrombus formation is a
complex situation where inhibition of platelets and coagulation pathways may be required
for optimal management of thrombosis.

3. Inhibition of Thrombin Generation
Inhibition of the formation of thrombin may prove to be more effective in
prevention and management of thrombotic disorders than direct inhibition of thrombin
after it has formed. The issue of whether monospecific targeting of thrombin is the most
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effective method for controlling thrombogenesis is a controversial one, and inhibition of
other proteases contributing to the generation of thrombin is under study. By inhibiting
the formation of thrombin, the hormone-like effects that it mediates may also be
prevented and complications may be avoided. In inhibiting the formation of thrombin,
the target sites should be the serine proteases that lead to this event. The candidates for
this type of targeting would be factor VIIa and/or TF and factors IXa, VIIIa, Xa and Va.
Considerable interest has been shown in the role of TFPI and in animal models
of DIC it has been found to be effective (Rapaport et al. 1985, 1989), but the clinical
usefulness of this recombinantly produced agent is not established. Recently, a report
of selective factor VIIa/TF inhibitors, derived from mutagenesis of the inhibitor of the
Alzheimer's amyloid fl-protein precursor, demonstrated that one of these proteins is
specific for factor VIIa/TF or factor VIIa, with no activity against thrombin, factors Xa
and Xla and kallikrein, but with some activity against plasmin (Lazarus et al. 1995).
These inhibitors exhibit promising anticoagulant effects, but their in vivo effects have not
been published (Refino et al. 1995, Kirchhofer et al. 1995). The same group has used
alanine-scan mutagenesis to develop a specific factor VIIa inhibitor that resembles TF.
This inhibitor inhibits selectively the extrinsic pathway (Kelley et al. 1995) but in vivo
studies are not complete.

An anti-rabbit TF antibody has been recently developed

(Himber et al. 1996) and was found to produce stringer in vivo antithrombotic effects
than heparin in a rabbit model of arterial thrombosis.
The same group that isolated the factor VIIa/TF inhibitors based on the inhibitor
of the Alzheimer's amyloid fl-protein precursor, also isolated during these studies an
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inhibitor of kallikrein, which also has weaker activities against factor Xia (Lazarus et al.
1995). This compound is also comparable to the factor VIIa/TF inhibitors in terms of
anticoagulant effects (Refino et al. 1995, Kirchhofer et al. 1995).
Although APC has been synthesized by recombinant technology, only the purified
product from human plasma has been used clinically in individual case studies of patients
with inherited protein C deficiency (Alhenc-Gelas et al. 1995, De Stefano et al. 1993)
or patients with purpura fulminans in meningococcemia (Rivad et al. 1995).

An

alternative approach resulting in activation of endogenous protein C has been reported
(Gibbs et al. 1995): a thrombin mutant (E229K) has been developed which has lost its
fibrinogen-cleaving ability but has retained its thrombomodulin-dependent activating
I

capability for protein C.

This compound produces dose-dependent and reversible

anticoagulant effects in Cynomolgus monkeys.

Based on the same principle of

developing a thrombin mutant which lacks its procoagulant activity while retaining its
protein C activating capabilities, a series of thrombin mutant molecules have been
constructed where the insertion loop that obstructs the catalytic site and the Na+ binding
site on thrombin have been mutated (Guinto et al. 1995). The in vivo effects of these
mutants remain to be examined.
Focusing on the role of APC in the coagulation system, another approach reported
recently was the design of a protein C mutant which can be activated by factor Xa,
instead of thrombin (Friedrich et al. 1996). This factor Xa activatable protein C mutant
was found to produce in vitro anticoagulant effects but the potential of this agent is
unclear at this time.
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Beside the direct inhibition of thrombin, an additional approach to develop new
antithrombotic agents is the inhibition of factor Xa. It is known for some time that low
molecular weight high antithrombin affinity heparin fractions, upon complexing with
antithrombin, produce selective inhibition of factor Xa (Barrowcliffe et al. 1986). Based
on this, a synthetic heparin pentasaccharide has been developed. This pentasaccharide
represents an indirect factor Xa inhibitor requiring the presence of plasmatic antithrombin
for its biological effects. Many different structural analogues of this pentasaccharide with
varying anti-Xa potency have been developed. This pentasaccharide is currently in phase
II clinical trials for the post hip replacement prophylaxis (personal communication). It
is also interesting to note that pentasaccharide also inhibits thrombi generation and almost
I

has no effects on formed thrombin (Lormeau and Herault 1993).
The direct factor Xa inhibitors include both the recombinant and synthetic agents.
Recombinant tick anticoagulant peptide (TAP) represents an anticoagulant principle which
was first isolated from the soft tick Ornithodoros moubata.

This 60 amino acid

containing peptide exhibits reversible tight binding to factor Xa (Vlasuk et al. 1991). It
has also been shown to exhibit varying degrees of antithrombotic actions in different
animal models. Despite its safety and low immunogenicity, this agent is not developed
clinically until now.
Another recombinant anti-Xa agent is antistatin, which represents a 15 ,000 peptide
isolated from the mexican leech Hirudo officinalis (Dunwiddie et al. 1989). This peptide
is found to be active in various animal models of thrombosis (Schaffer et al 1991).
However, in contrast to TAP, it is strongly immunogenic and thus, its development is
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carried out only in preclinical stages.
Novel factor Xa inhibitors from the saliva of the medicinal leech Hirudo

medicinalis have also been reported (Righi et al. 1995). These inhibitors share 503
homology and have similar patterns of inhibition, which include in addition to factor Xa,
chymotrypsin and trypsin.

However, apart from these enzymes, these inhibitors are

selective for factor Xa.
The synthetic anti-Xa agents include both the peptidic and peptidomimetic agents.
A series of orally active highly specific factor Xa inhibitors have been reported (Ostrem
et al. 1995). These include the series of compounds referred to as SEL followed by a
number which inhibit the free and prothrombinase factor Xa. These compounds are of
I

a low molecular weight (550-750). One of these agents has been found to be a selective
factor Xa inhibitor with lesser activities towards thrombin, plasmin and APC. While the
antithrombotic effects and the pharmacokinetics of this agent are species-dependent, this
agent exhibits oral and S.C. bioavailability.
Another peptidomimetic factor Xa inhibitor, DX 9065A, is a bis-amidino
derivative with relatively specific anti-Xa activities (Hara et al. 1994, Yamazaki et al.
1994). After I.V. and oral administration, this compound prolonged the global clotting
assays and did not exhibit any antithrombin activity. In animal models of thrombosis and
DIC, this agent produced dose-dependent antithrombotic effects.
In contrast to thrombin inhibitors, the factor Xa inhibitors are claimed to exhibit
much lesser bleeding effects. Furthermore, these agents are also reported to be superior
inhibitors of thrombin generation (Prasa et al. 1996).
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A novel broad-spectrum serine protease inhibitor has been isolated from

Eschericia coli, ecotin (Lauwereys et al. 1993). Notably, the inhibitory constant of this
agent for factor Xa is in the pM range. While ecotin inhibits chymotrypsin, elastase,
kallikrein, factor XIIa and Xia, it has no activities against APC, tPA and uPA. This
compound has been shown to be an effective dose-dependent antithrombotic agent in a
rat model of chemically induced arterial thrombosis.
Aprotinin is a broad-spectrum protease inhibitor that has been approved by the
U.S. FDA for clinical use as an anti-fibrinolytic drug during cardiac surgery.

The

primary structure of aprotinin is depicted in Fig. 3, lower panel. Based on the structure
of aprotinin, a series of mutants have been synthesized that have inhibitory activities
I

against coagulation enzymes in the nM range (Stassen et al. 1995). One of these mutants
was coupled to PEG to optimize biological half life, without affecting its inhibitory
activities. These aprotinin mutants were shown to inhibit factors Xia, Xa and TF/VIIa,
as well as plasmin, trypsin and kallikrein.

However, they possessed no detectable

activity against thrombin, uPA and APC.

4. Inhibition of Formed Thrombin
The most direct method of controlling the actions mediated by thrombin is by
inhibiting this enzyme directly. The thrombin inhibitors described earlier above are all
designed or selected for this direct approach in controlling thrombin. Understanding the
structure-activity relationship of thrombin is very important in this approach since
inhibitors of different epitopes of the thrombin molecule result in differential management
of thrombin's spectrum of activity (eg. although the anion-binding exosite of thrombin
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1
10
HV-1 Val-Val-Tyr-Thr-Asp-Cys-Thr-Glu-Ser-Gly-Gln-Asn-Leu-Cys-Leu-Cys-Glu-GlyHV-2 Ile-Thr
HV-3 Ile-Thr

20
30
HV-1 Ser-Asn-Val-Cys-Gly-Gln-Gly-Asn-Lys-Cys-Ile-Leu-Gly-Ser-Asp-Gly-Glu-LysHV-2
Lys
Asn
Lys-Gly
HV-3
Lys
Gln
Lys-Asp

40

HV-1
HV-2
HV-3
HV-1
HV-2
HV-3

50
Asn-Gln-Cys-Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-GlyAsn
Glu
Asn
Gln
60
*
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu- -Tyr-Leu-Gln
Pro

Asp-Ala

Asp-Glu

I

Aprotinin:

1
10
Arg-Pro-Asp-Phe-Cys-Leu-Glu-Pro-Pro-Tyr-Thr-Gly-Pro-Cys-Lys-Ala

20
30
Arg-Ile-Ile-Arg-Tyr-Asn-Ala-Lys-Ala-Gly-Leu-Cys-Gln-Thr-Phe-Val-Tyr

40
Gly-Gly-Cys-Arg-Ala-Lys-Arg-Asn-Asn-Phe-Lys-Ser-Ala-Glu-Asp-Cys
50
Met-Arg-Thr-Cys-Gly-Gly-Ala

Fig. 3. Primary structures of natural hirudin variants 1, 2 and 3 (HV-1, Dodt et al.
1984, HV-2, Harvey et al. 1986 and HV-3, Dodt et al. 1986) and bovine aprotinin
(Stassen et al. 1995).

* denotes sulfation, which is absent in the recombinant forms of these molecules.
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may be blocked, its catalytic activity towards smaller substrates may not be prevented).

E. Thrombin Inhibitors

The development of substrate-related synthetic inhibitors of thrombin started with
the discovery of the specificity of thrombin for hydrolysis of arginyl bonds. There is a
broad spectrum of interests from which the thrombin inhibitors related work stems,
including the identification of reactive groups in active site, demonstration of similarities
and differences between binding areas of related enzymes, selective inhibition of one
protease in the presence of another and in vivo anticoagulation. Physical methods such
as NMR and x-ray crystallography for topography of the thrombin active site have also
contributes substantially to these developments. Direct inhibitors of thrombin can be
classified according to source and structure into endogenous, analogues of natural
substrates, recombinant and synthetic inhibitors. Some of these are directed against the
catalytic site of thrombin while others bind to the exosites of thrombin. In addition,
some are reversible inhibitors while others are irreversible.

1. Inhibitors of Plasma Origin

The natural inhibitors of thrombin belong to a class of serpms called
antithrombins. The most important ones are antithrombin and HC-II (which recognizes
the anion binding site as well as the catalytic site of thrombin, Hortin et al. 1989). The
mechanisms of actions of these is discussed previously.

In addition to the above

thrombin inhibitors, thrombin forms complexes and is inhibited by two other proteins
secreted form platelets upon activation: platelet protease nexin and thrombospondin
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(Detwiler et al. 1992). Platelet protease nexin is secreted from activated platelets and
forms a 77,000 MW complex with thrombin through thrombin's anion binding exosite
to inactivate it (Detwiler et al. 1992). Thrombospondin is a 420,000 MW glycoprotein
secreted by activated platelets and binds to many cells and proteins (Lawler 1986) and
is incorporated into polymerizing fibrin (Bale et al. 1985) and extracellular matrix (Jaffe
et al. 1983). The nexin-thrombin complex is further complexed with thrombospondin
via a disulfide bond (Detwiler et al. 1992).

2. Synthetic Inhibitors
Prior to the development of peptide-based inhibitors of thrombin, several nonpeptidic inhibitors have been described (Geratz and Tidwell, 1977). These non-peptidic
inhibitors of thrombin can be classified according to the extent of the domain they occupy
(Geratz and Tidwell, 1977). There are three important binding sites in the catalytic
domains of the arginine specific proteases (Schechter and Berger, 1967):
1) The specificity pocket to which the protonated arginine side chain of a substrate is
attracted, located at the entrance of the enzyme's catalytic mechanism (the pocket
consisting of His-57, Asp-102, Ser-195).
2) The area to left of the specificity pocket which accommodates the amino terminal
leaving group of substrate (towards the apolar binding exosite or fibrinopeptide groove).
This is the S 1 site of the enzyme and corresponds to the Pl site of the substrate. The
sites following the SI and Pl sites, away from the catalytic site, are designated S2, S3 ...
and P2, P3 on the enzyme and the substrate respectively.
3) The area to the right of the specificity pocket which accepts the carboxy terminus of
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the substrate (towards the anion binding exosite or fibrin groove). This is the S 1' site
of the enzyme and corresponds to the Pl' site of the substrate. The sites following the
S 1' and P 1' sites, away from the catalytic site, are designated S2 ', S3 '. .. and P2 ', P3'
on the enzyme and substrate respectively.
The classification of the synthetic inhibitors can then fall into three categories
(Geratz and Tidwell, 1977), according to the extent of the catalytic domain of thrombin
that they occupy.

a. Compounds Restricted to the Specificity Pocket of the Catalytic Domain of Thrombin
Synthetic cationic compounds were used to decipher the spatial relationship of the
S'pecificity site of thrombin and establish an optimal structure for hydrophobic binding
and ionic interactions with the negatively charged aspartate moiety at the bottom of the
pocket (Geratz and Tidwell, 1977). Of the benzene analogues, the ones with an amidino
side chain rather than an aminomethyl or a guanidino side chain, exhibited a stronger Ki
(Geratz and Tidwell, 1977). This led to benzamidine incorporation as a building block
in more complex thrombin inhibitors. Ring systems other than benzene, had an even
tighter fit due to the improved hydrophobic interaction with the pocket (Geratz and
Tidwell, 1977). Introduction of a pyruvic acid group in the para position to the amidino
side chain of benzamidine led to an increase in inhibitory potency.

The augmented

inhibition extended to plasmin, trypsin and enterokinase (Geratz and Tidwell, 1977).
An alternative building block for these molecules was arginine and its modified
forms. The D-configuration of arginine had little activity while chemical modifications
on the guanidino part or the a-amino part of L-arginine decreased the antithrombin
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activity (Tonomura et al. 1980).

b. Compounds Extending Unidirectionally Beyond the Specificity Pocket of the Catalytic
Site of Thrombin
These compounds were molecularly designed by attaching a side chain to a starter
compound (benzamidine mostly).

The side chains were aliphatic, aromatic or aryl

aliphatic and extended usually to the right od the specificity pocket. Only the agents
resulting from the link-up of two benzamidine groupings were active (Geratz and
Tidwell, 1977), more so than benzamidine alone, and they led to the study of factors
affecting potency (length, nature and bulkiness of central chain, presence of various
substituents, position of amidino groups). Diamidines proved effective and it was shown
that the second amidino group is essential for full potency, especially for inhibition of
kallikrein (Geratz and Tidwell, 1977).
Based on the work done with arginine as a building block, C-terminal
modifications of L-arginine were synthesized and studied. Ester compounds were easily
hydrolyzed by thrombin and other trypsin-like enzymes, so non-hydrolyzable tertiary
amides that were found to combine only with thrombin were focused on (Okamoto et al.
1980, Kikumoto et al. 1980, Tonomura et al. 1980).
Modification on the N-terminal of L-arginine were also studied (Okamoto et al.
1980, Kikumoto et al. 1980).

Dansyl group incorporation as well as other bulky

aromatic substituents to the arginine increased the antithrombin activity of the arginine.
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c. Compounds Extending Bidirectionally Beyond the Specificity Pocket of the Catalytic
Domain of Thrombin
Since the most efficient natural substrates of thrombin bind to thrombin in the
binding groove on both sides of specificity pocket, the idea of furnishing diamidines with
a side chain that provides additional interaction with the thrombin groove led to the
alteration of the location of the amidino groups, substitution of the halogen and
replacement of one amidino moiety by a nitro group. In general, amidines exhibited
inhibitory effects against any arginyl or lysyl specific protease, but had a preference for
one protease over others. The degree of differential inhibition reflected the topographical
variations in active sites of related enzymes.
An alternative building block used to develop small inhibitors for the catalytic site
of thrombin is amidinopiperidine. Modifications of this molecule yielded competitive
inhibitors of thrombin with Ki's of 20-50 nM (Hilpert et al. 1994).

Further

modifications of the central building block has led to the development of napsagatran (Ro
46-6240) as a reversible thrombin inhibitor with a Ki of 0.27nM. This compound has
been found to be an effective antithrombotic agent in a variety of animal models (Gast
et al. 1994, Carteaux et al. 1995).
The compounds synthesized based on the L-arginine as the building block and
incorporating both C and N-terminal optimal modifications, were found to be highly toxic
due to inhibition of butyl cholinesterase (Hijikata-Okunomiya and Okamoto, 1992). The
introduction of a COOH group on the carboxy terminal resulted in decreased affinity for
butyl cholinesterase (and therefore less toxicity) and after further modifications an isomer
named argatroban (MD805 or MCI9038 or argipidine), depicted in Fig. 4, was generated
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Fig. 4. Chemical structures of thrombin inhibitors: D-Phe-Pro-Arg-H, D-MePhe-ProArg-H, Boc-D-Phe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH and argatroban.
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as a selective inhibitor of thrombin (Ki=0.039 µM, Hijikata-Okunomiya and Okamoto,
1992). This compound also has a sizeable affinity for trypsin (Ki=5.0 µM, HijikataOkunomiya and Okamoto, 1992). It has been characterized pharmacologically and has
a plasma half life of 40 minutes (in humans, Tamao et al. 1986 a, b). Argatroban is also
effective in preventing thrombus formation in various animal models at low
concentrations ( > 1 µM, Maruyama 1990, Hijikata-Okunomiya and Okamoto 1992, Hara
et al. 1994, Kawai et al. 1995). This compound is being tested clinically for several
indications (Yonekawa et al. 1986, Kumon et al. 1984, Oshiro et al. 1983, Matsui et al.
1992).
A new low molecular weight compound, that competitively inhibits thrombin with
I

a Ki of 15 nM is inogatran (pINN, Teger-Nilsson et al. 1995). Preclinical and phase I
studies have been completed with this compound in numerous investigations (Gustafsson
et al. 1995, Eriksson et al. 1995). This agents was found to be selective for thrombin
when compared to other serine proteases.

Inogatran was also found to have more

effective antithrombotic effects than hirudin and hirulog in an in vivo rat model of arterial
thrombosis. No interaction with fibrinolytic processes were noted when inogatran was
studied in rat and dog models of thrombolysis. The half life of inogatran is about one
hour (Teger-Nilsson et al. 1995).

This compound also has a substantial oral

bioavailability that is species and gender specific (Gustafsson et al. 1995, Eriksson et al.
1995).

3. Peptide Inhibitors
With the elucidation of the primary structure of procoagulant proteins and the
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identification of the proteolytic activation cleavage sites, specific chromogenic substrates
for thrombin and factor Xa were developed by synthesis of peptides mimicking the amino
acid sequence adjacent to the substrate's cleavage site and attaching a para nitro-aniline
(pNA) group on the carboxy terminus of these peptides (Bang and Mattler, 1977). A
comprehensive study reported on the effects of many peptide inhibitors belonging to
various classes on a spectrum of serine proteases using clotting and novel amidolytic
systems (Fareed et al. 1981).

a. Aldehyde Derivatives
In 1975 a series of tripeptide aldehydes containing arginine were developed as the
first reversible peptide thrombin inhibitors. The prototype compound to be synthesized
was D-Phe-Pro-Arg-H (GYKI 14166, Bajusz et al. 1975), depicted in Fig. 3, which
although was a selective and potent inhibitor of thrombin, was very unstable in neutral
aqueous solution where it cyclized and was inactivated (Bajusz et al. 1989). To prevent
cyclization, a derivative was synthesized with a protective amino terminal tbutyloxycarbonyl (Boe) group: Boc-D-Phe-Pro-Arg-H (GYKI 14451, Bajusz et al. 1978),
also depicted in Fig. 3. This compound was more stable than its parent compound but
was not as specific for thrombin since it inhibited plasmin as well. In order to achieve
compounds that are both stable and specific for thrombin, a series of N-alkyl derivatives
were synthesized (a basic amino terminus promotes thrombin specificity) and from this
series the methyl derivative D-MePhe-Pro-Arg-H (GYKI 14766, Bajusz et al. 1987),
depicted in Fig. 3, was found to be as potent and selective reversible inhibitor of
thrombin as the prototype aldehyde. The Ki for the aldehyde derivatives is around 0.1
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µM.

The aldehydes D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H have been studied

pharmacologically.

From toxicity studies in mice and rabbits, the LD 50 for these

compounds was about 40-45 mg/kg. Both agents were devoid of hemorrhagic effects as
determined by a rabbit ear bleeding model.

The unprotected aldehyde however did

produced a blood pressure lowering effect (40% decrease) when injected I.V. which may
have been due to contaminants. When these aldehydes were administered to rabbits and
dogs orally, they produced persistent anticoagulant effects, although the bioavailability
may have been low.

Similar results indicated a high bioavailability when these

compounds were administered subcutaneously. The biologic half life of both aldehydes
after I.V. administration to primates was estimated to be around 90-180 minutes. The
anticoagulant activities of the compounds were evident in the global clotting tests and
were independent of antithrombin (Bajusz et al. 1990, Bagdy et al. 1992). Both agents
inhibited thrombin-induced platelet aggregation in a concentration dependent manner, but
the platelet count was not reduced after systemic administration.

All three of the

tripeptide aldehydes had antithrombotic activities as tested in various models of
thrombosis (rats, rabbits, baboons).

The free aldehyde as well as the methylated

derivative were effective antithrombotics after I. V., S.C. and P.O. administration while
the Boe derivative was active only after I. V. administration.
An analogue of the D-MePhe-Pro-Arg-H aldehyde,

D-1-Piq-Pro-Arg-H

(LY303496), is being developed as an orally effective thrombin inhibitor.

This

compound has been shown to be an effective antithrombotic agent in rat models of deep
venous thrombosis (Wilson et al. 1995) and arterial thrombosis (Kurz et al. 1995).
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b. Chloromethyl Ketone Derivatives
Peptides of arginine chloromethyl ketones correspond to the primary structure of
physiological substrates of target proteases (Kettner and Shaw 1977). Chloromethyl
ketones inactivate serine proteases by the formation of an intermediate reversible
substrate-like complex with the protease followed by irreversible alkylation of the active
site histidine. Peptides of arginine chloromethyl ketone are more effective than lysine
analogues since thrombin hydrolyzes only specific arginine bonds in its substrates. Thus,
arginine in the Pl position of the substrates is more effective.

Factor XIII and

prothrombin cleavage sites as well as other thrombin substrates have praline at the P2
site while the A and B chains of fibrinogen do not have this proline in the P2 site. After
I

testing a series of these cleavage site analogues it has been found that the tripeptide
chloromethyl ketone analogues of factor XIII cleavage site (Val-Pro-Arg-CH2Cl) and the
prothrombin cleavage site (Ile-Pro-Arg-CH2Cl and Val-Ile-Pro-Arg-CH2Cl) are the most
potent thrombin inhibitors with the tetrapeptide being the optimal as well as the most
specific thrombin inhibitor, probably due to occupation of a fourth binding site. These
inhibitors also inactivate plasmin, kallikrein and urokinase but slowly and to a limited
extent. Binding at secondary sites contributes to the compounds' s selectivity for trypsinlike proteases. The most effective irreversible inhibitor of thrombin synthesized from
this class of substrates is D-Phe-Pro-ArgCH2 Cl (PPACK or FPRCH2Cl, Kettner et al.
1979). This compound's two first amino residues occupy the specificity pocket in a tight
manner, while the arginine drops into the catalytic pocket.

This allows for high

specificity for thrombin as opposed to other serine proteases.

Thus, D-Phe-Pro-
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ArgCH 2Cl has been utilized in biochemical studies of thrombin and hemostasis as well
as in pharmacological studies. The toxicity of this tripeptide chloromethyl ketone is
species dependent. Thus, although in mice are no toxic effects after I. V. infusions of
up to 50 mg/kg, in rabbits nearly all platelets agglutinate even though clotting is
prevented. The biological half life of this agent, as measured after I. V. administration
to rabbits, is about 3 minutes.

The agent is also absorbed in an active form

subcutaneously. The anticoagulant effects of the ketone are detectable in a concentration
dependent manner with the TT and APTT clotting tests as well as with the TEG whole
blood clotting test.

However, these effects are lost after incubation with plasma

suggesting inactivation of the compound by plasma components. The antithrombotic
effects of this tripeptide derivative have been examined extensively in various animal
models (rats, dogs and rabbits) and in all the compound is an effective antithrombotic
after both I.V. and S.C. administration.

c. Nitrile Derivatives
Tripeptide derivatives with cx-nitrile groups have been synthesized as competitive
inhibitors of thrombin.

The peptide derivative D-Phe-Pro-Arg-CN 112 is a strong

competitive inhibitor of thrombin with a Ki =0. 7 µM.

This agent has been studied

pharmacologically in mice, rats and rabbits. The LD50 is 30-40 mg/kg I.V. in mice.
Intravenous infusion of the agent to rats has serious blood pressure lowering effects (7080 % reduction). The bleeding effects are minimal (Stuber et al. 1988), an indication that
primary hemostasis is not affected by this compound. The biological half life of the
agent after I.V. injection to rabbits is around 12 minutes and it is effective after S.C.
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administration as well. Biliary excretion accounts for about 30 % of route of excretion
of the total agent administered. This tripeptide nitrile exhibits anticoagulant effects in
a concentration dependent manner as detected by the global clotting tests and the TEG
whole blood clotting assay. It is also an effective antithrombotic in various rat models
of thrombosis.

d. Boronic Acid Derivatives
The search for selective and potent inhibitors of thrombin has led to the
development of three more classes of reversible tripeptide inhibitors: a) Trifluoromethyl
ketones: the representative compound D-Phe-Pro-Arg-CF 3 (Neises et al. 1991) with a Ki
in the nM range b) a-aminophosphonic acid tripeptide derivatives with Kis in the nM
range. c) a-aminoboronic acid derivatives. The boronic acid derivatives were initially
developed as inhibitors of elastase and chymotrypsin. In order to develop a compound
that would be specific for thrombin, the arginine in the sequence D-Phe-Pro-Arg has
been substituted with its boronic acid derivative. This has led to the synthesis of Ac-(D)Phe-Pro-boroArg (Ki=41 pM), depicted in Fig. 3, Boc-(D)-Phe-Pro-boroArg (Ki=3.6
pM) and H-(D)-Phe-Pro-boroArg (Ki< 1 pM) (Kettner et al. 1990). The boroarginine
derivatives have been a recent development and their pharmacologies are not complete.
The Ac-(D)-Phe-Pro-boroArg appears to have a biological half life of around 15 minutes
after intravenous administration to rabbits and it is an effective anticoagulant after S.C.
administration.

The anticoagulant effects of this compound are dose dependent and

detectable with the global clotting tests after administration to rats, rabbits and baboons.
This agent also exhibits antithrombotic effects as demonstrated by two thrombosis
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models. The H-(D)-Phe-Pro-boroArg also exhibits antithrombotic effects in a baboon
model of thrombosis and when compared to the aldehyde analog (D)-Phe-Pro-Arg-H, the
boronic acid derivative achieves the same effect at a dose 20 times lower than that of the
aldehyde derivative.
In attempting to develop a more specific, orally bioavailable thrombin inhibitor,
the above boronic acid derivatives have been modified to yield the compound Ac-D-PheN-cyclopentylGly-boroArg (S18326, Verbeuren et al. 1995). Although this compound
is more specific than Ac-D-Phe-Pro-boroArg and it is shown not to interfere in vitro with
fibrinolysis, it possesses sizeable inhibitory activities against other fibrinolytic enzymes
(Verbeuren et al. 1995). However, this compound has potent antithrombotic activities
I

in rat models of arterial and venous thrombosis and is orally bioavailable (Verbeuren et
al. 1995).
The above described boronic acid derivatives lack specificity for thrombin. In an
attempt to overcome this, the C terminal of the tripeptides has been extended (Ketnner
et al. 1990). However, the resulting compounds still lack in specificity for thrombin.
Tapparelli et al. (1993) has further modified these compounds by replacing the boroArg
in the third position (corresponding to the S 1 pocket site of thrombin) with a neutral
boron containing moiety. The compound Z-D-Phe-Pro-boromethoxypropylGly-pinendiol
has a lower Ki for thrombin (8.9 nM) than its predecessors, but the specificity for
thrombin is improved (Tapparelli et al. 1993).

However, this compound is a weak

anticoagulant in the global clotting tests and does not inhibit thrombin induced platelet
aggregation in vitro and in vivo.
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Another series of boronic acid derivatives has been developed as specific
inhibitors of thrombin.
boroMpgOPinacol and

These are Z-D-Phe-Pro-boroMpgOPin, Z-D-Phe-ProZ-D-Phe-Pro-boroPgIOPin (TRI50,

TRI50b

and TRil 1

respectively, Esmail et al. 1995). The most promising antithrombin agent appears to be
the pinacol ester derivative, TRI50b, with a Ki of 7nM.

This compound is also an

effective antithrombotic in various animal model of arterial and venous thrombosis, after
intravenous and intraduodenal administration (Goddard et al. 1995, Gerrard et al. 1995).

e. Other Peptide Analogues
Substituting Arg with amidinoPhe in the D-Phe-Pro-Arg prototype sequence, led
t0 the development of a series of compounds with inhibitory activities for various
enzymes. The compound N-a-(2-napthylsulfonylGly)-4-amidinoPhepiperidine (NAPAP)
was found to be the most optimal thrombin inhibitor with a Ki of 6 nM (Stiirzebecher et
al. 1983). NAPAP is an effective antithrombotic in a series of animal models (Kaiser
et al. 1985). However, in addition to adverse side effects (hypotension and respiratory
depression, the half life of this compound is even shorter than most thrombin inhibitors
(less than 10 min versus greater than 20 min for other thrombin inhibitors, Kaiser et al.
1985) and thus clinical development has been abandoned.
Another direct thrombin inhibitor under current development is

CVS-1123

[(CH3CH2CH2) 2-CH-CO-Asp(OCH3)-Pro-Arg-CHO, Vlasuk et al. 1995]. This compound
has an oral bioavailability of > 30 % when administered to cynomolgous monkeys and
is an effective antithrombotic in a dog model of coronary artery thrombosis (Cousins et
al. 1995).
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4. Recombinant Inhibitors

a. Aptamers
Aptamers are oligonucleotides (double or single stranded DNA, or single stranded
RNA) which act directly on proteins to inhibit disease processes.

Thirty two such

aptamers have been recently isolated as inhibitors of thrombin with binding affinities in
the range of 20-200 nM (Boch et al. 1992). One of the most potent thrombin aptamers
has been found to interact with thrombin's anion binding exosite, so that it competes with
substrates that interact with that specific site, such as fibrinogen and thrombin platelet
receptors (Macaya et al. 1993, Paborsky et al. 1993). This aptamer has been shown
recently to reduce arterial platelet thrombus formation in an animal model, as well as to
inhibit clot bound thrombin in an in vitro system (Li et al. 1994). Recently, a second
pool of aptamers, with a different sequence composition than the first class, incorporating
modified bases, has been isolated, which has shown promising anticoagulant activities
(Latham et al. 1994).

Another recent development in the area of oligonucleotide

inhibitors of thrombin has been the isolation of two RNAs that bind thrombin with high
affinity (Kd in the nM range).

These oligonucleotides have been shown to inhibit

fibrinogen clotting in an in vitro test (Kubik et al. 1994).

b. Hirudin and its Variants
Hirudin is the most potent family of natural thrombin inhibitors, found in the
saliva of the leech Hirudo medicinalis. It is a single polypeptide chain of 64-66 amino
acid residues, stabilized in a characteristic conformation by three disulfide bridges in the
N-terminal (Petersen et al. 1976).

The Tyr moiety in position 63 is sulfated and
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important in imparting inhibitory potency against thrombin (Verstraete 1995). The mode
of interaction of hirudin with thrombin has been elucidated from X-ray studies on the
crystallized thrombin-hirudin complex (Griitter et al. 1990, Rydel et al. 1990). The
amino terminus of this polypeptide interacts with the apolar binding site of thrombin
(Wallace et al. 1989) while the carboxy terminus, which is highly acidic, interacts with
the anion binding exosite for fibrinogen recognition (Chang et al. 1990). Thus, by
binding to these two sites on thrombin, hirudin masks the catalytic site thus rendering
thrombin inactive. Because hirudin recognizes two different exosites on thrombin, rather
than its catalytic site, it is a highly specific inhibitor of thrombin.
Several isotypes of hirudin exist and they all have similar thrombin inhibitory
I

potencies. These hirudin variants are named HV-1 (Dodt et al. 1993), HV-2 (Harvey
et al. 1985) and HV-3 (Dodt et al. 1986) and their primary structures are shown in Fig.
4. All of these isoforms have been produced by recombinant technology (Harvey et al.
1986, Dodt et al. 1989, Scharf et al. 1989) and the expression systems include Eschericia

coli, Bacillus subtilis and Saccharomyces cerevisiae. The recombinant forms differ from
the natural ones in that the Tyr residue in position 63 is not sulphated in the recombinant
forms. Although this lack of sulfation reduces the antithrombin activity of hirudin, the
reduction is negligible since the formation of the thrombin-hirudin complex is almost
irreversible (Verstraete 1995). The recombinantly produced hirudins are also named
desulfatohirudins or desirudin, due to the lack of sulfation at position 63. The hybrid
recombinant hirudin CX-397 has been synthesized composed of the N-terminal fragment
of HV-1 and the C-terminal fragment of HV-3 (Komatsu et al. 1993). This hybridization
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results in a molecule that has an improved inhibitory potency for thrombin over the
natural occurring hirudins. Point mutations to develop variant forms of hirudin have
been used (Scharf et al. 1989).
Binding of recombinant hirudin to dextran has been reported (Markwardt et al.
1990) in an attempt to prolong its biologic t1h.

More recently, polyethylene glycol

coupling of recombinant hirudin, to develop longer lasting agents, has been accomplished
(Kurfurst et al. 1992, Zawilska et al. 1993). This modification results in a molecular
weight increase of hirudin from 7,000 to 17,000, which prevents extravasation of this
agent and retards renal elimination, substantially increasing its biological half life
(Riibsamen et al. 1991, Bucha et al. 1996). Furthermore, the PEG-hirudin metabolites
differ from those of hirudin, suggesting different renal metabolism of the two agents
(Lange et al. 1996). PEG-hirudin as well as hirudin are capable of inhibiting clot-bound
thrombin when compared to heparin (Iorio et al. 1993). PEG-hirudin has also been
shown to be effective in a rabbit model of DIC (Zawilska et al. 1993).

Another

application of PEG-hirudin is stent coating (Sternberger et al. 1996) and expansion to
usage of this agent in reducing the thrombogenicity of other biomaterials, such as
catheters, vascular prostheses and oxygenators is being considered.
In addition to PEG, albumin has also been linked to the carboxy terminus of
hirudin to prolong its half life, without impairing its antithrombin activity (Syed and
Sheffield, 1995). The albumin-hirudin product has not been tested in vivo.
Extensive pharmacological studies have been competed with recombinant hirudin.
This compound has been repeatedly shown to be effective in various venous and arterial

72
thrombosis model of the rat, rabbit and the pig (Verstraete 1995). The effects are always
dose-dependent at µmol/kg doses even after subcutaneous injection. Interestingly, the
pharmacokinetics of desirudin reveal that it is distributed in extracellular compartments
and that renal metabolism and excretion is an important component of the overall
excretion profile (Verstraete 1995).

5. Inhibitors of Thrombin not Directed Against its Catalytic Site
Based on the structure of the carboxy terminus of hirudin, which interacts with
the anion binding exosite of thrombin, a series of synthetic peptides cyclized via disulfide
linkages were synthesized as inhibitors of thrombin (Krstenansky et al. 1988). These
iRhibitors block the anion binding exosite of thrombin thus preventing fibrinogen cleavage
and subsequent fibrin clot formation and optimal N terminal substitution of these peptides
can lead to inhibition of fibrin formation (Owen et al. 1988).
A 22 and a 27 amino acid peptide has been synthesized, modelled after the
sequence of HC-II that interacts with thrombin's anion binding exosite, which prevents
proteolytic cleavage of fibrinogen. The IC50 values for these two peptides in inhibiting
thrombin are 38 and 28 µM respectively. These peptides however do not interfere with
thrombin's catalytic site (Glen et al. 1989, 1990).
The same group that studied the HC-II analogues, compared these to a fibrinogen
(18 residues) and a thrombomodulin (19 residues) cleavage site analog and to a peptide
corresponding to the 12 terminal amino acids of hirudin.

The IC50 values for these

compounds are 130, 140 and 1.3 µM respectively.
A fibrinogen analog has also been synthesized as a thrombin inhibitor (Binnie et
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al. 1991). This 24 amino acid peptide is modelled after the sequence of fibrinogen
downstream of the thrombin cleavage site (different from the one studies by Glen et al.
above). It is able to prevent fibrinogen clotting with a Ki of around 190 µM (Binnie et
al. 1991). This peptide also does not block the thrombin catalytic site.
A new thrombin inhibitor, triabin, is a 17,000 protein isolated and cloned from
the saliva of the assassin bug Triatoma pallidipanis (Noeske-Jungblut et al. 1995). This
agent inhibits thrombin by binding to its anion-binding exosite but does not interfere with
its catalytic site. A recent report (Glusa et al. 1996) shows that this agent is potent in
inhibiting thrombin mediated platelet aggregation and smooth muscle contraction.

6. Chimeric Thrombin Inhibitors

Coupling of peptides that mimic the carboxy terminal of hirudin to peptides that
are specific for inhibition of the catalytic site of thrombin (D-Phe-Pro-Arg) has led to the
development of a series of chimeric molecules termed hirulogs, in which the amino
terminus consists of the catalytic site-directed peptides, while the carboxy terminus
consists of the 12 terminal residues of hirudin. The two moieties are linked together by
a bridge of glycine residues of variable length (DiMaio et al. 1990, Maraganore et al.
1990). Thus, hirulogs inhibit thrombin by binding to both its catalytic site and its anion
binding exosite, thus conferring specificity to these molecules for thrombin. Hirulog-1
has been developed aggressively for several cardiovascular indications (Topol et al. 1993,
Cannon et al. 1993, Theroux and Lidon 1994). However, its superiority over heparin
has not been established.
Recently, there has been a report of a novel synthetic thrombin inhibitor,
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CVS#995 (Vlasuk et al. 1994), comprised of 19 amino acids, in which recognition
sequences for the catalytic and primary exosite binding domains of thrombin have been
linked by a transition state analog (Vlasuk et al. 1994). The Ki value for thrombin is in
the pM range for this slow and tight binding thrombin inhibitor. When compared to
hirulog-1, this agent is claimed to be superior at inhibiting platelet aggregation and
venous thrombosis in a rat model (Vlasuk et al. 1994, Biemond et al. 1995).
An interesting chimeric molecule has been developed, in which the 12 terminal
residues of hirudin are coupled to the tripeptide Arg-Gly-Asp (Church et al. 1991). This
tripeptide is a sequence found in thrombin and the adhesive proteins fibrinogen,
fibronectin, vitronectin and von Willebrand factor and is recognized by the platelet
surface receptor GPIIb/IIIa which mediates platelet cell adhesion and aggregation
(Ruoslahti et al. 1987, Phillips et al. 1988, Plow et al. 1989). The chimeric molecule
is able to inhibit platelet adhesion to surfaces as well as inactivate thrombin.

The

implications of this type of structuring are that thrombin inactivation can be targeted to
specific cells trapped in thrombi. Based on this hybrid molecule and the crystal structure
of the hirudin-thrombin complex, a new class of recombinant hirudin variants has been
developed, called hirudisins (Knapp et al. 1992) These recombinant hirudins have
residues 32-35 replaced by the sequence Arg-Gly-Asp-Ser or Lys-Gly-Asp-Ser to yield
molecules with characteristics similar to those of the Arg-Gly-Asp-C-terminal of hirudin
chimera.
In a novel approach to target a thrombin inhibitor to the surface of a clot, hirudin
was covalently linked to a fibrin specific monoclonal antibody (Bode et al. 1996). This
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chimeric agent was shown to be more effective than hirudin alone in preventing platelet
deposition and clot formation in vitro and in an in vivo baboon arteriovenous shunt
model.

7. Thrombin Directed Antibodies
Acquired antithrombin autoantibodies are rare and have been poorly characterized.
In one reported case (Sie et al. 1991) the patient had mild bleeding symptoms and
markedly prolonged clotting times and eventually died of cerebral hemorrhage.

The

antibody was found to be an immunoglobulin that recognized at least in part the apolar
binding site of thrombin, adjacent to the catalytic site.

In another case, the patient

developed antibodies against thrombin and factor Xa after exposure to topical treatment
with bovine thrombin (Zehnder and Leung, 1990).

Polyclonal antibodies against

thrombin have been raised by using the human a thrombin B chain (Noe et al. 1988).
These antibodies were found to inhibit the functions of thrombin that require involvement
of its anion binding site, such as activation of protein C when bound the
thrombomodulin, cleavage of fibrinogen and binding to hirudin. On the other hand, the
catalytic site of thrombin was not hindered and thus the enzyme retained its activity to
activate protein C and interact with small chromophores (directed against thrombin' s
catalytic site). These antibodies are useful tools in capturing complexes of thrombin
(Lackman and Geczy, 1991, Lackman et al. 1991) as well as in studying requirements
of thrombin sites in other interactions (Chang and Detwiler, 1991, Noe et al. 1988).
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F. Clinical Applications of Thrombin Inhibitors

Ever since their introduction, most of the clinical indications for these new
anticoagulants have been in the interventional cardiovascular areas (Herrman and
Serruys, 1994).

Initial focus has been on the prevention of abrupt closure during

coronary angioplasty (Topol et al. 1993, Topol 1995). These agents have also been tried
for the post-PTCA prevention of both the early and late reocclusion (Suzuki et al. 1995).
In addition, some of the thrombin inhibitors have been used for the treatment of unstable
angina (Topol 1995). More recently, some of these agents have been tested for their
efficacy in stenting (van Beusekom et al. 1994, Buchwald et al. 1993, Sternberger et al.
1996). Although several reports on the experimental use of these agents have been made
available on their use in cardiovascular surgery in animal models, only isolated reports
in human studies are available (Riess et al. 1995, Edmunds 1995). Concerns over the
use of these agents have been expressed (Edmunds 1995).
Thrombin inhibitors are attractive to both clinicians and surgeons as substitute
anticoagulants in heparin compromised patients in particular.

For patients requiring

anticoagulation, exhibiting heparin induced thrombocytopenia, several trials are currently
in progress to test the efficacy of new antithrombin agents (Edmunds 1995, Chamberlin
et al. 1995).
There is a growing interest in the use of these agents in the prevention and
treatment of DVT (Bridey et al. 1995). Eriksson (1995) reported on the successful use
of recombinant hirudin in the prophylaxis of post-orthopaedic surgery. In this study he
compared unfractionated heparin (5000 IU s.c. t.i.d.) with hirudin (15 mg s.c. b.i.d.)
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and found hirudin to be superior. Several additional trials are currently being conducted
on different antithrombin agents.

1. Antithrombin
The major application of antithrombin is in disorders associated with antithrombin
deficiency, acquired or hereditary. Antithrombin replacement therapy in patients with
hereditary antithrombin deficiency is in phase I and Phase II clinical studies.
Supplementation of antithrombin to these patients before and after undergoing various
surgical procedures with or without other treatments has proven effective (Menache
1991). The combination of antithrombin/heparin is effective in prophylaxis of venous
tllrombosis following total hip and total knee replacement surgery (Franscis et al. 1991).
The role of antithrombin replacement therapy in prophylaxis of thrombotic episodes
during pregnancy remains controversial (Owen 1991). From a study by Demers et al.
(1992), it appears that replacement therapy of antithrombin in people who are deficient
should be a mode of prophylaxis only during periods of high risk for thrombotic
phenomena. In addition to these uses, antithrombin has been evaluated in clinical trials
in patients with septic shock and DIC (Maki et al. 1987, Blauhut et al, 1985, Fourrier
et al. 1993).

The outcomes of these trials proved that antithrombin is effective in

attenuating and correcting DIC early, but the mortality rate is not affected.

2. Argatroban
Although argatroban has been studied in wide range of animal models and has been used
clinically in Japan for some years (it is approved for treatment of peripheral arterial
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occlusive disease), only recently has the European and American community started to
evaluate its clinical usefulness.
In an initial study in the U.S., argatroban was evaluated in patients with unstable
angina (Gold et al. 1993). Even though myocardial ischaemia did not occur during the
argatroban infusion, some patients had recurrent angina within 6 hours after discontinuing
the infusion.
protocol.

However, the outcomes may be improved by changing the infusion

This recurrent angina was correlated with an increase in the thrombin-

antithrombin complex and was described as a rebound phenomenon. This observation
was explained by either the premature cessation of argatroban infusion which resulted in
inhibition of thrombin but was not enough to inhibit the generation of thrombin Gold et
al. 1993), or by the heparin withdrawal prior to argatroban infusion, which itself results
in recurrent angina (Willerson and Casscells, 1993).

Furthermore, heparin alone

promotes antithrombin clearance, so that antithrombin levels may have been artificially
low prior to argatroban infusion (Willerson and Casscells, 1993).
There are currently two phase II trials in North and South America, in which
Argatroban is being evaluated as an adjunct to thrombolytic agents and aspirin. The
Argatroban in Myocardial Infarction (AMI) study is evaluating two doses of argatroban
in conjunction with streptokinase and aspirin in patients with acute myocardial infarction
(P. Theroux, M.D., Montreal Heart Institute, Principal Investigator). The Myocardial
Infarction with Novastan and tPA (MINT) study is comparing two doses of argatroban
to heparin in patients diagnosed with acute myocardial infarction and receiving tPA and
aspirin (1.K. Jang, M.D., Harvard Medical School, Massachusetts General Hospital,
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Principal Investigator). Argatroban is also evaluated in two phase II trials (ARG-911,
B. Lewis, M.D., Loyola University Medical Center, Principal Investigator and ARG912, G. Pineo, M. D. and R. Hull, M. D. , University of Calgary, Principal Investigators)
in patients with heparin induced thrombocytopenia. In the ARG-912 study, argatroban
is being compared to ancrod (a defibrinating enzyme). The results of these trial are
expected to be available in early 1997. Argatroban is also proposed as an anticoagulant
for cardiovascular bypass surgery. (ARG-240, R. Pifarre, Loyola University Medical
Center, Principal Investigator).

3. Efegatran
The tripeptide aldehyde D-MePhe-Pro-Arg-H is currently marketed under the
generic name efegtran sulfate by Eli Lily, U.S.A. Although efegatran has been examined
in various animal models and has been in studied experimentally for several years with
promising results, only in the last two years has it been considered for clinical usage.
Five clinical studies have been performed with efegatran in normal male volunteers, to
assess safety and pharmacokinetics/ pharmacodynamics.

Interestingly, some of the

subjects experienced short-lived headaches, postural dizziness and vasovagal episodes
when moving from a lying to a sitting position following I. V. infusion of efegatran. It
is currently being studied in a phase II trial, the Prevention of Reocclusion by Inhibition
of thrombin during Myocardial Events (PRIME) study, in patients with acute myocardial
infarction. This trial is comparing adjunct usage of tPA and aspirin with efegatran at
different doses versus adjunct usage of tPA and aspirin with heparin. The results of this
study are expected in the beginning of 1996.
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4. lnogatran
While inogatran is a new competitive thrombin inhibitor and limited information
on its pharmacology is available, phase I studies on this thrombin inhibitor are already
completed (Teger-Nilsson, 1995). It is shown that inogatran is an effective anticoagulant
with a biological half life of about 1 hour, which is longer than the other thrombin
inhibitors currently under clinical evaluation. There appear to be not metabolites of this
agent and it is excreted evenly between kidneys and faeces.

However, this thrombin

inhibitor prolongs the capillary bleeding time in some healthy human subjects.
Currently, inogatran is evaluated in a phase II trial in patients with unstable angina.

5. N apsagatran
As with inogatran, napsagatran is a newly developed reversible thrombin
inhibitor. It is currently evaluated in phase II clinical trials for the prevention of postoperative thrombosis and in treating established venous thrombosis.

6. Hirudin
The antithrombotic and anticoagulant effects of recombinant hirudin have been
well established in experimental animal models. In the clinical setting, hirudin has been
studied in various clinical trials for a range of indications. Hirudin was compared with
heparin in the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial, in acute myocardial
infarction patients treated with tPA and aspirin (Cannon et al. 1995). Although there was
an improvement in clinical endpoints with hirudin as compared with heparin, there was
no hirudin dose-dependence on the outcomes. The TIMI 6 Trial compared hirudin with
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heparin in acute myocardial infarction patients receiving streptokinase and aspirin (Lee
et al. 1995) and there was a trend for an improved outcome with the higher dose of
hirudin compared to the lower hirudin dose and to heparin. However, the subsequent
larger phase 3 Hirudin for Improvement of Thrombolysis (HIT Ill) trial, that compared
hirudin to heparin in acute myocardial infarction patients treated with tPA and aspirin
(Neuhaus et al. 1994), was stopped prematurely due to excessive intracranial bleeding
in the hirudin group. Another large phase 3 trial stopped prematurely due to excessive
intracerebral bleeding was the Global Use of Strategies to Open Occluded Arteries
(GUSTO) II trial (GUSTO Ila Investigators, 1994). In this trial, hirudin was again
compared to heparin, in patients with acute coronary syndromes (with unstable angina
or myocardial infraction). It was observed that the incidence of hemorrhagic strokes
increased in patients receiving concomitant thrombolytic therapy. Another interesting
finding of this study is that hirudin, irrespective of dose, is less effective in inhibiting
thrombin generation when compared to heparin (Zoldelhyi et al. 1995).

The

Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial,
designed to compare heparin and hirudin as adjuncts to thrombolytic therapy, was also
prematurely stopped because of increased incidence of hemorrhagic strokes in patients
receiving either heparin or hirudin (Antman and TIMI 9A Investigators, 1994). Both the
GUSTO II and TIMI 9A trials were re-initiated with lower doses of both hirudin and
heparin under the acronyms GUSTO Ilb and TIMI 9B (Verstraete and Zoldheyi, 1995).
In the GUSTO-Ilb, over 12,000 patients from 373 hospital sites in 13 countries were
included to compare intravenous recombinant hirudin and heparin.

Dr. Topol (45th
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Annual Scientific Session of the American College of Cardiology Meeting in Orlanso FL,
oral presentation) described this study as validating the direct thrombin inhibition
hypothesis where hirudin at adjusted dosage exhibited comparable anticoagulant actions
to heparin.

However, even at this dose, the hirudin treated group showed slightly

increased bleeding events. The HIT-SK trial, designed to compare hirudin and heparin
as adjunct treatments to streptokinase in patients with acute myocardial infarction
(Molhoek et al. 1996) was recently completed. The results of this study also showed that
no clear dose-response relationship was evident and furthermore major bleeding events
were also increased.
Hirudin has also been evaluated in the indication of coronary angioplasty, in the
phase III, Hirudin in a European Restenosis Prevention Trial Versus Heparin in
Treatment of PTCA Patients (HELVETICA, Serruys et al. 1994). When compared to
heparin, the hirudin group exhibited an improvement of clinical outcomes (fewer
myocardial infarctions, bypass surgeries and ischemic events) in the early stages of
treatment, but in the 7 month follow-up there was no difference in the rate of restenosis
between the two groups.
In the indication of unstable angina, hirudin has been compared with heparin and
found to decrease the rate for subsequent myocardial infarction (OASIS, Organization to
Assess Strategies for Ischemic Syndromes 1995). However, there was no dose-response
relationship in the hirudin group. Another problem emerging from treatment of unstable
angina with hirudin or heparin is that there is an increase of ischemic events after hirudin
or heparin is stopped. A recent study on coagulation markers in unstable angina patients
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treated with heparin or hirudin in conjunction with aspirin showed that although
coagulation was suppressed during treatment with these agents, coagulation was
reactivated when the treatment was stopped (Flather et al. 1995). Therefore, treatment
should be continued for longer time periods ( > 72 hours).
Hirudin has been compared to heparin in patients undergoing elective total hip
replacement in small phase 2 trials (Eriksson et al. 1994a,b, Ekman et al. 1996). In a
recent report (Eriksson et al. 1996) a fixed dose of 15 or 20 mg hirudin pre-operatively
and administered S.C. twice daily for at least 9 days, was shown to be superior to
heparin and safe prophylactic regimen for thromboembolic complications in patients
undergoing total hip replacement surgery. However, such a study should have compared
hirudin to the standard treatment, which is currently low molecular weight heparin S.C.
b.i.d. Thus, there is a need for additional clinical trials for hirudin in this indication.
A recent report describes the usage of hirudin in ten patients with severe venous
thromboembolism (Parent et al. 1993, Schiele et al. 1994).

It was concluded that

thrombin generation was only partial and the dose of hirudin should be increased in
subsequent studies and should be compared to heparin or low molecular weight heparin.
Novel and successful applications of hirudin have been reported recently in two
case studies, where the patients involved developed heparin induced thrombocytopenia.
In one case, the patient successfully underwent cardiopulmonary bypass surgery by using
hirudin instead of heparin for anticoagulation during this procedure (Potzsch et al. 1994).
In the second case, the another patient with heparin induced thrombocytopenia
successfully underwent cardiopulmonary bypass surgery with an aortic valve replacement,
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after being anticoagulated with hirudin in place of heparin (Riess et al. 1995). Since these
two isolated cases, an additional 11 patients with heparin-induced thrombocytopenia have
been successfully treated with hirudin during cardiopulmonary bypass for cardiac surgery
(Potzsch et al. 1996). However, concerns regarding replacement of heparin with hirudin
during cardiopulmonary bypass surgery include the absence of an antidote to hirudin and
the questionable ability of hirudin to suppress thrombin generation (Edmunds 1995).
Another novel application of hirudin was in a patient with diabetic nephropathy
and heparin induced thrombocytopenia (Nowak et al. 1996). The continual usage of
hirudin in this patient in conjunction with hirudin-impermeable dialyzers proved to be
safe and efficacious.
While hirudin has been regarded as a weakly immunogenic agent, a recent study
reports on the detection of IgG anti-hirudin antibodies in 38 out of 82 patients with
heparin induced thrombocytopenia that were treated successfully for more than 6 days
with hirudin (Eichler and Greinacher 1996, Greinacher et al. 1996). Even though no
allergic reactions were induced in any of the patients, the effects of these antibodies on
the pharmacologic responses of hirudin are not clear at this time.
The recombinant hirudin CX-397, a chimeric molecule between HV-1 and HV-3,
has been compared with heparin in two groups of 5 patients receiving aspirin, prior to
coronary angiography (Ffrench et al. 1995). This agent is shown to be a strong anticoagulant that warrants further investigations in patients undergoing coronary angioplasty.
The interactions of PEG-hirudin with aspirin were studied recently in 9 healthy
human volunteers (Breddin et al. 1996). It was shown that PEG-hirudin in combination
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with aspirin may be associated with a higher risk of bleeding. These bleeding additive
effects were not correlated with any of the platelet function tests nor any of the
coagulation parameters. To avoid bleeding complications, it was suggested that the PEGhirudin dose should be decreased or that aspirin should be given after PEG-hirudin
treatment was completed.
Phase I clinical studies on PEG-hirudin have shown that this agent is a safe
thrombin inhibitor in healthy human volunteers after I.V. or S.C. injection (Esslinger et
al. 1995). Due to its prolonged t1h when compared to hirudin, PEG-hirudin appeared
to be from these studies a promising agent for prophylactic development as a once daily
S.C. injection.

The rapid clearance of PEG-hirudin from the central compartment,

following I. V. injection also indicates that this agent may be suitable for low-dose
continuous infusions.
7. Hirulog

Hirulog peptides have been characterized biochemically extensively. They are
specific thrombin inhibitors and in the in vitro clotting studies they appear to be potent
anticoagulants (Ofosu et al. 1992, Witting et al. 1992, Maraganore et al. 1990). Hirulog
has been compared to heparin as an adjunct to streptokinase and aspirin in patients with
acute myocardial infarction (Lidon et al. 1994). Based on the favorable findings for
hirulog, a larger trial is now underway for the same indication (Weitz et al. 1995).
A large phase 3 trial, Hirulog Angioplasty Study, compared hirulog to heparin in
patients undergoing coronary angioplasty for unstable angina or for ongoing ischaemia
after myocardial infarction (Strony et al. 1995). Hirulog was found to be superior in
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high-risk patients undergoing angioplasty after myocardial infarction, although there was
no difference in the rate of primary outcome events (mortality, myocardial infarction,
emergency bypass) overall. The same study also revealed that hirulog does not prevent
restenosis after coronary angioplasty (Burchenal et al. 1995), even though the thrombin
rebound effect is more suppressed with hirulog than with heparin (Strony et al. 1995).
In the TIMI 7 trial, the effects of hirulog were examined in patients with unstable
angina receiving aspirin. Although death and myocardial infarction were reduced at the
higher doses of hirulog, there were no heparin controls included in this study.
Hirulog also has been evaluated in prophylaxis of venous thrombosis in high-risk
patients undergoing major orthopaedic surgery. The highest hirulog dose used proved
to be as effective as other forms of prophylaxis, including low molecular weight heparin
(Ginsberg et al. 1994).

G. Drug Interactions
Polypharmacology is necessary for an effective approach in the management of
thrombotic disorders, ranging from disseminated intravascular coagulation (DIC) to deep
venous thrombosis (DVT) to acute myocardial infarction (AMI). While different classes
of drugs currently used adjunctly have different targets, all of which contribute to the
ultimate safety and efficacy outcome, little has been done to study the direct interactions
of the antithrombotic agents with other drugs.

Because of the complex nature of

thrombotic disorders, the impact of drug interactions in various disorders has to be
carefully assessed.
The primary agents used in management of thrombotic disorders include either
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antiplatelet agents or inhibitors of thrombin and/or factor Xa. Fibrinolytics (thrombolytic
drugs) are also used in many of these disorders, often in conjunction with anticoagulants.
Since thrombolytic drugs are believed to target clots, relatively little attention has been
given to interactions of these agents with anticoagulant drugs such as heparin and newly
developed antithrombin agents. Antithrombin drug-induced impairment of physiologic
fibrinolysis may result in a hypercoagulable state, whereas impairment of pharmacologic
thrombolysis could lead to a compromised outcome, despite a strong systemic
anticoagulant state.
Although the above described thrombin inhibitors have been studied in terms of
their antithrombotic activity, little work has been completed in the area of fibrinolysis.
I

So far, only D-Phe-Pro-Arg-H, D-Me-Phe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H, argatroban
and D-Phe-Pro-ArgCH2Cl have been studied in vitro, for effects in fibrinolytic
mechanisms. A fibrin plate assay and thrombelastography were used to compare the
three arginals (Barabas et al. 1993) and it was concluded that the first two arginals were
more selective than third one for thrombin in comparison to fibrinolytic enzymes such
as plasmin, urokinase and streptokinase. In addition, the first two arginals were found
to promote fibrinolysis (Barabas et al. 1993). The effects of argatroban on the clot lysis
of human and rabbit plasma demonstrated that argatroban shortens the time to clot lysis
in these systems when fibrin is cross-linked (Tamao et al. 1986). In contrast, argatroban
has no effect in clot lysis when fibrin is not cross-linked (Tamao et al. 1986), indicating
that argatroban prevents thrombin from activating factor XIII which is the fibrin crosslinking enzyme. Furthermore, the same group demonstrated that argatroban had weak

88
inhibitory activities against tissue and urokinase type plasminogen activators. D-Phe-ProArgCH2Cl was found to inhibit tPA and plasmin (Gilboa et al. 1988), suggesting this
agent to be an anti-fibrinolytic agent.
Only a few animal models of thrombolysis have been studied for in vivo effects
of antithrombin agents on fibrinolytic processes. The thrombin inhibitors examined in
these model have been argatroban, D-Me-Phe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H, D-PhePro-ArgCH2Cl, hirulog-1 and hirudin. Argatroban has been shown to either decrease
time to reperfusion and/or increase time to reocclusion when administered in conjunction
with a fibrinolytic agent in dog and rabbit models of thrombolysis. In a dog model of
coronary arterial thrombosis, occlusive thrombi are produced by mechanical injury to
the vessel's endothelium (Martin et al. 1993). Thus the clots formed are platelet-rich and
the amount of fibrin is minimal. Argatroban was shown to improve reperfusion in this
model. In another model of dog femoral arterial thrombosis, the occlusive thrombus was
formed with thrombin (Yasuda et al. 1990). Thus, this clot structure was more fibrinrich. In this model, it was found that although time to reperfusion was not affected, time
to reocclusion was prolonged by argatroban.

In a dog model of femoral arterial

thrombosis, occlusive thrombi were again produced by mechanical injury to the vessel's
endothelium and thus platelet-rich clots are formed (Mellot et al. 1990).

In these

studies, argatroban enhanced time to thrombolysis. In the rabbit model of carotid artery
occlusion, the damage to the endothelium was chemically induced and the thrombi thus
generated were platelet aggregates (Tamao et al. 1986). Here, argatroban enhanced
thrombolysis. In a model of femoral artery thrombosis model, the occlusive clot was
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generated by thrombin and thus was a fibrin structure (Schneider 1991, Jang et al. 1990).
In this model, argatroban was also found to increase time to reocclusion and decrease
time to reperfusion in conjunction with a fibrinolytic agent.
The D-Me-Phe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H were studied for their
effects on time to reperfusion in a dog model of coronary artery thrombosis, where the
occlusive thrombus was induced electrochemically, thus producing a platelet-rich clot
(Jackson et al. 1993). It was found that while the D-Me-Phe-Pro-Arg-H increased the
time to reocclusion when used with tPA, the time to reperfusion was not influenced.
Furthermore, Boc-D-Phe-Pro-Arg-H increased the time to reperfusion when used
adjunctly with tPA. This finding indicates a fibrinolytic compromise induced by this
thrombin inhibitor, which in contrast to the first arginal is less specific for thrombin.
D-Phe-Pro-ArgCH2Cl, hirulog-I and hirudin were compared in a rat model of
abdominal aortic thrombolysis (Klement et al. 1992).

The occluding thrombus was

produced by a combination of endothelial injury and blood flow stasis. In these studies
it was found that all three agents prolonged the time to reocclusion and the number of
reocclusions. Interestingly enough, while D-Phe-Pro-ArgCH2Cl and hirulog-I decreased
the time to thrombolysis, hirudin did not, suggesting that hirudin does not access clotbound thrombin as effectively as the other two agents. However, the doses of these
agents were based on their prolongation of activated partial thromboplastin time (APTT)
to similar extents. The usage of this global clotting test to decipher equivalent doses of
thrombin inhibitors with distinct mechanisms of thrombin inhibition is arguable. Hirudin
was also studied in a dog model of coronary artery occlusion (Sitko et al. 1992, Martin
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et al. 1992, Lunch et al. 1994). Here, the occluding thrombus was induced by electrical
damage to the vessel and hirudin was found to decrease the time to reperfusion and
increase the time to reocclusion.
The above observations, both in vitro and in vivo, indicate that the effects of
thrombin inhibitors on fibrinolytic processes are complex and depend not only on the
specificity of the inhibitors for thrombin in comparison to other enzymes, but also on the
structure and type of the clot used to study the effects, the fibrinolytic agent used to lyse
the clot and the endpoints measured.
Drug interactions play an important role in the overall safety and efficacy of
anticoagulant agents such as thrombin inhibitors.

In many indications, antithrombin

agents are administered in conjunctions with other drugs. Many of the patients are often
on other medications. A systematic study on the interactions of antithrombin agents with
other drugs is not available. However, it wold be feasible to develop a testing system
for thrombin inhibitors before this interaction with other drugs can be studied.
Hirudin, unlike other peptide or peptidomimetic antithrombin agents, because of
its high specificity for thrombin does not exhibit any complex interactions (Callas et al.
1995, Fareed et al. 1995). Its actions are readily predictable because of the known
pharmacologic profile.

However, dosage optimization in the presence of other

anticoagulant/ antithrombotic drugs is important.

Hirudin and the other thrombin

inhibitors are expected to exhibit augmentation of the anticoagulant actions of oral
anticoagulant actions of oral anticoagulant drugs since these agents suppress the formation
of functional forms of factors II, VII, IX and X. In addition, these agents also augment
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the functional forms of protein C and S. In this situation, hirudin and the low molecular
weight thrombin inhibitors are capable of inhibiting thrombomodulin-bound thrombin,
which is needed for the activation of protein C. The consequences of this process are
not known. While there is no preclinical or clinical data available, the in vitro studies
suggest that thrombin inhibitors may produce other additive or synergistic actions of the
anticoagulant effects of these agents. Dosage adjustments may be required depending on
the dose of heparins, to optimize the therapeutic index of the direct antithrombin agents.
Most of the cardiovascular patients are on aspirin for prophylactic or therapeutic
reasons.

Since thrombin plays a key role in the activation of platelets, thrombin

inhibitors are expected to produce augmentation or synergism of the antiplatelet actions
of aspirin. This may be a complex situation, however, it would result in compromised
hemostasis. The bleeding complications observed in the TIMI 9A and GUSTO II trials
may be attributable to the use of aspirin by the patients included in this study (Antman
and TIMI 9A Investigators 1994, GUSTO II Investigators 1994). This is supported by
a recent report (Breddin et al. 1996), the interaction of hirudin and aspirin on normal
healthy human volunteers resulted in prolongation of the bleeding time which was not
correlated with any of the platelet function tests nor any of the coagulation parameters.
On the other hand, the interaction may also be of clinical benefit to the patients if the
dose of those agents are optimized.

Other platelet interactions such as the IIb/IIIa

inhibitors and ADP antagonists are expected to have similar interactions with hirudin.
Unlike many direct thrombin inhibitors, hirudin does not produce any direct
inhibition of such fibrinolytic enzymes as plasmin and plasminogen activators. However,
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hirudin is capable of inhibiting thrombomodulin-bound thrombin which would result in
inhibition of the anticoagulant action of thrombin (activation of protein C) and thus
precipitate a prothrombotic situation at higher doses. Furthermore, hirudin does augment
the anticoagulant actions of the fibrinogen/fibrin degradation products in various
experimental settings. Thus, hirudin is expected to produce an augmentation of the
thrombolytic efficacy and may prevent rethrombosis (reocclusion). The net effect of
hirudin can be validated only in clinical trials.

H. Synopsis
There is a continual influx of both the basic and clinical data in the area of
thrombin inhibitors. Ever since the introduction of commercially feasible antithrombin
agents such as hirudin and other synthetic inhibitors of thrombin, a strong interest in the
development of these drugs is eminent. It should also be noted that thrombin plays an
important role in several biological process such as mitogenesis, cellular proliferation,
vascular modulation and the modulation of ion channeling processes. The focus of this
review is primarily on the thrombogenic effects of this enzyme (thrombin), in context
with the pharmacology of various thrombin inhibitors included in this dissertation. It is
conceivable that many of the thrombin inhibitors discussed in this review also modulate
non-clotting/thrombogenic functions of thrombin. Additional information on some of
these actions of thrombin have been extensively reviewed.

At the present time,

additional information on the basic mechanism of thrombin as a procoagulant and the
behavior of thrombin inhibitors as anticoagulant/ antithrombotic drugs is far from
complete. A periodic update on the subject is therefore essential.

CHAPTER ill
MATERIALS AND METHODS

A. Synthesis and Characterization of Serine Protease Inhibitors
The tripeptide aldehydes D-Phe-Pro-Arg-H · H2S04 (GYKI 14166), D-MePhe-ProArg-H · H2S04 (GYKI 14766) and Boc-D-Phe-Pro-Arg-H · 1hH2S04 (GYKI 14451) were
synthesized and were obtained from the Institute for Drug Research, Budapest, Hungary.
All of these agents were provided in dried powder forms and were kept in refrigerated
desiccators. The procedures for the synthesis and the chemical characterization of these
I

compounds has been described (Bajusz et al. 1975, 1978, 1983, 1984, 1987, 1990).
Because the free tripeptide aldehyde D-Phe-Pro-Arg-H was found to be an unstable
compound and its functional inactivation was associated with the formation of a less polar
heterocyclic derivative, N substitution was employed to synthesize more stable analogues.
While the N-Boc derivative (Boc-D-Phe-Pro-Arg-H) was more stable than the free
tripeptide aldehyde, it was not as specific as the other agents. On the other hand, Nalkyl substitution resulted in synthesis of stable D-Phe-Pro-Arg-H analogues, such as DMePhe-Pro-Arg-OH, that retained the basic amino terminus characteristic which confers
specificity for thrombin. The structures of these peptide aldehydes are depicted in Fig.
3. The formula molecular weights of each of these peptides is D-Phe-Pro-Arg-H · H2S04
[500.6], D-MePhe-Pro-Arg-H · H2S04 [514.6] and Boc-D-Phe-Pro-Arg-H · 1hH 2S04
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[551.6] respectively. Stock solutions of these agents were made in appropriate buffers
and saline prior to use. The saline stock solutions were frozen at -70°C and thawed only
once prior to use. The same buffer and saline were used to make serial dilutions of these
agents.
The compound Ac-(D)Phe-Pro-boroArg-OH · HCl (DuP 714) was obtained from
DuPont Merck Pharmaceutical Company, Wilmington, DE, in a powder form.

The

procedure for the synthesis and chemical characterization of this compound has been
published (Kettner et al. 1990). The structure of this compound is depicted in Fig. 3.
The formula molecular weight for this compound is 496.8. Stock and working solutions
of this agent were also made prior to use in the appropriate buffers or saline. As with
the peptide aldehydes, the saline stock solutions of this agent were frozen at -70°C and
thawed once prior to usage.
Argatroban,

(2R,4R)-4-methyl-l-(N2-( (3-methyl-1, 2, 3 ,4-tetrahydro-8-

quinolinyl)sulfonyl]-L-arginyl)]-2-piperidine carboxylic acid, consists of a mixture of the
diastereoisomers 21-(R)- and 21-(S)- around the 2- and 4- positions of the piperidine
ring, in a ratio of approximately 65:35. The method for the synthesis of this compound
was described by Okamoto and Hijikata (1981). Argatroban was obtained from Texas
Biotechnology Corp., Houston, TX.

This compound was provided in a 0.5 mg/ml

solution. Light resistant vials containing 10 mg of argatroban in 20 ml sterile isotonic
solution were provided and kept at room temperature. The structure of this compound
is depicted in Fig. 3. The formula molecular weight of this compound was 532. Further
dilutions of argatroban were made also in saline and appropriate buffers prior to use.
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Recombinant hirudin variant 1 (rHV-1) was obtained from Knoll AG,
Ludwigshafen, Germany in lyophilized form in vial containing 20 mg, 17,000 ATU/mg,
(Batch No: 00300AL). This recombinant material was produced in Escherichia coli and
was a single 65 amino acid polypeptide chain. The primary structure of this hirudin is
given in Fig. 4.

The purity was > 95 % with 0.5 % moisture.

The additives were

succinate and sodium chloride. The molecular weight for this compound is 6,963. The
specification data provided with this material are found in Appendix 1.

Stock and

working solutions of his agent were also made in saline and appropriate buffers. The
saline stock solutions were frozen at -70°C and thawed once prior to use.
Unfractionated porcine mucosal heparin (PMH, lot no. RB 21055) was obtained
from Sanofi, Choay Institut, Paris, France. It was provided in a white powder form as
a sodium salt. The molecular weight for this compound is 10, 700. The specific activity
of this agent was found to be 160 U/mg.
Aprotinin is broad spectrum Kunitz-type serine protease inhibitor. Aprotinin was
obtained in powder form from Pentapharm AG, Basel, Switzerland (6,120 KIU1 /mg).
This compound is a Kunitz type of inhibitor, consisting of a single 58 amino acid
polypeptide chain, with a molecular weight of 6,512, extracted from bovine lungs (Fritz
and Wunderer, 1983). The primary structure of aprotinin is depicted in Fig. 4. This
polypeptide chain is cross-linked by 3 disulfide bridges (Fritz and Wunderer, 1983).

1

1 Kallikrein Inactivator Unit (KIU) = amount of aprotinin that reduces the
biologic activity of 2U of kallikrein by 503

96
B. Analytical Profile of Peptide Thrombin Inhibitors

Due to the instability of the D-Phe-Pro-Arg-H compound, methods for
determining the purity and stability of all tripeptide thrombin inhibitors studied in these
experiments were utilized. The HPLC system utilized for these studies was a Waters A45 system (2 Waters 510 HPLC pumps, Waters 712 Waters Intelligent Sample Processor,
Waters 484 Tunable Absorbance Detector). The column used was a reversed phase
analytical column (RAININ Microsorb-MV HPLC Column, C18, 5 µm, 100
reversed-phase column, 4.6 mm ID x 25 cm). The detection was at 214 nm.

A,
The

injection volume was 25 µl of 1 mg/ml of each peptide.
The eluent systems and gradients for determining the purity of the tripeptide
aldehydes (D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H) were
suggested and described in detail by Dr. Sandor Bajusz (Institute for Drug Research,
Budapest, Hungary) and also published by Bajusz et al. (1975, 1978). All peptides
eluted in 3 peaks corresponding to equilibrium structures, as was described by Bajusz et
al. 1990. All other additional peaks were due to impurities (side products, epimers,
racemized derivatives etc.). The amount of each peptide was determined by summing
the area under the three equilibrium peaks and subtracting it from the area under all
background-adjusted peaks.
The peptide Ac-(D)Phe-Pro-boroArg-OH was also profiled by an HPLC method,
utilizing the same equipment and parameters as with the peptide aldehydes. The eluent
system and gradients for determining the purity of Ac-(D)Phe-Pro-boroArg-OH, were
suggested by Dr. Charles Kettner (DuPont-Merck Pharmaceuticals, Wilmington, DE).
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1. D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H
Purity Determination
The purity and concentration of the tripeptide aldehyde thrombin inhibitors was
determined by standard HPLC methods, using the above described system.

The

specification data provided with these materials are provided in Appendix 2. The two
eluent systems, for pump A and pump B respectively, were distilled water with 0.1 3
trifluoroacetic acid (in which the peptides are dissolved at concentrations of 1 mg/ml) and
acetonitrile with 0.1 3 trifluoroacetic acid (as the gradient).

For D-Phe-Pro-Arg-

H · H2S04 and D-MePhe-Pro-Arg-H · H2S04 , the flow rate was 1.2 ml/min and the
gradient was 0-5 min: 0 - 8 3 pump B
5-30 min: 8 3 pump B (isocratic)
30-45 min: 8 - 60 3 pump B
45-50 min: 603 pump B (isocratic)
50-55 min: 60 - 0 3 pump B
55-60 min: 03 pump B

For the Boc-D-Phe-Pro-Arg-H · 1/2H 2S04 the flow rate was 1 ml/min and the
gradient was 0-10 min: 0 - 30 3 pump B
10-25 min: 303 pump B (isocratic)
25-40 min: 30 - 603 pump B
40-45 min: 603 pump B (isocratic)
45-50 min: 60 - 0 3 pump B
50-55 min: 0 3 pump B.
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2. Ac-(D)Phe-Pro-boroArg-OH Purity Determination

The purity and concentration of the tripeptide boronic acid thrombin inhibitor was
determined by using the above described system, as described by Dr. Kettner.

The

specification data provide with this material are in Appendix 3. The two eluent systems,
for pump A and pump B respectively, were distilled water with 10 3 methanol and 0. 005
M octane sulfonate sodium salt (in which the boronic acid derivative was dissolved at a
concentration of 1 mg/ml), and distilled water with 903 methanol and 0.005 M octane
sulfonate sodium salt. The flow rate was 1.5 ml/min and the gradient was 54 3 pump
A and 46 3 pump B. The total run time was 20 min.

C. Analytical Profile of the Unfractionated Heparin

Unfractionated heparins are poly-component agents and depending on the source
and method of purification they vary in composition.

The unfractionated porcine

mucosal heparin used in these studies was characterized by using a published GPC
method (Ahsan et al. 1994). The GPC-HPLC hardware used in this study was a Waters
A-45 system (2 Waters 510 HPLC pumps, Waters 712 Waters Intelligent Sample
Processor, Waters 484 Tunable Absorbance Detector and a differential refractometer
joined in series with the outlet end of the columns attached to the tunable absorbance
detector), equipped with Expert Ease software designed for polymer analysis.

The

columns used were a tandem column system (TSK 2000/TSK 3000, Beckman, San
Ramon, CA). The mobile phase was 0.5 M NaiS04 , the flow rate was 0.5 ml/min and
the injection volume was 20 µl. The run time was 65 min and the UV detection was at
234 nm.

A simultaneous recording of the heparin profile was also made using the
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refractive index detector. The calibration used in this system was described in detail in
the publication by Ahsan et al. 1994 and comprised of 19 narrow range calibrators. The
heparin used in this study was provided as a white-powder sodium salt and was dissolved
in 0.5 M Na2S04 to a concentration of 10 mg/ml for the GPC profiling.

D. Biochemical Assays
1. Thrombin Titration Assay
An amidolytic method was used to determine the direct antithrombin actions of
various thrombin inhibitors. This method was developed by Iyer and Fareed (1995), as
an assay for the determination of the specific activity of recombinant hirudin and as a
tool for quality assurance and for the determination of batch to batch variation. The
objective of these studies was to determine and compare the antithrombin potencies of
direct thrombin inhibitors in terms of antithrombin units (ATU), utilizing a thrombin
titration method. Since the definition of ATU is the amount of thrombin inhibitor that
inhibits 1 NIH unit of thrombin, this assay was developed so that the final concentration
of thrombin in the system was 1 NIH unit/ml.

Therefore, the amount of thrombin

inhibitor that produced 1003 inhibition of thrombin's activity was designated as the
potency of a thrombin inhibitor in ATU/mg. a-thrombin (E.C. # 3.4.21.5, lot a375,
specific activity 3,369 U/mg, protein concentration 0.68 mg/ml) was obtained from Dr.
John Fenton II, New York State Dept. of Health, Albany, NY.
diluted in buffer to a working concentration of 23.5 U/ml.

This thrombin was

Each of the thrombin

inhibitors were diluted to various working concentrations in sterile saline solution (Baxter
Healthcare Corp., Deerfield, IL). The amidolytic activity of thrombin was detected with
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the chromogenic substrate Spectrozyme®TH (H-D-HHTyr-Ala-Arg-pNA · 2AcOH,
American Diagnostica, Greenwich, CT), at a working concentration of 1.5 mM (diluted
in deionized water). Cleavage of this substrate by thrombin results in release of the
yellow chromophore pNA (para-nitroaniline).
The buffer used to dilute the a thrombin to 23.5 U/ml was composed of Tris
(0.05 M), NaCl (0.2 M) and polyethylene glycol 6000 (0.1 %), adjusted to pH 7.9. The
buffer used for the assay described below was composed of triethanolamine HCl (0.1 M)
and NaCl (0.2 M), adjusted to pH 8.4.
The method used was carried out as follows utilizing quartz cuvettes (path length
= 1 cm, Beckman Instruments, Inc., Irvine, CA) and a spectrophotometer (DU-7®,

Beckman Instruments, Inc., Fullerton, CA): 1975 µl of buffer were mixed and incubated
for 2 min at 37°C with 25 µl of the thrombin inhibitor at a particular concentration. 100
µl of thrombin were added to this mixture and allowed to incubate for 1 min at 37°C.
250 µl of Spectrozyme®TH were added and the rate of change in absorbance was
measured for the next min at 405 nm. Sterile saline solution was used in place of the
thrombin inhibitor as a control.
Residual thrombin activity, remaining after incubation with a thrombin inhibitor
was expressed as a percentage of the saline control by dividing the two respective rates
of change in absorbance. The final concentration of the thrombin inhibitor was plotted
against the residual thrombin activity.
The order of the regression analysis utilized was the lowest that yielded regression
coefficients >0.99. The thrombin inhibitor concentration that produced 503 residual
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thrombin activity was the concentration that inhibited 0.5 NIH U/ml thrombin and
therefore the thrombin inhibitor's ATU was double of that concentration. From these
values, the relative antithrombin activity of each agent is calculated in terms of ATU/mg
or ATU/nmole. Each concentration-response curve was repeated in triplicate on separate
runs.

2. Thrombin Time (TT) in a Fibrinogen Based System
The fibrinogen based TT is a biochemically defined functional method for
measuring the antithrombin effects of thrombin inhibitors, using human fibrinogen as the
substrate for thrombin. While the thrombin titration method, described in the previous
section, provides a measurement of the antithrombin activity of thrombin inhibitors
utilizing thrombin's amidolytic activity, the fibrinogen based TT provides a measurement
of the antithrombin activity of thrombin inhibitors utilizing thrombin's biologic activity
, where soluble fibrinogen is transformed into fibrin. To perform the TT assay, a known
amount of preformed human thrombin is added to the fibrinogen sample (containing
varying amounts of a thrombin inhibitor) and the time required for clot formation
measures the rate at which fibrin is formed. TT measurements were carried out using
a solution of human fibrinogen (IMCO, Stockholm, Sweden,

> 97% clottable fibrinogen,

each vial containing 0.25g fibrinogen, O. lg sodium chloride and 0.25g sodium citrate,
3 µg plasminogen/mg fibrinogen and < 5 µg plasmin/g fibrinogen) at 100 mg/dL, made
in Owren's Verona! Buffer (Baxter Dade, Miami, FL). Each of the thrombin inhibitors
was diluted at various concentrations in the buffered fibrinogen solution. Fibrindex™
brand of human thrombin (lyophilized, 50 U/ampule, Ortho Diagnostic Systems, Raritan,
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NJ) at a concentration of 10 NIH U/ml in 0.025 M CaC1 2 , or in sterile saline solution
(Baxter Healthcare Corp., Deerfield, IL) was used to initiate fibrinogen conversion to
fibrin. In this procedure 100 µl of 10 U/ml human thrombin prewarmed at 37°C were
added to 200 µl of fibrinogen prewarmed at 37°C for 3 min, and the clotting time was
measured. Each concentration-response curve was repeated in triplicate on separate days.

3. Antithrombin Assays

The antithrombin assays provided a measurement of thrombin inhibitor
concentration, utilizing the inhibitory effect against the amidolytic activity of thrombin
(Fibrindex™), quantitated by a chromogenic substrate for thrombin (Spectrozyme®TH).
This method was initially described by Walenga et al. 1983. Calibration curves (in vitro
supplementation of thrombin inhibitors at various concentrations) were constructed with
both normal human plasma and normal rabbit pool plasma. Due to the differences in
blood clotting factor levels between human and rabbit plasma, the antithrombin
amidolytic assay method varied, depending on the source of the plasma.
Regardless of the species the plasma was obtained from and the procedure
followed, the thrombin inhibition by each agent at each concentration or dose was
calculated by the following formula: % thrombin inhibition by agent = [l - agent
I saline

~A405 ]

~A405

x 100

The agent concentration versus % inhibition graphs provided the basis for the
calculation of the IC50 for each agent. Since the molecular weights of these agents are
known, all data were converted to molar concentrations or doses. Each concentrationresponse curve was repeated in triplicate on separate days.
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a. Preparation of Normal Human Plasma (NHP)
Normal human plasma was obtained from the Loyola Blood Bank and was
certified to be free of viral contamination (tested for Hepatitis B surface antigen,
Hepatitis B antibodies, Hepatitis C antibodies, Hepatitis core antibodies, HIV 1 and 2
antibodies, HTLV 1 antibodies, STS antibodies). The blood was collected from normal
healthy human volunteers in bags containing CPDA-1 mixture (26.3 g/L trisodium
citrate, 3.27 g/L citric acid, 31.9 g/L dextrose, 2.22 g/L monobasic sodium phosphate,
and 0.275 g/L adenine), so that 450 ml of blood were mixed with 63 ml of CPDA-1
anticoagulant-preservative. Within 8 hours of collection, this blood was centrifuged at
1,200xg for 30 min at 4 °C. The separated plasma was then frozen at -70°C. Routinely,
four or five frozen plasma bags were obtained from the blood bank and these were
thawed and the plasmas were mixed to obtain a pool. This pool was then aliquoted and
re-frozen at -70°C. The aliquots were thawed only once and used as needed. The
unused pool plasma was appropriately disposed.

b. Antithrombin Amidolytic Assay with NHP
Each of the thrombin inhibitors was diluted in NHP to obtain vanous
concentrations. When human plasma samples were evaluated, the assay was carried out
in a fast kinetic centrifugal analyzer (ACL 300 plus, Instrumentation Laboratory,
Lexington, MA). The procedure for the antithrombin amidolytic assay was as follows:
10 µl of a sample containing thrombin inhibitor were incubated with 100 µl of 5 U
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thrombin (diluted in Tris/EDTA buffer2) for 60 sec and then 40 µl of the thrombin
substrate (1 mM in deionized H2 0) were added and the optical density was measured
over a period of 30 sec.

c. Preparation of Normal Rabbit Plasma (NRP)
To study the concentration-dependent effects of thrombin inhibitors in the various
plasma based assays and to prepare calibration curves, pools of rabbit plasma were
prepared. To obtain these pools, 10 to 15 white male New Zealand rabbits weighing 2.5
to 3.5 kg were obtained from LSR Industries, Union Grove, WI and housed individually.
The animals were kept on standard rabbit chow diet and had access to water ad libitum.
Each rabbit was lightly anesthetized with ketamine hydrochloride (Ketaset®, 100 mg/ml,
Aveco Co. Inc., Fort Dodge, IA) at a dose of 50 mg/kg I.M. in combination with
xylazine (Rompun®, 100 mg/ml, Mobay Corporation, Shawnee, KS) at a dose of 25
mg/kg I.M. Blood was collected through the major ear artery of each rabbit. The first
3 ml were discarded, while the subsequent 9 ml were collected in 3. 8 % sodium citrate
(Vacutainer®, Becton Dickinson, Franklin Lakes, NJ). The rabbits were then monitored
for 20 min to ensure hemostasis and then returned to their cages. Subsequently, the
blood was centrifuged (Beckman GPR Centrifuge, Beckman Instruments Inc., Irvine CA)
at 1200xg at 4 °C for 20 min to achieve platelet poor plasma which was pooled, mixed
and frozen in aliquots at -70 °C. Aliquots were thawed and used immediately as needed
(never re-frozen).

2

Tris/EDTA buffer:50mM
Na2 EDTA · 2H20,pH 8.4.

Trizma

Base,

175mM

NaCl,

7.5mM
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d. Antithrombin Amidolytic Assay with NRP
Each of the thrombin inhibitors was supplemented at various concentration to
NRP. When rabbit plasma samples were tested, the antithrombin assay was carried out
in a spectrophotometer (DU-7®), utilizing quartz cuvettes.

The procedure for the

antithrombin amidolytic assay was as follows: 25 µI of a sample containing thrombin
inhibitor were incubated with 400 µI of Tris/EDTA buffer at 37°C for 1 min. Then,
25 µI of 10 U thrombin (diluted in sterile saline solution) were added and incubated for
1 min at 37°C. At the end of the incubation period, 50 µI of the thrombin substrate (1
mM in deionized H20) were added and the rate of change of optical density was
measured over a period of 1 min at 405 nm.

4. Anti-Xa Assays

The anti-Xa assay provided a measurement of the relative inactivating actions of
various agents, by measuring their inhibitory effects against the amidolytic activity of
factor Xa. Human factor Xa (E.C. # 3.4.21.6, 0.65 ng/ml, Enzyme Research, South
Bend, IN), was analyzed using a chromogenic substrate for factor Xa (Spectrozyme®FXa,
MeO-CO-D-CHG-Gly-Gly-Arg-pNA · AcOH, American Diagnostica, Greenwich, CT).
This method was described by Walenga et al. (1983).

Calibration curves (in vitro

supplementation of thrombin inhibitors at various concentrations) were constructed with
both normal human plasma and normal rabbit plasma. Due to the differences in factor
concentrations between human and rabbit plasma, the anti-Xa amidolytic assay method
differed, depending on the source of the plasma.
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Regardless of the species the plasma was obtained from and the procedure
followed, the factor Xa inhibition by each agent at each concentration or dose was
calculated by the following formula: % factor Xa inhibition by agent = [l - agent AA405
I saline AA405 ] x 100

The agent concentration versus % inhibition graphs provided the basis for the
calculation of the IC50 for each agent. Since the molecular weights of these agents are
known, all data were converted to molar concentrations or doses. Each concentrationresponse curve was repeated in triplicate on separate days.

a. Anti-Xa Amidolytic Assay with NHP
Each of the thrombin inhibitors was diluted to various concentrations in NHP.
When human plasma samples were evaluated, the assay was carried out in a fast kinetic
centrifugal analyzer (ACL 300 plus). The procedure for the anti-Xa amidolytic assay
was as follows: 10 µl of a sample containing thrombin inhibitor were incubated with 100
µl of factor Xa (6.6 pg/ml, diluted in Tris/EDTA buffer2) for 300 sec and then 75 µl of
the factor Xa substrate (2.5 mM in deionized H20) were added and the optical density
was measured over a period of 30 sec.

b. Anti-Xa Amidolytic Assay with NRP
Each of the thrombin inhibitors was supplemented at various concentration to
NRP. When rabbit plasma samples were tested, whether in vitro supplemented with a
thrombin inhibitor or obtained during the rabbit stasis thrombosis model for ex vivo
analyses, the anti-Xa assay was carried out in a spectrophotometer (DU-7®) utilizing
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quartz cuvettes. The procedure for the anti-Xa amidolytic assay was as follows: 25 µl
of a sample containing thrombin inhibitor were incubated with 375 µl of Tris/EDTA
buffer2 at 37°C for 2 min. Then, 50 µl of factor Xa (5 nkat/ml, diluted in Tris/EDTA
buffer2) were added and incubated for 2 min at 37°C. At the end of the incubation
period, 50 µl of the factor Xa substrate (2.5 mM in deionized H20) were added and the
rate of change of optical density was measured over a period of 1 min at 405 nm.

5. Inhibitory Actions of Various Thrombin Inhibitors on
Specific Serine Proteases

Although some thrombin inhibitors are designed to inhibit the catalytic site of
thrombin,
because of the similarity between the catalytic sites of all serine proteases, it
,
is possible that the agents that inhibit the catalytic site of thrombin, also inhibit the
catalytic site of other serine proteases. The following assays were designed to examine
the inhibitory effects that thrombin inhibitors may have against other serine proteases,
utilizing the amidolytic activity of these enzymes, in purified systems.

The general

procedure followed in the following assays was conducted on a fast kinetic centrifugal
analyzer (ACL 300 plus). Generally, each thrombin inhibitor was diluted in sterile saline
solution at various concentrations. Ten µl of the thrombin inhibitor were incubated with
100 µI a known amount of the specific enzyme for 1 min. At the end of the incubation
period, 40 µl a chromogenic substrate specific for the enzyme was added and the optical
density was measured over a period of 999 sec. The serine protease inhibition by each
thrombin inhibitor at each concentration was calculated by the following formula:

% protease inhibition

=

[l - inhibitor .AA405 I saline .AA405] x 100
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The thrombin inhibitor concentration versus 3 inhibition graphs provided the
basis for the calculation of the IC50 for each agent. Since heparin is devois of any direct
serpin activities and its actions are mediated primarily through potentiation of
antithrombin, the stock solution of heparin was made as 10 mg/ml in 1 U/ml
antithrombin (Kabi Vitrum, Stockholm, Sweden). Further dilutions of this mixture were
made in saline, as were for the other thrombin inhibitors. In addition to the thrombin
inhibitors, aprotinin was also tested in these system as a positive control for the
evaluation of the thrombolytic enzymes. Since the molecular weights of these agents are
known, all data were converted to molar concentrations. Each concentration-response
curve was repeated in triplicate on separate days.

a. Inhibition of Chymotrypsin
Chymotrypsin (E.C. # 3.4.21.1, Zolyse®, from ox pancreas, 750 U.S.P.
units/vial) was obtained from Ben Venue Laboratories,

Inc., Bedford,

OH.

Chymotrypsin was used at a final assay concentration of 6.67 U/ml. The chromogenic
substrate used to detect the activity of chymotrypsin was S-2586 (MeO-Suc-Arg-Pro-TyrpNA · HCl, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden), at a final assay
concentration of 0.27 mM.

b. Inhibition of Trypsin
Porcine pancreatic trypsin (E.C. # 3.4.21.4, type II, crude, trypsin activity: 1740
BAEE units 3 /mg, chymotrypsin activity: 1150 ATEE units4 /mg) was obtained from

3

1 BAEE unit = AA253 of 0.001/min in 3.2 ml at pH 7.6 at 25°C
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Sigma Chemical Company, St, Louis, MO.

Trypsin was utilized at a final assay

concentration of 66.67 µg/ml . The chromogenic substrate used to detect the activity of
trypsin was S-2423 (CH3 -CO-Ile-Glu-Gly-Arg-pNA · HCl, Kabi Diagnostica, KabiVitrum,
Stockholm, Sweden), at a final assay concentration of 0.27 mM.

c. Inhibition of Activated Protein C (APC)
APC (E.C. # 3.4.21.69) was obtained from American Red Cross, Holland
Laboratories, Rockville, MD, lyophilized, 5 mg/vial. The final assay concentration of
APC was 62.5 µglml.

S-2288 (H-D-Ile-Pro-Arg-pNA · 2HC1, Kabi Diagnostica,

KabiVitrum, Stockholm, Sweden) was the chromogenic substrate used to detect the
activity of APC, at a final assay concentration of 0.27 mM.

d. Inhibition of Glandular Kallikrein
Pancreatic kallikrein (E.C.# 3.4.21.35, 4.7 units 5/mg solid, 4.8 units/mg protein)
was obtained from Sigma Chemical Company, St, Louis, MO. kallikrein was used at
a final assay concentration of 0.67 mg/ml. The chromogenic substrate used to detect the
activity of kallikrein was S-2302 (H-D-Pro-Phe-Arg-pNA · 2HC1, Kabi Diagnostica,
KabiVitrum, Stockholm, Sweden), at a final assay concentration of 0.27 mM.

e. Inhibition of Tissue Plasminogen Activator (tPA)
tPA (E.C. # 3.4.21.68) was obtained from Genentech, South San Francisco, CA

4

5

1 ATEE unit = t:.A237 of 0.001/min in 3 ml at pH 7.0 at 25°C

1 unit hydrolyzes 1.0 µM of a-N-Benzoyl-Arg-Ethyl-Ester (BABE) to a-NBenzoyl-L-Arg and EtOH/min at pH 8.7 at 25°C
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(Activase®, Alteplase, recombinant, 50 mg or 29 million IU /vial).

The final assay

concentration oft-PA was 0.67 mg/ml. Spectrozyme®TH was the chromogenic substrate
used to detect the t-PA activity, at a final assay concentration of 0.27 mM.

f. Inhibition of Urokinase
Urokinase (E.C. # 3.4.21.73, Abbokinase®, 250,000 I.U./vial, from human
kidney cells by tissue culture, low molecular weight form) was obtained from Abbott
Laboratories, North Chicago, IL. The final assay concentration of urokinase was 6,667
U/ml.

The chromogenic substrate used to detect the urokinase activity was S-2444

( < Glu-Gly-Arg-pNA · HCl, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden) at a
final assay concentration of 0.27 mM.

g. Inhibition of Plasmin
Plasmin (E.C. # 3.4.21.7, 6 nKat/vial) was obtained from Diagnostica Stago,
Asnieres-Sur-Seine, France. Plasmin was utilized at a final assay concentration of 1.2
nKat/ml. The chromogenic substrate used to detect the activity of plasmin was S-2251
(H-D-Val-Leu-Lys-pNA · 2HC1, Kabi Diagnostica, KabiVitrum, Stockholm, Sweden), at
a final assay concentration of 0.27 mM.

6. Inhibition of Piasminogenolysis
While the direct effects of thrombin inhibitors on serine proteases were studied
utilizing the above described assay systems, the relevance of these effects to the process
of activation of plasminogen to plasmin, or plasminogenolysis, was not addressed.
Plasminogenolysis after activation by streptokinase or t-PA was measured in the systems
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described below. The source of the plasminogen was either purified plasminogen (25
CU 6 , 15 CU/mg, AB KABI, Stockholm, Sweden), or pooled human blood bank plasma
(Loyola Blood Bank).
In all plasminogenolysis assays, the inhibition of plasminogenolysis by each

thrombin inhibitor and aprotinin at each concentration was calculated by the following
formula: % inhibition = [1 - inhibitor Ll.A405 I saline Ll.A405] x 100
The inhibitor concentration versus % inhibition response curves provided the basis
for the calculation of the IC50 and IC25 for each agent. Since the molecular weights of
these agents are known, all data were converted to molar concentrations.

Each

concentration-response curve was repeated in triplicate.

a. Pure Plasminogen System
In these assays, each thrombin inhibitor and aprotinin was diluted at various
concentration in a TRIS/EDTA buffer2 • Pure plasminogen at a final assay concentration
of 0.97U/ml was lysed by either streptokinase (E.C. # 3.4.22.10, purified streptokinase
from Group C streptococci, 600,000 I.U./vial, AB KABI, Stockholm, Sweden) at a final
assay concentration of 2,500 U/ml, or t-PA (Activase®) at a final assay concentration of
5,000 U/ml. The generated plasmin was detected with a substrate specific for plasmin
(Spectrozyme®PL,

H-D-Nle-HHTyr-Lys-pNA · 2AcOH,

American

Diagnostica,

Greenwich, CT), at a final assay concentration of 0.75 mM. The effects of thrombin
inhibitors and of aprotinin on the process of plasminogenolysis were studied on a

6

CU = casein unit (Sgouris et.al, 1960)
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spectrophotometer (model 35, Beckman Instruments, Inc., Fullerton, CA) and quartz
cuvettes. 750 µl of a thrombin inhibitor were incubated for 1 min at 37°C. At the end
of this incubation period, 100 µl of streptokinase or t-PA and 25 µl of plasminogen were
added and the mixture was incubated for 3 min at 37°C. At the end of this incubation
period, 100 µl of Spectrozyme®PL were added and the rate of change of optical density
was measured over a period of 1 min.

b. NHP System
In these assays, each thrombin inhibitor and aprotinin was diluted at various
concentration in a TRIS/EDTA buffer2 • NHP at a final assay dilution of 1: 10, was used
as the source of human plasminogen. The plasminogen contained within the NHP was
lysed by either streptokinase (AB KABI) at a final assay concentration of 2,500 U/ml,
or t-PA (Activase®) at a final assay concentration of 5,000 U/ml. The generated plasmin
was detected with a substrate specific for plasmin (Spectrozyme®PL) at a final assay
concentration of 0. 75 mM. The effects of thrombin inhibitors and of aprotinin on the
process of plasminogenolysis were studied on a spectrophotometer (model 35) and quartz
cuvettes. 750 µl of a thrombin inhibitor were incubated for 1 min at 37°C. At the end
of this incubation period, 100 µl of streptokinase or t-PA and 50 µl of NHP were added
and the mixture was incubated for 3 min at 37°C. At the end of this incubation period,
100 µl of Spectrozyme®PL were added and the optical density was measured over a
period of 1 min.
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7. Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient
Human Plasma by Thrombin Inhibitors

While the antithrombin and anti-Xa assays are useful in determining the direct
antithrombin or anti-Xa effects of thrombin inhibitors, they do not provide information
on the effects of these inhibitors on the overall process of coagulation, or on the
generation of thrombin and factor Xa. These plasmatic methods were developed by
Kaiser et al. 1992, and were used to determine the thrombin and factor Xa generation
inhibitory actions of various thrombin inhibitors, following extrinsic activation of the
coagulation cascade.

In these assays the materials used were: chromogenic substrate

specific for thrombin (Spectrozyme®TH), chromogenic substrate specific for factor Xa
(Spectrozyme®FXa), fibrinogen deficient plasma (fibrinogen < 15mg/dL, George King
Biomedical, Overland Park, KS) and extrinsic activator (lyophilized acetone-dehydrated,
rabbit brain Thromboplastin C, Dade, Miami, FL). The instrument used was a fast
kinetic centrifugal analyzer (ACL 300 plus).
The extrinsic thrombin and factor Xa generation inhibition by each thrombin
inhibitor at each concentration was calculated by the following formula:
% thrombin or factor Xa generation inhibition by agent = [l - agent .lA405 I saline

.lA405 ] x 100
The thrombin inhibitor concentration versus % inhibition graphs provided the
basis for the calculation of the IC50 for each thrombin inhibitor. Since the molecular
weights of these agents are known, all data were converted to molar concentrations.
Each concentration-response curve was repeated in triplicate on separate days.
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a. Inhibition of Extrinsic Thrombin Generation
The chromogenic substrate for thrombin was reconstituted to 1 mM with 0.025
M CaC12 and subsequently mixed with thromboplastin C (1:6). The fibrinogen deficient
plasma was diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic
assay was as follows: 60 µl of a known gravimetric amount of thrombin inhibitor diluted
in sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300
sec. Then 60 µl of the thrombin substrate mixed with thromboplastin C were added and
the optical density was measured over a period of 999 sec.
b. Inhibition of Extrinsic Factor Xa Generation
The chromogenic substrate for factor Xa was reconstituted to 1 mM with 0.025
M CaC12 and subsequently mixed with thromboplastin C (1:6). The fibrinogen deficient
plasma was diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic
assay was as follows: 60 µl of a known gravimetric concentration of thrombin inhibitor
diluted in sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma
for 300 sec. Then 60 µl of the factor Xa substrate mixed with thromboplastin C were
added and the optical density was measured over a period of 999 sec.

8. Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient
Human Plasma by Thrombin Inhibitors
While the previous two methods were used to investigate effects of inhibitory
agents on the extrinsic activation of coagulation, the following plasmatic methods were
used to determine the thrombin and factor Xa generation inhibitory actions of various
thrombin inhibitors, following intrinsic activation of the coagulation cascade..

These
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assays were also developed by Kaiser et al. 1992. In these assays the materials used
were: chromogenic substrate specific for thrombin (Spectrozyme®TH), chromogenic
substrate specific for factor Xa (Spectrozyme®FXa), fibrinogen deficient plasma (George
King Biomedical) and intrinsic activator (Actin, Dade, Miami, FL). The instrument used
was a fast kinetic centrifugal analyzer (ACL 300 plus).
The intrinsic thrombin and factor Xa generation inhibition by each thrombin
inhibitor at each concentration was calculated by the following formula: % thrombin or
factor Xa generation inhibition by agent = [1 - agent AA405 I saline AA405 ] x 100
The thrombin inhibitor concentration versus % inhibition graphs provided the
basis for the calculation of the IC50 for each thrombin inhibitor. Since the molecular
weights of these agents are known, all data were converted to molar concentrations.
Each concentration-response curve was repeated in triplicate on separate days.

a. Inhibition of Intrinsic Thrombin Generation
The chromogenic substrate for thrombin was reconstituted to 1 mM with 0.025
M CaC12 and subsequently mixed with actin (1 :2). The fibrinogen deficient plasma was
diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic assay was as
follows: 60 µl of a known gravimetric concentration of thrombin inhibitor diluted in
sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300
sec. Then 60 µl of the thrombin substrate mixed with actin were added and the optical
density was measured over a period of 999 sec.
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b. Inhibition of intrinsic Factor Xa Generation
The chromogenic substrate for factor Xa was reconstituted to 1 mM with 0.025
M CaC12 and subsequently mixed with actin (1:2). The fibrinogen deficient plasma was
diluted with Tris/EDTA buffer2 (1:8). The procedure for this amidolytic assay was as
follows: 60 µl of a known gravimetric concentration of thrombin inhibitor diluted in
sterile saline solution were incubated with 60 µl of fibrinogen depleted plasma for 300
sec. Then 60 µl of the factor Xa substrate mixed with actin were added and the optical
density was measured over a period of 999 sec.

9. Inhibition of KONYNE® Based Systems by Thrombin Inhibitors
The extrinsic activation systems in human fibrinogen deficient plasma described
above are not devoid of intrinsic activation, since the two pathways of coagulation
interact at various levels, feedback loops amplify certain steps and all plasma factors with
the exception of fibrinogen are present. To develop systems in which only extrinsic
activation is possible without interference from the intrinsic factors, prothrombin complex
concentrates extrinsically activated were used in the following described methods. These
methods were initially developed by Kaiser et al. 1994. These defined methods were
used to determine the factor Xa and thrombin generation inhibitory actions of various
thrombin inhibitors.
In these assays the materials used were: chromogenic substrate specific for
thrombin

(Spectrozyme®TH),

chromogenic

substrate

specific

for

factor

Xa

(Spectrozyme®FXa), extrinsic activator (Thromboplastin C) and the prothrombin complex
KONYNE® (of human origin, lyophilized, 580 U/vial, Cutter Laboratories, Berkeley,
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CA), which represents a mixture of factors II, VII, IX and X. The instrument used was
a fluorescence light scattering micro centrifugal analyzer (Multistat III, Instrumentation
Laboratory, Lexington, MA).
The inhibition of thrombin and factor Xa generation by each thrombin inhibitor
at each concentration was calculated by the following formula: 3 inhibition of thrombin
or factor Xa generation = [ 1 - agent

~A405

at 660 sec I saline

~A405

at 660 sec] x 100

The thrombin inhibitor concentration versus 3 inhibition curves provided the
basis for the calculation of the IC50 for each agent. Since the molecular weights of these
agents were known, all data were converted to molar concentrations.

a. Inhibition of thrombin Generation from KONYNE®
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the thrombin
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in
0.025 M CaC1 2) for 30 sec. Then 25 µl of KONYNE® at 10 U/ml working concentration
(diluted with sterile saline solution), and 10 µl of buffer were added and the optical
density was measured every 60 sec for 12 min.

b. Inhibition of Factor Xa Generation from KONYNE®
The buffer used in this procedure was composed of 1 mM Tris/HCI and 6 mM
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the factor Xa
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substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (dilute 1: 10 in
0.025 M CaClz) for 30 sec. Then 25 µl of KONYNE® at 10 U/ml working concentration
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical
density was measured every 60 sec for 12 min.

10. Inhibition of FEIBA® Based Systems by Thrombin Inhibitors
These systems, like the KONYNE® based systems, also determine the inhibitory
activities of various agents on the extrinsic activation of the coagulation system. The
prothrombin complex KONYNE® used in the above described assays contains factors in
their pro-enzyme form only.

The prothrombin complex FEIBA® IMMUNO (anti-

inhibitor coagulant complex, of human origin, lyophilized, 490 U/vial, Osterreichisches
Institut fiir Haemoderivate GES.M.B.H., subsidiary of Immuno Ag, Vienna, Austria)
differs from KONYNE® in that in addition to factors II, VII, IX and X, it also contains
trace amounts of factor VIIa. In these assays the materials used were: chromogenic
substrate specific for thrombin (Spectrozyme®TH), chromogenic substrate specific for
factor Xa (Spectrozyme®FXa), extrinsic activator (Thromboplastin C) and the
prothrombin complex FEIBA ®IMMUNO. The instrument used was a fluorescence light
scattering micro centrifugal analyzer (Multistat III).
The inhibition of thrombin and factor Xa generation by each thrombin inhibitor
at each concentration was calculated by the following formula: % inhibition of thrombin
or factor Xa generation = [ 1 - agent .LlA405 at 660 sec I saline .LlA405 at 660 sec] x 100
The thrombin inhibitor concentration versus % inhibition graphs provided the
basis for the calculation of the IC50 for each agent. Since the molecular weights of these
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agents were known, all data were also converted into molar concentrations.

a. Inhibition of Thrombin Generation from FEIBA®
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM
CaC1 2 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the thrombin
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in
0.025 mM CaC12) for 30 sec. Then 25 µl of FEIBA® at 10 U/ml working concentration
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical
density was measured every 60 sec for 12 min.

b. Inhibition of Factor Xa Generation from FEIBA®
The buffer used in this procedure was composed of 1 mM Tris/HCl and 6 mM
CaC12 , adjusted to pH 8.1. The procedure for this amidolytic assay was as follows: 165
µl of the antithrombin agent diluted in buffer were incubated with 25 µl of the factor Xa
substrate (2.5 mM in deionized water) and 25 µl of Thromboplastin C (diluted 1: 10 in
0.025 mM CaCl2) for 30 sec. Then 25 µl of FEIBA® at 10 U/ml working concentration
(diluted with sterile saline solution) and 10 µl of buffer were added and the optical
density was measured every 60 sec for 12 min.

E. Anticoagulant Effects of Thrombin Inhibitors in NHP

Previously described amidolytic methods based on the intrinsic and extrinsic
activation of plasma, provide information on the effects of agents on the generation of
thrombin and factor Xa, utilizing the amidolytic activities of these factors. To study the
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functional inhibitory effects on clot formation, or the anticoagulant effects of thrombin
inhibitors and which pathways are inhibited most effectively, each of these agents was

in vitro supplemented to NHP and tested in the global clotting tests described below.
The following clotting time tests were performed on a fibrometer (Becton, Dickinson and
Company, Cockeysville, MD) according to the specifications set by each of the
manufacturers. NHP was obtained from the Loyola Blood Bank. Each concentrationresponse curve was repeated in triplicate on separate days.

1. Prothrombin Time (PT)
This method is based on the method originally described by Quick et al. ( 1935).
The PT reveals defects in the extrinsic system (factor VII) and in the factors common to
the extrinsic and intrinsic systems (factors V and X, prothrombin and fibrinogen).
Thromboplastin is added to a known amount of plasma and it activates factor VII to
factor VIIa, thus activating the extrinsic pathway of coagulation. PT was measured using
Thromboplastin C. In this procedure 100 µl of plasma were incubated for 3 min at
37°C. At the end of this incubation time 200 µ1 of Thromboplastin C prewarmed at
37°C were added and the clotting time was measured.

2. Activated Partial Thromboplastin Time (APTT)
The APTT is based on the originally described method be Proctor and Rapaport
(1961). This method measures the intrinsic coagulation factors (factors VIII, IX, XI and
XII), the factors common to both extrinsic and intrinsic systems (factors V, X and
prothrombin) and the conversion of fibrinogen to fibrin. Prolonged clotting times reflect
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deficiency or inhibition of one or more of the above factors. The time to clot formation
after citrated plasma has been activated by a platelet substitute (a rabbit brain
phospholipid with micronized silica as activator) and ca++ is measured. APTT was
measured using the APTT reagent from Organon Teknika Corporation, Durham, SC.
In this procedure 100 µl of plasma were incubated for 5 min with 100 µl of APTT

reagent (platelet substitute). At the end of this incubation time 100 µl of 0.025 M CaC12
prewarmed at 37°C were added and the clotting time was measured.

3. Thrombin Time (TT)
The TT method is based on the method described by Bonsnes and Sweeney
(1955).

In the determination of citrated plasma TT, a known amount of preformed

human thrombin is added to plasma and the time required for clot formation measures
the rate at which fibrin is formed. TT was carried out using Fibrindex™ human thrombin
at a concentration of 10 NIH U/ml in 0.025 M CaC1 2 • In this procedure 100 µl of 10
U/ml human thrombin prewarmed at 37°C were added to 200 µl of plasma prewarmed
at 37°C for 3 min, and the clotting time was measured.

4. Ecarin Clotting Time (ECT)
ECT is a new plasma-based clotting method, based on the original description by
Nowak and Bucha (1993). This method is similar to the TT described above with the
exception that an enzyme (ecarin) is used to activate the pre-existing prothrombin in the
citrated plasma to a procoagulant form, whereas in the TT, exogenous preformed
thrombin is added. Ecarin is an enzyme purified from the Echis carinatus snake venom.
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Ecarin activates prothrombin to meizothrombin and other intermediates, rather than fully
functional thrombin. However, meizothrombin has also procoagulant activities, although
weaker than thrombin.

This clotting time assay was carried out on a fast kinetic

centrifugal analyzer (ACL 300 plus).
incubated for 2 min at 37°C.

In this assay, 100 µl of citrated plasma were

At the end of the incubation period, 100 µl of ecarin

(Knoll AG, Ludwigshafen, Germany) were added and the time to clotting was measured.

5. Heptest
The Heptest assay, originally developed by Yin et al. (1973), measures the ability
of an agent to inhibit exogenous factor Xa. Heptest clotting time is measured using the
Heptest reagents (Haemachem, St. Louis, MO): bovine factor Xa and Recalmix™ (CaC1 2
and brain cephalin in a bovine plasma fraction). In this procedure 100 µl of plasma were
incubated with 100 µl of bovine factor Xa reagent for 2 min at 37°C. At the end of this
incubation time 100 µl of Recalmix™ were added and the clotting time was measured.At
the final stage of this assay, thrombin is generated and results in the formation of a
detectable clot.

F. Anticoagulant Effects of Thrombin Inhibitors in Native Human Whole Blood
While thrombin inhibitors can be effective anticoagulants when studied in the
plasma based clotting assays described above, the same agents may behave differently
when supplemented to whole blood, since plasma is only one component of whole blood.
The following thrombin inhibitors were studied in these assays: D-MePhe-Pro-Arg-H,
Ac-(D)Phe-Pro-boroArg-OH, argatroban, hirudin and heparin. To determine whether
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these thrombin inhibitors were effective anticoagulants after in vitro supplementation at
various concentrations to native whole blood and to compare these whole blood
anticoagulant effects to the plasmatic anticoagulant effects, each thrombin inhibitor was
studied in the two following assays.
Whole blood was collected from normal healthy human volunteers, after written
consent (blood donation consent form in Appendix 4), via venipuncture. The first 3 ml
of blood drawn were discarded. Each thrombin inhibitor concentration was repeated in
triplicate in normal human whole blood collected from three separate donors.

1. Activated Clotting Time (ACT)
ACT is an assay that also measures whole blood clotting time and was originally
described by Hattersley in 1966 (Hattersley 1984). Because native whole blood is used,
the clotting time depends on both coagulation and platelet functionality. In determining
the ACT of freshly drawn blood samples, special pre-filled glass tubes containing celite
(an intrinsic system activator) were used.

The activated clotting time was measured

utilizing a Hemochron coagulation timing instrument (International Techidyne
Corporation, Edison, NJ). The procedure for determining the ACT was carried out as
specified by the manufacturer. Briefly, 2 ml of freshly drawn whole blood were added
to celite pre-filled glass tube (International Techidyne Corporation, Edison, NJ) and the
tube was immediately inserted into the Hemochron coagulation timing instrument and the
timer was started.
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2. Thrombelastographic analysis

The Thrombelastograph® Coagulation Analyzer (Haemoscope Corp., Skokie, IL)
automatically records the viscoelastic changes in a sample of whole blood as the sample
clots, retracts and/or lyses. The resulting profile is a measure of the kinetics of clot
formation and dissolution and of clot quality. Thrombelastographic measurements were
made on freshly drawn whole blood samples, pre-incubated at 37°C in a glass tube for
3 min using an Hellige thrombelastograph (Haemoscope Corp., Skokie, IL.).

The

thrombelastograms (TEG) generated in this manner were analyzed using the standard
procedure as described by Fiedel and Ku (1986): the length from the beginning of the
recording until the point where the graph reaches a 2 mm divergence was recorded as
the r value; the length from the beginning of the thrombelastogram until the point where
the graph reaches a 2 cm divergence was recorded as the rk value; the difference
between the r and rk values was the k value; the angle defined by the center line
transversing the length of the graph and the tangent from the initial point of divergence
and the first inflection point of the tracing, was the cx angle.

G. Anticoagulant Effects of Thrombin Inhibitors in
Normal Rabbit Plasma (NRP)

To study the anticoagulant effects of thrombin inhibitors and which pathways are
inhibited effectively, and to construct calibration curves, each of the following agents was
supplemented to NRP in vitro and tested in the PT, APTT, TT and Heptest, as described
earlier for NHP: D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and
heparin.

The clotting time tests were performed on a fibrometer according to the
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specifications set by each of the manufacturers and described earlier. NRP was obtained
from rabbits as described previously. Each concentration-response curve was repeated
in triplicate on separate days.

H. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood
To determine the anticoagulant effects of thrombin inhibitors on normal rabbit
whole blood, the following thrombin inhibitors were supplemented in vitro in freshly
drawn rabbit whole blood: D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin
and heparin.

The rabbit whole blood was obtained from White male New Zealand

rabbits weighing 2.5 to 3.5 kg.

Each rabbit was lightly anesthetized with ketamine

hydrochloride at a dose of 50 mg/kg I.M. in combination with xylazine at a dose of 25
mg/kg J.M. Blood was drawn through the major ear artery. After the first 3 ml were
discarded, the subsequently drawn blood was immediately supplemented with each of the
thrombin inhibitors and tested in the ACT and TEG assays, as described above with the
normal human whole blood. The only modification was in the glass tubes used in the
ACT: when rabbit whole blood was tested, saline pre-filled glass tubes (International
Techidyne Corporation, Edison, NJ) were used instead of the celite pre-filled glass tubes.
Each thrombin inhibitor concentration was repeated in triplicate in normal rabbit whole
blood collected from three separate rabbits.

I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the
Rabbit Stasis Thrombosis Model

Although thrombin inhibitors are effective anticoagulants in various in vitro
systems, their anticoagulant effects do not always correlate with in vivo antithrombotic
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effects. Furthermore, the degree of anticoagulation as measured by clotting tests does
not always correspond to the degree of antithrombotic effects. To study the comparative
antithrombotic effects of various thrombin inhibitors, four representative anticoagulants
from the series studied in vitro were selected: D-MePhe-Pro-Arg-H, Ac-(D)Phe-ProboroArg-OH, hirudin and heparin. A modified Wessler stasis thrombosis model (Fareed
et al. 1985) was used for the determination of the in vivo antithrombotic effects of these
four agents. The principle of this model is that clot formation in the jugular segments
of the rabbit, in response to a thrombogenic trigger, can be prevented by administration
of anti thrombotic agents prior to administration of the thrombogenic trigger.

The

thrombogenic trigger used varies from serum to factor concentrates to snake venoms such
as the Russel's viper venom, and the resulting clots differ morphometrically accordingly
(Callas et al. 1995). In this series of experiments, recombinant tissue factor (1.38 µM
r-TF in 2.57 mM phospholipid, biosynthesized and reconstituted as described in Bach et
al. 1986, provided by Dr. Yale Nemerson, Mount Sinai School of Medicine, New York,
NY) was used as the trigger for clot formation in the jugular segments.

This

thrombogenic trigger represented a defined approach in which the r-TF activated the
clotting process through the extrinsic pathway.

1. Standardization of the Rabbit Stasis Thrombosis Model

The dose of r-TF to be used for comparing the antithrombotic effects of the
antithrombin agents was selected based on a series of experiments where the dosethrombogenic response relationship was established in this model. The r-TF was thawed
and reconstituted in sterile saline to a final concentration of 5.5 nM and re-frozen in
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aliquots. Immediately prior to the experiment, an aliquot was thawed and diluted in
sterile saline. In order to keep the volume of r-TF injected consistent independent of
dose, a dilution was made such that the injection volume was always 0.25 ml/kg in every
rabbit. Therefore, the r-TF was diluted to concentrations corresponding to quadruple the
doses that were used, eg. 5.41 pmol/ml for dosing at 1.35 pmol/kg. The r-TF doses that
were tested were 1.35, 0.68, 0.34, 0.17 and 0.04 pmol/kg. Groups of six rabbits were
tested at each r-TF dose.
The stasis thrombosis procedure was carried out as follows: White male New
Zealand rabbits weighing 2.5 to 3.5 kg were obtained from LSR Industries and housed
individually. The animals were kept on standard rabbit chow diet and had access to
,

water ad libitum. Ketamine hydrochloride at a dose of 50 mg/kg I.M. in combination
with xylazine at a dose of 25 mg/kg I.M. was used to anesthetize each rabbit. Both
jugular veins and the right carotid were carefully isolated.

The right carotid was

cannulated for blood collection utilized in ex vivo analyses. The left marginal ear vein
was also cannulated for I. V. administration of the thrombogenic and antithrombotic
agents or saline. After a baseline blood draw was performed, the sterile saline solution
was injected at 1 ml/kg, through the cannulated marginal ear vein. After 5 min of the
saline injection, a second blood draw was performed. Immediately following the second
blood draw, r-TF was injected through the cannulated marginal ear vein as the
thrombogenic challenge. Twenty sec after the I.V. administration of r-TF, the jugular
segments were tied.
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a. Clot Score Analyses
Ten min after the injection of r-TF the right segment was dissected in a petri dish
and the contained thrombi were graded. Twenty min after the administration of r-TF the
same procedure was repeated on the left segment. The grading system for the thrombi
was on a scale of 0 to +4, as previously established (Fareed et al. 1985). The animal
was euthanized with an I.V. injection of 0.5 ml sodium pentobarbital and phenytoin
sodium solution (Beuthanasia®-D, Steris Laboratories, Phoenix, AZ).
The r-TF dose that consistently gave a clot score of at least

+ 3 was determined

to be 0.68 pmol/kg and therefore was selected as the dose used in determining the
antithrombotic effects of the thrombin inhibitors, as described in the following sections.
In the following sections, each thrombin inhibitor was diluted in sterile saline to
various concentrations, so that the agent concentration matched the dose (eg. 1 mg/ml
thrombin inhibitor for dosing at lmg/kg). Thus, the volume injected in each rabbit
(either I. V. or S. C.) remained at a 1ml/kg animal weight.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Each time a blood draw was performed (at baseline and 5 min post saline
injection as described in the previous section), the first 3 ml were discarded, the next 3
ml were tested in the ACT and saline TEG assays, as described in section H.
Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood, and the
next 9 ml were collected in 3. 8 3 sodium citrate and processed as described in section
D.3.c. Preparation of Normal Rabbit Plasma and frozen in aliquots at -70°C. At the
conclusion of the rabbit stasis thrombosis model experiments, these aliquots were thawed
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in batches and the following amidolytic and clotting tests were performed as described
earlier: antithrombin assay (section D.3.d. Antithrombin Amidolytic Assay with NRP),
anti-Xa assay (section D.4.b. Anti-Xa Amidolytic Assay with NRP), PT, APTT, TT and
Heptest (section G. Anticoagulant Effects of Thrombin Inhibitors in NRP).

2. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors
After I. V. Administration at Fixed Time Points
To determine the dose-dependent antithrombotic effects of the thrombin inhibitors
after I. V. administration in the above described rabbit stasis thrombosis model, each
thrombin inhibitor was injected through the marginal ear vein of the left ear, 5 min prior
to injecting r-TF, in place of saline, as described above. Each thrombin inhibitor was
injected at various doses, to obtain a dose-response curve. The doses of each thrombin
inhibitor studied were for D-MePhe-Pro-Arg-H, 0.097, 0.194, 0.485, 0.971 and 1.942
µmol/kg; for Ac-(D)Phe-Pro-boroArg-OH, 0.010, 0.025, 0.050 and 0.101 µmol/kg; for
hirudin, 0.001, 0.004, 0.007, 0.014 and 0.036 µmol/kg and for heparin 0.002, 0.005,
0.009 and 0.023 µmol/kg.

Groups of six rabbits were tested at each dose.

Blood

samples were collected at baseline and 5 min post antithrombin agent injection.

a. Clot Score Analyses
The jugular vein segments were isolated in sequence and the clots contained
within were graded, as described earlier in section I.1.a Clot Score Analyses.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Blood samples drawn at baseline and 5 min post thrombin inhibitor injection were
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processed and analyzed in exactly the same manner as described earlier in section I.1.b.

Ex Vivo Analyses of Plasma and Whole Blood Samples.

3. Duration of Antithrombotic Effects of Thrombin Inhibitors
After I.V. Administration at a Fixed Dose
To determine the time-dependance of the antithrombotic effects of the thrombin
inhibitors studied in this rabbit stasis thrombosis model after I. V. administration, the dose
of each agent that produced sub-maximal antithrombotic effects in the dose-dependent
I.V. studies was selected and studied at different circulation times, prior to injecting r-TF
as described above. The dose of each thrombin inhibitor studied was: D-MePhe-ProArg-H at 1.942 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at
0.036 µmol/kg and heparin at 0.023 µmol/kg. The circulation time points selected for
studying the antithrombotic effects of these thrombin inhibitors at these doses were 5, 30,
60 and 90 min (prior to r-TF injection). Groups of six rabbits were tested at each time
point for each thrombin inhibitor. Blood draws were performed at baseline and prior to
r-TF injection (5 or 30 or 60 or 90 min post thrombin inhibitor injection).

a. Clot Score Analyses
The jugular vein segments were isolated in sequence and the clots contained
within were graded, as described earlier in section I.1.a Clot Score Analyses.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Blood draws were performed at baseline and prior to r-TF injection (5 or 30 or
60 or 90 min post thrombin inhibitor injection). These samples were processed analyzed
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in exactly the same manner as described earlier in section 1.1.b. Ex Vivo Analyses of
Plasma and Whole Blood Samples.

4. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors
After S.C. Administration at Fixed Time Points
To determine the dose-dependent antithrombotic effects of the thrombin inhibitors
after S.C. administration in the above described rabbit stasis thrombosis model, each
thrombin inhibitor was injected subcutaneously 45 min prior to injecting r-TF, in place
of saline, as described above. Each thrombin inhibitor was injected at various doses, to
obtain a dose-response curve. The doses of each thrombin inhibitor studied were for DMePhe-Pro-Arg-H, 0.194, 0.485, 0.971, 1.942 and 4.854 µmol/kg; for Ac-(D)Phe-ProboroArg-OH, 0.050, 0.097, 0.201and0.503 µmol/kg; for hirudin, 0.004, 0.007, 0.014,
0.036, 0.072 and 0.144 µmol/kg and for heparin 0.046, 0.091, 0.250 and 0.455
µmol/kg. Groups of six rabbits were tested at each dose. Blood samples were collected
at baseline and 45 min post thrombin inhibitor injection (prior to r-TF injection).

a. Clot Score Analyses
The jugular vein segments were isolated in sequence and the clots contained
within were graded, as described earlier in section 1.1.a Clot Score Analyses.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Blood draws were performed at baseline and 45 min post thrombin inhibitor
injection.

These samples were processed analyzed in exactly the same manner as

described earlier in section 1.1. b. Ex Vivo Analyses of Plasma and Whole Blood Samples.
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5. Duration of Antithrombotic Effects of Thrombin Inhibitors
After S.C. Administration at a Fixed Dose

To determine the time-dependance of the antithrombotic effects of the thrombin
inhibitors studied in this rabbit stasis thrombosis model after S.C. administration, the
dose of each agent that produced sub-maximal antithrombotic effects in the dosedependent S.C. studies was selected and studied at different circulation times, prior to
injecting r-TF as described above. The dose of each thrombin inhibitor studied was: DMePhe-Pro-Arg-H at 4.854 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg,
hirudin at 0.144 µmol/kg and heparin at 0.455 µmol/kg. The circulation time points
selected for studying the antithrombotic effects of these thrombin inhibitors at these doses
were 15, 45, and 90 min (prior to r-TF injection). Groups of six rabbits were tested at
each time point for each thrombin inhibitor. Blood samples were collected at baseline
and prior to r-TF injection (15, 30, 45, 60 or 90 min post antithrombin agent injection).

a. Clot Score Analyses
The jugular vein segments were isolated in sequence and the clots contained
within were graded, as described earlier in section 1.1.a Clot Score Analyses.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Each time a blood draw was performed, at baseline and prior to r-TF injection
(15, 30, 45, 60 or 90 min post thrombin inhibitor injection).

These samples were

processed analyzed in exactly the same manner as described earlier in section I.1.b. Ex
Vivo Analyses of Plasma and Whole Blood Samples.
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J. Antithrombotic Effects of Thrombin Inhibitors as Studied in the
Rat Model of Laser-Induced Thrombosis

The physiologic responses in the arterial and venous systems involve different
mechanisms which include differences in blood flow conditions and clot compositions.
Therefore, thrombin inhibitors may have different effects on arteries when compared to
veins. Since the rabbit stasis thrombosis model simulated venous thrombosis, a rat model
of laser-induced thrombosis was selected to study the antithrombotic effects of the
thrombin inhibitors in the arterial system, as described in detail by Weichert et al. 1988.
In this procedure the rat (Wistar, male, 300-350 g, LSR Industries, Inc., Union Grove,
WI) was anesthetized with sodium pentobarbital, 100 mg/kg I.P. (Butler Co., Colombus,
OH). An intestinal loop was exposed through a hypogastric incision and continuously
irrigated with sterile saline solution, spread on a stage mounted on a microscope table
(Nikon, inverted microscope, Diaphot-TMD, Nippon Kogaku K.K., Tokyo, Japan).
Vascular lesions were induced with an argon laser system (INNOVA® 70-2 Argon Laser,
Coherent, Inc., Santa Clara, CA). The laser beam was directed through the optical path
of the microscope on small mesenteric arterioles (10-15 µm I.D.) of the fat-free portion
of the mesentery. The laser beam pathway was controlled by means of a camera shutter
(Uniblitz® VS1452ZO, Vincent Associates, Rochester, NY) and driver (Uniblitz® Tl32,
Vincent Associates, Rochester, NY).

The effective constant energy was 50 mW as

measured with a power meter on the microscope stage (model 200/lOW, Coherent, Inc.,
Santa Clara, CA). The exposure time of the laser lesions was 150 msec. The time
interval between laser shots was 1 min. Results were evaluated by direct microscopic
observation of the occlusive changes in the blood vessel. The number of laser injuries
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required to induce a thrombus which was of a length equal to 1.5 x I.D. of the vessel,
or that produced complete occlusion was the endpoint. The rat was sacrificed at the end
of the experiment by I.V. injection of sodium pentobarbital (Beuthanasia®, 0.5 ml/kg).
Each thrombin inhibitor was diluted in sterile saline to various concentrations, so
that the agent concentration corresponded to the dose (eg. 1 mg/ml thrombin inhibitor
for dosing at lmg/kg). Thus, the volume injected in the rat (either I.V. or S.C.) was
always lml/kg animal weight. After the rat was prepared and placed on the microscope
stage and a suitable vessel was located, each thrombin inhibitor was injected I. V. through
one of the rat tail veins, at various concentrations. Each thrombin inhibitor was allowed
to circulate for 5 min prior to the initiation of the laser-induced vascular lesion. The
doses of each thrombin inhibitor used in this model were as follows: D-MePhe-Pro-ArgHat 0.97, 1.94, 3.40 and 4.86 µmol/kg; Ac-(D)Phe-Pro-boroArg-OH at 0.10, 0.15 and
0.20 µmollkg; hirudin at 0.07, 0.14 and 0.72 µmol/kg; heparin at 0.05, 0.09 and 0.46
µglkg. Groups of six rats were tested at each dose for each thrombin inhibitor.

K. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the
Rabbit Ear Bleeding Model

While thrombin inhibitors can be potent antithrombotic agents in vivo due to their
inhibitory actions on the coagulation cascade, they can also produce hemorrhagic effects
since coagulation is involved in hemostasis and platelet activation.

To study the

hemorrhagic effects of thrombin inhibitors, a rabbit model of ear blood loss as described
by Cade et al. 1975 was used.

In this procedure, white male New Zealand rabbits

weighing 2.5 to 3.5 kg were obtained from LSR Industries. The animals were kept on
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standard rabbit chow diet and had access to water ad libitum. Ketamine at a dose of 50
mg/kg I.M. was injected in combination with xylazine at a dose of 25 mg/kg I.M. to
induce anesthesia. The marginal ear vein was cannulated for I. V. administration of
antithrombin agents at various doses. After a constant circulation time, the right ear was
immersed in a 950 ml, 37°C saline bath for a few seconds and then 5 uniform, full
thickness incisions were made in the ear in areas free of major vascularization, and
returned to the saline bath for 10 min. The saline was collected and the red blood cells
were counted using a hemacytometer (Brightline, Improved Neubauer, Hausser Scientific
0. 100 mm deep). The same procedure was repeated on the other ear 15 min after the
procedure was initiated on the first ear. At the end of the experiment, hemostasis was
ensured and the animal was returned to its cage.
In the following sections, each thrombin inhibitor was diluted in sterile saline
(Baxter Healthcare Corp., Deerfield, IL) to concentrations corresponding to 10-fold the
dose to be used, so that the volume of the injected agent remained constant at 0.1 ml/kg
(1.V. or S.C.) animal weight for every rabbit.

1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After I. V. Administration at Fixed Time Points

To determine the dose-dependent hemorrhagic effects of the thrombin inhibitors
after I. V. administration, each thrombin inhibitor was injected through the marginal ear
vein of the left ear, 5 min prior to making the incisions in the right ear, as described
above. The incisions in the left ear were made 20 min after the I. V. injection of the
antithrombotic agent. Each thrombin inhibitor was injected at various doses, to obtain

136
a dose-response curve. The doses of each thrombin inhibitor studied were for D-MePhePro-Arg-H, 0.97, 1.94 and 4.85 µmollkg; for Ac-(D)Phe-Pro-boroArg-OH, 0.10, 0.25,
0.50 and 1.00 µmollkg; for hirudin, 0.07, 0.14 and 0.36 µmol/kg and for heparin 0.05,
0.09, 0.23 and 0.46 µmollkg. Groups of six rabbits were tested at each dose. Groups
of six rabbits were used for each treatment.

2. Duration of Hemorrhagic Effects of Thrombin Inhibitors
After I. V. Administration at a Fixed Dose

To determine the time-dependance of the hemorrhagic effects of the thrombin
inhibitors studied in this hemorrhagic model after I.V. administration, the dose of each
agent that produced sub-maximal hemorrhagic effects in the dose-dependent I.V. studies
was selected and studied at different circulation times, prior to making the incisions in
the ears as described above. The dose of each thrombin inhibitor studied was D-MePhePro-Arg-H at 4.85 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.50 µmollkg, hirudin at
0.36 µmollkg and heparin at 0.46 µmol/kg. The circulation time points selected for
studying the hemorrhagic effects of these thrombin inhibitor at these doses were 5, 20,
30, 45, 60 and 90 min after I.V. administration. Groups of six rabbits were tested at
each time point for each thrombin inhibitor.

3. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After S.C. Administration at Fixed Time Points

To determine the dose-dependent hemorrhagic effects of the thrombin inhibitors
after S.C. administration, each thrombin inhibitor was injected subcutaneously 45 min
prior to making the incisions in the right ear, as described above. The incisions in the
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left ear were made 60 min after the S.C. injection of the antithrombotic agent. Each
thrombin inhibitor was injected at various doses, to obtain a dose-response curve. The
doses of each thrombin inhibitor studied were for D-MePhe-Pro-Arg-H, 1.94, 4.84 and
9. 71 µmol/kg; for Ac-(D)Phe-Pro-boroArg-OH, 0.20, 0.50, 1.00 and 2.01 µmol/kg; for
hirudin, 0.07, 0.14, 0.36 and 0.77 µmol/kg and for heparin 0.46 and 0.91 µmol/kg.
Groups of six rabbits were tested at each dose.

4. Duration of Hemorrhagic Effects of Thrombin Inhibitors
After S.C. Administration at a Fixed Dose
To determine the time-dependance of the hemorrhagic effects of the thrombin
inhibitors studied in this hemorrhagic model after S.C. administration, the dose of each
agent that produced sub-maximal hemorrhagic effects in the dose-dependent S. C. studies
was selected and studied at different circulation times, prior to making the incisions in
the ears as described above. The dose of each thrombin inhibitor studied was D-MePhePro-Arg-H at 9.71 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 2.01 µmol/kg, hirudin at
0.77 µmol/kg and heparin at 0.91 µmol!kg. The circulation time points selected for
studying the hemorrhagic effects of these thrombin inhibitor at these doses were 15, 30,
45, 60 and 90 min after I.V. administration. Groups of six rabbits were tested at each
time point for each thrombin inhibitor.

L. Effects of Thrombin Inhibitors on Blood Pressure After
I. V. Administration to Rabbits
Since the building block for many of the synthetic thrombin inhibitors is arginine,
concerns have been expressed over the potential effects of these thrombin inhibitors or
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their metabolites on the vascular endothelium, independent of their actions on serine
proteases. Specifically, the potential blood-pressure lowering effects of these agents may
be compromising.
The effects of thrombin inhibitors on blood pressure after I. V. injection to rabbits
were monitored during the procedures of the stasis thrombosis model, for the highest
dose of each thrombin inhibitor used (D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at 0.036 µmol/kg and heparin at
0. 023 µmol/kg). After isolating and cannulating the femoral artery, the mean arterial
pressure was monitored via a pressure transducer (Type 4-327-C, range 0-400 mmHg,
Beckman Instruments Inc., Irvine, CA) connected to a physiograph (model R511A,
Beckman Instruments Inc., Irvine CA). The blood pressure was continuously monitored
from before any agents were injected into the rabbit (after induction of anesthesia and
cannulation of the femoral artery), until the rabbit was sacrificed at the end of the stasis
thrombosis model procedure.

M. Statistical analysis
The experimental data derived from the in vitro assays were compiled as mean

± SD (standard deviation of the sample).
studies were compiled as mean

The data derived from the in vivo and ex vivo

± SEM (standard error of the mean).

The sample mean

was the average of the measurements within each group. The SEM was reported along
with the mean to provide an indication of the precision of estimation of the population
mean and to facilitate comparison between means of different groups.
The data in the figures were presented as mean ± SD or mean ± SEM,
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depending on whether they were derived from in vitro or in vivo/ex vivo procedures. All
figures were drawn using SigmaPlot® software. The error bars were not shown if the
they were smaller than the size of the symbols in the figure.
The statistical tests performed on the data included one-way ANOVA followed
by Neuman Keuls multiple comparison test when the one-way ANOVA revealed a
significant difference. These statistical tests were used to evaluate the results from the
all studies except for the clot scores from the stasis thrombosis model. The KruskalWallis test was used to examine the differences between clot scores obtained in the rabbit
stasis thrombosis model.

CHAPTER IV
RESULTS

This dissertation represents an integrated account of both the biochemical and
phannacolgic properties of heparin and several thrombin inhibitors.

The results on

various experimental protocols are divided into various sections. In the first section, the
basic physicochemical and analytical properties of each of these agents are discussed.
The available information on the individual chemical and molecular properties along with
the data generated using gas permeation chromatography (GPC) is discussed.

The

comparative biochemical profiling included the studies on the potency evaluation,
inhibitory profiling utilizing purified serine proteases and the effects of these agents on
the generation of protease in both the coagulation and fibrinolytic based systems. The
global anticoagulant effects of each of these inhibitors are reported in terms of their
ability to prolong the clotting profile of either the normal human plasma or normal rabbit
plasma. A newly developed highly specific test, namely the ecarin clotting time (ECT),
is employed to determine the relative anticoagulant potency of these agents. Whole blood
studies using both the normal human whole blood and normal rabbit whole blood based
assays in the TEG and ACT analyses are also included. All of these results are reported
in statistically defined gravimetric and molar values.
The comparative pharmacological data on various agents included in this
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dissertation are presented in various sections representing the antithrombotic effects in
the venous stasis thrombosis model in the I.V. and S.C. studies, where the dose-response
relationship is reported. These data are also compared in terms of the ED 50 for each
individual agent in different experimental conditions. The duration of the fixed I. V. and
S.C. dosage of each of the antithrombin agents studied is also reported and the t 1h of
each agent is provided. The ex vivo analysis using different assays is also compiled to
compare the antithrombotic action with measurable ex vivo effects. The results of the
comparative antithrombotic actions for each of these agents in a rat model of laserinduced thrombosis are also presented.
included.

No ex vivo analyses from these studies are

The comparative hemorrhagic effects of various thrombin inhibitors and

heparin are reported for both the I.V. and S.C. studies, which were carried out in a
rabbit model for ear blood loss. Time-dependance of the hemorrhagic effects in this
model is also reported for the fixed dosage studies in both the I. V. and S. C. experiments.
The results on the effect of various thrombin inhibitors and heparin on blood pressure
measurements in rabbits are also compiled for the I. V. studies.
The comparative data for both the biochemical and pharmacological studies are
compiled in individual figures where the tabulated data are plotted to represent a
cumulative data analysis. Similarly, individual tables on the data compiled from various
experiments are tabulated in terms of means and standard deviations or standard error
of the means, to represent each of the data points in either gravimetric or molar values
or both. Appendix 4 represents supportive data tables for each of the tables included in
the text for both biochemical and pharmacologic study results. The tables in Appendix
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IV are numbered by arabic numerals corresponding to the main text tables, followed by
sequential lower-case letters.

A. Analytical Profile of Peptide Thrombin Inhibitors
All of the tripeptide thrombin inhibitors employed in these studies were obtained
in dry powdered form and were stored at 4 °C in desiccators. The purity of these agents
was evaluated by utilizing the HPLC methodology described in Chapter III. B. The
elution profiles described below were compared against reference elution profiles of the
medium in which each compound was dissolved in distilled H20. The background peaks
appearing in the elution buffer elution were then subtracted from the elution profile of
individual peptides. The background-adjusted peaks were then integrated by the system
software and assigned to particular structures, in accordance according to reported
analyzed values (Bajusz et. 1990).

1. Stability and Homogeneity Profile of D-Phe-Pro-Arg-H,
D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H.

The tripeptide aldehyde D-Phe-Pro-Arg-H has been reported to be unstable in
solution and

is

transformed

into an

inactive 5,6,8,9,10,10a-hexahydro-2-(3'-

guanidinopropyl)-5-benzyl-6-oxoimidazo[l ,2-a]pyrrolo[2, 1-c]pyrazine (Bajusz et al.
1989). To determine the extent of possible racemization, a validated HPLC method was
employed.

The result of this profile for the compound D-Phe-Pro-Arg-H · H2S04 is

depicted in the panel A of Fig. 5. This peptide eluted between the 36 and 42 min after
injection of the compound into the column. Peaks B', A and B represented the three
equilibrium structures of the D-Phe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A)
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Fig. 5. Analytical profile of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-PhePro-Arg-H, as detected at 214 nm. The X axis represents the time (min) at which the
various components of the agent injected eluted, while the Y axis represents the intensity
of the signal (mV) emitted by the substance detected. Panel A depicts the HPLC profile
of D-Phe-Pro-Arg-H, represented by peaks B' (retention time 37.5 min), A (retention
time 38.5 min) and B (retention time 39.0 min). Panel B depicts the HPLC profile of
D-MePhe-Pro-Arg-H, represented by peaks B' (retention time 37.1 min), A (retention
time 38.3 min) and B (retention time 39.4 min). Panel C depicts the HPLC profile of
Boc-D-Phe-Pro-Arg-H represented by peaks B' (retention time 25.2 min), A (retention
time 29.2 min) and B (retention time 33.8 min).
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and the two amino cyclols (peaks B and B'). The poorly resolved peak between peaks
A and B was due to the additional equilibrium structure of either the aldehyde or to the
impurity arising from one of the three forms of the DLD epimer (the D-Arg-H containing
epimer). The three peaks following peak B were due to the other two forms of the DLD
epimer and the inactive decomposition product respectively. All peaks appearing during
its elution were integrated and their % area, based on the sum of all background-adjusted
peaks, was calculated by the system software. The % peptide content was calculated by
summing the % area under peaks B', A and B and was found to be 89. 64 %.

Table 3 -- Integration of various peaks eluted during the analysis of D-Phe-Pro-ArgH · H2S04
Structure

Retention
Time (min)

% Area

Peak B'

equilibrium structure, amino cyclol

37.5

40.73

Peak A

equilibrium structure, aldehyde hydrate

38.5

3.89

Unknown

equilibrium aldehyde or DLD epimer

38.7

0.59

Peak B

equilibrium structure, amino cyclol

39.0

45.02

Unknown

DLD epimer

39.7

2.51

Unknown

DLD epimer

40.5

4.12

Unknown

inactive decomposition product

41.6

3.14

The peptide D-MePhe-Pro-Arg-H · H2S04 was also eluted in a similar manner as
the D-Phe-Pro-Arg-H · H2S04, as depicted in the panel B of Fig. 5. The equilibrium
peaks that appeared during its elution profile were also due to the three equilibrium
structures of the D-MePhe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A) and the
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two amino cyclols (peaks B and B'). As in the case of D-Phe-Pro-Arg-H, the peak
between peaks A and B was due to an impurity arising from one of the three forms of
the DLD epimer (the D-Arg-H containing epimer). The peak following peak B was due
to one of the other two forms of the DLD epimer. Unlike the D-Phe-Pro-Arg-H elution
profile, D-MePhe-Pro-Arg-H did not exhibit any unstable products. All peaks appearing
during this elution were integrated and their % area, based on the sum of all backgroundadjusted peaks appearing, was calculated by the system software. The % peptide content
was calculated by summing the % area under peaks B', A and B and was found to be
94.99 %.

Table 4 -- Integration of various peaks eluted during the analysis of D-MePhe-Pro-ArgH ·H2S04
Structure

Retention
Time (min)

% Area

Peak B'

equilibrium structure, amino cyclol

37.1

17.60

Peak A

equilibrium structure, aldehyde hydrate

38.3

31.32

Unknown

DLD epimer

39.0

2.89

Peak B

equilibrium structure, amino cyclol

39.4

46.07

Unknown

DLD epimer

40.8

2.11

The compound Boc-D-Phe-Pro-Arg-H · 1/2H2S04 also eluted in a similar manner
as D-MePhe-Pro-Arg-H · H2S04 , as depicted in panel C of Fig. 5. The equilibrium peaks
appearing in the elution of this peptide were due to the three equilibrium structures of
the Boc-D-Phe-Pro-Arg-H aldehyde, the aldehyde hydrate (peak A) and the two amino
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cyclols (peaks B and B'). No additional peaks due to impurities or epimers appeared
during the elution of Boc-D-Phe-Pro-Arg-H. All peaks appearing in this analysis were
integrated and their respective 3 area, based on the sum of all background-adjusted
peaks appearing, was calculated by the system software. The 3 peptide content was
calculated by summing the 3 area under peaks B' , A and B and was found to be 100 3 .

Table 5 -- Integration of various peaks during the analysis of Boc-D-Phe-Pro-ArgH · 1hH2S04
Structure

Retention
Time (min)

3 Area

Peak B'

equilibrium structure, amino cyclol

25.2

34.18

,Peak A

equilibrium structure, aldehyde hydrate

29.2

9.12

Peak B

equilibrium structure, amino cyclol

33.8

56.70

/

2. Ac-(D)Phe-Pro-boroArg-OH Purity Determination

The elution profile of Ac-(D)Phe-Pro-boroArg-OH · HCl is depicted in Fig. 6.
After subtracting the background peaks this agent eluted in 4 distinct peaks. These peaks
were integrated and the respective 3 area was calculated and reported in Table 6. The
elution of this peptide exhibited a rather heterogeneous polycomponent behavior. As
stated, 4 distinct peaks were eluted. The first peak represented the major compound with
a retention time of 8 min and a relative abundance of about 60 3. Close to the first
peak, the second peak eluted at 8.4 min and showed a rather sharp distribution profile
with a relative abundance of 293. Two minor peaks eluted at 9.2 and 9.7 min with
baseline separation with a 1.4 and 9.43 abundance respectively.
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Fig. 6. Analytical profile of Ac-(D)Phe-Pro-boroArg-OH, as detected at 214 nm. The
X axis represents the time (min) at which the various components of the agent injected
eluted, while the Y axis represents the intensity of the signal (mV) emitted by the
substance detected. The elution profile of this compound was composed of four peaks,
starting at retention times of 8.0, 8.4, 9.2 and 9.7 min respectively.
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Table 6 -- Integration of various peaks during the analysis
of Ac-(D)Phe-Pro-boroArg-OH · HCI
Retention
Time (min)

Area%

1st Peak

8.0

60.27

2nd Peak

8.4

28.91

3rd Peak

9.2

1.44

4th Peak

9.7

9.37

B. Analytical Profile of the Unfractionated Heparin

The molecular profile of unfractionated heparin mainly depends on the source.
P,0rcine mucosa! heparin usually has a lower molecular mass distribution.

The

unfractionated heparin used in these studies was of porcine origin and was provided in
a white powdered sodium salt form (Sanofi, Paris, France). To determine the molecular
profile of this glycosaminoglycan mixture and the relative purity, this agent was analyzed
using a GPC method. The elution profile of heparin is depicted in Fig. 7, with panel A
being the profile detected in the UV detector at 234 nm and panel B being the profile
detected in the differential refractometer (RI). In both panels, the first peak from the left
is due to heparin, eluted between 23 and 45 min. The subsequent peaks represent the
salt peaks. In both panels, the heparin peak was integrated by the system software and
the % distribution was calculated. As described by Ahsan et al. 1994, based on narrow
range calibrators, the software system also assigned molecular weights corresponding to
retention time. Thus, for each heparin peak, the % heparin falling in a particular range
of molecular weight was calculated. Table 7 summarizes the molecular weight

149

mV

55
50

A

45
40
35
30
25
20
15
10
5

0

10

20

30

40

50

60

40

50

60

Minutes

mV

120
100

B

80
60
40
20
0
-20
-40
-60

0

10

20

30
Minutes

Fig. 7. Analytical profile of unfractionated porcine mucosa! heparin. The X axis
represents the time (min) at which the various components of the agent injected eluted,
while the Y axis represents the intensity of the signal (mV) emitted by the substance
detected. Panel A represents the GPC profile of heparin as detected by the UV detector
at 234 nm. Panel B represents the GPC profile of heparin as detected by the RI detector.
As detected by both methods, heparin eluted in a profile represented by a single peak,
between retention times of 23 and 45 min. The peaks eluted at 47 min represent NazS04 •
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distribution in this unfractionated heparin.

The results from both the UV and RI

detectors were in close agreement. Nearly half of the material was found to be between
8,000-12,000. About 203 of heparin was in the 5,000-8,000 range and just as much
was in the 16,000-20,000 range. Less than 103 of the total heparin was found to be
greater than 16,000 or lower than 5,000. The weight average was approximately 10,700,
with a peak MW of 11, 100 and 11,400 for the UV and RI analyses respectively.

Table 7 -- Molecular Weight Distribution of Unfractionated Heparin
UV (234 nm)

RI

Weight
Average

10,717

10,680

Peak MW

11, 121

11,445

>20,000

4.13

3.63

16,000-20,000

5.13

5.33

12,000-16,000

21.23

20.73

8,000-12,000

45.43

48.33

5,000-8,000

20.03

16.83

2,500-5,000

4.03

4.33

<2,500

0.23

1.03

C. Biochemical Assays

The inhibition of the activity of thrombin can be explored in vitro utilizing the amidolytic
and the clotting activities of thrombin, by using chromogenic substrates that yield color
when cleaved by thrombin, and by using fibrinogen which is converted to fibrin when
digested by thrombin. The following studies were designed to explore the relative in
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vitro inhibition of the formed thrombin by various agents, amidolytically with the
thrombin titration assay and the plasma-based antithrombin assay, and functionally with
thrombin time in the fibrinogen-based assay. In addition, the inhibition of the generation
of thrombin in various assay systems was also explored in the fibrinogen-deficient plasma
assay systems, as well as in the KONYNE® and FEIBA® assays. The effect of these
thrombin inhibitors on other serine proteases, such as factor Xa, chymotrypsin, trypsin,
activated protein C, tissue-type plasminogen activator, urokinase and plasmin was studied
in assays based on the amidolytic activity of these enzymes.

The effects of these

antithrombin agents on the generation of some of these enzymes was also examined in
the thrombin and factor Xa generation assay systems. Each of these inhibitors was also
tested for its effects on the plasminogenolysis assays where the generation of plasmin was
measured.

1. Thrombin Titration Assay
An amidolytic method was used to compare the direct antithrombin activity of
thrombin inhibitors. The results of the studies of inhibition of the amidolytic activity of
thrombin by specific thrombin inhibitors are depicted in Fig. 8. Panel A represents the
inhibitory activity of D-Phe-Pro-Arg-H, panel B shows the effects of D-MePhe-Pro-ArgH, panel C represents the inhibition produced by Boc-D-Phe-Pro-Arg-H. The inhibitory
profile exhibited by Ac-(D)Phe-Pro-boroArg-OH is shown in Panel D, while Panel E
represents the effects of argatroban and Panel F depicts the effects of hirudin.

The

concentration of each antithrombin agent that resulted in 50 % inhibition of thrombin was
the agent concentration that inhibited 0.5 thrombin units, since a total of 1 thrombin
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unit/L was present in the assay. Therefore, based on this value, the amount of thrombin
units inhibited by a mg or a nmol of each thrombin inhibitor was calculated.

The

specific activities in terms of ATU potencies for each thrombin inhibitor, based on the
results depicted in Fig. 8, are reported in Table 8. On a gravimetric basis, the most
potent thrombin inhibitor appeared to be Ac-D-Phe-Pro-boroArg-OH with about 200, 700
ATU/mg. The aldehydes D-Phe-Pro-Arg-H and D-Me-Phe-Pro-Arg-H followed with
about half of the activity of Ac-D-Phe-Pro-boroArg-OH (about 118,500 and 102,400
ATU/mg respectively), while Boc-D-Phe-Pro-Arg-H and hirudin exhibited much weaker

( < 10%) activities when compared to Ac-D-Phe-Pro-boroArg-OH (around 29,600 and
22,400 ATU/mg respectively).

Argatroban appeared to be the weakest thrombin

inhibitor with about 1 % of the activity of Ac-D-Phe-Pro-boroArg-OH (2,800 ATU/mg).

Table 8 -- Specific Activities of Various Thrombin Inhibitors as Assessed
by Utilizing an Amidolytic Assay.
ATU/mg

±

D-Phe-Pro-Arg-H

118,493

D-MePhe-Pro-Arg-H

± 6,342
± 2,326
200,669 ± 11,825
2,774 ±
138

Boc-D-Phe-Pro-Arg-H
Ac-D-Phe-Pro-boroArg-OH
Argatroban
Hirudin

6,868

102,422
29,605

22,382

±

1,929

ATU/nmol

± 3,441
± 3,266
16,342 ± 1,284

59,365
52,747

99,732
1,476
155,849

±

5,877

± 73
± 13,432

Each value represents the mean ± 1 SD of three separate determinations.
On the ATU/mg basis, all values were significantly different from each
other, except for those produced by Boc-D-Phe-Pro-Arg-H and hirudin.
On the ATU/nmol basis, all values were significantly different from each
other except for those produced by D-Phe-Pro-Arg-H and D-MePhe-ProArg-H. (p < 0.05, ANOVA followed by Student-Newman-Keuls test).
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Fig. 8. Fig. 9. Concentration dependent inhibition of the amidolytic activity of
thrombin by antithrombin agents. Panel A depicts the results produced by D-Phe-ProArg-H. Panel B represents results produced by D-MePhe-Pro-Arg-H. Panel C
represents results produced by Boc-D-Phe-Pro-Arg-H. Panel D represents results
produced by Ac-(D)Phe-Pro-boroArg-OH. Panel E represents results produced by
argatroban. Panel F represents results produced hirudin. Each agent was tested in
triplicate. The mean % residual thrombin activity ± SD for each concentration and the
gravimetric equivalent is given in Tables 8a-8f.
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The order of potency for each of these thrombin inhibitors on a molar basis was
found to be different from the order of potency on a gravimetric basis.

On a molar

basis, hirudin was found to be the strongest thrombin inhibitor with 155,800 ATU/nmol,
followed by Ac-(D )Phe-Pro-boroArg-OH with about 99, 700 ATU /nmol. D-Phe-Pro-ArgH and D-MePhe-Pro-Arg-H exhibited about 59,400and 52,700 ATU/nmol, while Boc-DPhe-Pro-Arg-H exhibited about 16,300 ATU/nmol. Argatroban was again the weakest
thrombin inhibitor in this assay with 1,500 ATU /nmol. Individual 3 inhibitory values
for each thrombin inhibitor concentration are given in Tables 8a through 8f.

2. Thrombin Time (TT) in a Fibrinogen Based System
A buffered fibrinogen based clotting assay was developed to evaluate the
comparative antithrombin effects of individual inhibitors on the clotting function of
thrombin in an isolated test system. Human thrombin was added to a human fibrinogen
solution to mediate clotting, with no feedback and amplification processes involved (as
there would be in a plasmatic medium where other factors are present). The results of
these studies are depicted in Fig. 9. Panel A depicts the results from the assay where
thrombin reconstituted in sterile saline was used, while panel B depicts the results from
the test where thrombin was reconstituted in 0.025 M CaC12 •

To evaluate the

comparative effects of thrombin inhibitors in these assays, an index was devised whereby
the concentration of a thrombin inhibitor required to prolong the fibrinogen clotting time
to 100 sec (CT 100) was calculated. These values are reported in Table 9. The clotting
time at each concentration point for the individual inhibitors can be found in Tables 9a 9d

and Tables 9e - 9h, for the saline/thrombin and the CaCl2 /thrombin tests,
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respectively. The order of potencies for each of the individual inhibitors was similar in
both assays: hirudin was consistently found to be the strongest anticoagulant with CT100s
of 47 and 56 nM in the saline and CaC12 tests respectively, followed closely by Ac(D)Phe-Pro-boroArg-OH with CT100 of 49 and 100 nM in the same assay systems.
Table 9 -- Antithrombin potencies of thrombin inhibitors as determined in fibrinogen
clotting systems.
Prolongation of clotting time to 100 sec [nM]
10 UTT

10 Ca++TT

Hirudin

±5
134 ± 10
586 ± 190
49 ± 1
140 ± 24
47 ± 3

±5
592 ± 12
1542 ± 150
100 ± 6
422 ± 128
56 ± 3

Heparin

>9,090

>9,090

D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
'Ac-D-Phe-Pro-boroArg-OH
Argatroban

181

512

Each value represents the mean ± 1 SD of three separate determinations. In the 10 U
TT fibrinogen-based assay, only the value produced by Boc-D-Phe-Pro-Arg-H was
significantly different from all others. In the 10 U ca++TT fibrinogen-based assay, all
values were significantly different from each other except for the following pairs: D-PhePro-Arg-H vs D-MePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs argatroban, D-MePhe-Pro-ArgH vs argatroban and Ac-(D)Phe-Pro-boroArg-OH vs hirudin. (p <0.05, ANOVA
followed by Student-Newman-Keuls test).

Heparin had no effects in these assays at concentrations as high as 9 µM. In the
saline/thrombin system, D-MePhe-Pro-Arg-H with a CT 100 of 134 nM was more potent
than argatroban, D-Phe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H (CT100s of 140, 181 and
586 nM respectively), while in the CaClzfthrombin assay system argatroban with a CT100
of 422 nM was more potent than D-Phe-Pro-Arg-OH, D-MePhe-Pro-Arg-H and Boc-D-
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Fig. 9. Concentration dependent prolongation of the fibrinogen-based TI by various
agents. Panel A depicts the effects produced by thrombin inhibitors in the fibrinogenbased TI system where thrombin was reconstituted in saline. The individual values at
each concentration point and their gravimetric equivalents are given in Tables 9a-9d.
Panel B represents effects produced by antithrombin agents in the fibrinogen-based TT
system where thrombin was reconstituted in CaC12 • The individual values at each
concentration point and their gravimetric equivalents are given in Tables 9e-9h. ( •) DPhe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (~) Ac-(D)PhePro-boroArg-OH, (•) argatroban, (0) hirudin, ( +) heparin. Each point represents a
mean ± 1 SD of three individual determinations.
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Phe-Pro-Arg-H with CT100s of 512, 592 and 1542 nM respectively. With the exception
of heparin, all thrombin inhibitors were capable of prolonging the clotting time to > 300
sec at nM concentrations. Hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-Phe-Pro-Arg-H
appeared to have all-or-none anticoagulant effects, while the other thrombin inhibitors
exhibited a more graded concentration-anticoagulant response relationship.

3. Antithrombin Effects of Thrombin Inhibitors
As in the thrombin titration assay, these assays are based on the ability of
antithrombin agents to inhibit the amidolytic activity of thrombin, as detected by the
release of pNA from a specific chromogenic substrate. In these assays the thrombin
inhibitors are diluted in plasma rather than buffer, to mimic circulating plasma matrix.
Thus, these assays represent a more physiologic condition in which the effects of
plasmatic factors on the antithrombin agents can be readily observed. Both the NHP and
NRP preparations were used to carry out these studies.

a. Antithrombin Amidolytic Assay with NHP
The results of the antithrombin activities of various agents after in vitro
supplementation to NHP are depicted in panel A of Fig. 10. With the exception of
heparin, all other thrombin inhibitors exhibited a sigmoidal concentration-response curve,
that eventually reached 1003 thrombin inhibition. After calculating the IC50 for each
thrombin inhibitor, as seen in Table 10, it was apparent that even though heparin did not
completely inhibit the amidolytic activity of thrombin, it appeared to be the strongest
inhibitor with an IC 50 of 9.6 nM. Hirudin, D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-
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Fig. 10. Concentration dependent inhibition of the amidolytic activity of thrombin by
various agents. Panel A depicts the effects produced by thrombin inhibitors in the NHPbased system. The individual values at each concentration point and their gravimetric
equivalents are given in Tables 10a-10d. Panel B represents effects produced by
antithrombin agents in the NRP-based system.
The individual values at each
concentration point and their gravimetric equivalents are given in Table lOe. (•) D-PhePro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (L>) Ac-(D)Phe-ProboroArg-OH, (•) argatroban, (D) hirudin, (+)heparin. Each point represents a mean
± 1 SD of three individual determinations.
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boroArg-OH followed closely, with IC50s of 21, 28 and 32 nM respectively, while BoeD-Phe-Pro-Arg-H was weaker with an IC50 of 110 nM. The weakest inhibitor in this test
was found to be argatroban with an IC50 of 1,250 nM. While most thrombin inhibitors
reached maximal thrombin inhibition in the nM range, Boc-D-Phe-Pro-Arg-H and
argatroban produced its effects only in the µM range.

The individual % thrombin

inhibitory values for each thrombin inhibitor concentration are given in Tables lOa - lOd.

Table 10 -- Antithrombin potencies of thrombin inhibitors as determined in amidolytic
systems in NHP and NRP.
IC 50 [nM]
NHP
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
Ac-D-Phe-Pro-boroArg-OH
Argatroban

NRP

28 ± 5
32.2 ± 7
110

19.4 ± 4.2

± 30

26.8 ± 5

21.8

±

1.2

1,250 ± 140

Hirudin

21

Heparin

9.6

±2
± 0.5

25 ± 4
6.1

±

1.1

Each value represents the mean ± 1 SD of three separate determinations. In the NHPbased antithrombin amidolytic assay, only the value produced by argatroban was
significantly different from all others. In the NRP-based antithrombin amidolytic assay,
the value produced by heparin was significantly different from those produced by DMePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH and hirudin. (p<0.05, ANOVA
followed by Student-Newman-Keuls test).

b. Antithrombin Amidolytic Assay with NRP
Fig. 10, panel B depicts the results of the antithrombin activities of D-MePhe-Pro-
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Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin, after in vitro supplementation
into NRP. All four agents produced a sigmoidal concentration-response. In this test,
heparin appeared to be the most potent inhibitor of the amidolytic activity of thrombin
with an IC 50 of 6.1 nM. The activity of heparin was followed by that of D-MePhe-ProArg-H, Ac-(D)Phe-Pro-boroArg-OH and hirudin with IC50 values of 19.4, 21.8 and 25
nM respectively.

The concentration-response curves of the three other agents

overlapped. Although heparin was the most potent inhibitor in this assay, its inhibitory
activity plateaued around 803 inhibition, in contrast to the other antithrombin agents,
which achieved maximal inhibition of thrombin at the higher concentrations used. The
individual inhibitory values for every agent concentration can be found in Table lOe.

4. Anti-Xa Effects of Thrombin Inhibitors
These assays are based on the ability of thrombin inhibitors to suppress the
amidolytic activity of factor Xa, as detected by a specific chromogenic substrate. As in
the antithrombin assays, the thrombin inhibitors were diluted in plasma, to demonstrate
any matrix effects.

a. Anti-Xa Amidolytic Assay with NHP
The results of the anti-Xa activities of thrombin inhibitors after in vitro
supplementation to NHP are depicted in the panel A of Fig. 11. With the exception of
heparin and Ac-(D)Phe-Pro-boroArg-OH, none of the thrombin inhibitors exhibited any
anti-factor Xa activity.

After calculating the IC 50 for heparin and Ac-(D)Phe-Pro-

boroArg-OH, as described in Table 11, it was apparent that even though heparin failed
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to achieve a complete inhibition of the amidolytic activity of factor Xa, it was the most
potent inhibitor with an IC50 value in the nM range (5.4 nM). While Ac-(D)Phe-ProboroArg-OH also exhibited concentration-dependent anti-Xa effects with an IC50 also in
the nM range (390 nM), it was about 72 fold weaker than heparin. Interestingly, a
gradual decrease in the inhibitory activity of heparin against factor Xa was noted at
concentrations greater than 100 nM with a concomitant increase in the scatter of the data.
The individual % factor Xa inhibitory values for each thrombin inhibitor concentration
point are found in Tables lla and llb.

Table 11 -- Anti-factor Xa potencies of thrombin inhibitors as determined in amidolytic
systems in NHP or NRP.
IC50 [nM]
NHP
D-Phe-Pro-Arg-H

> 11,000

D-MePhe-Pro-Arg-H

> 10,500

Boc-D-Phe-Pro-Arg-H

> 10,000

Ac-D-Phe-Pro-boroArg-OH
Argatroban

390 ± 60

NRP

>5,000

-1,000

> 10,000

Hirudin

>800

>300

Heparin

5.4 ± 0.2

56

Each value represents the mean ± 1 SD of three separate determinations. In the NHPbased factor Xa amidolytic assay, the values produced by Ac-(D)Phe-Pro-boroArg-OH
and heparin were significantly different. (p < 0.05, ANOVA followed by StudentNewman-Keuls test).
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Fig. 11. Concentration dependent inhibition of the amidolytic activity of factor Xa by
various agents. Panel A depicts the effects produced by thrombin inhibitors in the NHPbased system. The individual values at each concentration point and their gravimetric
equivalents are given in Tables lla-llb. Panel B represents effects produced by
antithrombin agents in the NRP-based system.
The individual values at each
concentration point and their gravimetric equivalents are given in Table 1lc. ( •) D-PhePro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (c.) Ac-(D)Phe-ProboroArg-OH, (•) argatroban, (D) hirudin, (+)heparin. The broken line denotes that
results may be due to a precipitation effect mediated by heparin. Each point represents
a mean ± 1 SD of three individual determinations.
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b. Anti-Xa Amidolytic Assay with NRP
Fig. 11, panel B depicts the anti-Xa activities of various thrombi inhibitors after
in vitro supplementation to NRP. While D-MePhe-Pro-Arg-H and hirudin exhibited no
anti-Xa activities, heparin and Ac-(D)Phe-Pro-boroArg-OH produced concentrationdependent inhibition of the amidolytic activity of factor Xa. The IC50 values for these
compounds were found to be 52 and -1,000 nM, respectively. The individual values
for the factor Xa inhibition produced by each agent concentration are given in Table 1 lc.

5. Inhibitory Actions of Various Thrombin Inhibitors on
Specific Serine Proteases

To evaluate the anti-protease spectrum of thrombin inhibitors, amidolytic assays
utilizing enzyme specific synthetic substrates were used. In these biochemically defined
assays, only one enzyme was present in purified form, thus ensuring that inhibition of
amidolytic activity was due to inhibition of the particular enzyme.

Since heparin is

devoid of any direct antiprotease activities and its mechanism of action is mediated
primarily through antithrombin, stock solutions of heparin were made with antithrombin,
and then further diluted in saline, prior to studying the effects of heparin on each one of
the following serine proteases. In addition to the thrombin inhibitors, aprotinin was also
included as a broad spectrum serine protease inhibitor and a positive control.

a. Inhibition of Chymotrypsin
Fig.12 depicts the inhibitory activities of various agent against the amidolytic
activity of chymotrypsin. In this study, none of the thrombin inhibitors studied were
capable of producing any inhibition of this amidolytic activity at high concentrations:

Table 12 -- Inhibition of serine proteases by thrombin inhibitors as determined in biochemically defined amidolytic systems.
IC 5o [µM]
Chymotrypsin

Trypsin

APC

Glandular
Kallikrein

tPA

Urokinase

Plasmin

D-Phe-Pro-Arg-H

>27

0.47±0.13

4.2±0.4

>67

33.6±2.2

>67

3.2±0.2

D-MePhe-Pro-Arg-H

>26

0.18±0.02

8.4±0.8

>65

52.7±2.9

>65

1.58±0.10

Boc-D-Phe-Pro-Arg-H

>24

0.24±0.02

14.6± 1.4

>60

7.3±0.06

15.3±0.7

0.33±0.05

Ac-D-Phe-ProboroArg-OH

>27

0.095 ±0.025

0.75±0.05

14.7±0.6

6.8±0.05

1.3±0.3

0.095±0.02

Argatroban

>25

> 125

> 115

> 115

> 115

> 115

> 115

Hirudin

> 1.9

> 1.9

>9.6

>9.6

>9.6

>9.6

>9.6

Heparin

> 1.2

> 1.2

>62

>62

>62

>62

>62

0.8

0.39±0.09

16.6±0.2

0.322±0.015

>5

>5

0.057 ±0.005

Aprotinin

Each value represents the mean ± 1 SD of three separate determinations. In the trypsin assay, D-Phe-Pro-Arg-H and aprotinin were
significantly different from D-MePhe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH. In the APC assay, all
values (except for argatroban, hirudin and heparin) were significantly different from each other. In the kallikrein assay, the values
produced by Ac-(D)Phe-Pro-boroArg-OH and aprotinin were significantly different from each. In the tPA assay, all values (except
for argatroban, hirudin, heparin and aprotinin) were significantly different from each other except for the pair Boc-D-Phe-Pro-Arg-H
vs Ac-(D)Phe-Pro-boroArg-OH. In the urokinase assay, the values produced by Boc-D-Phe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArgOH were significantly different from each other. In the plasmin assay, the values produced by all thrombin inhibitors (except for
argatroban, hirudin and heparin) were significantly different from each other, with the exception of the Boc-D-Phe-Pro-Arg-H vs
Ac-(D)Phe-Pro-boroArg-OH comparison. (p < 0.05, ANOVA followed by Student-Newman-Keuls test).
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Fig. 12. Concentration dependent inhibition of the amidolytic activity of chymotrypsin
by various agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-PhePro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin,
( <>) aprotinin. The individual values at each aprotinin concentration point and the
gravimetric equivalents are given in Table 12a.
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Fig. 13. Concentration dependent inhibition of the amidolytic activity of trypsin by
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-PhePro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin,
( <>) aprotinin. Each point represents a mean± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Table 12b.
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D-Phe-Pro-Arg-H > 27 µM, D-MePhe-Pro-Arg-H > 26 µM, Boc-D-Phe-Pro-Arg-H > 24
µM, Ac-(D)Phe-Pro-boroArg-OH

> 27

µM, argatroban

> 25

µM, hirudin

> 1.9

µM,

heparin > 1.2 µM. However, aprotinin, produced a concentration-dependent inhibition
of chymotrypsin with an apparent IC50 of 0.8 µM, as reported on Table 12.

The

individual inhibitory values produced by aprotinin are given in Table 12a.

b. Inhibition of Trypsin
Fig. 13 depicts the results from the trypsin inhibitory studies by various agents.
In this assay, argatroban, hirudin and heparin had relatively weaker inhibitory activities
against the amidolytic activity of trypsin at concentrations higher than 125, 1.9 and 1.2
µM respectively. The other thrombin inhibitors demonstrated a concentration dependent

inhibition of trypsin.

According to the IC50 values for each thrombin inhibitor, as

reported in Table 12, the most potent thrombin inhibitor in this assay was Ac-(D)PhePro-boroArg-OH (IC50 0.095 µM), followed by D-MePhe-Pro-Arg-H (IC50 0.18 µM),
Boc-D-Phe-Pro-Arg-H (IC 50 0.24 µM) and then by D-Phe-Pro-Arg-H (IC50 0.47 µM).
The anti-fibrinolytic agent aprotinin, used in these studies as the positive control, also
exhibited a concentration-dependent ant-trypsin effect with an IC50 of 0.39 µM. The
inhibition produced by each antithrombin agent is found in Table 12b.

c. Inhibition of Activated Protein C (APC)
The inhibitory effects of thrombin inhibitors against the amidolytic activity of
APC are depicted in Fig. 14. With the exception of heparin, hirudin and argatroban, all
of the other thrombin inhibitors exhibited a concentration-dependent inhibitory effect
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Fig. 14. Concentration dependent inhibition of the amidolytic activity of APC by various
agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H,
(.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, ( +) heparin, ( O)
aprotinin. Each point represents a mean ± 1 SD of three individual determinations. The
individual values at each concentration point and their gravimetric equivalents are given
in Table 12c.
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Fig. 15. Concentration dependent inhibition of the amidolytic activity of kallikrein by
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-PhePro-Arg-H, (.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin,
( O) aprotinin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Table 12d.

168
against APC.

While heparin, hirudin and argatroban did not exhibit any inhibitory

actions at high concentrations ( > 9, > 10 and > 100 µM, respectively), the other
thrombin inhibitors had IC50 values < 10 µM, as shown in Table 12. The most potent
inhibitor was Ac-(D)Phe-Pro-boroArg-OH with an IC50 of 0. 75 µM, followed by D-PhePro-Arg-H, D-MePhe-Pro-Arg-H and Boc-D-Phe-Pro-Arg-H with IC 50s of 4.2, 8.4 and
14.6 µM respectively.

Aprotinin was slightly weaker than the thrombin inhibitors.

However, this agent also inhibited APC in a concentration-dependent manner with an IC50
of 16.6 µM. All four agents were capable of completely inhibiting the APC amidolytic
activity at concentrations around 100 µM. The individual % APC inhibitory values for
each inhibitor concentration point are found in Table 12c.

d. Inhibition of Glandular Kallikrein
The representative data of the inhibition of glandular kallikrein by various
thrombin inhibitors are depicted in Fig. 15. In this assay, only heparin and Ac-(D)PhePro-boroArg-OH exhibited concentration-dependent inhibitory effects against the
amidolytic action of glandular kallikrein. When compared to aprotinin (IC50 0.32 µM),
these thrombin inhibitors were found to be relatively weaker inhibitors, with Ac-(D)PhePro-boroArg-OH exhibiting an IC50 of 14. 7 µM, whereas for heparin it was > 62 µM.
Furthermore, neither of the thrombin inhibitors was capable of completely inhibiting
kallikrein at concentrations higher than 60 µM.

The IC 50 values of these agents are

found in Table 12, while the individual % kallikrein inhibitory values for each inhibitor
concentration point are found in Table 12d.
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e. Inhibition of Tissue Plasminogen Activator (tPA)
The amidolytic activity of tPA was inhibited by all of the tripeptide thrombin
inhibitors, as seen in Fig. 16. As can be seen in this figure, argatroban, hirudin, heparin
and aprotinin did not affect the amidolytic activity of tPA at extremely higher
concentrations of up to 60, 10, 62 and 5 µM respectively. The tripeptide thrombin
inhibitors exhibited a concentration-dependent tPA inhibition. The estimated IC 50 values
for these inhibitions are shown in Table 12. The most potent inhibitor was found to be
Ac-(D)Phe-Pro-boroArg-OH (IC50 6.8 µM) followed closely by Boc-D-Phe-Pro-Arg-H
(IC 50 7.3 µM). The peptides D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H also inhibited
the amidolytic activity of tPA, but at higher concentrations wit IC50s of 33. 6 and 52. 7
µM respectively. Furthermore, while Ac-(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-

Arg-H reached 1003 inhibition of tPA at concentrations under 60 µM, the other two
tripeptides were not as potent at similar concentrations. The individual 3 tPA inhibitory
values for each inhibitor concentration point are found in Table 12e.

f. Inhibition of Urokinase
Fig. 17 depicts the inhibitory activities of various agents on the amidolytic action
of urokinase. Argatroban, hirudin, heparin and aprotinin did not inhibit the amidolytic
activity of urokinase at high concentrations ( > 60, > 10, > 62 and > 5 µM respectively).
While all tripeptide thrombin inhibitors reduced the amidolytic activity of tPA in a
concentration-dependent manner, only two of these were capable of inhibiting the
amidolytic action of urokinase. Table 12 depicts the IC 50 values for Ac-(D)Phe-ProboroArg-OH and Boc-D-Phe-Pro-Arg-H, which were 1.3 and 15.3 µM respectively. On
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Fig. 16. Concentration dependent inhibition of the amidolytic activity of t-PA by
antithrombin agents. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-D-PhePro-Arg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin,
( <>) aprotinin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Table 12e.

100
c

80

......

60

0

..0

..c
c

40

~

20
0

o. 1

1

10

100

Concentration [µM]
Fig. 17. Concentration dependent inhibition of the amidolytic activity of urokinase by
various agents. ( •) D-Phe-Pro-Arg-H, ( o) D-MePhe-Pro-Arg-H, ( •) Boc-D-Phe-ProArg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, (+)heparin, ( <>)
aprotinin. Each point represents a mean ± 1 SD of three individual determinations. The
individual values at each concentration point and their gravimetric equivalents are given
in Table 12f.
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the other hand, D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H did not exhibit inhibitory
activities in this assay at concentrations > 60 µM. The individual % urokinase inhibitory
values for each inhibitor concentration point are found in Table 12f.

g. Inhibition of Plasmin
As depicted on Fig. 18, with the exception of hirudin, the amidolytic activity of
plasmin was inhibited by all thrombin inhibitors and aprotinin. Argatroban exhibited the
weakest inhibitory activity and even the highest concentration (115 µM) did not achieve
50% inhibition of plasmin. Interestingly, heparin exhibited inhibitory activity against
plasmin at concentrations

> 10 µM which was not concentration-dependent and plateaued

around 20 % inhibition.

All tripeptide thrombin inhibitors and aprotinin exhibited

concentration-dependent anti-plasmin activity, and all were capable of maximal plasmin
inhibition at µM concentrations.

After calculating the IC50 value for each of these

inhibitors, reported in Table 12, the most potent plasmin inhibitor was aprotinin (IC50
0.057 µM), followed by Ac-(D)Phe-Pro-boroArg-OH (IC 50 0.095 µM), Boc-D-Phe-ProArg-H (IC 50 0.33 µM), D-MePhe-Pro-Arg-H (IC50 1.58 µM) and D-Phe-Pro-Arg-H (IC 50
3.2 µM). The individual % plasmin inhibitory values for each inhibitor concentration
point are found in Tables 12g and 12h.

6. Inhibition of Plasminogenolysis
Since it was found that some of the thrombin inhibitors studied in the above
described assays had inhibitory activities against serine proteases other than thrombin and
because some of these proteases are involved in the regulation of fibrinolysis, more
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Fig. 18. Concentration dependent inhibition of the amidolytic activity of plasmin by
thrombin inhibitors. (•) D-Phe-Pro-Arg-H, (O) D-MePhe-Pro-Arg-H, (•) Boc-D-PhePro-Arg-H, (.A) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (0) hirudin, (+)heparin,
( <> ) aprotinin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 12g-12h.
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specifically, the activation of plasminogen to plasmin, the effect of these agents on the
generation of plasmin was also investigated. In these assays, plasminogen was activated
to plasmin by either streptokinase or tPA in buffered plasminogen and NHP-based assays.

a. Pure Plasminogen System
Fig. 19 depicts the effects of various agents on the process of plasminogenolysis
in the assays where plasminogen is provided in a purified form. Except for argatroban,
all thrombin inhibitors studied in these assay systems exhibited inhibitory activities in the
process of plasminogenolysis, although to varying degrees, regardless of whether
activation was mediated by streptokinase (Fig. 19, panel A) or tPA (Fig. 19, panel B).
The inhibitory patterns that emerged from the two assays were parallel.
As depicted in Fig. 19, panel A, in the streptokinase-mediated plasminogenolysis
assay, hirudin appeared to be the weakest inhibitor (IC50 > 1.2 µM), with a maximal
inhibition of around 20% at the highest concentration used (1 µM), concentrationindependently.

On the other hand Ac-(D)Phe-Pro-boroArg-OH was the strongest

inhibitor (IC 50 < 1.97 µM) followed closely by Boc-D-Phe-Pro-Arg-H (IC50 4.9 µM).
While the effects of D-MePhe-Pro-Arg-H (IC 50 7 µM) and D-Phe-Pro-Arg-H (IC 50 12.6
µM) followed those of Ac-(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-Arg-H, aprotinin

was a stronger concentration-dependent inhibitor of plasminogenolysis. The inhibitory
pattern of heparin was weakly concentration-dependent in this assay (IC50 >0.73 µM).
The IC 50 value for each thrombin inhibitor in the streptokinase assay are reported in
Table 13.

The individual % plasminogenolysis inhibitory values for each inhibitor

concentration point are found in Tables 13a - 13c.
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Fig. 19. Concentration dependent inhibition of the process of plasminogenolysis by
antithrombin agents. Panel A depicts the effects mediated by various agents in the pure
plasminogen system, activated by streptokinase. The individual values at each
concentration point and their gravimetric equivalents are given in Tables 13a-13c. Panel
B depicts the effects mediated by agents in the pure plasminogen system, activated by tp A. The individual values at each concentration point and their gravimetric equivalents
are given in Tables 13d-13f. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) BocD-Phe-Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (0) hirudin, ( +) heparin, ( O)
aprotinin. Each point represents a mean ± 1 SD of three individual determinations.

Table 13 -- Inhibition of plasminogenolysis by thrombin inhibitors as -determined in biochemically defined and NHP amidolytic
systems.
Pure Plasminogen Assay, IC 50 in [µM]

NHP-Derived Plasminogen Assay, IC 50 in [µM]

Streptokinase

tPA

Streptokinase

± 1.6
7.0 ± 0.8
4.9 ± 0.5

± 0.02
0.62 ± 0.02
<0.089

± 1.6
5.24 ± 0.97
4.3 ± 0.7

Ac-D-Phe-Pro-boroArg-OH

< 1.97

<0.098

< 1.97

< 1.97

Argatroban

> 1.0

> 1.0

> 1.0

> 1.0

Hirudin

> 1.22

> 1.22

> 1.22

> 1.22

Heparin

>0.73

>0.73

>0.73

>0.73

Aprotinin

>3.84

D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H

12.6

1.18

0.355

± 0.215

7.0

>3.84

tPA

± 0.1
3.5 ± 0.1

2.5

< 1.77

1.92

± 0.02

Each value represents the mean ± 1 SD of three separate determinations. In the pure plasminogen lysed by streptokinase assay, the
value produced by D-Phe-Pro-Arg-H was significantly different from those produced by D-MePhe-Pro-Arg-H and Boc-D-Phe-ProArg-H. In the pure plasminogen lysed by tPA assay, the value produced by Boc-D-Phe-Pro-Arg-H was significantly different from
those produced by D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. In the NHP-derived plasminogen lysed by streptokinase assay, non
of the values were significantly different from each other. Similarly, in the NHP-derived plasminogen lysed by tPA assay, non of
the values were significantly different from each other. (p < 0.05, ANOVA followed by Student-Newman-Keuls test).
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Fig. 19, panel B depicts the inhibitory effects of various agents on the
plasminogenolysis mediated by tPA. Hirudin was found to be again the weakest inhibitor
(IC50 > 1.2 µM), producing a plateau at around 20% inhibition even at the highest
concentration (1 µM).

Ac-(D)Phe-Pro-boroArg-OH was found to be the strongest

inhibitor of the tPA-induced plasminogenolysis (IC 50 < 0.1 µM), followed by Boc-D-PhePro-Arg-H (IC 50 < 0.09 µM), aprotinin (IC 50 0.36 µM), D-MePhe-Pro-Arg-H (IC 50 0.6
µM) and D-Phe-Pro-Arg-H (IC 50 1.2 µM).

Heparin produced weak inhibitory effects

which plateaued at 35 % inhibition at concentration in the nM range. The IC 50 values for
each of the antithrombin agents are reported in Table 13. The individual inhibitory
values at each agent concentration point are given in Tables 13d - 13f.

b. NHP System
Fig. 20 represents the effects of various inhibitors on the process of
plasminogenolysis in assays where the source of plasminogen is NHP.

With the

exception of argatroban and heparin, all thrombin inhibitors studied in these tests
exhibited inhibitory activities in the process of plasminogenolysis, although to varying
degrees, regardless of whether activation was mediated by streptokinase (Fig. 20, panel
A) or tPA (Fig. 20, panel B). The inhibitory patterns that resulting from the two tests
were parallel.
In the streptokinase-induced plasminogenolysis assay (Fig. 20, panel A), heparin
appeared to be the weakest inhibitor, with a maximal inhibition of around 25 % at the
highest concentration used (0.73 µM), followed by hirudin with a maximal inhibition of
30% at the highest concentration studied (1 µM). On the other hand Ac-(D)Phe-Pro-
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Fig. 20. Concentration dependent inhibition of process of plasminogenolysis by
antithrombin agents. Panel A depicts the effects mediated by various agents in the NHP
system, activated by streptokinase. The individual values at each concentration point and
their gravimetric equivalents are given in Tables 13g-13i. Panel B depicts the effects
mediated by agents in the NHP system, activated by t-PA. The individual values at each
concentration point and their gravimetric equivalents are given in Tables 13j-131. ( •)
D-Phe-Pro-Arg-H, ( o) D-MePhe-Pro-Arg-H, ( •) Boc-D-Phe-Pro-Arg-H, (A) Ac-(D)PhePro-boroArg-OH, (0) hirudin, ( +) heparin, ( O) aprotinin. Each point represents a
mean ± 1 SD of three individual determinations.
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boroArg-OH was the strongest inhibitor (IC 50 < 2.0 µM), followed closely by Boc-DPhe-Pro-Arg-H (IC50 4.3 µM). While the concentration-dependent effects of D-MePhePro-Arg-H (IC 50 5.2 µM) and D-Phe-Pro-Arg-H (IC 50 7 µM) followed those of Ac(D)Phe-Pro-boroArg-OH and Boc-D-Phe-Pro-Arg-H, they were superimposable with
those of aprotinin. The IC 50 values for each thrombin inhibitor are given in Table 13,
while the values for the individual concentrations of each agent are reported in Tables
13g - 13i.
In the tPA-induced plasminogenolysis, heparin had no effects even at the highest
concentration studied (0. 73 µM). Hirudin was again found to be the weakest inhibitor
of plasminogenolysis (IC 50

< 1 µM) and inhibited only 33 % of the process. The

strongest inhibitor in this assay was found to be Ac-(D)Phe-Pro-boroArg-OH (IC50

µM), followed by Boc-D-Phe-Pro-Arg-H (IC 50

<2

< 1.8 µM), aprotinin (IC 50 1.9 µM), D-

Phe-Pro-Arg-H (IC 50 2.5 µM) and D-MePhe-Pro-Arg-H (IC 50 2.5 µM). Table 12 reports
the IC 50 values of each thrombin inhibitor in this assay. Tables 13j - 131 contain the
inhibitory values at each concentration for the individual antithrombin agents.

7. Inhibition of Extrinsic Activation Systems in Fibrinogen Deficient
Human Plasma by Thrombin Inhibitors
Although the antithrombin and anti-Xa assays provided data on the direct
inhibitory activities of thrombin inhibitors against thrombin and factor Xa, their effects
on protease generation were not addressed in these assays. The coagulation cascade is
a complex enzyme network with feedback mechanisms and amplification loops. Thus,
it is conceivable that even if a thrombin inhibitor is effective in directly inhibiting
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thrombin or factor Xa, it may not inhibit the generation of various proteases and
thrombin. Therefore, the inhibitory effects of thrombin inhibitors on the generation of
thrombin and factor Xa were studied in the fibrinogen deficient plasma where specific
activators of the extrinsic and intrinsic assay systems were used. The human plasma
used in these assays was fibrinogen deficient, in which clot formation was avoided to
minimize clotting interference.

a. Inhibition of Extrinsic Thrombin Generation
Fig. 21. panel A depicts the data of the inhibition of thrombin generation after
extrinsic activation by various thrombin inhibitors. All agents produced a concentrationdependent inhibition of thrombin. While hirudin was the most potent inhibitor (IC50
0.02µM) in this assay, the maximal inhibitory activity plateaued around 803. With the

exception of argatroban, the rest of the thrombin inhibitors were relatively weaker
inhibitors but were able to completely inhibit the generation of thrombin at higher
concentrations. According to the IC 50 values for each thrombin inhibitor in this test,
reported in Table 14, after hirudin, the most potent inhibitor was heparin (IC50 0.2 µM),
closely followed by Ac-(D)Phe-Pro-boroArg-OH (IC 50 0.4 µM). The effects of D-PhePro-Arg-H (IC 50 5.3 µM) and D-MePhe-Pro-Arg-H (IC 50 5.1 µM) were superimposable.
Although Boc-D-Phe-Pro-Arg-H had a similar IC 50 value as the other two aldehydes (5.5
µM), the slope of the response was steeper, indicating improved efficacy. Argatroban

was found to be the weakest inhibitor in this test. The individual % thrombin generation
inhibitory values for each inhibitor concentration point are found in Tables 14a - 14e.

Table 14 -- Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as determined in fibrinogendeficient amidolytic systems.
Extrinsic Generation, IC50 [µM]

D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
Ac-D-Phe-Pro-boroArg-OH
Argatroban
Hirudin
Heparin

Intrinsic Generation, IC50 [µM]

Thrombin

Factor Xa

Thrombin

± 0.6
5.1 ± 0.5
5.5 ± 0.5
0.4 ± 0.1
19 ± 3
0.02 ± 0.01
0.2 ± 0.1

± 1.5
13 ± 1.5
2.2 ± 0.4
0.24 ± 0.06

± 0.8
1.4 ± 0.4
1.4 ± 0.2
0.14 ± 0.04
6.5 ± 0.6
0.04 ± 0.005
0.032 ± 0.004

5.3

10

>60
>5
0.045

± 0.01

3.8

Factor Xa
0.07
0.106
0.16
0.036
0.17
0.018
0.006

± 0.01
± 0.005
± 0.01
± 0.005
± 0.03
± 0.002
± 0.002

Each value represents the mean ± 1 SD of three separate determinations. In the extrinsic generation of thrombin
assay, all values were significantly different from each other except for the following pairs: D-Phe-Pro-Arg-H vs DMePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs Boc-D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H vs Boc-D-Phe-Pro-Arg-H, Ac(D)Phe-Pro-boroArg-OH vs hirudin, Ac-(D)Phe-Pro-boroArg-OH vs heparin and hirudin vs heparin. In the extrinsic
generation of factor Xa, the values produced by D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H were significantly
different when compared to each other and when compared to Boc-D-Phe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH
and heparin. In the intrinsic thrombin generation assay, all values produced by all thrombin inhibitors were
significantly different from each other, with the exception of the following pairs: D-MePhe-Pro-Arg-H vs Boc-D-PhePro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH vs hirudin, Ac-(D)Phe-Pro-boroArg-OH vs heparin and hirudin vs heparin.
In the extrinsic factor Xa generation assay, all values were significantly different from each other, except for the
comparison between Boc-D-Phe-Pro-Arg-H and argatroban. (p < 0.05, ANOVA followed by Student-Newman-Keuls
test).
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Fig. 21. Concentration-dependent inhibition of the extrinsic activation of coagulation,
by antithrombin agents, in the fibrinogen-deficient system. Panel A depicts the effects
mediated by various agents in the extrinsic thrombin generation system. The individual
values at each concentration point and their gravimetric equivalents are given in Tables
14a-14e. Panel B depicts the effects mediated by agents in the extrinsic factor Xa
generation system. The individual values at each concentration point and their
gravimetric equivalents are given in Tables 14f-14j. (•) D-Phe-Pro-Arg-H, (o) DMePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (.6.) Ac-(D)Phe-Pro-boroArg-OH, (•)
argatroban, (D) hirudin, (+)heparin. Each point represents a mean ± 1 SD of three
individual determinations.

182
b. Inhibition Extrinsic Factor Xa Generation
Fig. 21, panel B depicts the results on the inhibition of factor Xa generation after
extrinsic activation by various agents. All inhibitors produced a concentration-dependent
inhibition of factor Xa. Hirudin appeared to be a weak inhibitor of extrinsic factor Xa
generation and only about 20 % of factor Xa generation was maximally inhibited at
concentration as high as 5 µM. With the exception of argatroban, the other thrombin
inhibitors were able to completely inhibit the generation of factor Xa. According to the
IC 50 values for each antithrombin agent in this assay reported in Table 14, the most
potent inhibitor was heparin (IC 50 0.045 µM), followed by Ac-(D)Phe-Pro-boroArg-OH
(IC50 0.24 µM) and then by Boc-D-Phe-Pro-Arg-H (IC50 2.2 µM). The effects of D-PhePro-Arg-H (IC50 10 µM) and D-MePhe-Pro-Arg-H (IC50 13 µM) were superimposable.
Argatroban was the weakest inhibitor in this assay system (IC50 > 62 µM).

The

individual % factor Xa generation inhibitory values for each inhibitor concentration point
are found in Tables 14f - 14j.

8. Inhibition of Intrinsic Activation Systems in Fibrinogen Deficient
Human Plasma by Thrombin Inhibitors
The extrinsic and intrinsic activation of the coagulation cascade trigger different
sequences of clotting factor activations. Therefore, the proportions of active factors
generated, as well as the speed at which they are generated are different. To study the
effects of thrombin inhibitors on the coagulation cascade after intrinsic activation, their
effects on the generation of thrombin and factor Xa were studied in the following tests,
where human plasma was activated intrinsically and the amount of thrombin and factor

183
Xa generated was detected with specific chromogenic substrates. As with the extrinsic
assays described earlier, fibrinogen deficient human plasma was used in these assays.

a. Inhibition of Intrinsic Thrombin Generation
Fig. 22, panel A depicts the inhibition of thrombin generation after intrinsic
activation by various thrombin inhibitors. The inhibition produced by these agents was
concentration-dependent. While heparin was found to be the most potent inhibitor in this
test (IC 50 0.032 µM), followed closely by hirudin (IC 50 0.04 µM), the maximal inhibitory
activity of both agents plateaued around 80 %. With the exception of argatroban, the
other thrombin inhibitors appeared to be weaker than heparin and hirudin but were able
to completely inhibit the generation of thrombin at higher concentrations. According to
the IC50 values for each thrombin inhibitor in this assay, reported in Table 14, after
hirudin and heparin, the most potent inhibitor was Ac-(D)Phe-Pro-boroArg-OH with an
IC 50 of 0.14 µM. The effects of D-MePhe-Pro-Arg-H (IC 50 1.4 µM) and Boc-D-Phe-ProArg-H (IC 50 1.4 µM) were superimposable, followed by D-Phe-Pro-Arg-H (IC50 3.8
µM). Argatroban was found to be the weakest inhibitor in this assay system (IC50 6.5
µM) and it also appeared to plateau around 65 %. The individual % thrombin generation

inhibitory values for each inhibitor concentration point are found in Tables 14k - 140.

b. Inhibition of Intrinsic Factor Xa Generation
Fig. 22, panel B, represents the inhibition of factor Xa generation after intrinsic
activation by various agents. The inhibition produced by these thrombin inhibitors was
concentration-dependent and all agents were capable of completely inhibiting factor Xa
generation at the higher concentrations. The order of potency of these antithrombin
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Fig. 22. Concentration dependent inhibition of the intrinsic activation of coagulation, by
antithrombin agents, in the fibrinogen-deficient system. Panel A depicts the effects
mediated by various agents in the intrinsic thrombin generation system. The individual
values at each concentration point and their gravimetric equivalents are given in Tables
14k-14o. Panel B depicts the effects mediated by agents in the intrinsic factor Xa
generation system. The individual values at each concentration point and their
gravimetric equivalents are given in Tables 14p-14t. (•) D-Phe-Pro-Arg-H, (o) DMePhe-Pro-Arg-H, (•) Boc-D-Phe-Pro-Arg-H, (£.) Ac-(D)Phe-Pro-boroArg-OH, (•)
argatroban, (D) hirudin, (+)heparin. Each point represents a mean ± 1 SD of three
individual determinations.
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agents was heparin (IC 50 0.006 µM) > hirudin (IC 50 0.018 µM) > Ac-(D)Phe-ProboroArg-OH (IC 50 0.17 µM) > D-Phe-Pro-Arg-H (IC 50 0.11 µM) > D-MePhe-Pro-Arg-H
(IC 50 0.07 µM) >Boc-D-Phe-Pro-Arg-H (IC50 0.16 µM) >argatroban (IC50 0.17 µM),
as indicated by their IC50 values, reported in Table 14. The individual % factor Xa
generation inhibitory values for each inhibitor concentration point are found in Tables
14p - 14t.

9. Inhibition of KONYNE® Based Systems by Thrombin Inhibitors
In the extrinsic thrombin and factor Xa generation experiments described above,
while the initial activation was provided extrinsically, the intrinsic pathway was also
eventually activated due to the feedback loops mediated by thrombin. To devise a test
where only extrinsic activation was present without interference from the intrinsic
factors, a mixture of factors II, VII, IX and X purified from human plasma (KONYNE®)
was utilized instead of fibrinogen deficient human plasma.

Thus, with extrinsic

activation only the extrinsic and common pathway were amplified.

The amount of

thrombin and factor Xa generated were detected based on their amidolytic activity on
chromogenic substrates, specific for thrombin and factor Xa respectively.

a. Inhibition of Thrombin Generation from KONYNE®
Inhibition of thrombin generated from KONYNE® after extrinsic activation, by
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 23, panel A.
Hirudin was the most potent inhibitor in this assay but the maximal inhibitory activity
plateaued around 40 %. On the other hand, the rest of the thrombin inhibitors were
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Fig. 23. Concentration-dependent inhibition of the extrinsic activation of coagulation in
the KONYNE® system, by antithrombin agents. Panel A depicts the effects mediated by
various agents in the extrinsic thrombin generation system. The individual values at each
concentration point and their gravimetric equivalents are given in Tables 15a-15c. Panel
B depicts the effects mediated by agents in the extrinsic factor Xa generation system.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 15d-15f. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-DPhe-Pro-Arg-H, (Ll) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin, ( +)
heparin. Each point represents a mean ± 1 SD of three individual determinations.
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relatively weaker but were able to inhibit the generation of thrombin to a greater extent
at higher concentrations. According to the IC 50 values for each thrombin inhibitor in this
assay system, reported in Table 15, the most potent inhibitor Ac-(D)Phe-Pro-boroArgOH with an IC50 of 0.25 µM. The effects of D-MePhe-Pro-Arg-H (IC 50 1.94 µM) and
Boc-D-Phe-Pro-Arg-H (IC50 1.59 µM) were superimposable. As with hirudin, D-PhePro-Arg-H and heparin also appeared to plateau in their inhibitory activities around 40 %.
Argatroban was the weakest inhibitor in this test with an IC50 of 10.0 µM.

The

individual % thrombin generation inhibitory values for each inhibitor concentration point
are found in Tables 15a - 15c.

Table 15 -- Inhibition of generation of thrombin and factor Xa by thrombin inhibitors as
determined in FEIBA® and KONYNE amidolytic systems.
KONYNE® System
IC 50 [µM]
Thrombin
D-Phe-Pro-Arg-H

FEIBA ® System
IC50 [µM]

Factor Xa

Thrombin

2.58

2.73

>3.0

Factor Xa
2.8

D-MePhe-Pro-Arg-H

1.94

0.41

>2.9

1.68

Boc-D-Phe-Pro-Arg-H

1.59

0.91

>2.7

2.21

Ac-(D )Phe-Pro-boroArg-OH

0.25

0.10

Argatroban

10.0

10.0

0.66
> 18.8

Hirudin

>2.15

1.28

0.54

Heparin

> 1.8

0.75

1.66

Each value was derived from a single determination.

0.36
0.82
0.54
> 1.8
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b. Inhibition of Factor Xa Generation from KONYNE®
Inhibition of factor Xa generated from KONYNE®, after extrinsic activation, by
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 23, panel B.
Hirudin appeared to be a weak inhibitor of factor Xa generation and only about 50 % of
factor Xa generation was maximally inhibited at concentrations around 2.9 µM. The
antithrombin agents were able to inhibit the generation of factor Xa to a greater extent.
According to the IC 50 values for each thrombin inhibitor in this assay reported in Table
15, the most potent inhibitor was Ac-(D)Phe-Pro-boroArg-OH (IC50 0.1 µM), followed
by D-MePhe-Pro-Arg-H (IC50 0.9 µM), heparin (IC 50 0.8 µM), Boc-D-Phe-Pro-Arg-H
(IC 50 0.9 µM), hirudin (IC 50 1.3 µM), D-Phe-Pro-Arg-H (IC 50 2.6 µM) and lastly by
argatroban (IC 50 10 µM).

The individual % factor Xa generation from KONYNE®

inhibitory values for each inhibitor concentration point are found in Tables 15d - 15f.

10. Inhibition of FEIBA® Based Systems by Thrombin Inhibitors
These assays are similar to the KONYNE® based reaction mixtures as described
earlier. However, FEIBA® mainly contains factor VIia and factors II, VII, IX and X,
in both the native and active forms. This product is purified from human plasma. In
these studies thromboplastin C was used an activator. Thus, with this activation only the
extrinsic and common pathway were activated. The amount of thrombin and factor Xa
generated were detected based on their amidolytic activity on chromogenic substrates,
specific for thrombin and factor Xa respectively.
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Fig. 24. Concentration-dependent inhibition of the extrinsic activation of coagulation in
the FEIBA ® system, by antithrombin agents. Panel A depicts the effects mediated by
various agents in the extrinsic thrombin generation system. The individual values at each
concentration point and their gravimetric equivalents are given in Tables 15g-15i. Panel
B depicts the effects mediated by agents in the extrinsic factor Xa generation system.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 15j-151. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•) Boc-DPhe-Pro-Arg-H, (~) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (0) hirudin, ( +)
heparin. Each point represents a mean ± 1 SD of three individual determinations.
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a. Inhibition of Thrombin Generation from FEIBA®
Fig. 24, panel A depicts the inhibition of thrombin generation from FEIBA ®after
extrinsic activation by various thrombin inhibitors. All agents exhibited concentrationdependent inhibition of thrombin generation in this assay. Hirudin was the most potent
inhibitor in this assay (IC50 0.54 µM) but the maximal inhibitory activity plateaued
around 90%. The effects of hirudin were closely followed by those of Ac-(D)Phe-ProboroArg-OH (IC 50 0.66 µM). While heparin (IC 50 1.66 µM) and D-Phe-Pro-Arg-H (2. 73
µM) had weaker inhibitory activities in this test than Ac-(D)Phe-Pro-boroArg-OH, D-

MePhe-Pro-Arg-H, Boc-D-Phe-Pro-Arg-H and argatroban where devoid of any effects
at high concentrations (IC50 >2.9, 2.7 and 18.8 µM respectively). The IC 50 values for
each thrombin inhibitor in this assay system are reported in Table 15 and the individual
% thrombin generation inhibitory values for each inhibitor concentration point are found
in Tables 15g - 15i.

b. Inhibition of Factor Xa Generation from FEIBA®
Inhibition of factor Xa generated from FEIBA ® after extrinsic activation, by
thrombin inhibitors was concentration-dependent, as illustrated in Fig. 24, panel B. Ac(D)Phe-Pro-boroArg-OH was the most potent inhibitor in this assay (IC50 0.36 µM)
followed by hirudin (IC 50 0.54 µM), argatroban (IC 50 0.82 µM), D-MePhe-Pro-Arg-H
(IC 50 1.68 µM), Boc-D-Phe-Pro-Arg-H (IC50 2.21 µM) and D-Phe-Pro-Arg-H (IC 50 2.8
µM). Heparin was devoid of any effects at high concentrations ( > 1.9 µM). The IC50

values for all agents are reported in Table 15. The individual % factor Xa generation
from KONYNE® inhibitory values for each inhibitor concentration point are given in
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Tables 15j - 151.

D. Anticoagulant Effects of Thrombin Inhibitors in NHP
All of the results described in section C. Biochemical Assays, with the exception
of the TT in the human fibrinogen based test, were based on the inhibition of the
amidolytic activity of thrombin, factor Xa and other serine proteases. Furthermore, the
TT in the fibrinogen based test was a defined assay in which no other clotting factors
except for thrombin and fibrinogen were present. Therefore, the in vitro anticoagulant
effects of thrombin inhibitors, based on the inhibition of thrombin clotting activity, were
studied in the following global clotting tests, where all clotting factors were present in
normal human plasma. Each assay was based on the activation of the coagulation in a
distinct manner, thus providing specific data on the inhibitory actions of these
antithrombin agents at various sites. To compare the relative anticoagulant effects of
thrombin inhibitors in these assays, the concentrations of each inhibitor that resulted in
prolongation of the clotting time to 100 sec (CT100) was calculated and is given in Table
16.

1. Prothrombin Time (PT)
In the PT assay, thromboplastin was added to NHP to activate the coagulation
cascade extrinsically (starting with factor VII), leading to thrombin formation which
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this assay
system were concentration-dependent, as seen in Fig. 25. Heparin had no effects in this
test at high concentrations ( > 0. 9 µM). When comparing the concentrations of each

Table 16 -- Comparative anticoagulant effects of thrombin inhibitors in NHP.
Concentrations that prolong clotting time to 100 sec in [µM]
PT

APTT

TT

ECT

Hep test

D-Phe-Pro-Arg-H

61 ± 2

11.9 ± 0.4

5.1 ± 0.2

0.16 ± 0.04

21.4 ± 0.8

D-MePhe-Pro-Arg-H

33 ± 1

8.2 ± 0.2

2.7 ± 0.3

0.22 ± 0.05

11.2±0.4

Boc-D-Phe-Pro-Arg-H

101 ± 4

7.7 ± 0.5

5.5 ± 0.2

0.89 ± 0.03

23.8 ± 0.6

Ac-D-Phe-Pro-boroArg-OH

6.2 ± 1

0.68 ± 0.05

0.60 ± 0.02

0.095 ± 0.010

2.05 ± 0.05

28 ± 1

6.90 ± 0.20

8.9 ± 0.2

0.21 ± 0.01

3.65 ± 0.10

Hirudin

2.3 ± 0.5

1.44 ± 0.05

0.009 ± 0.006

0.065 ± 0.015

1.3 ± 0.05

Heparin

>0.9

0.22 ± 0.03

0.155 ± 0.005

>10.0

0.30 ± 0.05

Argatroban

Each value represents the mean ± 1 SD of three separate determinations. In the PT assay, values produced by all
thrombin inhibitors (except for heparin) were significantly different from each other. In the APTT assay, values
produced by all thrombin inhibitors were significantly different from each other, with the exception of the Ac-(D)PhePro-boroArg-OH vs heparin comparison. In the 10 U ca++TT assay, values produced by all thrombin inhibitors were
significantly different from each other, with the exception of the hirudin vs heparin comparison. In the ECT assay,
values produced by all thrombin inhibitor (except for heparin) were significantly different from each other with the
exception of the following pairs: D-Phe-Pro-Arg-H vs D-MePhe-Pro-Arg-H, D-Phe-Pro-Arg-H vs argatroban, DMePhe-Pro-Arg-H vs argatroban and Ac-(D)Phe-Pro-boroArg-OH vs hirudin. In the Heptest assay, values produced
by all thrombin inhibitors were significantly different from each other. (p < 0.05, ANOVA followed by StudentNewman-Keuls test).
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Fig. 25. Comparative anticoagulant effects of antithrombin agents, after supplementation
to NHP, as studied in the PT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•)
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin,
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 16a-16c.
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Fig. 26. Comparative anticoagulant effects of various agents, after supplementation to
NHP, as studied in the APTT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•)
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin,
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 16d-16f.
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thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec, reported
in Table 16, it was found that the most potent inhibitor of the PT was hirudin (CT100 : 2.3
µM) followed by Ac-(D)Phe-Pro-boroArg-OH (CT 100 : 6.2 µM). Both hirudin and Ac(D)Phe-Pro-boroArg-OH appeared to have an all-or-none effects on the PT. The effects
of Ac-(D)Phe-Pro-boroArg-OH were followed by argatroban (CT100 : 28 µM), D-MePhePro-Arg-H (CT 100 : 33 µM), D-Phe-Pro-Arg-H (CT 100 : 61 µM) and lastly by Boc-D-PhePro-Arg-H (CT100 : 101 µM).

Even though argatroban produced a clotting time

prolongation to 100 sec at a lower concentration than D-MePhe-Pro-Arg-H, the latter
inhibitor prolonged the PT to over 300 sec at lower concentrations than argatroban (97
µM versus 188 µM respectively).

The individual clotting times for each thrombin

inhibitor concentration point are reported in Tables 16a - 16c.

2. Activated Partial Thromboplastin Time (APTT)
In the APTT assay, a contact activator was added to NHP to activate the
coagulation cascade intrinsically (starting with factor XII), leading to thrombin formation
which resulted in clot formation. As seen in Fig. 26, the inhibitory activities of various
thrombin inhibitors in this assay were concentration-dependent. When comparing the
concentrations of each thrombin inhibitor that resulted in prolongation of the clotting time
to 100 sec as given in Table 16, it was found that the most potent inhibitor of the APTT
was heparin (CT 100 : 0.22 µM) followed by Ac-(D)Phe-Pro-boroArg-OH (CT 100 : 0.68 µM)
and then closely by hirudin (CT 100 : 1.44 µM). The effects of hirudin were followed by
argatroban (CT 100 : 6.9 µM), Boc-D-Phe-Pro-Arg-H (CT 100 : 7.7 µM), D-MePhe-Pro-ArgH (CT 100 : 8.2 µM) and D-Phe-Pro-Arg-H (CT 100 : 11.9 µM). The inhibitory profiles of
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the last four thrombin inhibitors were superimposable. The individual clotting times for
each thrombin inhibitor concentration point are reported in Tables 16d - 16f.

3. Thrombin Time (TT)
In the TT assay, thrombin was added to NHP to convert the existing fibrinogen

to fibrin clots. Furthermore, the added thrombin activated the coagulation cascade at
multiple points (extrinsically via factors VII and V, intrinsically via factor XI and
common pathway via factor VIII), leading to additional thrombin formation which
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this assay
system were concentration-dependent, as seen in Fig. 27. The concentrations of each
thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec are given
in Table 16.

The most potent inhibitor of the TT was hirudin (CT100 : 0.009 µM),

followed by heparin (CT100 : 0.155 µM). The effects of heparin were followed by Ac(D)Phe-Pro-boroArg-OH (CT100 : 0.6 µM) and then by D-MePhe-Pro-Arg-H (CT 100 : 1.7
µM), D-Phe-Pro-Arg-H (CT100 : 5.1 µM), Boc-D-Phe-Pro-Arg-H (CT 100 : 5.5 µM) and
lastly by argatroban (CT100 : 8.9 µM). The inhibitory profiles of D-Phe-Pro-Arg-H and
Boc-D-Phe-Pro-Arg-H were superimposable.

The individual clotting times for each

thrombin inhibitor concentration point are given in Tables 16g - 16i.

4. Ecarin Clotting Time (ECT)
In the ECT assay, ecarin was added to NHP to activate the existing prothrombin
to meizothrombin and other intermediates with clotting activity, which led to fibrinogen
conversion to fibrin clots. This was different from the TT, where exogenous thrombin
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Fig. 27. Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to NHP, as studied in the TT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•)
Boc-D-Phe-Pro-Arg-H, (.c.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin,
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations.
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given in Tables 16g-16i.
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Fig. 28. Comparative anticoagulant effects of antithrombin agents, after supplementation
to NHP, as studied in the ECT. (•) D-Phe-Pro-Arg-H, (o) D-MePhe-Pro-Arg-H, (•)
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(+)heparin. Each point represents a mean ± 1 SD of three individual determinations.
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given in Tables 16j-16k.
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was added to the NHP. Fig. 28 depicts the inhibitory activities of thrombin inhibitors
in this assay system. With the exception of heparin, the inhibitory activities of the other
agents were concentration-dependent.

Table 16 shows the concentrations of each

thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec. When
comparing these CT100s, it was found that the most potent inhibitor of the ECT was
hirudin (CT 100 : 0.065 µM), followed closely by Ac-(D)Phe-Pro-boroArg-OH (CT 100 :
0.095 µM). The effects of Ac-(D)Phe-Pro-boroArg-OH were followed by D-Phe-ProArg-H (CT100 : 0.16 µM), Boc-D-Phe-Pro-Arg-H (CT 100 : 0.89 µM) and lastly by
argatroban (CT100 : 3.65 µM). In this assay, heparin was devoid of any effects at high
concentrations ( > 0. 91 µM). The individual clotting times for each thromb in inhibitor
concentration point are given in Tables 16j and l 6k.

5. Heptest
In the Hep test assay, factor Xa added to NHP activated the common pathway
which lead to thrombin formation with subsequent fibrinogen conversion to fibrin clots.
The inhibitory activities of antithrombin agents in this test were concentration-dependent,
as seen in Fig. 29. When comparing the concentrations of each thrombin inhibitor that
resulted in prolongation of the clotting time to 100 sec, as reported in Table 16, heparin
was found to be the most potent inhibitor of the Heptest with a CT100 of 0.3 µM. The
effects of heparin were followed closely by Ac-(D)Phe-Pro-boroArg-OH (CT100 : 2.1 µM)
and then by argatroban (CT 100 : 3.7 µM), D-MePhe-Pro-Arg-H (CT100 : 11.2 µM), Boc-DPhe-Pro-Arg-H (CT 100 : 23.8 µM) and lastly by D-Phe-Pro-Arg-H (CT100 : 21.4 µM). The
individual clotting times for each thrombin inhibitor concentration point are reported in
Tables 161 - 16n.
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Fig. 29. Comparative anticoagulant effects of various agents, after supplementation to
NHP, as studied in the Heptest. (•) D-Phe-Pro-Arg-H, (O) D-MePhe-Pro-Arg-H, (•)
Boc-D-Phe-Pro-Arg-H, (.t.) Ac-(D)Phe-Pro-boroArg-OH, (•) argatroban, (D) hirudin,
(+)heparin. Each point represents a mean ± 1 SD of three individual determinations.
The individual values at each concentration point and their gravimetric equivalents are
given in Tables 161-16n.
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E. Anticoagulant Effects of Thrombin Inhibitors in Normal Human Whole Blood
The coagulation process in vivo takes place in whole blood, so that in addition to
the coagulation factors present in plasma, the rest of the blood components, such as
platelets and white cells may also play a role in the clotting process. To investigate the
anticoagulant activities of thrombin inhibitors in normal human whole blood, the ACT
and TEG were utilized to compare D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH,
argatroban, hirudin and heparin. Freshly drawn blood samples were supplemented in

vitro with various concentrations of thrombin inhibitors prior to studying their effects in
these assay systems.

1. Activated Clotting Time (ACT)
The results of the concentration-dependent anticoagulant activities of thrombin
inhibitors in whole blood, as studied in the ACT, are depicted in Fig. 30. Ac-(D)PhePro-boroArg-OH, hirudin and heparin produced similar concentration-dependent pattern
of prolongation of the ACT with a prolongation of this assay to 300-370 sec at
concentrations of 1 µM. D-MePhe-Pro-Arg-H and argatroban had weak anticoagulant
activities even at the highest concentration, producing a prolongation of the ACT to 150180 sec at 1 µM concentrations.

The individual clotting times for each inhibitor

concentration are reported in Table 160.

2. Thrombelastographic Analysis (TEG)
The results of the concentration-dependent anticoagulant activities of thrombin
inhibitors in whole blood, as studied in the TEG, are depicted in Fig. 31. As seen in this
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Fig. 30. Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal human whole blood, as detected in the ACT assay. (•) D-MePhe-Pro-Arg-H,
(•) Ac-(D)Phe-Pro-boroArg-OH, (T) argatroban, (•) hirudin, (+)heparin. Each point
represents a mean ± 1 SD of three individual determinations. The individual values at
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Fig. 31. Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal human whole blood, as studied in the TEG assay. (•) D-MePhe-Pro-Arg-H,
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each concentration point and their gravimetric equivalents are given in Table 16p.
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profile, D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin
produced similar concentration-dependent pattern of prolongation of the r value of the
TEG (38-47 mm) at equimolar concentrations (0.1 µM).

Argatroban had weak

anticoagulant activities even at the highest concentration, producing a prolongation of the
TEG r value to 31 mm at 1 µM.

The individual TEG r values for each inhibitor

concentration are reported in Table 16p.

F. Anticoagulant Effects of Thrombin Inhibitors in NRP

Human plasma and rabbit plasma differ in their composition and the relative
levels of clotting factors.

Since it was shown in the biochemical studies that each

thrombin inhibitor had a distinct pattern of inhibition of serine proteases and generation
assays, it was reasonable to assume that the anticoagulant effects of these inhibitors
would differ depending on the plasma origin.

Therefore, to compare the in vitro

anticoagulant effects of thrombin inhibitors, based on the inhibition of thrombin clotting
activity in the following global clotting tests, D-MePhe-Pro-Arg-H, Ac-(D)Phe-ProboroArg-OH, hirudin and heparin were supplemented to normal rabbit plasma. As with
the NHP tests, each assay was based on the specific activation of the coagulation system,
thus providing different insights into the inhibitory actions of these thrombin inhibitors.
To compare the anticoagulant effects of thrombin inhibitors in these assay systems, the
concentrations of each inhibitor that resulted in prolongation of the clotting time to 100
sec (CT 100) was calculated and compiled in Table 17.

Table 17 -- Comparative anticoagulant effects of thrombin inhibitors in NRP.
Concentrations that prolong clotting time to 100 sec in [µM]
PT
D-MePhe-Pro-Arg-H
Ac-(D )Phe-Pro-boroArg-OH
Hirudin
Heparin

107

±4

>20.1
3.6

± 0.4

>9.3

APTT
4.8
0.52
0.7
0.38

± 0.4
± 0.08
± 0.1
± 0.10

TT
4.5
1.0
0.18
0.18

± 0.4
± 0.2
± 0.02
± 0.02

Heptest
3.3
1.1
0.24
0.27

± 0.2
± 0.1
± 0.03
± 0.06

Each value represents the mean ± 1 SD of three separate determinations. In the PT assay, values produced
by D-MePhe-Pro-Arg-H and hirudin were significantly different from each other. In the APTT assay, the value
produced by D-MePhe-Pro-Arg-H was significantly different from those produced by the other thrombin
inhibitors. In the 10 U ca++TT assay, values produced by all thrombin inhibitors were significantly different
from each other, with the exception of the hirudin vs heparin comparison. In the Heptest assay, as in the TT
assay, values produced by all thrombin inhibitors were significantly different from each other, with the
exception of the hirudin vs heparin comparison. (p <0.05, ANOVA followed by Student-Newman-Keuls test).
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1. Prothrombin Time (PT)

In the PT assay, thromboplastin added to NRP activated the coagulation cascade
extrinsically (starting with factor VII), leading to thrombin formation which resulted in
clot formation. The inhibitory activities of antithrombin agents in this assay are depicted
in Fig. 32, panel A. Heparin and Ac-(D)Phe-Pro-boroArg-OH had minimal effects in
this assay at high concentrations: heparin produced a pt of 17 sec at 9.4 µM, while Ac(D)Phe-Pro-boroArg-OH produced a PT of 24 sec at 20 µM.

When comparing the

concentrations of each thrombin inhibitor that resulted in prolongation of the clotting time
to 100 sec, given in Table 17, it was found that the most potent inhibitor of the PT was
hirudin (CT 100 : 3.6 µM) followed by D-MePhe-Pro-Arg-H (CT 100 : 107 µM).

Both

hirudin and D-MePhe-Pro-Arg-H appeared to have an all-or-none effects on the PT. The
individual clotting times for each thrombin inhibitor concentration point are reported in
Table 17a.

2. Activated Partial Thromboplastin Time (APTT)

In the APTT, a contact activator mixture added to NRP activated the coagulation
cascade intrinsically (starting with factor XII), leading to thrombin formation which
resulted in clot formation. The inhibitory activities of thrombin inhibitors in this test
were concentration-dependent, as seen in Fig. 32, panel B.

Table 17 depicts the

concentrations of each agent that resulted in prolongation of the clotting time to 100 sec.
In comparing the CT100 value for each antithrombin agent, it was found that the most
potent inhibitor of the APTT was heparin (CT 100 : 0.4 µM) followed by closely by Ac(D)Phe-Pro-boroArg-OH (CT 100 : 0.5 µM), hirudin (CT 100 : 0.7 µM) and lastly by D-
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Fig. 32. Comparative anticoagulant effects of thrombin inhibitors, after supplementation
to normal rabbit plasma, as studied in the global clotting tests. Panel A represents the
effects of antithrombin agents in the PT assay. The individual values at each
concentration point and their gravimetric equivalents are given in Table 17a. Panel B
represents the effects of various agents in the APTT assay. The individual values at each
concentration point and their gravimetric equivalents are given in Table 17b. Panel C
represents the effects of agents in the TT assay. The individual values at each
concentration point and their gravimetric equivalents are given in Table 17c. Panel D
represents the effects of antithrombin agents in the Heptest. The individual values at
each concentration point and their gravimetric equivalents are given in Table 17d. ( •)
D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) hirudin, (+)heparin. Each
point represents a mean ± 1 SD of three individual determinations.

205
MePhe-Pro-Arg-H (CT100 : 4.8 µM). The individual clotting times for each thrombin
inhibitor concentration point are reported in Table 17b.

3. Thrombin Time (TT)

In the TT, thrombin added to NRP directly converted the existing fibrinogen to
fibrin clots.

Furthermore, the added thrombin activated the coagulation cascade at

multiple points (extrinsically via factors VII and V, intrinsically via factor XI and
common pathway via factor VIII), leading to additional thrombin formation which
resulted in clot formation.
antithrombin agents.

Fig. 32, panel C, represents the inhibitory activities of

In this assay, all agents produced a concentration-dependent

prolongation of the PT. When comparing the concentrations of each thrombin inhibitor
that resulted in prolongation of the clotting time to 100 sec, reported in Table 17, it was
found that the most potent inhibitor of the TT was hirudin (CT100 : 0.18 µM) followed
closely by heparin (CT100 : 0.18 µM). However, prolongation of the TT to over 300 sec
was achieved with a lower concentration of heparin (0.47 µM) than of hirudin (0. 72
µM). The effects of heparin were followed by Ac-(D)Phe-Pro-boroArg-OH (CT100 : 1
µM) and then by D-MePhe-Pro-Arg-H (CT 100 : 4.5 µM). The individual clotting times

for each thrombin inhibitor concentration point are reported in Table 17c.

4. Heptest
In the Heptest, factor Xa added to NRP activated the common pathway which lead

to thrombin formation with subsequent fibrinogen conversion to fibrin clots.

The

inhibitory activities of antithrombin agents in this assay system were concentration-
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dependent, as seen in Fig. 32, panel D. Table 17 reports the concentrations of each
thrombin inhibitor that resulted in prolongation of the clotting time to 100 sec. When
comparing the CT100 in this assay, it was found that the most potent inhibitors of the
Heptest were heparin (CT100 : 0.27 µM) and hirudin (CT 100 : 0.24 µM), which exhibited
similar effects at the same concentrations.

The effects of heparin and hirudin were

followed by Ac-(D)Phe-Pro-boroArg-OH (CT 100 : 1.1 µM) and then by D-MePhe-ProArg-H (CT100 : 3.3 µM).

The individual clotting times for each thrombin inhibitor

concentration point are given in Table 17d.

G. Anticoagulant Effects of Thrombin Inhibitors in Normal Rabbit Whole Blood

Since the concentration of plasma factors differ depending on the species utilized,
the thrombin inhibitors D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and
heparin were also supplemented to freshly drawn rabbit whole blood, to compare their
anticoagulant effects to each other and to their respective effects in the normal human
whole blood assays.

The effects of these agents in the ACT and TEG assays were

studied.

1. Activated Clotting Time (ACT)

The results of the anticoagulant activities of thrombin inhibitors in rabbit whole
blood, as studied in the ACT, are depicted in Fig. 33. Ac-(D)Phe-Pro-boroArg-OH,
hirudin and heparin produced similar prolongation of the ACT at the concentrations
utilized, exhibiting a prolongation of the ACT of 180-230 sec from the baseline, at
concentrations of 201, 144 and 187 nM respectively. D-MePhe-Pro-Arg-H had the
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weakest anticoagulant activities, producing only a 92 sec prolongation of the ACT from
the baseline at a concentration of 389 nM.

The individual clotting times for each

thrombin inhibitor are reported in Table 17e.

2. Thrombelastographic Analysis (TEG)
The results of the anticoagulant activities of thrombin inhibitors in whole rabbit
blood, as studied in the TEG, are depicted in Fig. 34. D-MePhe-Pro-Arg-H produced
similar prolongation of the TEG r value as Ac-(D)Phe-Pro-boroArg-OH and hirudin.
This prolongation was 30-40 mm from the baseline value at 389, 201 and 144 µM
respectively by the three thrombin inhibitors.

Heparin produced the strongest

prolongation of the r value of the TEG, to > 200 mm at a concentration of 187 nM. The
individual TEG r values for each thrombin inhibitor are reported in Table 17f.

H. Antithrombotic Effects of Thrombin Inhibitors as Studied in the
Rabbit Stasis Thrombosis Model
The Wessler stasis thrombosis model (Wessler et al. 1959) is a rabbit model of venous
thrombosis and has been widely used in the evaluation of antithrombotic activity of
various substances.

Although this model has provided useful information on the

antithrombotic activities of various anticoagulant agents, the results obtained are relative
to the type of thrombogenic challenge used to produce the thrombotic processes. Defined
thrombogenic agents to activate the hemostatic system of rabbits have been previously
utilized in a standardized manner where the site of activation is controlled (Fareed et al.
1985). In previous studies specific components of the hemostatic system were selectively
activated with various agents such as Prothrombin Complex Concentrate (PCC) and
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Russell's Viper Venom (RVV) (Fareed et al. 1985). However, additional activation of
other enzymes and the presence of protein C in these activation mixtures may influence
the results. The availability of TF in a recombinant form (Bach et al. 1986) allows for
a specific investigation of thrombogenesis and its pathophysiological mechanisms. In this
study, the objective was to characterize r-TF in terms of its thrombogenicity in a
standardized model of stasis thrombosis and subsequently to compare the antithrombotic
potential of thrombin inhibitors following I.V. or S.C. administration. In addition, the
duration of the antithrombotic effects of thrombin inhibitors was also studied.
Representative thrombin inhibitors compared in this model were D-MePhe-Pro-Arg-H,
Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin.

1. Standardization of the Rabbit Stasis Thrombosis Model
In these studies, r-TF was injected at various doses in the procedure described in
Chapter III, Section I. 1. After I.V. injection of r-TF, at 1.351, 0.676, 0.338, 0.169
and 0.042 pmol/kg, followed by a 20 sec circulation time, the jugular vein segments of
the rabbit were isolated and after 10 and 20 minutes of stasis, each of the jugular vein
segments was dissected and the contained clots were graded on a previously established
scale from 0 to +4 (Fareed et al. 1986). Blood samples were collected at baseline and
after r-TF injection, for ex vivo whole blood and plasma analyses. Six rabbits were
studied at each r-TF dose.

a. Clot Score Analyses
Injection of r-TF produced dose-dependent thrombotic effects, as depicted in Fig.
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35. At doses of 1.35 pmol/kg the clot scores obtained were always maximal ( +4) at
both the 10 minute and the 20 minute endpoints. The estimated ED 50 from this curve for
r-TF was about 0.34 and 0.4 pmol/kg for the 10 and 20 min stasis respectively. At
doses as low as 42.3 fmol/kg there was always a clot of at least + 1 observed after a 20
minute stasis time. When saline was used in place of r-TF in this procedure, there were
no clots observed (clot score=O). A dose of 0.68 pmol/kg consistently resulted in clot
scores of at least

+ 3.

This was the dose selected for assessing the antithrombotic effects

of thrombin inhibitors in this model in the following studies. The clot score value for
each r-TF dose for both the 10 and 20 min stasis time are given in Table 18.

Table 18 -- Standardization of the rabbit model of jugular vein stasis
thrombosis, with r-TF: dose-dependent thrombotic effects of r-TF after
I.V. injection, 20 sec circulation, after 10 and 20 min stasis.
Clot Score
Dose
Dose
10 min stasis
20 min stasis
ng/kg
pmol/kg
1.351
50
4.0±0.0
4.0±0.0
25
0.676
3.2±0.2
3.6±0.3
12.5
0.338
1.7±0.6
2.0±0.0
0.169
6.25
1.2±0.4
1.8±0.4
0.042
1.56
1.5±0.0
1.0±0.0
0
0
0.0±0.0
0.0±0.0
Each value represents the mean

± SEM of 6 independent determinations.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
The ex vivo effect of r-TF on the protease inhibition profile of rabbit plasma as
studied by the antithrombin and anti-Xa amidolytic methods did not reveal any detectable
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Fig. 35. Dose-dependent thrombotic effects of r-TF as studied in the rabbit model of
jugular vein stasis thrombosis. r-TF was administered through I.V. injection and allowed
to circulate for 20 sec prior to ligation of the jugular segments. ( •) represent clot scores
obtained after 10 minutes stasis, ( o) represent clot scores obtained after 20 min stasis.
Each point represents a mean ± S.E.M. (n=6). * denotes statistical significance
(p < 0. 05) when compared to control (saline produced 0. 0 ± 0. 0, both after 10 and 20
min stasis) as analyzed with the Kruskal-Wallis test. The individual clot score values at
each rTF dose and their gravimetric equivalents are given in Table 18.
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antithrombin or anti-Xa activity at any of the doses of r-TF administered. However, as
shown in Fig. 36, comparison of the ACT values of samples obtained at baseline and 5
minutes after r-TF administration, revealed a prolongation of the ACT.

This

prolongation was dose-dependent, which was significant at r-TF doses of 0. 68 pmol/kg
or greater. However, at doses below 0.34 pmol/kg there was no prolongation in the
ACT.
Fig. 37 depicts the comparison of the measured r distance on the TEG of samples
obtained from the rabbits which had undergone the stasis model before and after the
administration of r-TF at various doses. A clear dose-dependent prolongation of the TEG
r duration occurred, which became significant when a 1. 35 pmol/kg dose was
administered.

The other TEG parameters (k, rk and angle) also exhibited a parallel

prolongation to the r value (data not shown).
When the plasma samples collected before and after r-TF injection were
compared, r-TF had no effects on any of the global clotting tests, as seen in Fig. 38.
r-TF did not exhibit any effect on the PT of rabbit plasma when administered in vivo at
doses as high as 1.35 pmol/kg, as seen in Fig. 38, panel A. Panel B of Fig. 38 depicts
the results from the APTT analysis of the samples obtained from the stasis thrombosis
experiments. The in vivo administration of r-TF did not appear to have any effect on the
APTT at doses up to 1.35 pmol/kg. Similar results to those from the PT and APTT (i.e.
no difference between baseline and post r-TF injection) were obtained from the ex vivo
Heptest analysis of the blood samples obtained during the stasis thrombosis experiments
(Fig. 38, panel C). In addition, r-TF appeared to have no effect on the TT profile when
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Fig. 38. Dose-dependent pro-coagulant ex vivo effects of r-TF as studied in the rabbit
model of jugular vein stasis thrombosis. Blood samples were collected prior to r-TF
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rabbit ± S.E.M. (n=6 at each dose).
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administered at doses as high as 1.35 pmol/kg (Fig. 38, panel D).

2. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors
After I. V. Administration at a Fixed Time Point

From the above standardization studies, an r-TF dose of 0.68 pmol/kg was chosen
for the standard procedure as the thrombogenic source in this rabbit jugular vein stasis
thrombosis model. The antithrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D)Phe-ProboroArg-OH, hirudin and heparin were compared in a dose-dependent manner, after I.V.
injection and after a 5 min circulation time prior to injection of r-TF. Twenty sec after
injection of r-TF, the jugular segments of the rabbit were isolated and after 10 and 20
minutes of stasis, each jugular segment was dissected and the contained clots were
analyzed on a previously established scale from 0 to +4 (Fareed et al. 1986). Blood
samples were collected at baseline and 5 min after thrombin inhibitor injection (prior to
r-TF injection), for ex vivo whole blood and plasma analyses. Six rabbits were studied
at each thrombin inhibitor dose.

a. Clot Score Analyses
Injection of all four thrombin inhibitors produced dose-dependent antithrombotic
effects, after 10 and 20 min stasis time, in a dose range of 0.001 to 2 µmol/kg, as
depicted in Fig. 39, panels A and B respectively. The strongest antithrombotic agent
appeared to be heparin at doses in the nmol/kg range, both after 10 and 20 min stasis
time, with ED 50s of 0.008 and 0.009 µmol!kg respectively. The effects of heparin were
closely followed by those of hirudin, with ED 50s of 0.003 and 0.11 µmol/kg respectively.
After 20 min stasis time, the antithrombotic effects of heparin and hirudin were
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Fig. 39. Comparative dose-dependent antithrombotic effects of various agents as studied
in the rabbit model of jugular vein stasis thrombosis. Each thrombin inhibitor was
administered through I. V. injection and circulated for 5 minutes prior to initiation of the
stasis procedure. The results depicted in panel A represent clot scores obtained after 10
minutes stasis. The results depicted in panel B represent clot scores obtained after 20
min stasis. (•) D-MePhe-Pro-Arg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +)
heparin. Each point represents a mean ± S.E.M. (n=6). * denotes statistical
significance (p < 0.05) when compared to control (3.2 ± 0.2 after 10 min stasis in panel
A, 3.6 ± 0.3 after 20 min stasis in panel B), as analyzed with the Kruskal-Wallis test.
The individual clot score values at each antithrombin agent dose and their gravimetric
equivalents at both the 10 and 20 min stasis end points are given in Tables 19a-19b.
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superimposable at doses higher than 0.01 µmol/kg. The effects of heparin and hirudin
were followed by those of Ac-(D)Phe-Pro-boroArg-OH, with ED50s of 0.032 and 0.045
µmol/kg after 10 and 20 min stasis.

D-MePhe-Pro-Arg-H was the weakest

antithrombotic agent after both 10 and 20 min stasis time, with ED50 s of 0.242 and 1.60
µmol/kg respectively. The estimated ED 50 from each thrombin inhibitor dose-response
curve is reported in Table 19. The clot score value for each thrombin inhibitor dose
after 10 and 20 min stasis time are found in Tables 19a - 19d.

Table 19 -- Comparative antithrombotic potencies of thrombin inhibitors
after I. V. injection as determined in the rabbit model of jugular vein stasis
thrombosis.
Dose of each agent that results in a clot
score of + 2 in [µmol/kg].
10 min stasis time

20 min stasis time

D-MePhe-Pro-Arg-H

0.242

1.60

Ac-D-Phe-Pro-boroArg-OH

0.032

0.045

Hirudin

0.003

0.011

Heparin

0.008

0.009

Each value represents a single determination from the respective doseresponse curve depicted in Fig. 39.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
Fig. 40 depicts the ex vivo effect of thrombin inhibitors on the protease inhibition
profile of rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods
revealing dose-dependent antithrombin effects but only minimal anti-Xa activities. Even
at the highest doses administered, most of these agents produced only weak anti-Xa
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Fig. 40. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I.V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts
the results of the amidolytic antithrombin analysis. Panel B depicts the results from the
amidolyticanti-Xaanalysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH,
(•) hirudin, ( +) heparin. Each point represents a mean of the difference between
baseline and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each
agent).
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Fig. 41. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts
the results from the ACT analysis. Panel B depicts the results from the TEG r analysis.
(•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•) hirudin, (+)heparin.
Each point represents a mean of the difference between baseline and post-agent values
for each rabbit ± S.E.M. (n=6 at each dose, for each agent).
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actions. While heparin produced the strongest antithrombotic effects, as assessed by the
clot scores, hirudin produced the most potent antithrombin effects. As in the clot score
profiling, Ac-(D)Phe-Pro-boroArg-OH, relatively weaker than heparin and hirudin, it
produced slightly stronger antithrombin effects in comparison to D-MePhe-Pro-Arg-H.
A comparison of the ACT values of samples obtained at baseline and 5 minutes
after thrombin inhibitor injection, depicted in Fig. 41 panel A, showed a dose-dependent
prolongation of the ACT, for all thrombin inhibitors, in a pattern parallel to the one
emerging from the clot scores. The strongest prolongation of the ACT was produced by
heparin producing a 600 sec ACT prolongation from the baseline value at a dose of
0.023 µmol/kg, followed by hirudin, Ac-(D)Phe-Pro-boroArg-OH and then D-MePhePro-Arg-H.

While Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H produced

similar prolongation of the ACT at the highest dose used to that of heparin, hirudin
resulted in only a 300 sec prolongation at the highest dose injected.
Fig. 41, panel B, depicts the comparison of the measured r distance on the TEG
of samples obtained from the rabbits which underwent the stasis model before and after
the administration of antithrombin agents at various doses. Dose-dependent prolongation
of the TEG r duration occurred with all thrombin inhibitors, in a pattern similar to the
ACT and to the clot score profile. At the highest doses injected, heparin produced the
longest prolongation of the TEG r value, followed by Ac-(D)Phe-Pro-boroArg-OH, DMePhe-Pro-Arg-H and lastly by hirudin.
When the plasma samples collected before and after thrombin inhibitor injection
were compared, global clotting test-dependent results were obtained, as seen in Fig. 42.
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Fig. 42. Dose-dependent ex vivo anticoagulant effects of antithrombin agents after I.V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min post agent injection (prior to r-TF). Panel A depicts
the results of the PT analysis. Panel B depicts the results from the APTT analysis.
Panel C depicts the results from the Heptest analysis. Panel D depicts the results from
the TT analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•)
hirudin, ( +) heparin. Each point represents a mean of the difference between baseline
and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each agent).
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None of the thrombin inhibitors had any effects on the PT of rabbit plasma, even at the
highest dose injected, as seen in Fig. 42, panel A. The panel B of Fig. 42 depicts the
results from the APTT analysis and comparison of the samples obtained from these stasis
thrombosis experiments. The in vivo administration of heparin and D-MePhe-Pro-Arg-H
did not appear to have any effect on the APTT, even at the highest doses injected.
Hirudin and Ac-(D)Phe-Pro-boroArg-OH produced mild dose-dependent prolongation of
the APTT. When the plasma samples collected before and after the injection of thrombin
inhibitors were compared in the Heptest assay (Fig. 42, panel C), it was found that all
agents produced dose-dependent prolongation of the Heptest. In the Heptest, heparin
appeared to produce more potent anticoagulant effects than hirudin, followed by Ac(D) Phe-Pro-boroArg-0 H and then by D-MePhe-Pro-Arg-H. When the same plasma
samples were compared in the TT (Fig. 42, panel D), all thrombin inhibitors produced
a prolongation of the TT. Hirudin produced the most potent prolongation of the TT,
followed closely by heparin, then by Ac-(D)Phe-Pro-boroArg-OH and lastly by DMePhe-Pro-Arg-H.

While hirudin at the highest dose injected produced weaker

antithrombotic activities than heparin and Ac-(D)Phe-Pro-boroArg-OH at their highest
doses, hirudin produced the longer prolongation of the TT than the other two compounds.
Furthermore, while D-MePhe-Pro-Arg-H at the highest dose injected produced similar
antithrombotic effects to those of heparin and Ac-(D)Phe-Pro-boroArg-OH at the highest
dose injected, the prolongation of the TT was longer with D-MePhe-Pro-Arg-H (about
15 fold increase from baseline) than with heparin and Ac-(D)Phe-Pro-boroArg-OH (about
5 fold increase from baseline).
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3. Duration of Antithrombotic Effects of Thrombin Inhibitors
After I. V. Administration at a Fixed Dose
To determine the time-dependance of the antithrombotic effects of the thrombin
inhibitors studied in this rabbit stasis thrombosis model after I.V. administration, the dose
of each agent that produced sub-maximal antithrombotic effects was selected and studied
at different circulation times, prior to injecting r-TF as described above. The dose of
each thrombin inhibitor studied was: D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac-(D)PhePro-boroArg-OH at 0.101 µmol/kg, hirudin at 0.036 µmollkg and heparin at 0.023
µmol/kg. The circulation time points selected for studying the antithrombotic effects of
these thrombin inhibitors at these doses were 5, 30, 60 and 90 min (prior to r-TF
injection). Six rabbits were tested at each time point for each thrombin inhibitor. Blood
draws were performed at baseline and prior to r-TF injection (5 or 30 or 60 or 90 min
post thrombin inhibitor injection) and utilized in the ex vivo whole blood and plasma
analyses.

a. Clot Score Analyses
Intravenous administration of all four thrombin inhibitors produced time-dependent
antithrombotic effects, as depicted in Fig. 43, after 10 and 20 min stasis time, panels A
and B respectively. The thrombin inhibitor which lost its antithrombotic activities at the
fastest rate was Ac-(D)Phe-Pro-boroArg-OH (t1h about 20 min post I.V. injection, after
both the 10 and 20 min stasis time), followed by heparin (t1h around 40 min and 25 min
post I.V. injection, after the 10 and 20 min stasis respectively) and then by D-MePhePro-Arg-H (tl/z around 60 min and 45 min post I.V. injection after the 10 and 20 min
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Fig. 43. Time dependance of antithrombotic effects of various agents in the rabbit model
of jugular vein stasis thrombosis. Each agent was administered through I.V. injection
and allowed to circulate for varying time periods prior to initiation of the stasis
procedure. The results depicted in panel A represent clot scores obtained after 10
minutes stasis. The results depicted in panel B represent clot scores obtained after 20
min stasis. (•) D-MePhe-Pro-Arg-H at 1.942 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH
at 0.101 µmol/kg, (•) hirudin at 0.036 µmol/kg, (+)heparin at 0.023 µmol/kg. Each
point represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05)
when compared to control (3.2 ± 0.2 after 10 min stasis in panel A, 3.6 + 0.3 after 20
min stasis in panel B), as analyzed with the Kruskal-Wallis test. The individual clot
score values for each thrombin inhibitor at each time point at both the 10 and 20 min
stasis end points are given in Tables 19e-19f.
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stasis respectively). Hirudin also exhibited a gradual diminution of its antithrombotic
activities at the slowest rate (t1h around 75 min and 65 min post I. V. injection, after 10
and 20 min stasis respectively). The clot score values for each thrombin inhibitor at each
circulation time are found in Tables 19e and 19f, following 10 and 20 min stasis
respectively.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of
rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods revealed
time-dependent antithrombin effects but minimal anti-Xa activities, as can be seen in Fig.
44, panels A and B respectively. The antithrombin effects of heparin were minimal as
well. D-MePhe-Pro-Arg-H and hirudin produced an antithrombin pattern indicating peak
antithrombin activity at 30 min post I. V. injection, in contrast to their time-dependent
antithrombotic profile, in which their peak antithrombotic activities were observed 5 min
after I.V. injection. The antithrombin activities of Ac-(D)Phe-Pro-boroArg-OH were
steadily lost with time.
Comparison of the ACT values of samples obtained at baseline and 5, 30, 60 and
90 min after thrombin inhibitor injection, depicted in Fig. 45, panel A, revealed a timedependent prolongation of the ACT, for all antithrombin agents, in a pattern parallel to
the one emerging from the clot score time-dependent profile. The thrombin inhibitors
that lost their ACT prolongation effects at the fastest rate were Ac-(D)Phe-Pro-boroArgOH and heparin, followed by D-MePhe-Pro-Arg-H. Hirudin lost its ACT prolongation
effects at the slowest rate.
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Fig. 44. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I. V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results of
the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic
anti-Xa analysis. (•) D-MePhe-Pro-Arg-H at 1.942 µmollkg, (•) Ac-(D)Phe-ProboroArg-OH at 0.101 µmol/kg, (•) hirudin at 0.036 µmollkg, ( +) heparin at 0.023
µmollkg. Each point represents a mean of the difference between baseline and post-agent
values for each rabbit ± S.E.M. (n=6 at each time point, for each agent).
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Fig. 45. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after I.V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results
from the ACT analysis. Panel B depicts the results from the TEG r analysis. (•) DMePhe-Pro-Arg-H at 1.942 µmollkg, (•) Ac-(D)Phe-Pro-boroArg-OH at0.101 µmollkg,
(•) hirudin at 0.036 µmol/kg, (+)heparin at 0.023 µmollkg. Each point represents a
mean of the difference between baseline and post-agent values for each rabbit ± S.E.M.
(n=6 at each time point, for each agent).
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Fig. 45, panel B, depicts the comparison of the measured r distance on the TEG
of samples obtained from the rabbits which underwent the stasis model before and after
the administration of thrombin inhibitors at various blood sampling times.

Time-

dependent prolongation of the TEG r value was observed with all thrombin inhibitors,
in a pattern parallel to the one emerging from the clot score time-dependent profile and
the ACT profile. The thrombin inhibitor that lost its TEG prolongation effects at the
fastest rate was Ac-(D)Phe-Pro-boroArg-OH, followed by heparin and then by D-MePhePro-Arg-H. Hirudin lost its TEG prolongation effects at the slowest rate.
When the plasma samples collected before and 5, 30, 60 and 90 min after
thrombin inhibitor injection were compared, global clotting test-dependent and timedependent results were obtained, as seen in Fig. 46. None of the thrombin inhibitors had
any effects on the PT of rabbit plasma as seen in Fig. 46, panel A. Panel B of Fig. 46
depicts the results from the APTT analysis and comparison of the samples obtained from
these stasis thrombosis experiments. While the in vivo administration of heparin and DMePhe-Pro-Arg-H did not appear to have any effect on the APTT, the anticoagulant
effects produced by hirudin and Ac-(D)Phe-Pro-boroArg-OH were time-dependent.
When the plasma samples collected before and after the injection of thrombin inhibitors
were compared in the Heptest assay (Fig. 46, panel C), it was found that all thrombin
inhibitors produced time-dependent prolongation of the Heptest. While the anticoagulant
effects in the Heptest assay steadily decreased with time for Ac-(D)Phe-Pro-boroArg-OH,
hirudin and heparin, D-MePhe-Pro-Arg-H appeared to produce peak anticoagulant
activities abut 30 min post I.V. injection, similarly to its effects in the antithrombin
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Fig. 46. Time-dependent ex vivo anticoagulant effects of antithrombin agents after I. V.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min prior to r-TF injection (post-thrombin inhibitor
injection for various circulating time periods). Panel A depicts the results of the PT
analysis. Panel B depicts the results from the APTT analysis. Panel C depicts the
results from the Heptest analysis. Panel D depicts the results from the TT analysis. (•)
D-MePhe-Pro-Arg-H at 1.942 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OH at 0.101
µmollkg, (•) hirudin at 0.036 µmol/kg, ( +) heparin at 0.023 µmol/kg. Each point
represents a mean of the difference between baseline and post-agent values for each
rabbit ± S.E.M. (n=6 at each time point, for each agent).
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assay. When the same plasma samples were compared in the TT (Fig. 46, panel D), all
thrombin inhibitors produced a steadily declining time-dependent prolongation of the TT.
The effects of D-MePhe-Pro-Arg-H were cleared at the fastest rate, in contrast to its
time-dependent antithrombotic effects.

4. Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors
After S.C. Administration at a Fixed Time Point
As in the above studies, a r-TF dose of 0. 68 pmol/kg was chosen for the standard
procedure as the thrombogenic source in this rabbit jugular vein stasis thrombosis model.
The antithrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D) Phe-Pro-boroArg-0 H, hirudin
and heparin were compared in a dose-dependent manner, after S.C. injection and after
a 45 min circulation time prior to injection of r-TF. Twenty sec after injection of r-TF,
the jugular segments of the rabbit were isolated and after 10 and 20 minutes of stasis,
each jugular segment was dissected and the contained clots were analyzed on a previously
established scale from 0 to +4 (Fareed et al. 1986). Blood samples were collected at
baseline and 45 min after thrombin inhibitor injection (prior to r-TF injection), for ex

vivo whole blood and plasma analyses.

Six rabbits were studied at each thrombin

inhibitor dose.

a. Clot Score Analyses
Injection of all four thrombin inhibitors produced dose-dependent antithrombotic
effects, after 10 and 20 min stasis time, as depicted in Fig. 47, panels A and B
respectively. The most potent antithrombotic agent appeared to be hirudin at doses in
the nmol/kg range, both after 10 and 20 min stasis time, with ED50s of 0.036 and 0.07
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Fig. 47. Comparative dose-dependent antithrombotic effects of various agents as studied
in the rabbit model of jugular vein stasis thrombosis. Each agent was administered
through S.C. injection and allowed to circulate for 45 minutes prior to initiation of the
stasis procedure. The results depicted in panel A represent clot scores obtained after 10
minutes stasis. The results depicted in panel B represent clot scores obtained after 20
min stasis. ( •) D-MePhe-Pro-Arg-H, ( •) Ac-D-Phe-Pro-boroArg-0 H, ( •) hirudin, ( +)
heparin. Each point represents a mean ± S.E.M. (n=6). * denotes statistical
significance (p < 0. 05) when compared to control (3. 2 ± 0. 2 after 10 min stasis in panel
A, 3.6 ± 0.3 after 20 min stasis in panel B), as analyzed with the Kruskal-Wallis test.
The individual clot score values at each thrombin inhibitor dose and their gravimetric
equivalents at both the 10 and 20 min stasis end points are given in Tables 20a-20d.
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µmol/kg respectively. The effects of hirudin were followed by those of Ac-(D)Phe-ProboroArg-OH (ED 50 s of 0.152 and 0.29 µmol/kg after 10 and 20 min stasis respectively)
and heparin (ED 50s od 0.185 and 0.25 µmol/kg respectively. After 20 min stasis time,
the

antithrombotic

superimposable.

effects

of Ac-(D)Phe-Pro-boroArg-OH

and

heparin

were

Similar to the antithrombotic effects after I. V. administration, D-

MePhe-Pro-Arg-H was the weakest antithrombotic agent after both 10 and 20 min stasis
time, with ED 50s of 1.22 and 2.78 µmol/kg respectively. The estimated ED 50 from each
thrombin inhibitor dose-response curve is reported in Table 20. The clot score value for
each thrombin inhibitor dose are found in Tables 20a - 20d, for the 10 and 20 min stasis
time.

Table 20 -- Comparative antithrombotic potencies of thrombin inhibitors
after S.C. injection, as determined in the rabbit model of jugular vein
stasis thrombosis.
Dose of each agent resulting in a clot score
of + 2 in [µmol/kg]
10 min stasis time

20 min stasis time

D-MePhe-Pro-Arg-H

1.22

2.78

Ac-D-Phe-Pro-boroArg-OH

0.152

0.29

Hirudin

0.036

0.07

Heparin

0.185

0.25

Each value represents a single determination from the respective doseresponse curves depicted in Fig. 47.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of
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rabbit plasma as studied by the antithrombin and anti-Xa amidolytic methods revealed
dose-dependent antithrombin effects but minimal anti-Xa activities even at the highest
doses administered, as can be seen in Fig. 48, panels A and B respectively. Hirudin
produced the strongest antithrombin effects, which corresponded to the antithrombotic
effects. As in the clot score profiling, Ac-(D)Phe-Pro-boroArg-OH produced the second
most potent antithrombin effects, followed by heparin and lastly by D-MePhe-Pro-Arg-H.
Even though all thrombin inhibitors produced similar antithrombotic effects at the highest
doses used, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H produced a markedly
higher antithrombin effects than hirudin and heparin.
Comparison of the ACT values of samples obtained at baseline and 45 minutes
after thrombin inhibitor S.C. injection, depicted in Fig. 49, panel A, revealed a dosedependent prolongation of the ACT, for all thrombin inhibitors, in a pattern parallel to
the one emerging from the clot scores.

The strongest prolongation of the ACT was

produced by hirudin, followed by Ac-(D)Phe-Pro-boroArg-OH and then by heparin and
D-MePhe-Pro-Arg-H. Even though all agents produced similar antithrombotic effects
at the highest doses used, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H
produced a markedly longer ACT prolongation than hirudin and heparin, similar to the
antithrombin effects.
Fig. 49, panel B, depicts the comparison of the measured r distance on the TEG
of samples obtained from the rabbits which underwent the stasis model before and after
the S.C. injection of thrombin inhibitors at various doses. Dose-dependent prolongation
of the TEG r duration occurred with all thrombin inhibitors. Unlike the antithrombotic,
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Fig. 48. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 45 min post agent injection. Panel A depicts the results of
the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic
anti-Xa analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-Pro-boroArg-OH, (•)
hirudin, ( +) heparin. Each point represents a mean of the difference between baseline
and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for each agent).
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Fig. 49. Dose-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 45 min post agent injection. Panel A depicts the results from
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rabbit ± S.E.M. (n=6 at each dose, for each agent).
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antithrombin and ACT effects, in the TEG r value comparisons it was found that the dose
response effects of Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin overlapped.
However, D-MePhe-Pro-Arg-H consistently resulted in the weakest effects on the TEG
r value.
When the plasma samples collected before and after thrombin inhibitor S.C.
injection were compared, global clotting test-dependent results were obtained, as seen in
Fig. 50. None of the thrombin inhibitors had any effects on the PT of rabbit plasma,
even at the highest dose injected, as seen in Fig. 50, panel A. Panel B of Fig. 50 depicts
the results from the APTT analysis and comparison of the samples obtained from these
stasis thrombosis experiments.

All thrombin inhibitors produced dose-dependent

anticoagulant effects after S.C. injection. Similar to the effects that these agents had on
the TEG r value, the anticoagulant effects of Ac-(D)Phe-Pro-boroArg-OH, hirudin and
heparin after S.C. administration overlapped.

Even though all thrombin inhibitors

produced similar antithrombotic effects at the highest doses used, the anticoagulant
effects of heparin were markedly higher than those produced by the other agents. When
the plasma samples collected before and 45 min after the S.C. injection of thrombin
inhibitors were compared in the Heptest assay (Fig. 50, panel C), it was found that all
agents produced dose-dependent prolongation of the Heptest.

As seen in the

antithrombotic profile, in the Heptest hirudin appeared to produce the strongest
anticoagulant effects. These effects were followed by those produced by heparin and
then by Ac-(D)Phe-Pro-boroArg-OH. Consistently with all other effects produced by DMePhe-Pro-Arg-H after S.C. injection, this agent was the least potent anticoagulant in
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Fig. 50. Dose-dependent ex vivo anticoagulant effects of antithrombin agents after S.C.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 45 min post thrombin inhibitor injection (prior to r-TF).
Panel A depicts the results of the PT analysis. Panel B depicts the results from the
APTT analysis. Panel C depicts the results from the Heptest analysis. Panel D depicts
the results from the TT analysis. (•) D-MePhe-Pro-Arg-H, (•) Ac-(D)Phe-ProboroArg-OH, (•) hirudin, (+)heparin. Each point represents a mean of the difference
between baseline and post-agent values for each rabbit ± S.E.M. (n=6 at each dose, for
each agent).
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the Heptest assay as well. As observed with the anticoagulant effects in the APTT, even
though all thrombin inhibitors produced similar antithrombotic effects at the highest doses
used, the anticoagulant effects of heparin in the Heptest assay were markedly higher than
those produced by Ac-(D)Phe-Pro-boroArg-OH and hirudin. Like heparin, D-MePhePro-Arg-H also produced higher anticoagulant effects in the Heptest than Ac-(D)Phe-ProboroArg-OH and hirudin, at the highest doses injected. When the same plasma samples
were compared in the TT (Fig. 50, panel D), all thrombin inhibitors produced a
prolongation of the TT in manner parallel to their antithrombotic effects, so that hirudin
produced the most potent prolongation of the TT, followed closely by heparin, then by
Ac-(D)Phe-Pro-boroArg-OH and lastly by D-MePhe-Pro-Arg-H. While all thrombin
inhibitors at the highest dose injected produced similar antithrombotic activities, hirudin
and Ac-(D)Phe-Pro-boroArg-OH produced longer prolongation of the TT than the other
two compounds.

5. Duration of Antithrombotic Effects of Thrombin Inhibitors
After S.C. Administration at a Fixed Dose
To determine the time-dependance of the antithrombotic effects of the thrombin
inhibitors studied in this rabbit stasis thrombosis model after S.C. administration, the
dose of each agent that produced sub-maximal antithrombotic effects in the dosedependent S.C. studies was selected and studied at different circulation times, prior to
injecting r-TF as described above. The dose of each antithrombin agent studied was: DMePhe-Pro-Arg-H at 4.854 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg,
hirudin at 0.144 µmol/kg and heparin at 0.455 µmol/kg. The circulation time points
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selected for studying the antithrombotic effects of these thrombin inhibitors at these doses
were 15, 45 and 90 min (prior to r-TF injection). Six rabbits were tested at each time
point for each thrombin inhibitor. Blood samples were collected at baseline and prior
to r-TF injection (15, 30, 45, 60 and 90 min post thrombin inhibitor injection) and
utilized in the ex vivo whole blood and plasma analyses.

a. Clot Score Analyses
Subcutaneous administration of all four thrombin inhibitors produced a timedependent antithrombotic effects, as depicted in Fig. 51, after 10 and 20 min stasis time,
panels A and B respectively. In the 10 min stasis clot score results (Fig. 51, panel A),
it was observed that while Ac-(D)Phe-Pro-boroArg-OH lost its antithrombotic activities
progressively with time after 15 min post S.C. injection, the effects of D-MePhe-ProArg-H and hirudin started to diminish after 45 min post S.C. injection. In contrast to
the antithrombotic effects produced by the other thrombin inhibitors, the effects of
heparin steadily increased with time, with the maximal antithrombotic effects achieved
90 min post S.C. injection.
The duration of the antithrombotic effects of thrombin inhibitors after S.C.
injection, as assessed by the clot scores obtained after 20 min stasis time (Fig. 51, panel
B), differed only slightly from those obtained after 10 min stasis time.

The

antithrombotic effects of Ac-(D)Phe-Pro-boroArg-OH appeared to have steady
antithrombotic effects over the 90 min period studied, rather than being progressively lost
with time after 15 min post S.C. injection, as observed in the 10 min stasis panel. DMePhe-Pro-Arg-H appeared to time-dependently lose its antithrombotic activities starting
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Fig. 51. Time dependance of antithrombotic effects of various agents in the rabbit model
of jugular vein stasis thrombosis. Each agent was administered through S.C. injection
and allowed to circulate for varying time periods prior to initiation of the stasis
procedure. The results depicted in panel A represent clot scores obtained after 10
minutes stasis. The results depicted in panel B represent clot scores obtained after 20
min stasis. (•) D-MePhe-Pro-Arg-H at 4.854 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH
at 0.503 µmol/kg, (•) hirudin at 0.144 µmol/kg, ( +) heparin at 0.455 µmol/kg. Each
point represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05)
when compared to control (3.2 ± 0.2 after 10 min stasis in panel A, 3.6 + 0.3 after 20
min stasis in panel B), as analyzed with the Kruskal-Wallis test. The individual clot
score values for each thrombin inhibitor at each time point at both the 10 and 20 min
stasis end points are given in Tables 20e-20f.
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at 15 min post S.C. injection, as opposed to 45 min post S.C. injection, as observed in
the 10 min stasis panel. Hirudin, like Ac-(D)Phe-Pro-boroArg-OH, appeared to have
steady antithrombotic effects over the 90 min period studied, rather than being
progressively lost with time after 45 min post S.C. injection, as observed in the 10 min
stasis panel. Heparin time-dependently increased its antithrombotic effects, reaching a
maximum around 60 min post S.C. injection, as opposed to 90 min post S.C. injection,
as observed in the 10 min stasis panel. The clot score values for each thrombin inhibitor
at each circulation time are found in Tables 20e and 20f, following 10 and 20 min stasis
respectively.

b. Ex Vivo Analyses of Plasma and Whole Blood Samples
The ex vivo effect of thrombin inhibitors on the protease inhibition profile of
rabbit plasma as studied by the antithrombin amidolytic method revealed time-dependent
antithrombin effects, as can be seen in Fig. 52, panel A. While the antithrombin effects
of D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH were steady over the 90 min
period monitored, the effects of hirudin and heparin steadily increased with time,
reaching a maximum at 60 min post S.C. injection. Heparin exhibited time-dependent
anti-Xa effects, as measured in the amidolytic assay, depicted in Fig. 52, panel B. These
effects reached a maximum about 60 min post S.C. injection of heparin. The other three
agents had weak effects on the inhibition factor Xa, as measured in this assay.
Comparison of the ACT values on samples obtained at baseline and 5, 30, 60 and
90 min after thrombin inhibitor injection, depicted in Fig. 53, panel A, revealed a timedependent prolongation of the ACT, for all thrombin inhibitors. Parallel to the
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injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
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the amidolytic antithrombin analysis. Panel B depicts the results from the amidolytic
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Fig. 53. Time-dependent ex vivo anticoagulant effects of thrombin inhibitors after S.C.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min prior to r-TF injection. Panel A depicts the results
from the ACT analysis. Panel B depicts the results from the TEG r analysis. (•) DMePhe-Pro-Arg-H at4.854 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OHat0.503 µmol/kg,
(•) hirudin at 0.144 µmol/kg, (+)heparin at 0.455 µmollkg. Each point represents a
mean of the difference between baseline and post-agent values for each rabbit ± S.E.M.
(n=6 at each time point, for each agent).
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antithrombotic effects, D-MePhe-Pro-Arg-H gradually lost its anticoagulant effects in the
ACT.

In contrast to their antithrombotic effects, Ac-(D)Phe-Pro-boroArg-OH and

hirudin time-dependently increased their anticoagulant activities in the ACT during the
90 min following S.C. injection. Heparin, parallel to its antithrombotic effects after S.C.
injection, also time-dependently increased its anticoagulant actions in the ACT.
Fig. 53, panel B depicts the comparison of the measured r distance on the TEG
of samples obtained from the rabbits which underwent the stasis model before and after
the S.C. injection of thrombin inhibitors at various blood sampling times.

Time-

dependent prolongation of the TEG r value was observed with hirudin and heparin. The
effects of both agents were maximal at 60 min post S.C. injection, parallel to their
antithrombotic effects. D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH produced
maximal TEG r value prolongation from the first blood sampling time at 15 min, and
these effects were steady throughout the 90 min post S.C. injection period, even though
their respective antithrombotic effects were slowly diminishing.
When the plasma samples collected at the baseline and 5, 30, 60 and 90 min after
thrombin inhibitor injection were compared, global clotting test-dependent and timedependent results were obtained, as seen in Fig. 54. With the exception of D-MePhePro-Arg-H, none of the thrombin inhibitors had any effects on the PT of rabbit plasma
as seen in Fig. 54, panel A.

The effects of D-MePhe-Pro-Arg-H on the PT were

noticeable only 45 min post S.C. injection. Panel B of Fig. 54 depicts the results from
the APTT analysis and comparison of the samples obtained from these stasis thrombosis
experiments. D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH produced maximal
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Fig. 54. Time-dependent ex vivo anticoagulant effects of antithrombin agents after S.C.
injection as studied in the rabbit model of jugular vein stasis thrombosis. Blood samples
were collected prior to and 5 min prior to r-TF injection (post-agent S.C. injection for
various circulating time periods). Panel A depicts the results of the PT analysis. Panel
B depicts the results from the APTT analysis. Panel C depicts the results from the
Heptest analysis. Panel D depicts the results from the TT analysis. (•) D-MePhe-ProArg-H at 4.854 µmol/kg, (•) Ac-(D)Phe-Pro-boroArg-OH at 0.503 µmol/kg, (•) hirudin
at 0.144 µmol/kg, (+)heparin at 0.455 µmol/kg. Each point represents a mean of the
difference between baseline and post-agent values for each rabbit ± S.E.M. (n=6 at
each time point, for each agent).
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prolongation of the APTT throughout the 90 min post S.C. injection period, even though
the corresponding antithrombotic effects slowly decreased with time. The anticoagulant
effects of hirudin on the APTT increased with time and plateaued around 60 min after
S.C. injection, similarly to its antithrombotic effects.

The anticoagulant effects of

heparin on the APTT closely paralleled the antithrombotic effects after S.C. injection,
20 min stasis time. Time-dependent increase in the antithrombotic and anticoagulant
activity of heparin was observed until 60 min post S.C. injection, after which time point,
both activities declined.

When the plasma samples collected prior to and after the

injection of thrombin inhibitors were compared in the Heptest assay (Fig. 54, panel C),
it was found Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin produced time-dependent
prolongation of the Heptest. D-MePhe-Pro-Arg-H produced maximal prolongation of the
Heptest throughout the 90 min period post S.C. injection. The anticoagulant effects of
the other three inhibitors in the Heptest, steadily increased with time, reaching a peak
at 60 min post S.C. injection, after which the anticoagulant effects started to decrease.
When the same plasma samples were compared in the TT (Fig. 54, panel D), hirudin and
heparin produced a steadily increasing time-dependent prolongation of the TT.

The

anticoagulant effects of D-MePhe-Pro-Arg-H reached a maximum at 30 min post S.C.
injection, which started to decrease 45 min post S.C. injection. Ac-(D)Phe-Pro-boroArgOH also produced time-dependent prolongation of the TT after S.C. injection, similar to
its anticoagulant effects in the APTT and Heptest, reaching a maximum at 60 min post
S.C. injection and then declining with time.
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I. Antithrombotic Effects of Thrombin Inhibitors as Studied in the
Rat Model of Laser-Induced Thrombosis
The rabbit jugular vein stasis thrombosis model used in the previous experiments
is venous model of thrombosis that results in fibrin-rich clots. Since veins and arteries
have different physiologic make ups (hemodynamics, smooth muscle, size) and exhibit
distinct pathophysiologic responses, it is probable that thrombin inhibitors have different
antithrombotic effects depending on the type of blood vessel studied and the thrombotic
injury. Therefore, in the following studies, a rat model of laser-induced thrombosis was
utilized to compare the antithrombotic effects of D-MePhe-Pro-Arg-H, Ac-(D)Phe-ProboroArg-OH, hirudin and heparin. This model of arterial thrombosis is based on the
development of a platelet-rich thrombus in response to focused laser-mediated thermal
injuries to the vascular wall. The endpoint in this model was the number of standardized
laser exposures required to produce either a clot completely occluding the arteriole
injured or a semi-occluding clot with a length equal to 1.5 x the vessel diameter.
Thrombin inhibitors were injected at various concentrations through the rat tail vein 5
min prior to induction of the laser injury.
The results of these studies are depicted in Fig. 55. In control rats (injected with
saline) 3 laser shots were needed to reach an endpoint. All thrombin inhibitors produced
dose-dependent antithrombotic effects in this model. In comparing the dose of each agent
required to extend the endpoint to 6 laser shots, as given in Table 21, heparin was the
most potent antithrombotic agent (0.08 µmol/kg), followed by Ac-(D)Phe-Pro-boroArgOH (0.154 µmol/kg) and then by hirudin (0.28 µmol/kg). Consistent with the rabbit
jugular vein stasis thrombosis model, D-MePhe-Pro-Arg-H had the weakest effects in the

244

12
(/J

·-

10

:J

8

Q)

*

L...

.c._.
L...
Q)
(/J

0

6

4

_J

==It:::

*

2

0
0.01

*

0

o. 1

1

10

Dose (µmol/kg, I. V.)
Fig. 55. Comparative dose-dependent antithrombotic effects of various agents as studied
in the rat laser-induced thrombosis model. Each thrombin inhibitor was injected through
the rat tail vein circulated for 5 minutes prior to initiation of the laser injury procedure.
(•) D-MePhe-Pro-Arg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin.
Each point represents a mean ± S.E.M. (n=6). * denotes statistical significance
(p < 0.05) when compared to control (2.9 ± 0.1) as analyzed with ANOVA followed by
the Student-Newman-Keuls test. The individual values for each thrombin inhibitor dose
and their gravimetric equivalents are given in Tables 21a-2ld.
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rat laser-induced thrombosis model as well (2 µmol/kg). In this model, the ceiling for
heparin and hirudin appeared to be around 8 laser exposures. However, in the case of
Ac-(D)Phe-Pro-boroArg-OH, this ceiling was extended to about 10 laser shots.
Furthermore, D-MePhe-Pro-Arg-H produced dose-dependent antithrombotic effects up
to a dose of 3. 4 µmol/kg, while with higher doses the antithrombotic effects were
weaker. In the rats that received D-MePhe-Pro-Arg-H at doses higher than 3.4 µmol/kg,
it was visually observed that the blood flow was reduced within 3-10 min after injection
of the thrombin inhibitor. Similar observations were made in the rats that received Ac(D)Phe-Pro-boroArg-OH at doses higher than 0.2 µmollkg.

These results were not

reported, since the blood flow completely stopped prior to induction of laser injury. The
number of laser exposures required to achieve the endpoint for each thrombin inhibitor
at each dose are reported in Tables 21a - 2ld.

Table 21 -- Comparative antithrombotic potencies of thrombin inhibitors,
as determined in the rat model of laser-induced thrombosis in isolated
mesenterial arterioles.
Dose of each agent that results in
increase of laser shots to 6 in [µmol/kg].
D-MePhe-Pro-Arg-H

2.0

Ac-D-Phe-Pro-boroArg-OH

0.15

Hirudin

0.28

Heparin

0.08

Each value represents a single determination from the respective doseresponse curves depicted in Fig. 53. Saline, as the control, required 2.9
± 0.1 laser shots for occlusive thrombus formation.
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J. Hemorrhagic Effects of Thrombin Inhibitors as Studied in the
Rabbit Ear Bleeding Model
Thrombin inhibitors can be potent antithrombotic agents, as seen in the previous
results on the thrombosis models. While species-dependent, their antithrombotic actions
are mediated mainly through their inhibitory actions against thrombin. However, the
same process is involved in normal hemostasis, where the primary hemostatic plug is
formed by activated platelets (which thrombin can activate) and reinforced by fibrin
deposition (formed by the catalytic action of thrombin). Inhibition of these processes
may lead to hemorrhage. To compare the hemorrhagic potential of thrombin inhibitors,
D-MePhe-Pro-Arg-H, Ac-(D)Phe-Pro-boroArg-OH, hirudin and heparin were studied in
a rabbit model of ear bleeding (Cade et al. 1984).

The thrombin inhibitors were

administered to rabbits at various doses and following varying circulation times, 5
standardized cuts were made into their ears. The blood released from the punctured sites
for the ensuing 10 min was collected and measured.

To compare the hemorrhagic

potential of these agents, an index was devised, whereby the dose of the antithrombin
agent that produced bleeding of 2 · 109 RBC/L was estimated as the BD2 • Six rabbits
were tested at each thrombin inhibitor dose and circulation time studied.

1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After I. V. Administration at Fixed Time Points
The dose-dependent hemorrhagic effects of thrombin inhibitors after I.V.
injection, as assessed in the rabbit ear bleeding model are depicted in Fig. 56. In panel
A, the hemorrhagic procedure was initiated 5 min after I.V. injection of the thrombin
inhibitor, while in panel B, the hemorrhagic procedure was initiated following 20 min
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Fig. 56. Comparative dose-dependent hemorrhagic effects of thrombin inhibitors as
studied in the rabbit ear bleeding model. In panel A, each agent was administered
through I. V. injection and allowed to circulate for 5 minutes prior to initiation of the
incision procedure. In panel B, each agent was administered through I.V. injection and
circulated for 20 minutes prior to initiation of the incision procedure. ( •) D-MePhe-ProArg-H, (•) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. Each point
represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when
compared to control (0.100 ± 0.060) as analyzed with ANOVA followed by the StudentNewman-Keuls test. The individual values for each thrombin inhibitor dose and their
gravimetric equivalents for both the 5 an 10 min post I. V. end points are given in Tables
22a-22d.
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I. V. injection of the thrombin inhibitor.

Except for heparin, the other thrombin

inhibitors resulted in dose-dependent hemorrhagic effects. The agent with the strongest
hemorrhagic effects was hirudin, 5 min post and 10 min post I. V. injection, with BD2
of 0.11 and 0.30 µmol/kg respectively. The effects of hirudin were followed by Ac(D)Phe-Pro-boroArg-OH (BD2s of 0.55 and 0.54 µmol/kg after 5 and 20 min injection)
and then by D-MePhe-Pro-Arg-H (BD2s of 2.82 and >4.85 µmol/kg, after 5 and 20 min
post injection). Heparin exhibited minimal hemorrhagic effects, as seen in both the 5
min and 20 min post I. V. injection panels (BD2s of > 0 .45 µmol/kg in both cases).
While the hemorrhagic effects of D-MePhe-Pro-Arg-H and hirudin were decreased 20
min post I. V. injection when compared to 5 min post I. V. injection, the effects of Ac(D)Phe-Pro-boroArg-OH appeared to increase with time. The dose of each thrombin
inhibitor that resulted in bleeding of 2 · 1()9 RBC/L, 5 min and 20 min post I. V. injection,
is reported in Table 22. The amount of RBCs released at each thrombin inhibitor dose
is reported in Tables 22a - 22d for the 5 min and 10 min post I. V. injection.

Table 22 -- Comparative hemorrhagic potencies of thrombin inhibitors after I.V.
injection, as determined in the rabbit model of ear bleeding.
Dose of each agent that resulted in bleeding of
2 · 109 RBC/L in [µmol/kg].
5 min post I. V injection

20 min post I. V. injection

D-MePhe-Pro-Arg-H

2.82

>4.85

Ac-D-Phe-Pro-boroArg-OH

0.55

0.54

Hirudin

0.11

0.30

Heparin

>0.45

>0.45

Each value represents a single determination from the respective dose-response curves
depicted in Fig. 56. Saline produced bleeding of 0.100 ± 0.070 109 RBC/L.
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2. Duration of Hemorrhagic Effects of Thrombin Inhibitors
After I. V. Administration at a Fixed Dose
To determine the duration of the hemorrhagic effects of thrombin inhibitors, the
dose of each agent that produced sub-maximal hemorrhagic effects in the above studies
was selected and the hemorrhagic procedure was initiated at different times post I. V.
injection of these agents. The individual doses for these studies were 4.85 µmol/kg for
D-MePhe-Pro-Arg-H, 0.50 µmol/kg for Ac-(D)Phe-Pro-boroArg-OH, 0.36 µmol/kg for
hirudin and 0.46 µmol/kg for heparin. The hemorrhagic process was initiated 5, 20, 30,
45, 60 and 90 min post I.V. injection of each thrombin inhibitor. Six rabbits were
studied at each circulation time point.
The data of the comparative hemorrhagic effects are depicted in Fig. 57. All
thrombin inhibitors exhibited time-dependent hemorrhagic profiles which generally
diminished within 45 min post I.V. injection. D-MePhe-Pro-Arg-H lost its hemorrhagic
effects at the fastest rate (t1/2 around 15 min), while Ac-(D)Phe-Pro-boroArg-OH (t1h
around 35 min) and hirudin (t 1/2 around 25 min) showed a decrease in their hemorrhagic
effects only after 20 min post I. V. injection. The individual data on the hemorrhagic
effects of each antithrombin agent at each time point are found in Table 22e.

3. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After S.C. Administration at Fixed Time Points
The dose-dependent hemorrhagic effects of thrombin inhibitors after S.C.
injection, as assessed in the rabbit ear bleeding model are depicted in Fig. 58. In panel
A, the hemorrhagic procedure was initiated 45 min after S.C. injection of the thrombin
inhibitor, while in panel B, the hemorrhagic procedure was initiated following 60 min
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Fig. 57. Time dependance of hemorrhagic effects of antithrombin agents in the rabbit
ear bleeding model. Each agent was administered through I. V. injection and allowed to
circulate for varying time periods prior to initiation of the incision procedure. ( •) DMePhe-Pro-Arg-H at 4.85 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH at 0.50 µmol/kg,
(•) hirudin at 0.36 µmol/kg, ( +) heparin at 0.46 µmol/kg. Each point represents a
mean+ S.E.M. (n=6). *denotes statistical significance (p<0.05) when compared to
control (0.100 ± 0.060) as analyzed with ANOVA followed by Student-Newman-Keuls
test. The individual values for each thrombin inhibitor at each time point are given in
Table 22e.
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Fig. 58. Comparative dose-dependent hemorrhagic effects of various agents as studied
in the rabbit ear bleeding model. In panel A, each agent was administered through S.C.
injection and allowed to circulated for 45 minutes prior to initiation of the incision
procedure. In panel B, each agent was administered through S.C. injection and
circulated for 60 minutes prior to initiation of the incision procedure. ( •) D-MePhe-ProArg-H, ( .. ) Ac-D-Phe-Pro-boroArg-OH, (•) hirudin, ( +) heparin. Each point
represents a mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when
compared to control (0.100 ± 0.060) as analyzed with ANOVA followed by the StudentNewman-Keuls test. The individual values for each thrombin inhibitor dose and their
gravimetric equivalents for both the 5 an 10 min post I. V. end points are given in Tables
23a-23d.
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S.C. injection of the antithrombin agent. Similar to the hemorrhagic effects following
I. V. administration, except for heparin, the other thrombin inhibitors resulted in dosedependent hemorrhagic effects. As observed after I.V. injection, the agent with the
strongest hemorrhagic effects 45 min post S.C. administration, was hirudin (BD2 0.80
µmol/kg), followed by Ac-(D)Phe-Pro-boroArg-OH (BD2 1.13 µmol/kg) and then by DMePhe-Pro-Arg-H (BD 2 > 9. 7 µmol/kg). Heparin had minimal hemorrhagic effects, as
seen in both the 45 min and 60 min post S.C. injection panels, with BD2 of >0.9
µmollkg in both cases.

Except for Ac-(D)Phe-Pro-boroArg-OH, none of the other

inhibitors appeared to have any hemorrhagic effects 60 min post S.C. injection, as seen
in panel B of Fig. 58. However, the effects of Ac-(D)Phe-Pro-boroArg-OH were lower
at 60 min post S.C. injection, when compared to the effects produced 45 min post S.C.
injection. The dose of each thrombin inhibitor that resulted in bleeding of 2 · 109 RBC/L,
45 min and 60 min post S.C. injection, is reported in Table 23. The amount of RBCs
released at each thrombin inhibitor dose is reported in Tables 23a - 23d, for the 45 min
and 60 min post S.C. injection.

4. Duration of Hemorrhagic Effects of Thrombin Inhibitors
After S.C. Administration at a Fixed Dose
To determine the duration of the hemorrhagic effects of thrombin inhibitors after
S.C. injection, the dose of each agent that produced sub-maximal hemorrhagic effects in
the above studies was selected and the hemorrhagic procedure was initiated at different
times post S.C. injection of these agents. The dose of each thrombin inhibitor selected
was: D-MePhe-Pro-Arg-H at 9.71 µmol/kg, Ac-(D)Phe-Pro-boroArg-OH at 2.01
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µmollkg, hirudin at 0.77 µmol/kg and heparin at 0.91 µmol/kg.

The hemorrhagic

procedure was initiated 15, 30, 45, 60 and 90 min post S.C. injection of each thrombin
inhibitor. Six rabbits were studied at each circulation time point.

Table 23 -- Comparative hemorrhagic potencies of thrombin inhibitors after S.C.
injection, as determined in the rabbit model of ear bleeding.
Dose of each agent that resulted in bleeding of
2 · 109 RBC/L in [µmol/kg].
45 min circulation
D-MePhe-Pro-Arg-H

60 min circulation

>9.71

>9.7

Ac-D-Phe-Pro-boroArg-OH

1.13

Hirudin

0.80

>0.7

Heparin

>0.91

>0.9

1.57

Each value represents a single determination from the respective dose-response curves
depicted in Fig. 58. Saline produced bleeding of 0.100 ± 0.070 109 RBC/L.

The results of these studies are depicted in Fig. 59. Except for heparin, the other
thrombin inhibitors had time-dependent hemorrhagic effects.

For Ac-(D)Phe-Pro-

boroArg-OH and hirudin, their hemorrhagic effects became maximal at 45 min post S.C.
injection. While both thrombin inhibitors progressively lost their hemorrhagic activities
after 45 min, the effects of hirudin were abolished at 60 min post S.C. injection. DMePhe-Pro-Arg-H lost its hemorrhagic effects progressively with time, similar to its
time-dependent hemorrhagic effects after I. V. injection.

Heparin, as in all other

hemorrhagic studies, had minimal effects at all time points. The hemorrhagic effects of
each thrombin inhibitor at each time point are found in Table 23e.

254

8
7
...-_J

'

*

6

())

5
4
..........
3
w

0

~

()
(])
~

2
1
0

*
**
0

10

20

30

40

50

60

70

80

90

Circulation Time (minutes)
Fig. 59. Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit
ear bleeding model. Each agent was administered through S.C. injection and allowed
to circulate for varying time periods prior to initiation of the incision procedure. ( •) DMePhe-Pro-Arg-H at 9.71 µmol/kg, (•) Ac-D-Phe-Pro-boroArg-OH at 2.01 µmol/kg,
(•) hirudin at 0. 77 µmol/kg, ( +) heparin at 0.91 µmol/kg. Each point represents a
mean± S.E.M. (n=6). *denotes statistical significance (p<0.05) when compared to
control (0.100 ± 0.060) as analyzed with ANOVA followed by the Student-NewmanKeuls test. The individual values for each thrombin inhibitor at each time point are given
in Table 23e.
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K. Effects of Thrombin Inhibitors on Blood Pressure
After I. V. Administration in Rabbits
Thrombin inhibitors may mediate vascular effects independent of their
antithrombin activities.

To asses whether the thrombin inhibitors used in the rabbit

model of ear blood loss had any effects on the blood pressure of rabbits, the blood
pressure during the stasis thrombosis procedure was monitored for the highest dose of
each thrombin used after I.V. injection (D-MePhe-Pro-Arg-H at 1.942 µmol/kg, Ac(D)Phe-Pro-boroArg-OH at 0.101 µmol/kg, hirudin at µmol/kg and heparin at 0.023
µmol/kg).
The blood pressure monitoring of the rabbits during the stasis thrombosis
procedure, in the studies where the dose-dependent effects of r-TF were also studied.
These studies revealed a slight transient drop in the blood pressure lasting 5 ± 1 minutes
after the first baseline blood draw and the subsequent infusion of saline (Fig. 60, panel
A). Similar results were obtained when r-TF was used in place of saline, as seen in Fig.
60, panel B. The results obtained with each of the thrombin inhibitors (injected 5 min
prior to the r-TF injection) were similar to those obtained with r-TF alone.
Representative graphs from a rabbit treated with hirudin and Ac-(D)Phe-Pro-boroArg-OH
are seen in Fig. 60, panels C and D respectively. Panel E shows the effect of D-MePhePro-Arg-H on the blood pressure response. Consistent with the results obtained with the
other agents, this peptide derivative did not produce any significant effects on the blood
pressure.
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Fig. 60. Intra-arterial blood pressure monitoring of rabbits during in vivo investigation
with rTF and antithrombotic agents. Five min following the I. V. injection of each agent,
9 ml of blood was collected via the carotid artery. Panel A depicts the effects of rTF
at 1.35 pmol/kg, I.V. Panel B depicts the effects of saline. Panel C depicts the effects
of hirudin at 0.04 µmol/kg, I.V. Panel D depicts the effects of Ac-(D)Phe-Pro-boroArg0 H at 0. 1 µmol/kg, I. V. Panel E depicts the effects of D-MePhe-Pro-Arg-H at 1. 9
µmol/kg, I.V.

CHAPTER V
DISCUSSION

This dissertation represents an integrated account of the pharmacological
properties of several thrombin inhibitors which are not different only in their structural
characteristics, but also exhibit varying degrees of specificity towards thrombin. The
experimental approaches are designed to test the hypothesis that the inhibition of
thrombin may not be the sole determinant of their endogenous antithrombotic and
hemorrhagic actions. It is likely that several other endogenous factors are responsible
for their pharmacologic effects. These effects include both the plasmatic and cellular
sites. Furthermore, metabolic transformations of the individual thrombin inhibitors could
also contribute to their endogenous pharmacodynamics.
In this dissertation, heparin has been used as a reference anticoagulant. However,
unlike all of the antithrombin agents used, this drug produces its actions through
potentiation of antithrombin and HC-II.

Furthermore, this agent exhibits poly-

pharmacologic behavior and targets several plasmatic and vascular sites (Lindahl et al.
1991, Jeske et al. 1995). On the other hand, the synthetic and recombinant thrombin
inhibitors included in this study represent chemically pure homogeneous agents.

A

comparison of the biochemical and pharmacological characteristics of heparin and
thrombin inhibitors is given in Table 24.
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Table 24 -- Comparative properties of heparin and thrombin inhibitors.
Heparin
Thrombin Inhibitors
Thrombin inhibition
Clot-bound thrombin
Inhibition of other serine
proteases
Fibrinolytic interactions
Serpin interactions
Platelet interactions
Endothelial interactions
Hemodynamic modulation
Immunogenicity
Bioavailability
Liver toxicity
Antagonists

Indirect
No interaction
Indirect, Xa and to a lesser
extent XIIa, Xla, Xa and IXa.
Activation
Requires antithrombin,
potentiates HC-II, releases TFPI
Inhibition
t vascular permeability, release
of TFPI, binds endothelial lining
Activation
HIT
20-30% S.C., <5% oral
t liver enzymes
Protamine, PF4, several serpins

Direct
Inactivation
Variable
Variable
None
Inhibition only of thrombininduced aggregation
Unknown
Unknown
Barely immunogenic
80-100% S.C., 5-30% oral
None
None

N

Vl
00
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Beside the antithrombin mediated inhibition of thrombin, heparin produces its
overall antithrombotic effects through various mechanisms, while thrombin inhibitors are
believed to act only through the inhibition of thrombin. Thus, while heparin is capable
of inhibiting other coagulation factors via antithrombin and HC-II, antithrombin agents
antagonize the final stages of coagulation. In addition, heparin interacts ionically with
the vascular lining to mediate a series of antithrombotic and pro-fibrinolytic effects, such
as release of tPA, TFPI and anti thrombotic glycosaminoglycans from the endothelial
lining (Verstraete and Zoldelhyi 1995). Heparin is also capable of inhibiting platelet
functions, while antithrombin agents only inhibit thrombin-induced aggregation. On the
other hand, most of the antithrombin agents are smaller in size and therefore are capable
of inhibiting clot-bound thrombin, which may be important in clot stabilization and its
subsequent lysis (Gast et al. 1994, Berry et al. 1994). The main reason for clinical
interest in antithrombin agents as a potential replacement for heparin is due to the fact
that heparin has certain limitations, which include wide subject-to-subject variability,
poor response and allergic manifestations. One of the most serious adverse effects with
heparin is heparin induced thrombocytopenia (HIT), a deleterious immune reaction where
the patient's platelets aggregate in response to heparin to form white clots. Both heparin
and the higher molecular weight thrombin inhibitors (hirudin) exhibit immunogenicity
(Eichler and Greinacher 1996). The clinical implications of the anti-hirudin antibodies
are not clear at this time. Another reason for evaluating alternative antithrombotic agents
to heparin is the limited S.C. bioavailability of heparin.

Heparin exhibits S.C. bio-

availability of 20-303 whereas the thrombin inhibitors have 80-100% S.C.
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bioavailability. The oral bioavailability of the thrombin inhibitors ranges from 5-30 3
whereas heparin has a rather limits absorption ( < 5 3) by this route. Another major a
problem that needs to be addressed for all direct thrombin inhibitors is their
pharmacologic neutralization.

While heparin is readily neutralizable by protamine,

currently, there is no available pharmacologic antagonist for any of the direct thrombin
inhibitors.
Thrombin inhibitors as a class of new anticoagulants represents compounds with
significant structural variations.

Recombinant hirudin represents a protein analog of

natural hirudin with absolute specificity for thrombin. The peptide arginals represent low
molecular weight peptide derivatives with strong antithrombin potency. However, they
also exhibit varying degrees of inhibitory actions towards other serine proteases. The
boronic acid tripeptide Ac-(D)Phe-Pro-boroArg-OH represents a transition state analogue
with a high degree of reactivity and broad serine protease inhibitory spectrum. The
peptidomimetic agent argatroban, represents a relatively weaker inhibitor of thrombin,
with a high degree of specificity.
While the antiprotease spectrum of these agents has been extensively investigated,
very little is known regarding their interactions with the cellular components of blood and
vasculature.

It is generally perceived that the antithrombin actions of these agents

correlate directly with their in vivo pharmacologic effects. Theoretically, this hypothesis
appears logical, however, experimental validation of this widely accepted concept is not
available until now.

The data reported in this dissertation represent the first

comprehensive account where the different antithrombin agents are compared in defined
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biochemical systems mimicking thrombogenesis and valid pharmacological models are
utilized to investigate the relative antithrombotic and bleeding actions of these agents.
This research provides an integrated account of the biochemical and pharmacologic
actions of these agents, that may be useful in predicting the relative therapeutic index
of these new anticoagulants.
Despite the extensive trials on the use of the new thrombin inhibitors in
appropriately chosen clinical indications, supportive studies on their biochemical and
pharmacologic influences of these agents have been rather limited. Due to the absence
of this important fundamental information, both the safety and efficacy problems have
been obvious during the newer clinical trials. The comparative studies reported in this
dissertation address the following key questions:
1.

Is the sole inhibition of thrombin sufficient to control thrombogenesis in various
thrombotic states?

2.

Are thrombin inhibitors similar to heparin in their pharmacologic actions?

3.

Are there any differences among the currently available thrombin inhibitors?

4.

Do thrombin inhibitors manifest non-thrombin mediated pharmacologic actions?
This dissertation therefore attempts to address some of the previously unresolved

issues in carefully designed biochemical and pharmacologic studies. A direct comparison
of thrombin inhibitors as a new class of drugs with conventional heparin provides an
important database for the relative antithrombotic and hemorrhagic profiles of these
drugs, which will be helpful in their clinical development.
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A. Molecular and Structural Characterization of
Heparin and Antithrombin agents
The peptide aldehyde D-Phe-Pro-Arg-H has been reported to be unstable in
solution (Bajusz et al. 1990). The peptides D-MePhe-Pro-Arg-H and Boc-D-Phe-ProArg-H were developed to minimize cyclization and racemization.

To determine the

extent of cyclization and racemization in all of these agents, the HPLC studies were
undertaken. All peptides resulted in elution profiles composed of more than one peaks.
The identity of the structure which was represented by each one of the backgroundadjusted peaks was deciphered by isolating the material represented by each peak and
then analyzing it with NMR techniques, which have been previously published (Bajusz
et al. 1990). The HPLC studies revealed that almost 903 of the D-Phe-Pro-Arg-H, 95 %
of the D-MePhe-Pro-Arg-H and 100% of the Boc-D-Phe-Pro-Arg-H remained in the
active form, in three equilibrium structures, after reconstitution in distilled H20.
The HPLC analysis of the boronic acid peptide derivative Ac-(D)Phe-ProboroArg-OH revealed that this compound eluted in several peaks. However, the identity
of the structures represented by each one of these peaks is not known at this time.
Furthermore, in contrast to the peptide arginals, the elution profile of this agent was
rather complex.

Because of the highly reactive nature of this agent, molecular

interactions and other structural transformations may be responsible for this complex
behavior. The boronic acid residue is highly reactive and the unusual HPLC elution
profile may also be attributable to the interaction of this reactive peptide to the column.
The heparin preparation employed in these studies is a polycomponent mixture
of glycosaminoglycans of different molecular weights. To determine the homogeneity
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of this preparation of porcine origin, the GPC studies were carried out. The heparin
preparation was examined by using two different detectors, the UV and the RI. The
peaks resolved in the UV detector are generally due to the amount of sulfation and the
presence of double bonds in the heparin. The peaks detected with the RI are due to the
mass of the material studied. The results obtained from both detectors were in close
agreement.

The molecular weight average of this particular heparin preparation was

determined to be approximately 10,700 and about half of the material was determined to
be in the 8,000-12,000 range.

While no analytical studies were carried out on the

recombinant hirudin, this preparation was certified to be homogeneous and 95 3 pure by
the manufacturer. It is apparent that the agents used in this investigation represent wide
differences in their physicochemical and structural characteristics. While hirudin is a
recombinant protein and the synthetic thrombin inhibitors represent structurally distinct
peptidomimetics, heparin is a complex mixture of sulfated glycosaminoglycans.
Therefore, molar conversions of the effects of heparin in these reported studies were
based on the apparent molecular weight of heparin. In contrast, the molecular weights
of all other agents were based on their formula molecular weights.

B. Relative Antithrombin Potencies of Thrombin Inhibitors
Thrombin inhibitors are being extensively investigated for a variety of clinical
applications. As the number of thrombin inhibitors is increasing, there is a growing need
for the development of a method for the potency standardization of these agents.
Currently, outside the structural characterization using HPLC methods and the
biochemical characterization of these agents measuring inhibitory constants for thrombin
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(Bajusz et al. 1978, Bagdy et al. 1994, Kettner et al. 1990, Kikumoto et al. 1984, Braun
et al. 1988), no other valid methods are available for the direct comparison of the
antithrombin potency of these agents. Furthermore, a study where antithrombin potency
for a specific antithrombin agent is directly compared with its pharmacologic actions is
not available.
In the thrombin titration studies, where the amidolytic effect of thrombin on a
chromogenic substrate was used to determine the inhibitory activities of antithrombin
agents, an attempt was made to evaluate and compare various thrombin inhibitors in
terms of ATU potencies. The order of potency of the thrombin inhibitors was found to
be hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-OH > D-Phe-Pro-ArgH > Boc-D-Phe-Pro-Arg-H > argatroban. With the exception of argatroban, the order
of potencies of the other agents matched the order of their respective Ki values. Even
though all of these thrombin inhibitors interact with thrombin on a 1: 1 stoichiometric
ratio, these agents form complexes with thrombin in kinetically distinct manners. More
specifically, the tripeptide aldehydes (D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and BocD-Phe-Pro-Arg-H) are slowly reversible thrombin inhibitors with Ki values of around 80
nM (Bajusz et al. 1978, Bagdy et al. 1994), Ac-(D)Phe-Pro-boroArg-OH is a transition
state analogue with a Ki of 41 pM, which means a tight-binding and slowly reversible
competitive thrombin inhibitor (Kettner et al. 1990), argatroban is a fast reversible
antithrombin agent with a Ki of 39 nM (Kikumoto et al. 1984), while hirudin is a tightbinding inhibitor with a Ki of 21 fM (Stiirzebecher and Walzman 1991). To overcome
these kinetic differences, prior to the addition of the substrate, each of the thrombin
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inhibitors was pre-incubated with thrombin, to achieve steady-state kinetics. Despite this
pre-incubation period, the activity of argatroban in this amidolytic assay in relationship
to the other thrombin inhibitors was not correlated with the order of their Ki values.
The amidolytic activity of thrombin is not predictive of the clotting activity of
thrombin. The amidolytic activity of thrombin may be unaffected even if the clotting
activity of this enzyme is diminished (Sonder and Fenton 1986).

Furthermore, the

affinity (Km) and the specificity constant (k.:,,/Km) of thrombin for the chromogenic
substrate used in this method (51 · 106 M- 1s- 1) are different from those of the natural
substrates for thrombin (Sonder and Fenton 1986), such as factor V (3.26 · 106 M- 1s- 1 ,
Monkovic and Tracy 1990), factor XI (0.0026 · 106 M- 1s- 1 , Gailiani and Broze 1991),
factor XIII (0.12 · 106 M- 1s- 1 , Janus et al. 1983), protein C (Esmon et al. 1983) and
fibrinogen (3.8 · 106 M- 1s- 1 and 1.1·106 M- 1s-1, for fibrinopeptides A and B, De Cristofaro
and Di Cera 1992, Picozzi et al. 1994).

Therefore, a competition between the

chromogenic substrate and each of the thrombin inhibitors cannot be readily related to
and be predictive of pathophysiologic events.
To determine the relative antithrombin effects of these inhibitory agents utilizing
the functional property of thrombin to cleave fibrinogen into fibrin, the fibrinogen-based
clotting systems were developed.

In these assays, the order of potency of the

antithrombin agents was found to be hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhePro-Arg-H > argatroban> D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H. As with their
respective Ki values, hirudin and Ac-(D)Phe-Pro-boroArg-OH were the strongest
thrombin inhibitors in this test, while Boc-D-Phe-Pro-Arg-H was the weakest. However,
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the order of potencies of D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H and argatroban were
of a different sequence in this assay than the order of their Ki values. Furthermore,
argatroban exhibited more potent activities in relationship to the rest of the antithrombin
agents in this clot-based system, unlike its weak effects in the amidolytic systems.
As published previously (Iyer and Fareed, 1995), the amidolytic thrombin titration
assay is a rapid and reproducible method that can be used for the in vitro potency
evaluation and quality assurance purposes for a specific thrombin inhibitor. However,
the value of this method in screening all new thrombin inhibitors for their anticoagulant
and antithrombotic potential may be limited and can be applied only to the agents that
are known to be tight, slowly reversible thrombin inhibitors. In this method, only the
IC50 values are comparable and doubling of this value may not give the correct number
for 100% thrombin inactivation (Dr. J. Fenton II and Ms. Brezniak, New York State
Department of Health, personal communication). The example of argatroban illustrates
this point: argatroban is found to be 100 fold weaker than hirudin (on a molar basis) in
this assay.

However, in the fibrinogen-based method, where the end-point is clot

formation and is also a rapid and reliable screening method for antithrombin activities
of agents, argatroban exhibited comparable antithrombin potencies to those of D-MePhePro-Arg-H and D-Phe-Pro-Arg-H. Furthermore, argatroban has been used clinically for
a variety of indications in Japan (Kario et al. 1995) and is in clinical trials in both
Europe and the U.S., with promising efficacy and beneficial outcomes. Thus, the in

vitro potency evaluation of these agents may or may not be relevant to the in vivo
actions. This chromogenic method may be useful in the comparison of various batches
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of the same thrombin inhibitor, or even in the comparison of different thrombin inhibitors
with the exact mechanism of thrombin inhibition. The fibrinogen-based method may be
more relevant in comparing thrombin inhibitors that differ in their mechanisms of
actions.

As demonstrated recently by Bagdy et al. 1994, it is important to utilize a

battery of several different methods to assess relative potencies of thrombin inhibitors,
since it appears that different methods may be more suitable for evaluating one agent in
comparison with other thrombin inhibitors.

C. Antithrombin and Anti-Xa Activities of Thrombin Inhibitors
in Plasmatic Systems
While defined assay systems, such as the amidolytic tests discussed earlier, can
provide useful information on the relative antithrombin potency of various agents, these
assays are based on buffered conditions where thrombin is the only enzyme present. To
examine the matrix effect that plasma has on the antithrombin activities of thrombin
inhibitors, the human plasma-based amidolytic antithrombin assay was utilized. The
order of potency of the antithrombin agents was found to be hirudin> Ac-(D)Phe-ProboroArg-OH > D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H >
argatroban. In this system, heparin was also studied and was found to be an even more
potent antithrombin agent than hirudin.

The effects of heparin in this system are

mediated through the antithrombin contained within the plasma and therefore the
antithrombin effects exhibited by this drug are a reflection of the potentiation of
antithrombin and not of direct effects of heparin on thrombin. Since the previously
discussed thrombin titration systems are devoid of antithrombin, heparin had no
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antithrombin effect and comparisons with the other thrombin inhibitors were not possible.
When rabbit plasma was used instead of human plasma in the same assay, heparin
was again found to be the strongest thrombin inhibitor. However, the order of potencies
of hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H were reversed,
although very close in absolute value. This difference in the order of potency in the
human and rabbit plasma systems is probably a reflection of the differences in the plasma
matrices and the concentrations of various factors.

Rabbit plasma contains higher

concentrations than human plasma of most coagulation factors, with the exception of
prekallikrein, factor X, prothrombin and fibrinogen (Walenga 1987). In addition, rabbit
plasma contains about the same amount of antithrombin as human plasma (Walenga
1987).

Since rabbit plasma contains 18 fold higher concentrations of factor V than

human plasma, which serves as a cofactor for factor Xa, and since addition of thrombin
to plasma activates the coagulation cascade via multiple feedback mechanisms, it may be
that direct inhibition of factor Xa in the rabbit plasma-based assay by such agents as Ac(D)Phe-Pro-boroArg-OH may be more important in the generation and subsequent
inhibition of generated thrombin than in the human plasma-based system. On the other
hand, in the human plasma-based test, the direct inhibition of the added thrombin may
mask any effects that thrombin inhibitors may have on the generation of thrombin from
the endogenous factors by inhibiting other coagulation factors.

Thus, the inhibitory

constants for thrombin, as represented by the reported Ki values, may be more relevant
in predicting the antithrombin potency of these agents.
An automated method for the determination of hirudin in plasma has been recently
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published (Hafner et al. 1995). This method is also based on the amidolytic activity of
thrombin on a chromogenic substrate. However, in this method bovine thrombin is used
instead of human enzyme as is in the studies described in this dissertation. This may
also influence the comparative effects of various thrombin inhibitors on the amidolytic
activity of this thrombin. Furthermore, the chromogenic substrate is added to the plasma
before thrombin, therefore decreasing the possibility that low reaction velocity thrombin
inhibitors, such as heparin/antithrombin complex, will have an effect on this assay. The
comparative effects of hirudin in the chromogenic assay and the APTT results reported
by Hafner et al. 1996 are in agreement with the results reported in this dissertation,
where no correlation was found between the antithrombin amidolytic activities of various
thrombin inhibitors and their effects in the APTT assay.
To examine the specificity of the antithrombin agents compared in these studies
for thrombin, the amidolytic anti-Xa assays were also utilized.

These assays were

plasma-based systems and it was found that with the exception of heparin and Ac-(D)PhePro-boroArg-OH, the other thrombin inhibitors were devoid of anti-Xa activity. As
expected, heparin exhibited measurable anti-Xa activity in this assay which is mediated
by plasmatic antithrombin.

Antithrombin also inhibits most of the factors in the

coagulation cascade, especially thrombin and factor Xa.
The effects of Ac-(D)Phe-Pro-boroArg-OH validate the observation that this
compound is not a specific thrombin inhibitor, even though its potency for factor Xa
inhibition is lower than that of heparin. When the same inhibitors were studied in the
rabbit plasma-based assay, similar results were obtained: except for heparin ·and Ac-
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(D)Phe-Pro-boroArg-OH, none of the other agents had any anti-Xa effects. Even though
heparin was again found to be a more potent factor Xa inhibitor than Ac-(D)Phe-ProboroArg-OH, its anti-Xa potency in the human plasma in comparison to the rabbit plasma
was 10 fold stronger, while Ac-(D)Phe-Pro-boroArg-OH's potency was only 3 fold
stronger in the human plasma than in the rabbit plasma. This difference in the ratios is
most likely reflective of the limiting factor in heparin's activity, namely the antithrombin
concentration in each plasma system in relation to the factor Xa/factor Va levels.
Another plasma-based assay that provides data on the antithrombin and anti-Xa
effects of various agents is the Heptest, which is a clot-based method, unlike the
previously discussed plasma-based assays, which are amidolytic methods. In this assay,
activated factor Xa is added to the plasma, which results in direct activation of the
common pathway and generation of thrombin.

The order of potency of thrombin

inhibitors in the human plasma-based Heptest assay was heparin> hirudin > Ac-(D)PhePro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H > Boc-DPhe-Pro-Arg-H. With the exception of heparin, and the change in the rank order of
argatroban and D-MePhe-Pro-Arg-H, this potency order closely followed that obtained
in the fibrinogen-based antithrombin assay.

In addition, the order of potency of the

antithrombin agents in the Heptest closely followed the order of their respective Ki
values. When rabbit plasma was used instead of human plasma in the Heptest assay,
hirudin was found to be more potent than heparin. This difference is probably due to the
difference in antithrombin concentration in relation to factor Xa/factor Va concentration
in the two plasmas, which limits the heparin antithrombin and anti-Xa activity.

271

In all of the systems discussed earlier, argatroban was found to be a weak
inhibitor in the amidolytic assays, while in the clotting assays its activity appeared to be
more potent in relation to the tripeptide aldehydes, corresponding to their respective Ki
values. Since argatroban is the most reversible of all thrombin inhibitors examined, this
indicates that an agent's antithrombin potency as measured by a Ki value rather than its
amidolytic potential may be more predictive of its anticoagulant effects.

D. Antiprotease Spectrum of Various Thrombin Inhibitors
The objective of adjunctive therapy of anticoagulants with fibrinolytics is to
simultaneously control thrombogenesis and facilitate thrombolysis. However, the specific
agents which are to be combined should be carefully selected.

Many of the new

antithrombin agents target the catalytic site of thrombin, which is similar in many bloodborne enzymes, including most of the enzymes involved in coagulation and fibrinolysis.
Thus, it is possible that some of these catalytic site directed thrombin inhibitors may
inhibit other enzymes, involved in both coagulation and fibrinolysis, regardless of their
relative affinity for thrombin. In addition, highly specific thrombin inhibitors without
additional antiprotease activities, such as hirudin, may also impair physiological
fibrinolysis by inactivating thrombomodulin-bound thrombin. Since thrombomodulinbound thrombin has an anticoagulant action and no procoagulant activities, by activating
protein C, which in turn inhibits the coagulation cascade by inactivating cofactors Va and
VIIIa and promotes the fibrinolytic system by inactivating one of its inhibitors (PAI-1),
inhibition of this bound thrombin would compromise the endogenous fibrinolytic system.
These experimental studies, where the inhibitory effects of various thrombin

272
agents on the amidolytic activities of purified enzymes were studied and designed to
assess the inhibitory range of several thrombin inhibitors on pro-fibrinolytic enzymes.
In the defined enzyme systems, it was evident that Ac-D-Phe-Pro-boroArg-OH was the
thrombin inhibitor with the widest and strongest range of antiprotease actions. Boc-DPhe-Pro-Arg-H also had a wide range of antiprotease activities, although these were
achieved at higher concentrations (0.24 - 15 µM). D-Phe-Pro-Arg-H and D-MePhe-ProArg-H did not affect kallikrein and urokinase but did inhibit the other enzyme systems
at concentrations comparable to those of Ac-D-Phe-Pro-boroArg-OH or Boc-D-Phe-ProArg-H.

In contrast to these tripeptide derived thrombin inhibitors, argatroban, a

peptidomimetic of comparable mass, hirudin and heparin/antithrombin had minimal
activities on the enzymes systems examined. Heparin was used in conjunction with
antithrombin, since heparin mediates its inhibitory activities through potentiation of
antithrombin. Aprotinin, an anti-fibrinolytic agent, followed the inhibitory profile of Ac(D)Phe-Pro-boroArg-OH at equivalent concentrations. This agent however is devoid of
antithrombin activity at this concentration range. It should be noted that the inhibition
of these purified enzymes by thrombin inhibitors is competitive utilizing a substrate
which is different than the natural ones for each enzyme, e.g. the natural substrates of
APC are factors Va and VIiia and their Ki values are different from that of the
chromogenic substrate used in the amidolytic assay. Therefore, the in vivo and clinical
relevance of these data is questionable and will depend among other factors on the local
concentrations of the antithrombin agent, the endogenous and exogenous enzymes and
the natural substrates. A valid approach to demonstrate the inhibitory effects of thrombin

273
inhibitors on APC is to utilize an animal model in which the regulatory physiologic
effects of this anticoagulant protein can be assessed (::::; 100 µM). Nevertheless, these
results suggest that agents such as the tripeptide derivatives may exhibit direct
interactions with these enzymes and they may show varying degrees of compatibility with
fibrinolytic agents since they can directly interact and compromise these actions. Agents
such as argatroban, hirudin and heparin that lack direct inhibitory activities against the
fibrinolytic enzymes, are expected to behave differently when administered with
thrombolytic agents.
The relationship of these in vitro non-thrombin effects of the antithrombin agents
to the in vivo process of fibrinolysis was examined in a rabbit model of jugular vein
thrombolysis (Callas et al. 1995). In contrast to most animal models of thrombolysis
used by other investigators where the clots formed are platelet-rich and are designed to
detect thrombolytic facilitation, the clots formed and lysed in this model are fibrin-rich
clots and the model is designed to detect thrombolytic compromise. The studies on the
effects of thrombin inhibitors on this thrombolytic model confirm the results from the in

vitro studies.

The antithrombin agent with the broadest and strongest spectrum of

activity against the fibrinolytic enzymes, Ac-D-Phe-Pro-boroArg-OH, also compromised
thrombolysis the most.

D-MePhe-Pro-Arg-H and aprotinin also had marked anti-

fibrinolytic activities in this animal model. In contrast, argatroban, hirudin and heparin
had minimal effects, correlating with their narrow spectrum of activity. Interestingly,
the last three agents did have some activity, which may be due to inhibition of the
thrombomodulin-bound thrombin.

Although the doses used in this rabbit model of

274
jugular clot lysis were higher than those required for antithrombotic effects of these
thrombin inhibitors, these levels may be relevant to those achieved clinically in localized
delivery in procedures such as coronary thrombolysis. Preliminary results of a clinical
trial where patients with acute myocardial infarction were administered adjunctive therapy
of strep tokinase and hirulog-I indicate that lower doses of hirulog-1 are more beneficial
than higher concentrations (Theroux 1995). This unexpected effect may be attributed to
inhibition of thrombomodulin-bound thrombin at higher doses of hirulog-1, so that
inhibition of the activation of protein C and subsequent compromise of the physiological
anticoagulant and fibrinolytic system is strong enough to manifest a clinical impact.
Several investigators have published experimental studies on the interactions of
various thrombin inhibitors with thrombolytic processes. A summary of these studies is
given in the last section of the literature review. The difference between the previous
studies and those reported in this dissertation is that these assays were developed so that
only inhibitory effects on pro-fibrinolytic enzymes were detected, while any potential
facilitating activities were not accountable.
Currently there are several thrombin inhibitors in clinical development as
anticoagulants for the management of vascular and cardiovascular disorders. Hirudin,
hirulog-1, efegatran are being developed for the management of abrupt closure during
coronary angioplasty. The on-site concentrated delivery of these agents has also been
advocated. In such clinical applications a direct fibrinolytic compromise by the inhibition
of tPA and plasmin may seriously impair thrombolytic processes. An indirect fibrinolytic
deficit due to the inhibition of thrombin's regulatory effect on activated protein C
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formation can also lead to impaired fibrinolysis. Thus, prophylactic antithrombotic use
of newly developed antithrombin drugs may also lead to an impairment of physiologic
fibrinolysis which can manifest itself into various forms of thrombotic syndromes.
Therefore, it is important to determine the relative fibrinolytic compromising actions of
these agents to achieve optimal clinical results.

E. Inhibitory Actions of Thrombin Inhibitors in Protease Generating Systems
While in the previously discussed assays, the direct inhibitory activities of various
agents on serine proteases was examined, the effects of the same agents on more complex
assays, where activation of one factor leads to the generation of another was studied in
a series of appropriately designed assays.

Three different assays were used to study

different aspects of coagulation and fibrinolysis:

1.

Extrinsic generation systems, where the coagulation cascade was activated with
thromboplastin and the source of clotting factors ranged from fibrinogen-deficient
plasma to prothrombin complexes.

2.

Intrinsic generation systems, where coagulation was activated by a contact
activator and the source of clotting factors was fibrinogen-deficient plasma.

3.

Plasminogenolysis systems, where streptokinase or tPA mediated plasmin
generation from either human plasma derived or purified plasminogen.

In the first two types of assays, the detection of generation of both factor Xa and
thrombin was possible.

Thus, data was obtained on the importance of inhibition of

thrombin versus factor Xa and the impact of these inhibitions on the further amplification
of each system.
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1. Extrinsic Activation Systems
In the fibrinogen deficient plasma-based assay where thrombin and factor Xa are
generated after extrinsic activation, the order of potency of the various thrombin
inhibitors studied varied depending on whether thrombin or factor Xa were detected.
Thus, with regards to thrombin, the order of potency was hirudin> heparin> Ac(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-ProArg-H > argatroban. Hirudin however, plateaued at about 803 inhibition of thrombin
generation, while the other antithrombin agents were able to completely block this
process, with the exception of argatroban. When considering the factor Xa generated in
the same system, the order of potency of the various agents changed to heparin> Ac(D)Phe-Pro-boroArg-OH > Boc-D-Phe-Pro-Arg-H, D-Phe-Pro-Arg-HandD-MePhe-ProArg-H. Hirudin and argatroban had minimal inhibitory activities in the generation of
factor Xa, never exceeding about 20 3 inhibition. Considering the hirudin results and
knowing that hirudin inhibits only thrombin, it seems that the feedback activation of
factor Xa by the generated thrombin accounts for about 20 3 of the generated factor Xa
in this system, or the amount that hirudin is able to block through thrombin inhibition.
Alternatively, hirudin maximally inhibits 80 3 of the generated thrombin, which indicates
that the remaining 20 3 of thrombin is responsible for 80 3 of factor Xa generation, after
extrinsic activation. These explanations on the differential activities of hirudin do not
contradict the results obtained with heparin and Ac-(D)Phe-Pro-boroArg-OH, which are
capable of completely inhibiting the generation of both thrombin and factor Xa, probably
due in part to their ability to directly inhibit factor Xa. However, when considering the

277
activities of the tripeptide aldehydes, it is difficult to understand why these thrombin
inhibitors, unlike hirudin, are capable of completely blocking both thrombin and factor
Xa generation. The differences in the kinetics of thrombin inhibition may be accountable
for these differences from hirudin, so that if hirudin binds thrombin relatively slower as
11

11

it is generated, enough thrombin escapes to perpetuate the feedback amplifications and
further generation of thrombin. In addition, while the tripeptide aldehydes do not inhibit
factor Xa, they may have inhibitory activities on other coagulation factors in addition to
thrombin, since as seen in the pro-fibrinolytic enzyme assay studies, the tripeptide
aldehydes are capable of inhibiting other serine proteases to varying degrees. These
explanations are in accordance with the actions of argatroban, the other monospecific
thrombin inhibitor which, like hirudin, is not capable of completely inhibiting the
generation of either thrombin or factor Xa. The comparative effects of heparin and
hirudin utilizing this system have been previously published (Kaiser et al. 1992) and are
in agreement with the results described in this dissertation.
In the fibrinogen deficient plasma assays, the intrinsic pathway is also activated
at some point via the feedback actions of thrombin. However, in the KONYNE® and
FEIBA® based tests, only factors involved in the extrinsic and common pathways of
coagulation are present. In these systems, heparin exhibited markedly weaker inhibitory
activities in relation to the other thrombin inhibitors, in contrast to its profile in the
fibrinogen-deficient plasma-based assays. This difference in the actions of heparin are
probably due to the absence of antithrombin from the KONYNE® and FEIBA®
preparations. Trace amounts of antithrombin or HC-11 must exist however, since heparin
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has some effects. The comparative effects of hirudin and heparin and Ac-(D)Phe-ProboroArg-OH in the KONYNE® system have been recently published (Kaiser et al. 1994).
In this publication, addition of antithrombin is shown to potentiate the inhibitory activities
of heparin. However, addition of factor V does not influence the inhibitory activities of
any of the three studied agents, indicating that the factor V concentration in the
KONYNE® preparation and consequently in this system, is not a rate limiting a factor.
The difference between the KONYNE® and FEIBA®preparations is that FEIBA ®
contains factor VIIa in addition to factors II, VII, IX and X. In the KONYNE® based
assays, Ac-(D)Phe-Pro-boroArg-OH was the only inhibitor that was capable of
completely inhibiting the generation thrombin and factor Xa, while the other antithrombin
agents exhibited activities similar to those of hirudin in the fibrinogen deficient plasmabased systems. The difference in activity between Ac-(D)Phe-Pro-boroArg-OH and the
other agents is probably due to the ability of Ac-(D)Phe-Pro-boroArg-OH to directly
inhibit both thrombin and factor Xa. Furthermore, since the tripeptide aldehydes also
lose their ability to inhibit the generation of both thrombin and factor Xa in this assay,
in contrast to their activities in the fibrinogen deficient plasma systems, the previous
hypothesis that these aldehydes may exert their inhibitory effects via inhibition of other
coagulation factors can be narrowed to the intrinsic coagulation factors.
In the FEIBA® based assay, while Ac-(D)Phe-Pro-boroArg-OH remains a potent
inhibitor of both the thrombin and factor Xa generation, hirudin is also a potent inhibitor
of this generation test. In this assay, hirudin is capable of almost completely blocking
the generation of both thrombin and factor Xa, in contrast to the previous systems.
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These results suggest that the relative speed or the activation status of coagulation at
which thrombin is generated is important in the activity of thrombin inhibitors. The
results obtained from the KONYNE® and FEIBA®assays are difficult to interpret in light
of the fact that thrombin and factor Xa are generated even in the absence of cofactors
VIII and V, according to the specification sheets of the products. This indicates that
either both products or thromboplastin which is added to extrinsically activate the
coagulation system retain trace amounts of these cofactors.

2. Intrinsic Activation Systems
To examine the effects of antithrombin agents on the inhibition of the intrinsic
generation of thrombin and factor Xa, the fibrinogen deficient plasma was activated with
a contact activator and the generated thrombin and factor Xa were detected with
chromogenic substrates. With the exception of heparin, all antithrombin agents inhibited
the intrinsic generation of thrombin in a manner parallel to their inhibitory profiles in the
extrinsic generation of thrombin and similar explanations for their activities can be
offered. However, in contrast to its extrinsic thrombin activation profile, the activities
of heparin plateaued around 80 3 inhibition of intrinsic thrombin generation. Similarly,
argatroban and hirudin also produced comparable results to heparin in both systems. The
difference in the activities of heparin is probably due to the differences in the inhibition
of various clotting factors by antithrombin, through which heparin exerts its actions.
When examining the effects of antithrombin agents on the generation of factor Xa in the
same system, all agents including heparin, hirudin and argatroban, were capable of
completely inhibiting the generation of factor Xa.

Thus, it appears that none of the
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factor Xa generated is a result of feedback activation through thrombin. These results
are in agreement with the comparative effects of hirudin and heparin in these systems
reported in a previous publication (Kaiser et al. 1992).

3. Plasminogenolysis Systems

Since various antithrombin agents were found to inhibit various fibrinolytic
enzymes, to assess their effects on the process of activation of plasminogen, the in vitro
plasminogenolysis experiments were carried out. Activation of plasminogen to plasmin
was also inhibited to various degrees by the different agents, with the activities of hirudin
and heparin being always minimal. The inhibitory profile of the thrombin inhibitors
remained the same regardless of activators, streptokinase and tPA, or source of
plasminogen, purified or human plasma.

Therefore, the inhibitory effects of the

antithrombin agents on these processes are probably due to direct inhibition of plasmin,
while direct inhibition of the plasminogen activators may also contribute to the overall
inhibitory effects of each agent in this system. These results are in agreement with the
published effects of thrombin inhibitors on fibrinolytic enzymes (Barabas et al. 1993),
where it was shown that the tripeptide aldehydes D-Phe-Pro-Arg-H, D-MePhe-Pro-Arg-H
and Boc-D-Phe-Pro-Arg-H, produced concentration-dependent antifibrinolytic effects in
the fibrin plate assay and the TEG. However, according to these published studies, while
these thrombin inhibitors produce clear inhibitory effects on TEG measured fibrinolysis,
they also decrease the elasticity of the clots formed, which is suggested to be a profibrinolytic effect. The results of these studies reinforce the importance of the specificity
of antithrombin agents for thrombin.
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F. Global Anticoagulant Effects of Thrombin Inhibitors:
PT, APTT, ACT and TEG
The information provided by the antiprotease and protease generation assays is
valuable in understanding the mechanism of action of each agent in more global settings,
such as in plasma and whole blood clotting processes.

The PT and APTT are the

plasmatic clot-based assays that are the equivalents of the extrinsic and intrinsic
fibrinogen deficient plasma amidolytic-based assays respectively.
In the PT assay, heparin has no anticoagulant effects in contrast to its effects in
the extrinsic generation system.

The differences in the plasma dilutions and the

concentrations of the activator (thromboplastin) in the two systems may be responsible
for this difference in heparin's action. With the exception of heparin and hirudin, the
order of potency of the anticoagulant effects of the other antithrombin agents was the
same as in the extrinsic thrombin generation system and similar to their Ki value rank
order: hirudin > Ac-(D )Phe-Pro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H >
D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H.

The observations on the effects of

argatroban reinforce the concept that the effects of an agent on the clotting activity of
thrombin correlate better with its Ki value than its effects on the amidolytic activity of
thrombin.
In the APTT assay, the order of potency of the antithrombin agents was found to
be heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin> argatroban> Boc-D-Phe-Pro-ArgH > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H. This rank order does not correspond to
the one obtained from the intrinsic thrombin generation system, or to any other obtained
from the rest of the assays. This is the only test where Ac-(D)Phe-Pro-boroArg-OH was
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found to be a more potent anticoagulant than hirudin. However, heparin was the most
effective anticoagulant overall in this assay, as it was in the Heptest and the intrinsic and
extrinsic generation of factor Xa in the fibrinogen deficient plasma-based assays. This
is probably reflective of the importance of generation of factor Xa in the coagulation
pathway after intrinsic activation, which is the rate limiting step in the generation of
thrombin.
Species differences between human and rabbit plasma affect the anticoagulant
activities of thrombin inhibitors, as seen when studying the effects of heparin, hirudin,
Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H in the rabbit plasma-based PT
assay. In this assay, while hirudin was a stronger anticoagulant than D-MePhe-Pro-ArgH and heparin exhibited no anticoagulant effects, Ac-(D)Phe-Pro-boroArg-OH also
exhibited no anticoagulant effects, in contrast to its activities in the human plasma-based
PT. However, when examining the anticoagulant effects of the same inhibitors in the
rabbit plasma-based APTT, the rank order of anticoagulant potencies of these agents was
the same as in the human plasma-based APTT.
The ACT and TEG assays provide tools for studying the anticoagulant effects of
thrombin inhibitors in whole blood, so that clot formation is the composite result of the
intrinsic activation of the coagulation cascade and its interactions with other blood
components. When heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH, D-MePhe-Pro-Arg-H
and argatroban were compared in these assays, both of these tests provided comparable
results. In both systems, hirudin, heparin and Ac-(D)Phe-Pro-boroArg-OH appeared to
be stronger anticoagulants than D-MePhe-Pro-Arg-H and argatroban. However,.the TEG
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assay appeared to be more sensitive to the anticoagulant effects of these agents, in that
their differences in the extent of anticoagulation were more pronounced. Similar results
were obtained when heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-ProArg-H were compared in rabbit whole blood, where again the TEG assay appeared to be
more sensitive to the anticoagulant effects of these agents than the ACT assay.

G. Specific Measurements of Antithrombin Actions: TT and ECT
The plasma-based amidolytic antithrombin assay gives useful information on the
relative antithrombin activities of various agents. However, as seen from the previous
studies, the results of the amidolytic assays are not always correlated with the Ki values
of thrombin inhibitors and the anticoagulant effects of these compounds depends on the
assay end-point, amidolysis versus clotting.

The clot-based equivalent test of this

antithrombin assay is the TT, where a specific amount of thrombin is added to plasma
to stimulate clot production. The relative activities of various agents in this clotting
assay revealed that they all exhibited concentration-dependent anticoagulation with a rank
order of potency of hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-ProArg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban. This rank order is
quite different from that obtained in the amidolytic plasma-based antithrombin assay,
where heparin was found to be the strongest antithrombin agent. Interestingly, the TT
derived order of potency of thrombin inhibitors was exactly the same as that obtained
from the thrombin titration assays where the ATU potency for each agent was
determined. Similarly, the TT derived rank potency order paralleled that obtained from
the extrinsic generation of thrombin in the fibrinogen deficient plasma-based system.
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Another interesting observation in the TT assay was that this was the only clot-based
assay in which argatroban was the weakest anticoagulant, similar to its inhibitory
amidolytic actions in the previous studies.
The ECT assay is a newly developed assay that utilizes the snake venom derived
enzyme ecarin to activate prothrombin in the plasma to procoagulant thrombin
intermediates, rather than adding exogenous thrombin as in the TT assay. This assay
was developed as a plasma clotting test that is specific for direct thrombin inhibitors.
Since heparin inhibits thrombin only through potentiation of the activities of antithrombin
and HC-11 and since the thrombin resulting from ecarin activation is not fully formed and
the antithrombin recognition sites are not exposed, heparin has no effects in this assay.
Hirudin and Ac-(D)Phe-Pro-boroArg-OH had the strongest anticoagulant effects in this
assay, as seen in all other tests. However, the effects of the other antithrombin agents
had the following rank order of potency: D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H >
argatroban> Boc-D-Phe-Pro-Arg-H, which did not correlate with the results of any of
the other assays apart from Boc-D-Phe-Pro-Arg-H being the weakest agent in some
assays.
Even though the ECT may not be an optimal assay to compare the anticoagulant
effects of antithrombin agents in relationship to their Ki values for thrombin, this test
may be of clinical usefulness in the monitoring of thrombin inhibitor levels in patients
receiving antithrombin drugs in conjunction with other anticoagulant agents, eg. in a
patient receiving hirudin while on oral anticoagulants or heparin. In a recent report
(Callas et al. 1996), it was shown that when plasma from patients on oral anticoagulants
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or heparin was supplemented with hirudin or other thrombin inhibitors, the ECT assay
was not affected, as compared with their effects after supplementation to normal human
plasma. Furthermore, two recent publications (Riibsamen et al. 1996, Radziwon et al.
1996) report on the effectiveness of the ECT test in patient bedside monitoring of PEGhirudin.

Both studies show that the ECT is not influenced by other anticoagulant

treatments such as aspirin, low molecular weight heparins and unfractionated heparin.
In addition, the ECT results correlated with the absolute PEG-hirudin concentration in
the plasma of the patients systemically administered with PEG-hirudin. However, the
results obtained with the APTT and the ACT assays did not produce a similar
correlation. The wide range of sensitivity of this assay is an added advantage (Radziwon
et al. 1996).
Most of the patients treated with antithrombin agents are simultaneously
administered with heparin or oral anticoagulant drugs. The conventional clotting tests
such as the PT, APTT and TT are not reliable measures of the specific effects of
antithrombin agents in these circumstances.

The results reported in this dissertation

suggest that ECT can be used for the absolute monitoring of the antithrombin agents in
the presence of other anticoagulants. Therefore, this test is of major value in the specific
monitoring of antithrombin drugs during PTCA, thrombolysis and stenting.

H. Comparative Antithrombotic Actions of Various Thrombin Inhibitors

The in vitro antithrombin and anticoagulant actions of various agents did not
correlate with their in vivo antithrombotic effects. To examine the relative antithrombotic
effects of selected thrombin inhibitors, four of the agents studied in the in vitro assays
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were compared in the modified rabbit model of jugular vein stasis thrombosis. rTF was
used as a thrombogenic challenge to determine the relative antithrombotic effects of
various thrombin inhibitors. Unlike the previously reported studies, this thrombogenic
trigger provided a more defined activation approach. This is also more relevant to the
interventional cardiovascular procedures where TF is generated. The agents selected
were heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. Heparin
was studied because it has been the traditional antithrombotic agent used clinically, in
addition to being the target for replacement by some of the newer antithrombin agents.
Since hirudin is currently in many clinical trials for various indications and is the
strongest and specific thrombin inhibitor, it was also used in these comparative studies.
Based on the broad anti-serine protease profile of Ac-(D)Phe-Pro-boroArg-OH, this agent
was suitable for examining the relative contribution of thrombin inhibition in relation to
inhibition of other clotting factors and serine proteases in antithrombotic efficacy. DMePhe-Pro-Arg-H was compared with the previous antithrombin agents since its
inhibitory spectrum is narrower than Ac-(D)Phe-Pro-boroArg-OH but not as specific as
hirudin. During the course of these experiments, several ex vivo whole blood and plasma
analyses were made, in an attempt to determine which test would be optimal and
correlate best with the observed antithrombotic effects of each agent.

1. Standardization of rTF as a Thrombogenic Trigger in the
Rabbit Stasis Thrombosis Model
The Wessler stasis thrombosis model (Wessler et al. 1959) is a rabbit model of
venous thrombosis and has been widely used in the evaluation of antithrombotic activity
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of various substances.

Although this model has provided useful information on the

antithrombotic activities of various anticoagulant agents, the results obtained are relative
to the type of thrombogenic trigger used to produce the thrombotic processes (Fareed et
al. 1985). Defined thrombogenic agents to activate the hemostatic system of rabbits have

been previously utilized in a standardized manner where the site of activation is
controlled (Fareed et al. 1985).

In previous studies, specific components of the

hemostatic system were selectively activated with various agents such as Prothrombin
Complex Concentrate (PCC) and Russell's Viper Venom (RVV) (Fareed et al. 1985).
The availability of TF in a recombinant form (Bach et al. 1986) allows for an in-depth
investigation of the activation of hemostasis and its pathophysiological mechanisms.
TF is a 37,000 MW protein that is required for the activation of factor VII
(Nemerson 1988). This TF/VIIa complex is then capable of converting factor X to Xa
directly or via activation of factor IX to IXa (Osterud and Rapaport 1977). Activated
factor Xa can then form a complex with factor V and this complex catalyzes the
conversion of prothrombin to active thrombin, which then in turn converts fibrinogen to
fibrin. The concentration of factor V in plasma is lower than that of factor X (Nesheim
et al. 1981, Miletich et al. 1981) and without TF available, as under normal conditions,
only the VIIIa/IXa complex can catalyze the activation of factor X (Moshier 1990).
Thus, as in the PT assay, the supplementation of large exogenous TF, after complexation
with factor VII, causes a direct activation of factor X that is then able to saturate all of
the available factor V. The generated factor Xa can then further catalyze the activation
of factor VII, thus resulting in an amplified response of the extrinsic pathway of
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coagulation, leading to generation of massive amounts of thrombin with the end result
of formation of thrombi. The effectiveness of TF in initiating this amplified cascade is
evident in the clotting results of the modified stasis thrombosis model as demonstrated
in these studies, where rTF was capable of producing clots in this model at doses as low
as 0.04 pmol/kg.
From the ex vivo analysis of the blood samples collected before and after
administration of rTF in this rabbit model, a decrease in the clotting times of the global
clotting tests would have been expected after the rTF administration. However, in the
ex vivo studies performed in the rTF treated animals, no shortening of any of the plasma
clotting assays (PT, APTT, TT and Heptest) was observed. This may be due to assay
limitations, since these tests have been designed to detect anticoagulant effects in plasma
samples and they may not be sensitive to procoagulant states.

Another possible

explanation is that rTF may bind to the cellular components of blood and vasculature,
so that in preparing and testing the plasma fraction all rTF is removed. Furthermore,
it is also conceivable that the administered rTF may have been neutralized by TFPI at
the endothelial or plasmatic sites.

The possibility that rTF may not exert any

procoagulant effects in plasma systems has been excluded, since in a previous publication
of these studies (Callas et al. 1995), the in vitro effects of rTF on plasma were studied
in the PT assay in place of thromboplastin and it was observed that r-TF produced
concentration-dependent shortening of the PT test.
The ex vivo ACT and TEG methods of monitoring the degree of whole blood
coagulation in these experiments revealed unexpected results at the higher doses of rTF
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(0.68 and 1.35 pmol/kg), where a significant prolongation of these tests was observed,
in contrast to what was indicated from the clot scores obtained from the same animals.
While the ex vivo analyses of plasma samples obtained after rTF administration in rabbits
revealed no procoagulant effects in comparison to the baseline plasma samples, none of
the plasma samples were found to be in an anticoagulant state either.

This was in

contrast to the ex vivo whole blood TEG and ACT results. Thus, prolongation of the
whole blood clotting parameters is not due to hypofibrinogenemia or coagulation factor
depletion effect due to excessive amounts of circulating TF since decrease in fibrinogen
would result in prolongation of the plasma clotting assay results as well.
There are several possible explanations for this apparent ex vivo anticoagulant
activity of rTF at the higher doses. The biological actions of TF, outside from its role
in the coagulation cascade have been poorly characterized and it may well be that TF
interacts with other cells, maybe endothelial cells or platelets, and through signal
transduction mechanisms TF may promote fibrin formation and deposition so that even
though in the end there is clot formation, it is not due to extrinsic pathway activation of
blood coagulation alone and activation of coagulation may not be the only rTF mediated
effect.
Another explanation for this ACT and TEG prolongation may be related to tissue
factor pathway inhibitor (TFPI) which is present in plasma in different molecular forms
which are primarily determined by its association with circulating lipoproteins. TFPI is
a Kunitz-type protease inhibitor (Wun et al. 1988, Girard et al. 1989). One domain of
this protease binds to the factor VII/TF complex while the other binds to factorXa, thus

290
blocking both the extrinsic pathway leading to thrombin formation and the amplification
of the same pathway by factor Xa (Broze 1989, Broze et al. 1988). TFPI is present in
the plasma at ng/ml concentrations (Gramzinski et al. 1989) and thus it may inactivate
all the factor VII/TF complexes more so when TF is available at higher concentrations,
thus leaving only the factor IXa/factor VIII complex available for initiation of coagulation
procedures.

The vascular endothelium secretes TFPI in culture (Broze and Miletich

1987, Warr et al. 1989) but the mechanisms that lead to release or increase in plasma
TFPI are not well defined and neither is their mode of action. Also, there is evidence
that intravenous heparin may cause the release of TFPI bound to the luminal surface of
the vascular endothelium (Sandset et al. 1988). It may be that rTF at higher doses
displaces TFPI bound to the endothelium. Normal plasma levels of TFPI are unable to
protect rabbits against DIC and glomerular thrombosis after 4 hours infusion of rabbit
brain TF (Warr et al. 1990). Rapaport reported that the ability of TFPI to protect
against lower concentrations of TF in the rabbits is under study (Rapaport 1991).
However, no defined studies on the thrombogenic effects of rTF have been reported,
where any simultaneous measurements of TFPI have been obtained.
In addition to cofactors, ca++ and the coagulation factors, the following steps in

the coagulation cascade require a phospholipid surface: activation of factors IX and X by
factor VIIa in the presence of TF, factor X activation by factor IXa in the presence of
factor VIIIa, and thrombin formation (from prothrombin) by factor Xa in the presence
of factor Va. In each reaction both the factor acting as the activator (protease) as well
as the inactive zymogen form of the factor to be activated bind to the phospholipid
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matrix. The cofactors have specific domains for binding to proteases, zymogens, ca++
and phospholipids (Moshier 1990). This phospholipid matrix is normally supplied by the
platelets. However, in these studies the rTF used is already packaged in phospholipid
vesicles. It is thus possible that the large doses of rTF provide a phospholipid surface
which can sufficiently bind cofactors and the other components of the previously listed
steps in a manner that they are less likely to produce procoagulant effects which are
measurable by TEG and ACT methods. On the other hand, in the tests performed on
plasma samples, a procoagulant effect as measured by the shortening of the clotting time
may not be detectable due to assay limitations. In order to fully assess the effects of
rTF, measurements of markers of protease activation such as the F1 +2 fragment,
fibrinopeptide A and thrombin-antithrombin complex may have been useful. However,
these tests are only available for the human markers and it was not possible to perform
these tests in the rabbit stasis thrombosis model.
Thus, the in vivo hypercoagulable state (formation of thrombi) as observed with
the modified stasis model, cannot be correlated with either the ex vivo whole blood
clotting tests (ACT and TEG) or the ex vivo plasma clotting tests (PT, APTT, Heptest,
TT). Furthermore, while the two whole blood clotting tests correlate well with each
other, they do not correlate with the plasma clotting tests.
As reported in the previous publication of this study (Callas et al. 1995), when
the surface of clots generated in this animal model were examined under electron
microscopy, the clots generated were found to be dense fibrin-rich clots with few other
cellular components entrapped. When these clots were compared to the clots obtained
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from the FEIBA® treated rabbits, the morphologic characteristics of these clots differed,
with the rTF clots appearing denser and of finer fibrin structure. Therefore, activation
of the coagulation pathway at different levels influences the quality of the generated clot.
This may be of clinical relevance and may aid in understanding qualitative differences
in various thrombotic states.
The current model used for the study of the thrombogenic effects of rTF
represents a defined pathophysiologic model in which the cumulative clot formation is
dependent on both the rTF and vascular stasis. Although in the whole blood system the
suggested evidence on the release of TFPI or a TFPI-like substance is observed, the
created thrombogenic event in the isolated jugular segment is strong enough to overpower
the anticoagulant effects observed in the whole blood clotting assays.

2. Comparative Antithrombotic Actions of Thrombin Inhibitors
From the studies of the dose-dependent thrombogenic effects of rTF in the rabbit
model of jugular vein stasis thrombosis, a dose of 0.68 pmol/kg was selected for the
subsequent studies in which the antithrombotic effects of various agents were compared.
This dose was selected because it consistently resulted in clot scores of at least

+ 3, both

after 10 and 20 min stasis. The following thrombin inhibitors were compared in this
model: heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H.

a.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After I. V.
Administration
All agents produced dose-dependent anti thrombotic effects after I. V. injection.

The clots obtained after 10 min stasis revealed that the order of anti thrombotic potency
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of these agents was hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-ProArg-H. However, the shape of the dose-response curve for each agent was different and
while heparin and Ac-(D)Phe-Pro-boroArg-OH produced sigmoid responses, hirudin and
D-MePhe-Pro-Arg-H resulted in more linear responses indicating a decreased efficacy
in comparison to heparin and Ac-(D)Phe-Pro-boroArg-OH. When examining the results
from the 20 min stasis, again all antithrombin agents produced dose-dependent
antithrombotic effects. The order of potency of these agents was different from the 10
min results in that the dose-response curves obtained with hirudin and heparin were
almost superimposable, indicating that heparin retains its antithrombotic effects relatively
longer than hirudin. The dose-response relationships by all thrombin inhibitors were
linear, indicating decreased efficacy in comparison to their 10 min stasis effects. This
decreased efficacy may be due to the clots becoming more stable with time via the crosslinking activities of factor XIIIa.
The comparative antithrombotic effects of heparin, hirudin, hirulog and argatroban
in a rat model of jugular vein thrombosis have been recently published (Hayes et al.
1996). In this report, consistent with the earlier described results, on a molar basis
hirudin was found to be a stronger antithrombotic agent than heparin after I.V. injection.
The ex vivo analyses of blood samples obtained before and after the administration
of each of the antithrombins, revealed that the relative effects of each agent were assaydependent. In the amidolytic antithrombin assay, all agents produced dose-dependent
thrombin inhibition and their order of potency in this assay correlated with their relative
antithrombotic responses.

However, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-
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Arg-H produced 30 and 503 thrombin inhibition at the lowest doses injected, even
though their corresponding antithrombotic effects were minimal. In the anti-Xa assay
heparin and Ac-(D)Phe-Pro-boroArg-OH produced dose-dependent effects, but these
never exceeded 40 and 303 inhibition respectively. These anti-Xa effects produced by
heparin and Ac-(D)Phe-Pro-boroArg-OH are not surprising since both agents produced
concentration-dependent anti-Xa effects in the in vitro studies, which were also weaker
than their amidolytic antithrombin effects. Their relative ex vivo anti-Xa activities also
corresponded with their relative in vitro anti-Xa effects. Minimal anti-Xa effects were
also produced by hirudin and D-MePhe-Pro-Arg-H and these were probably indirect and
due to inhibition of thrombin and subsequent suppression of feedback amplifications.
The ex vivo whole blood analyses of the samples obtained prior and post thrombin
inhibitor administration revealed that all agents resulted in dose-dependent prolongation
of both assays, which correlated with each other although they did not correlate with the
relative antithrombotic effects of these agents. With the exception of hirudin which was
weaker than heparin, the other agents retained the rank order of potency in the whole
blood clotting assays.

While both the ACT and the TEG were sensitive to the

anticoagulant effects of heparin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H,
neither assay was sensitive to the effects of hirudin: at the highest doses that each agent
was administered, hirudin produced the weakest ex vivo ACT and TEG prolongation,
even though the antithrombotic effects produced by each agent were similar.

The

anticoagulant responses of heparin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-ArgH at the higher concentrations were similar only in the ACT, correlating to the similarity
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of their antithrombotic effects at these doses. Furthermore, the inter-animal variations
were less pronounced in the ACT than in the TEG, as measured by the S.E.M.
The ex vivo anticoagulant effects of antithrombin agents as measured in the plasma
clotting assays revealed that these effects were assay-dependent. None of the thrombin
inhibitors produced any effects in the PT, while the dose-dependent effects produced in
the APTT were minimal. On the other hand, the Heptest and the TT revealed clear
dose-dependent anticoagulant effects of all thrombin inhibitors after I.V. injection. The
rank order of potency of these effects in the Heptest was heparin> hirudin > Ac-(D)PhePro-boroArg-OH > D-MePhe-Pro-Arg-H, which was similar to the whole blood assay
results but different from the antithrombotic effects. The TT appeared to be the most
sensitive test in detecting the anticoagulant effects of all thrombin inhibitors, as
determined by the fold increase from baseline values. At the highest doses used, none
of the thrombin inhibitors resulted in more than a 5-fold increase in the Heptest, while
in the TT, hirudin and D-MePhe-Pro-Arg-H exceeded 10-fold increase from baseline
values. Furthermore, the rank order of potency of these agents in the TT followed that
observed in the antithrombotic effects: hirudin> heparin> Ac-(D)Phe-Pro-boroArgOH> D-MePhe-Pro-Arg-H.

However, the extent of the TT anticoagulant effects

achieved with the highest dose of each thrombin inhibitor was different and did not
correspond to the extent of their antithrombotic actions.

b.

Dose-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration
The relative antithrombotic actions of antithrombin agents are dependent on the
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route of administration, as seen in the rabbit stasis thrombosis studies where all agents
were injected subcutaneously. While all agents produced dose-dependent antithrombotic
effects and the rank order of antithrombotic actions was similar to those obtained after
I. V. administration of these agents in the same model, the dose-response curve of heparin
was close to that of Ac-(D)Phe-Pro-boroArg-OH in the S.C. studies after 10 min stasis
and was the same after 20 min stasis. This was different from the response observed in
the I. V. studies, where the effects of heparin were closer to those of hirudin. A possible
explanation for this relative decrease in the activities of heparin is that this agent, being
a multi-component drug of varying molecular weights, does not cross the subcutaneous
barrier entirely, so that the higher molecular weight components do not reach the
circulation. Based on the molecular weight of hirudin (6963 DA), this compound is
expected to have weaker antithrombotic effects after S.C. administration, as opposed to
I. V. administration, relative to Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H.
Taking into consideration the ratio of the ED 50 values for each agent in the I.V. and S.C.
studies, while there was a 5-fold decrease in the absolute value for Ac-(D)Phe-ProboroArg-OH and D-MePhe-Pro-Arg-H, for hirudin this decrease was 12-fold and for
heparin it was 23-fold, which supports the view regarding the S.C. barrier influence on
the transport of heparin and hirudin. Another difference in the two studies (I. V. versus
S.C. administration) was that the dose-response relationship for all thrombin inhibitors
was linear after both 10 and 20 min stasis. As seen in the I. V. studies, after 20 min
stasis, all agents decreased in efficacy (the slope of the dose-response curves decreased)
in comparison to their 10 min stasis effects.
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The ex vivo amidolytic antithrombin effects of the same agents after S.C.
administration were dose-dependent. However, the extent of antithrombin activity did
not correlate with the extent of antithrombotic effects, as seen when comparing these
agents at the highest doses administered. With the exception of heparin which produced
weak dose-dependent anti-Xa effects, none of the other three agents had any apparent
dose-dependent effects on the amidolytic anti-Xa assay. The effects of heparin can be
explained by the ability of antithrombin, through which heparin mediates its anticoagulant
effects, to inhibit factor Xa in addition to thrombin. The whole blood clotting analyses
of blood samples obtained before and after thrombin inhibitor S.C. injection revealed that
all agents produced dose-dependent anticoagulant effects.

The potency order of the

anticoagulant effects of these agents was similar to their antithrombotic order of potency.
The TEG assay appeared to be more sensitive to the anticoagulant effects of these agents
than the ACT, where hirudin and heparin produced about 25 3 and 35 3 of the
anticoagulant effects of Ac-(D)Phe-Pro-boroArg-OH at the highest doses where their
antithrombotic effects where equivalent.
The anticoagulant effects of antithrombin agents after S.C. administration, as
detected in the plasma-based clotting assays revealed that, as with the I.V. studies, the
effects were test-dependent. As seen in the I.V. studies, none of these agents produced
any effects in the PT assay.

The effects on the APTT, Heptest and TT were dose-

dependent. Hirudin exhibited the strongest effects, correlating with the antithrombotic
effects produced by this agent. However, the TT was the most sensitive assay to the
effects of hirudin at the highest injected dose in comparison with the other agents.
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c.

Time-Dependance of Anti thrombotic Effects of Thrombin Inhibitors After I. V.
Administration
The studies on the time-dependance of the antithrombotic effects of heparin,

hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H after I.V. administration
showed that the effects of all agents decreased with time, both after 10 and 20 min stasis.
Ac-(D)Phe-Pro-boroArg-OH and heparin lost their antithrombotic activities at a faster
rate than hirudin and D-MePhe-Pro-Arg-H, as determined by the slopes of their timedependent responses. The ex vivo antithrombin analyses of the plasma samples obtained
before and after the injection of each antithrombin agent, showed that with exception of
heparin which had minimal antithrombin activities, the antithrombin effects of the other
agents where time-dependent.

While the effects of Ac-(D)Phe-Pro-boroArg-OH

decreased steadily with time, the effects of D-MePhe-Pro-Arg-H where maximal at 30
min and those of hirudin where maximal around 45 min. The antithrombotic effects of
D-MePhe-Pro-Arg-H were steadily maximal for the first 30 min after administration
(correlating with the antithrombin effects) but the antithrombotic effects of hirudin
steadily declined after I. V. injection. This dichotomy in the antithrombotic/ antithrombin
effects of hirudin may be due to compartmentalization of hirudin and subsequent slow
release of this agent so that the ex vivo antithrombin effects are sustained, even though
the antithrombotic effects are diminished. As seen in the previous studies, none of the
agents had any substantial effects on the anti-Xa assay.

In contrast to the plasma

amidolytic antithrombin and anti-Xa assays, the whole blood clotting tests, ACT and
TEG, showed that all agents produced time-dependent anticoagulant effects that paralleled
their antithrombotic effects, with heparin and Ac-(D)Phe-Pro-boroArg-OH exhibiting the
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fastest rates of decrease of their anticoagulant activities, similar to their antithrombotic
activities.
As observed in the previous studies, none of the antithrombin agents had any
effects on the PT assay after I. V. administration during the observation period.

In

contrast, the other plasma-based clotting assays revealed a time-dependent decrease of
the anticoagulant activities of all thrombin inhibitors, with one notable exception: DMePhe-Pro-Arg-H produced a time-dependent increase in the Heptest assay until 30 min
post I. V. injection, after which these effects started to rapidly decrease. This particular
effect of D-MePhe-Pro-Arg-H is similar to that seen in the antithrombin amidolytic assay
and is consistent with the antithrombotic effects of this agent, which are maximally
sustained for the first 30 min post I. V. administration. Overall, as seen in the previous
studies, the TT was the most sensitive assay to the anticoagulant effects produced by
thrombin inhibitors.

d.

Time-Dependent Antithrombotic Effects of Thrombin Inhibitors After S.C.
Administration
The studies on the time dependance of the anti thrombotic effects of various agents

after S.C. administration revealed the differences in the ability of each agent to cross
through the S. C. barrier. When examining the comparative antithrombotic effects of
heparin, hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H in the rabbit
stasis thrombosis model after 10 min stasis, it was observed that the agents that exhibited
the maximal antithrombotic effects at the shortest interval after S.C. injection were
hirudin, Ac-(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H, in that order. . The two

300
tripeptide derivatives have similar low molecular weights (496.8 and 514.6 DA
respectively), which probably allows them to cross rapidly through to the circulation.
While the effects of Ac-(D)Phe-Pro-boroArg-OH steadily and slowly declined with time
after 15 min, the effects of D-MePhe-Pro-Arg-H remained maximal up to 45 min after
S.C. administration before declining, indicating perhaps a difference in the clearance
rates of the two agents. Similar to the effects of D-MePhe-Pro-Arg-H, hirudin also
exhibited steady maximal antithrombotic effects for 45 min after S.C. injection, before
these effects started to subside.

The molecular weight difference between the two

tripeptides and hirudin is 14-fold, but this does not compromise the ability of hirudin to
cross the S.C. barrier. In contrast to the time-dependent effects of these agents, heparin
exhibited a steady increase in its antithrombotic effects after S.C. administration up to
the last time point examined at 90 min post injection. This is to be expected considering
the multi-component nature of this drug and expecting the smaller antithrombotic
components to cross the S.C. barrier earlier than the heavier counterparts.
The time-dependent effects of these agents are also dependent on the duration of
stasis, so that at the 20 min stasis end point, the time-dependent antithrombotic profile
of each agent changed. While the effects of D-MePhe-Pro-Arg-H were maximal 15 min
post S.C. administration, these effects steadily declined, rather than remaining constant
for 45 min as observed in the 10 min stasis. On the other hand, the effects of Ac(D)Phe-Pro-boroArg-OH and hirudin remained constant over the 90 min period following
post S.C. injection, in contrast to their 10 min stasis effects which slowly declined after
15 min. The effects of hirudin after 20 min stasis were steady over the 90 min period
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studied as well and this was again in contrast to the effects of this agent after 10 min
stasis, where a decline was observed after 45 min post S.C. administration. However,
the sustained effects of both Ac-(D)Phe-Pro-boroArg-OH and hirudin after 20 min stasis
were decreased when compared to the maximal effects at the 10 min stasis end point,
indicating that these agents had decreased antithrombotic effects against cross-linked
fibrin. Heparin exhibited a gradual and continual increase in its antithrombotic effects
over the 90 min observation period, following S.C. injection and 10 min stasis. This
was also in contrast to its effects after 20 min stasis, where heparin increased its
antithrombotic effects until 45 min post S.C. administration, after which these
antithrombotic activities gradually decreased. This may also be indicative of the limited
antithrombotic potential of heparin on cross-linked fibrin.
The time-dependent ex vivo amidolytic antithrombin effects of heparin after S.C.
injection, revealed a correlation with its antithrombotic effects, as did the amidolytic antiXa test and the whole blood clotting tests (ACT and TEG). As seen previously, none
of the other thrombin inhibitors had any effects on the anti-Xa amidolytic assay. The
antithrombin, ACT and TEG effects of hirudin correlated with its antithrombotic effects
after 10 min stasis, with the ACT being the most sensitive assay. Ac-(D)Phe-ProboroArg-OH produced sustained maximal antithrombin and TEG effects, correlating with
its 20 min stasis antithrombotic effects, while in the ACT results correlated more with
its 10 min stasis antithrombotic effects (a steady increase with time over the 90 min
period). D-MePhe-Pro-Arg-H also exhibited sustained maximal antithrombin and TEG
effects, throughout the 90 min observation time after S.C. administration. However, in
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the ACT, a time-dependent decline in this agent's anticoagulant activity was observed,
correlating well with its effects after 20 min stasis. The assay that was most sensitive
to all of the agents' effects without reaching the upper limit was the ACT, while the
amidolytic antithrombin and TEG results often approached the upper limits of the assays,
with the exception of hirudin.
When examining the time-dependent ex vivo anticoagulant effects of these agents,
as studied in the plasma-based clotting assays, once again, it was observed that none of
these agents had any effects on the PT. The results of heparin on the APTT, Heptest and
TT correlated well with its antithrombotic effects after 20 min stasis. Hirudin produced
minimal effects on the APTT and the Heptest, while its effects on the TT increased with
time throughout the 90 min observation period post S.C. injection. The effects of Ac(D)Phe-Pro-boroArg-OH on the APTT were always maximal, while the time-dependent
anticoagulant effects in the Heptest and the TT paralleled the antithrombotic effects of
this agent. D-MePhe-Pro-Arg-H produced sustained maximal effects in the APTT and
the Heptest, while its effects in the TT correlated with its antithrombotic effects. Thus,
the TT appeared to be the most sensitive plasma clotting assay for these agents, without
exceeding the upper limits at the doses producing maximal antithrombotic effects.
Another observation was that at 75 min post S.C. administration at 10 min stasis and 35
min post S.C. injection at 20 min stasis, all agents produced similar antithrombotic
results. However, of all ex vivo analyses, only the TT assay results converged around
the 75 time point.
To date, a comparison of the duration of action of the four agents investigated
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after S.C. administration in any animal models is not available. The duration of in vivo
antithrombotic actions may therefore have relevance to the prophylactic use of these
agents.

I. Comparative Hemorrhagic Profile of Thrombin Inhibitors

The rabbit ear bleeding model used in these studies was introduced by Cade in
1959. This model has been extensively utilized to profile the hemorrhagic effects of
various drugs and is based on the ability of superficial minor vessels to occlude after
transection within minutes. The primary hemostatic plug is formed by platelets, which
is then reinforced by fibrin deposition resulting from activation of coagulation. The
clotting process is triggered by the exposure of blood to TF on the subendothelial sites
of the transected vessels, resulting in thrombin formation which mediates platelet
activation. Therefore, inhibitors of the coagulation cascade as well as platelet inhibitors
are expected to have dose-dependent hemorrhagic effects in this model, which manifest
by increased blood loss in a specified period of time. This model was used to compare
the relative hemorrhagic effects of heparin, hirudin Ac-(D)Phe-Pro-boroArg-OH and DMePhe-Pro-Arg-H, to allow for comparison of these effects with the antithrombotic
effects, discussed previously, in the same species. During the course of the rabbit ear
bleeding experiments blood samples were not obtained for concomitant ex vivo analysis
to minimize blood loss and to avoid hemodynamic alterations in this model.

1. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After I. V. Administration
When the dose-dependent hemorrhagic effects of thrombin inhibitors were
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examined in the rabbit ear blood loss model, heparin produced weak but steady
hemorrhagic effects at all doses studied, 5 min after I. V. administration.

The

hemorrhagic effects of heparin after 20 min of I. V. injection were diminished. These
weak bleeding effects of heparin may be attributed to the fact that heparin works through
potentiating the anticoagulant effects of circulating antithrombin and HC-II. Therefore,
the available amount of antithrombin and HC-II can be saturated by heparin and beyond
a dose of 0.1 mg/kg I.V. heparin no additional anticoagulant effects can be achieved.
Hirudin and D-MePhe-Pro-Arg-H produced dose-dependent hemorrhagic effects both
after 5 and 20 min post I. V. administration and similar to heparin their effects were
diminished after 20 min. Because of their mechanism of action, these direct thrombin
inhibitors do not achieve a ceiling effect as seen with heparin. While Ac-(D)Phe-ProboroArg-OH also produced dose-dependent hemorrhagic effects after 5 and 20 min post
I. V. injection, the effects of this agent after 20 min post I. V. administration were
potentiated, in contrast to the bleeding effects of the other agents. This enhancement of
the bleeding effects of Ac-(D)Phe-Pro-boroArg-OH with time may be due to vascular
binding and subsequent slow release of this agent, or more likely, to non-anticoagulant
effects of this agent and may involve vascular compromise.

The observation

substantiating the latter hypothesis is that at the 1 µmol/kg I. V. dose tested, 3 rabbits
presented with respiratory depression within the first 5 min after I. V. injection, became
cyanotic and expired within 30 min after the administration. Necroscopic examination
of vital organs did not reveal any unusual findings. These rabbits were substituted to
maintain the rabbit group size at 6 animals.
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2. Dose-Dependent Hemorrhagic Effects of Thrombin Inhibitors
After S.C. Administration

The hemorrhagic effects of thrombin inhibitors after S.C. injection were also
examined. Heparin was found to have significant bleeding effects only at the highest
dose administered (0.9 µmol/kg) and only after 45 min post S.C. administration. At 60
min post S.C. injection, this effect was diminished. These minimal bleeding effects after
S.C. administration are also likely to be due to inability of all heparin fractions to pass
the S.C. barrier. Hirudin produced dose-dependent hemorrhagic effects, 45 min post
S.C. injection, but similar to the effects of heparin, these effects were also diminished
60 min post S.C. administration. In contrast to the relatively weak bleeding effects of
hirudin and heparin, the dose-dependent effects of Ac-(D)Phe-Pro-boroArg-OH were
maximal 45 min post S.C. injection and although they decreased 60 min post S.C.
administration, these remained stronger than any effects produced by the other thrombin
inhibitors. This observation supports the previous hypothesis that the hemorrhagic effects
produced by Ac-(D)Phe-Pro-boroArg-OH may be due in part to additional non-thrombin
related activities of this agent. D-MePhe-Pro-Arg-H exhibited a bleeding profile similar
to that produced by hirudin, in that 45 min post S.C. injection it produced dosedependent effects which were diminished 60 min post S.C. administration. Since Ac(D)Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H are of similar molecular weights and
probably cross the S.C. barrier at similar rates, the limited effects of D-MePhe-Pro-ArgH after S.C. injection further support the possibility of Ac-(D)Phe-Pro-boroArg-OH

exhibiting hemorrhagic effects through non-thrombin mediated actions.
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3. Time-Hemorrhagic Effects of Thrombin Inhibitors After
I.V. and S.C. Administration

The time-dependent hemorrhagic effects of these thrombin inhibitors revealed a
progressive agent specific decrease in the hemorrhagic activities. However, after S.C.
administration, heparin, hirudin and Ac-(D)Phe-Pro-boroArg-OH produced increasing
hemorrhagic effects with time with a maximal effect at 45 min post administration, after
which these started to decline. In contrast to the S.C. hemorrhagic effects of heparin,
hirudin and Ac-(D)Phe-Pro-boroArg-OH, S.C. injection of D-MePhe-Pro-Arg-H resulted
in gradually decreasing bleeding effects from the first time point observed (15 min post
S.C. administration). This suggests that D-MePhe-Pro-Arg-H is capable of crossing the
S.C. barrier in less than 15 min post injection, further supporting the hypothesis that the
maximal hemorrhagic effects produced by Ac-(D)Phe-Pro-boroArg-OH 45 min post S.C.
administration are due to additional non-coagulation related effects of this agent.

J. Integration of Data on Antithrombotic and Hemorrhagic Effects
of Thrombin Inhibitors

In comparing the dose-dependent antithrombotic and hemorrhagic effects of
various thrombin inhibitors, it was found that even though overall hirudin was the
strongest antithrombotic agent in the stasis thrombosis model after both 1.V. and S.C.
administration, it also had the strongest bleeding effects in the rabbit ear blood loss
model, with the exception of the 60 min post S.C. injection results, where Ac-(D)PhePro-boroArg-OH was the strongest agent. On the other hand, heparin produced strong
antithrombotic effects, which were weaker than hirudin, after l.V. and S.C.
administration, while producing the weakest hemorrhagic effects of all agents after both
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I.V and S.C. administration.

The effects of Ac-(D)Phe-Pro-boroArg-OH were

consistently stronger than those produced by D-MePhe-Pro-Arg-H in both animal models
after both I.V. and S.C. injection.
The comparison of the antithrombotic and hemorrhagic effects of each thrombin
inhibitor can be best illustrated by comparing the ED 50 value of the effects that each
agent produced in the stasis model to the dose that resulted in bleeding of 2 · 1D9 RBC/L
in the rabbit ear blood loss model. When comparing the ED 50 values of each thrombin
inhibitor derived in the stasis model after I.V. administration and 10 min stasis, and the
doses the produced 2 · 109 RBC/L blood loss 5 min post I. V. injection, it was found that
D-MePhe-Pro-Arg-H had the lowest ratio of the two respective parameters, with the
bleeding dose being about 12-fold greater than the antithrombotic dose. Ac-(D)Phe-ProboroArg-OH closely followed with a 17-fold difference in its bleeding/antithrombotic
values. Hirudin, on the other hand, producing less hemorrhagic effects than D-MePhePro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH at high doses, had a 37-fold difference of
its respective hemorrhagic/antithrombotic indices.

Heparin, producing minimal

hemorrhagic effects at all doses had a ratio of > 56-fold of the respective indices. These
differences indicate that while hirudin is a more potent antithrombotic agent than heparin,
as assessed in the rabbit stasis thrombosis model, heparin has a wider safety margin.
This is most likely attributable to the fact that heparin mediates its actions through
potentiation of a limiting amount of antithrombin and HC-11 in plasma, which imposes
a ceiling on its maximal effects, whether antithrombotic or hemorrhagic.
The relative antithrombotic/hemorrhagic effects of antithrombin agents after I.V.
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administration depend on the time period studied. Thus, when the ED50 of each thrombin
inhibitor in the stasis thrombosis model after I. V. injection and 20 min stasis is compared
with the bleeding effects produced 20 min post I. V. administration, it was found that
because D-MePhe-Pro-Arg-H exhibited a decrease in its hemorrhagic effects the ratio to
the antithrombotic effects could be determined only as

> 3. The bleeding/antithrombotic

index for Ac-(D)Phe-Pro-boroArg-OH was found to decrease from 17 to 12, which may
be explained by increased non-thrombin related hemorrhagic effects of this agent with
time. When comparing the hemorrhagic/antithrombotic effects of hirudin at these time
points, the ratio decreased to 27, which could be attributed to sequestration of this drug
and subsequent slow release, resulting in high enough circulating concentrations to
produce an antiplatelet effect (through thrombin inhibition) but not sufficient for an
antithrombotic effect. The bleeding/antithrombotic ratio of heparin remained high at

> 50, suggesting that this drug has the widest safety/efficacy window.
The ratios of the hemorrhagic and antithrombotic effects of various thrombin
inhibitors after S.C. injection is not as clear, since in most cases these agents produced
minimal hemorrhagic effects. Thus, for Ac-(D)Phe-Pro-boroArg-OH, the ratio of the
ED 50 from the 45 min post S.C. administration and 10 min stasis dose-response compared
with the dose that results in 2 · 109 RBC/L bleeding was 7, and the ratio of the ED50 after
20 min stasis to the bleeding effects after 60 min post S.C. injection was 5. These ratios
for the safety/efficacy of Ac-(D)Phe-Pro-boroArg-OH are lower than the ratios observed
after I. V. administration. Hirudin had a safety /efficacy ratio of 22, when comparing the
ED 50 from the 45 min post S.C. injection and 10 min stasis antithrombotic dose-response
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compared with the dose that results in 2 · 109 RBC/L 45 min post S.C. administration,
which was also lower than the ratio produced after I.V. injection.

The lower

safety/efficacy ratios after S.C. administration as compared to those after I.V. injection,
for both inhibitors may be attributable mostly to decreased antithrombotic effects after
S.C. administration, as discussed earlier.
It is interesting to note that these experimental observations on the relative
bleeding/antithrombotic effects of antithrombin agents are consistent with the recently
available clinical data where increased risk of hemorrhage was found to be associated
with the use of antithrombin agents such as hirudin (Antman and TIMI 9A Investigators,
1994, GUSTO Ila Investigators, 1994, GUSTO Ilb Investigators, 1996).

In the

experimental studies, a dose-response for both the hemorrhagic and antithrombotic
actions was evident. Such relationships in the clinical trials have not been established.
These observations clearly suggest the need of individual dose-response investigation for
different antithrombin agents. To obtain valid results, these studies should be optimally
carried out in the same species.

K. Rat Laser-Induced Thrombosis Model
The comparative antithrombotic effects of thrombin inhibitors, as studied in the
rabbit stasis thrombosis model, provide information on the antithrombotic activities of
these agents in the venous system. Since the pathophysiology of thrombotic processes
in the arterial and the venous systems differ, these compounds were also compared in a
rat model of laser-induced arterial thrombosis as performed in the mesenteric arterioles.
This model is standardized so that exposure of an arteriole to 2-3 sequential laser shots
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results in thrombus formation that is either occluding or is of a length 1.5 x vessel
diameter. The thrombi formed with this procedure are platelet-rich clots that do not
stabilize unless continued laser exposure occurs.
towards the vessel wall.

The laser exposures are directed

The laser injury is thermal in nature and after histologic

examination of these vessels, it appears that only endothelial cells are affected (Dr. Klaus
Breddin, personal communication). The injury is concentrated enough so that usually
only the surface membrane of the endothelial cells is detached.

However, in some

instances the whole cell appears to be "dehydrated". This indicates that exposure of TF
from sub-endothelial sites triggers local coagulation to generate enough thrombin to
activate platelets, or it may be that coagulation is triggered by contact activation through
exposed sub-endothelial matrices.
Heparin,

hirudin,

Ac-(D)Phe-Pro-boroArg-OH and

D-MePhe-Pro-Arg-H

exhibited dose-dependent antithrombotic effects in this animal model.

The order of

antithrombotic potencies was heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin> DMePhe-Pro-Arg-H. This order of potencies was different from those observed in the
rabbit stasis thrombosis model. While D-MePhe-Pro-Arg-H was consistently the weakest
antithrombotic agent in both the rabbit venous stasis model and the rat arterial thrombosis
model, hirudin was the strongest antithrombotic agent in the rabbit stasis thrombosis
model and in this rat model it ranked third. The fact that heparin was found to be the
strongest antithrombotic agent in the rat arterial thrombosis model, in contrast to its
effects in the rabbit venous thrombosis model suggest that heparin is more effective than
hirudin in inhibiting the formation of thrombus in this model. On the other hand, when
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coagulation is activated extrinsically with greater amounts of TF, as is the case with the
rabbit stasis thrombosis procedure, the endogenous levels of antithrombin may not be
sufficient or as effective as hirudin in inhibiting coagulation. Since Ac-(D)Phe-ProboroArg-OH was also found to be a stronger antithrombotic agent than hirudin in the rat
model, and both heparin and Ac-(D)Phe-Pro-boroArg-OH exhibit both antithrombin and
anti-Xa effects, it may be that inhibition of coagulation at multiple sites is more effective
in preventing platelet activation due to generation of thrombin.
While D-MePhe-Pro-Arg-H dose-dependently prevented clot formation in the rat
model in a dose-dependent fashion, a ceiling effect was reached at about a dose of 2
µmol/kg. This ceiling effect was of about 6 laser shots, which is lower than that of 8

laser shots observed with heparin and hirudin. Furthermore, at D-MePhe-Pro-Arg-H
doses higher than 3.4 µmol/kg, the antithrombotic effects of this agent progressively
decreased. It was visually observed that the blood flow markedly decreased at these
higher doses, so that the thrombus formation could be an indirect effect of altered
hemodynamics. Similar decreases in blood flow were observed with Ac-(D)Phe-ProboroArg-OH at doses above 0.2 µmol/kg, I.V. These effects by both D-MePhe-Pro-ArgH and Ac-(D)Phe-Pro-boroArg-OH on the rat blood flow are indicative of the nonthrombin related effects that these agents may produce. Another interesting finding is
that the ceiling effect of Ac-(D)Phe-Pro-boroArg-OH was about 10 laser shots which is
higher than that produced by heparin and hirudin. Since Ac-(D)Phe-Pro-boroArg-OH
is a direct thrombin and factor Xa inhibitor and is not limited by endogenous amounts
of antithrombin as is heparin, the higher ceiling effect for this agent is not surprising.
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Although the differences in the potency orders in the rabbit venous stasis
thrombosis model and the rat laser-induced arterial thrombosis model are most likely due
to the differences in the pathophysiologic processes, the possibility of species dependance
cannot be excluded.
When the bleeding results of the 1.V. administered heparin and antithrombin
agents were compared with the observed antithrombotic actions in the rat laser model of
arterial thrombosis, there was no relevance that could be established.

Although the

vascular sites are the primary trigger for the laser model and vascular compromise could
also contribute to bleeding, the lack of any relationship between these two findings may
be due to the species differences.

L. Species Dependence of Antithrombotic and Anticoagulant Effects
of Thrombin Inhibitors
To compare the relative anticoagulant actions of newer agents, whole blood and
plasma-based assays have been performed in rat, rabbit, dog, monkey and human blood
and plasma (Schlam et al. 1975). In this dissertation, the in vitro studies are primarily
carried out in the human and rabbit plasma and whole blood. In comparing the baseline
coagulation profile of whole blood and plasma, it was evident that rabbit plasma and
whole blood clotted faster in various assays.

This may be due to the compositional

variations in the coagulation pathways and number of blood cells. Interestingly, this
trend was not followed when individual antithrombin agents were tested in several assays.
In other words, each of the inhibitors exhibited a distinct assay-dependent profile in both
the human and rabbit studies.

These observations reinforce the notion that while
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antithrombin agents primarily target thrombin in mediating their anticoagulant effects in
plasma, these agents may exhibit complex interactions in different activation states and
therefore exhibit variable responses which are both species and activation dependent.
Species dependent antithrombotic actions also play an important role in the
determination of the antithrombotic potency of various antithrombin agents.

In this

investigation, a rabbit model of venous stasis thrombosis was employed to compare the
relative antithrombotic actions of these agents. To investigate the comparative effects of
these agents in arterial thrombosis, a laser model of rat arterial thrombosis was used.
Although the model-dependent variations are predictable, the ED50 for each of the
inhibitors were markedly higher in the rat laser model (5-10 fold) in contrast to the rabbit
stasis thrombosis model. This observation may be partly dependent on the species used.
In this research dissertation, the primary intent was to compare the relative potency of
various thrombin inhibitors with heparin. In a consistent fashion such comparisons where
carried out to determine the rank order of potency. The relevance of the ED 50s obtained
in different models to projected human responses may be questionable. Regardless, such
an exercise is of crucial value in the preclinical profile of a new antithrombin drug.
Beside the measurable anticoagulant actions of heparin and antithrombin agents,
species dependent variations in the pharmacokinetic and pharmacodynamics effects may
also contribute to the different responses noted during this research. Thus, it is clear that
both the in vitro and ex vivo profile of various agents are not only dependent on the
blood/plasma matrix but also on the endogenous transformations and interactions with the
cellular and vascular sites.
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M. Integration of in vitro Studies with Observed
Phannacologic Actions of Thrombin Inhibitors
The general order of potency of the antithrombotic effects of thrombin inhibitors
in the rabbit stasis thrombosis model was hirudin> heparin> Ac-(D)Phe-Pro-boroArgOH> D-MePhe-Pro-Arg-H. This order correlated well in a number of in vitro assays.
Specifically, the antithrombotic effects of hirudin, Ac-(D)Phe-Pro-boroArg-OH and DMePhe-Pro-Arg-H correlated with their published Ki values, the amidolytic thrombin
potency evaluation results and the fibrinogen-based clotting assay results.

The

antithrombotic effects of all four thrombin inhibitors in the rabbit model correlated with
their respective results in the extrinsic and intrinsic thrombin generation from fibrinogen
deficient plasma results, as well as with the in vitro PT and TT clotting assays.
The order of potency of the four antithrombin agents in the rat laser model
correlated with only one of the in vitro assay profiles of these agents, namely the APTT.
This observation supports the hypothesis that platelet activation and clot formation in this
model may not be due to intrinsic activation of coagulation.
The overall order of potency of the bleeding effects of antithrombin agents, as
observed in the rabbit model of ear blood loss, was hirudin> Ac-(D)Phe-Pro-boroArgOH> D-MePhe-Pro-Arg-H > heparin. The order of the three first agents followed the
same trend with the order of their Ki values, the results of the amidolytic thrombin
potency evaluation studies, the fibrinogen-based clotting results, the PT assay and the
ECT test. However, when the antithrombotic effects of heparin are also considered,
none of the in vitro assays correlate with the hemorrhagic results, indicating the necessity
of in vivo evaluation of the hemorrhagic effects of antithrombin agents.
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The above observations point to the usefulness of standardization of various
thrombin inhibitors. Caution should be taken to compare various agents in the same
system though, and with agents such as heparin which are not direct thrombin inhibitors,
standardization is not possible in the same manner as with the direct antithrombin agents.
Furthermore, it may be that some in vitro assays are not suitable for comparison of
agents with different mechanisms of thrombin inhibition, as is the case with argatroban
and its effects on the amidolytic assays.

For the same reason, while the amidolytic

protease generation assays provide useful information on the mechanisms of action of
thrombin inhibitors and their relative efficacies and potencies, argatroban cannot be
compared with the other agents in these systems in a manner that can be related to its
effects in clot-based assays or to its in vivo antithrombotic effects. Therefore, apart from
the Ki comparison of agents for thrombin, clot-based assays may be more applicable in
comparing these thrombin inhibitors.
While concomitant ex vivo analyses were not carried out in the rat arterial
thrombosis model due to animal weight and methodological limitations, the rabbit venous
thrombosis ex vivo analyses indicate that the whole blood clotting assays (ACT and TEG)
and the TT plasma clotting assay are the optimal tests for correlating antithrombotic with
anticoagulant effects, since in the other tests (with the exception of the PT), while all
agents produced dose-dependent anticoagulant effects, the relative extent of their ex vivo
effects did not correlate with the relative extent of their antithrombotic effects. Similar
observations have been recently reported (Carteaux et al. 1995). In this publication, the
comparative antithrombotic effects of hirudin, heparin and Ro 46-6240 (low molecular
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weight direct thrombin inhibitor) correlated with the ex vivo ACT effects but not with the
ex vivo APTT results. It should be noted that the relative extent of ex vivo anticoagulant

effects of hirudin in all tests utilized did not correlate to the relative extent of
antithrombotic effects when compared to the other agents, pointing to the need for
development of assays that correspond to antithrombotic effects and the importance of
comparing thrombin inhibitors in a battery of assays both in vitro and in vivo.
In terms of therapeutic monitoring of an individual thrombin inhibitor, the ECT
assay may be useful since the range of sensitivity of this test is wider than any other
assay.

Furthermore, this assay is not affected by the presence of indirect thrombin

inhibitors, which makes this test ideal for thrombin inhibitor monitoring in situations
where additional antithrombotic agents may have been used. However, the suitability of
this assay for comparison of various anticoagulants and extrapolation of these relative in
vitro effects to their relative in vivo antithrombotic effects is unclear at the time.

N. Significance of Studies in Understanding the
Pharmacology of Thrombin Inhibitors

The relative potency of the thrombin inhibitors included in this investigation is
usually expressed in terms of Ki or IC50 values which are carried out in defined in vitro
systems, in which thrombin titration is used. Whether or not the assigned inhibitory
constants translate into pharmacologic effects is not known. This investigation represents
the first comprehensive study to simultaneously compare the biochemical and
pharmacologic actions of heparin and antithrombin agents. An agent may show strong
antithrombin potency, however, due to its complex pharmacodynamics and other
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endogenous interactions, its behavior may not be predictable simply by assigning to it an
antithrombin potency.

For example, hirudin exhibited the strongest antithrombin

potency, however, in the laser model of arterial thrombosis, its potency was relatively
weaker in relation to thrombin inhibitors such as Ac-(D)Phe-Pro-boroArg-OH. This
observation clearly suggests that beside the inhibition of thrombin, additional factors
contribute to the observed pharmacologic actions of antithrombin agents.
Heparin is a complex polypharmacologic agent with multiple plasmatic and
vascular sites of action.

Although the overall anticoagulant activity of this drug is

usually standardized in anticoagulant units (USP assays), the potency designation of
antithrombin agents may not be directly comparable to that assigned to heparin and
related drugs. Thus, an APTT elevation to 3 or 4 times the baseline level by a thrombin
inhibitor may or may not be relevant to the overall anticoagulant/antithrombotic response
observed with heparin. This investigation has provided clear evidence on this hypothesis.
At equivalent levels of APTT, the relative antithrombotic actions of these agents are not
the same. This is not just true for the comparison of heparin and antithrombin agents
but thrombin inhibitors at equivalent prolongation of clotting tests exert different degrees
of antithrombotic and/or hemorrhagic effects.

This dissertation therefore provides

evidence that the bioequivalence of these agents is not predictable by any of the ex vivo
tests available at this time.
Significant difference in the pharmacodynamic effects of these agents are found
regardless of the potency, molarity and gravimetric adjustments.

Thus, each

antithrombin agent exhibits its own unique biochemical and pharmacologic profile. The
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data obtained in various studies is readily transformed into molar values which may have
a closer relevance to the observed pharmacologic actions. An in-depth analysis of the
dose and the time-dependent pharmacodynamics of each of these agents can therefore be
useful in projecting some of the clinical effects of these agents.

This dissertation

therefore has addressed some of the pharmacologic and biochemical parameters in molar
terms which can be applied for limited direct comparisons.
One of the most significant questions regarding the relative importance of
thrombin in the mediation of thrombogenesis and its inhibition as the main target for
controlling the thrombotic events has been objectively addressed in this dissertation.
From the experimental evidence provided, it is clear that the sole inhibition of thrombin
is not the primary determinant of the antithrombotic actions of antithrombin agents and
heparin.

In the case of thrombin inhibitors, additional plasmatic and non-plasmatic

processes also contribute to the control of thrombogenesis by these agents. In the case
of heparin, it is obvious that the antithrombin mediated inhibition of thrombin is only one
of the multiple mechanisms for the pharmacologic action of this drug.
Another significant observation in this dissertation is related to the dichotomy
between the in vitro and in vivo behavior of these agents. It is commonly believed that
antithrombin agents are usually inert. If this was true, a steady decrease in the observed
antithrombotic and bleeding effects after I.V. administration would have been noted.
This certainly does not hold true for some of these agents, therefore, endogenous
transformations and other cellular and vascular interactions contribute to their observed
effects.
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Therefore, a classification of thrombin inhibitors can be proposed on the basis of
the spectrum of their pharmacologic actions, as depicted on Table 25. Antithrombin
agents can be grouped into three major categories. Hirudin, hirulog and their analogues
are clearly agents with plasmatic actions only, solely targeting the generated thrombin
and its regulatory functions. On the other end, agents such as heparin and aptamers
mediate diverse pharmacologic actions including vascular, anti-inflammatory, anti-platelet
and anti-proliferative effects. Agents such as the tripeptide and peptidomimetic thrombin
inhibitors possess vascular effects in addition to their plasmatic actions, placing these in
a category between the two described above.

Table 25 -- Classification of Thrombin Inhibitors Based on their Pharmacologic Actions
Agents with plasmatic actions only
Hirudin, hirulog
Agents with dual mechanisms of action (plasmatic and
Peptides,
vascular)
peptidomimetics
Agents with additional regulatory effects (antiHeparin, aptamers
proliferative, platelet interactions, anti-inflammatory)

An additional significant observation during this investigation relates to the fact
that antithrombin agents are considered inhibitors which only target thrombin. However,
their effects on other serine proteases and modified forms of thrombin are not taken into
account. Many of the thrombin inhibitors such as D-MePhe-Pro-Arg-H and Ac-(D)PhePro-boroArg-OH, significantly inhibit non-thrombin serine proteases and this may have
a complex outcome. In addition, most of the thrombin inhibitors inhibit thrombomodulin
bound thrombin, which can have significant implications in the management of
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thrombotic and cardiovascular disorders. This dissertation has provided an additional
insight on the potential clinical implications due to the non-specificity of these agents.
Another classification of thrombin inhibitors can thus be generated based on the
spectrum of their serine protease activities, as depicted on Table 26. Hirudin, hirulog
and their analogues, argatroban, HC-II and aptamers are monospecific agents that interact
solely with thrombin. On the other hand, agents such as Ac-(D)Phe-Pro-boroArg-OH
interact with almost every serine proteases involved in systems other than coagulation and
including the fibrinolytic system. Agents with limited serine protease inhibitory activities
but not restricted to thrombin are included in the narrow spectrum class of thrombin
inhibitors. These agents include napsagatran, inogatran and antithrombin and beside their
antithrombin activities, these also exhibit weaker inhibition of other coagulation factors.

Table 26 -- Classification of Thrombin Inhibitors Based on their Serine Protease
Inhibitory Spectrum
Monospecific
Hirudin, hirulog, argatroban, HC-II,
aptamers
Narrow spectrum
Napsagatran, inogatran, antithrombin
Ac-(D)Phe-Pro-boroArg-OH, peptide arginals
Broad spectrum

While preclinical screening of new antithrombin agents have mostly relied on
thrombin titration methods to assign relative potency for antithrombin derived drugs, such
potency designation has not been very useful in the prediction of the in vivo
pharmacologic behavior of these drugs. One of the most important contributions of this
research is based on the fact that it provides the first comprehensive database for the
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comparative biochemical profile, in vitro anticoagulant actions and pharmacologic
information relevant to their efficacy and safety. It is also for the first time that these
agents are compared at a molar level. Table 27 shows the data on the comparative rank
order of potencies of heparin and these antithrombin agents in several biochemically
defined assays. It is interesting to note that heparin and hirudin exhibit the strongest
potency profiles while the rank order for other agents varies depending on the type of
assay used. Similarly, when heparin and these agents are tabulated in terms of their
anticoagulant potency ranking, assay dependent rank order variations were obvious as
shown on Table 28. While heparin and hirudin once again showed strong effects, Ac(D)Phe-Pro-boroArg-OH exhibited relatively comparable effects.

The rank order of

other antithrombin agents varied with the type of test used. Of notable interest was the
behavior of these agents in the ECT assay, where heparin failed to show any
anticoagulant effects and hirudin remained the strongest anticoagulant agent tested.
Interestingly, argatroban in this assay was found to have comparable effects to the
peptide arginal derivatives.
The animal models of thrombosis and bleeding provided a useful preclinical
approach to compare the in vivo effects of heparin, hirudin and other antithrombin agents
and relate these results to the biochemical and anticoagulant studies. These results are
tabulated on Table 29. These studies were carried out only on heparin, hirudin, Ac(D )Phe-Pro-boroArg-OH and D-MePhe-Pro-Arg-H. While hirudin was found to be
strongest in most of these in vivo studies, heparin and Ac-(D)Phe-Pro-boroArg-OH also
exhibited comparable or stronger effects in some models. To a large extent, the order

Table 27 -- Comparative rank order of potencies of various antithrombin agents in various biochemical assays.
1
2
4
3
5
6
7
hirudin
Ac-FPboroR
Ki
argatroban
FPR
Me-FPR
Boc-FPR
ATU potency
hirudin
Ac-FPboroR
Me-FPR
FPR
Boc-FPR
argatroban
hirudin
Ac-FPboroR
Me-FPR
Fibrinogen-based
argatroban
FPR
Boc-FPR
clotting
heparin
hirudin
Amidolytic anti-Ila
Ac-FPboroR
FPR
Me-FPR
Boc-FPR argatroban
in NHP
Heparin
Ac-FPboroR
Amidolytic anti-Xa
inNHP
Fibrinogen-deficient
hirudin
heparin
Ac-FPboroR
Me-FPR
Ac-FPboroR
Boc-FPR argatroban
assay: thrombin
generation
heparin
Ac-FPboroR
FPR, Me-FPR,
Fibrinogen-deficient
Boc-FPR
assay: factor Xa
generation
FPR = D-Phe-Pro-Arg-H
Me-FPR = D-MePhe-Pro-Arg-H
Boc-FPR = Boc-D-Phe-Pro-Arg-H
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH

Table 28 -- Comparative rank order of potencies of various antithrombin agents in in vitro anticoagulant assays.
PT
APTT
TT
ECT
Hep test
ACT
TEG

1
hirudin
heparin
hirudin
hirudin
heparin
Ac-FPboroR,
hirudin, heparin
Ac-FPboroR,
hirudin, heparin

2
Ac-FPboroR
Ac-FPboroR
heparin
Ac-FPboroR
hirudin
Me-FPR,
argatroban
Me-FPR

FPR = D-Phe-Pro-Arg-H
Me-FPR = D-MePhe-Pro-Arg-H
Boc-FPR = Boc-D-Phe-Pro-Arg-H
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH

3
argatroban
hirudin
Ac-FPboroR
FPR
Ac-FPboroR

argatroban

4
Me-FPR
argatroban
Me-FPR
Me-FPR
argatroban

5
FPR
Boc-FPR
FPR
argatroban
Me-FPR

6
Boc-FPR
Me-FPR
Boc-FPR
Boc-FPR
FPR

7
FPR
argatroban
Boc-FPR

Table 29 -- Comparative rank order of potencies of various antithrombin agents in in vivo pharmacologic models.
1
2
3
4
Rabbit stasis thrombosis,
I. V. 10 min stasis
Rabbit stasis thrombosis,
I.V. 20 min stasis
Rabbit stasis thrombosis,
S.C. 10 min stasis
Rabbit stasis thrombosis,
S.C. 20 min stasis
Rat laser induced
thrombosis
Rabbit hemorrhagic model,
I.V., 5 and 20 min
Rabbit hemorrhagic
model, S.C., 45 min
Rabbit hemorrhagic
model, S.C., 60 min

hirudin

heparin

Ac-FPboroR

Me-FPR

heparin

hirudin

Ac-FPboroR

Me-FPR

hirudin

Ac-FPboroR

heparin

Me-FPR

hirudin

heparin

Ac-FPboroR

Me-FPR

heparin

Ac-FPboroR

hirudin

Me-FPR

hirudin

Ac-FPboroR

Me-FPR

heparin

hirudin

Ac-FPboroR

Me-FPR, heparin

Ac-FPboroR

Me-FPR, hirudin,
heparin

FPR = D-Phe-Pro-Arg-H
Me-FPR = D-MePhe-Pro-Arg-H
Boc-FPR = Boc-D-Phe-Pro-Arg-H
Ac-FPboroR = Ac-(D)Phe-Pro-boroArg-OH
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of potency in the rabbit model of thrombosis followed consistent patterns. This order
followed a different ranking pattern for the rat laser model of thrombosis, where heparin
was found to be strongest and hirudin was relatively weaker than both heparin and Ac(D )Phe-Pro-boroArg-OH. Similarly, in the bleeding model, the order of hemorrhagic
effects followed a different pattern, which was also route dependent. Heparin was found
to be relatively weaker in comparison to all other antithrombin agents. These studies
clearly warrant the necessity of evaluating the results of the in vitro and in vivo screening
in a multiparametric integrated fashion. The data presented here is therefore of crucial
importance in projecting the biochemical and pharmacological actions of newly developed
antithrombin agents.
This dissertation therefore emphasizes the importance of pharmacologic profiling
for new antithrombin agents as the direct antithrombin effects and other plasmatic or
vascular actions of these agents can only be evaluated in valid pharmacologic studies.
It is important to point out that some of the recent adjustments of clinical trials and the

reported adverse events due to both the safety and efficacy compromise were largely
based on incomplete preclinical pharmacological information.

0. Developmental Perspectives
The current developmental perspectives on various thrombin inhibitors are
summarized in Table 30. Site-directed antithrombin agents such as recombinant hirudin,
hirulog and synthetic tripeptides are currently undergoing various phases of clinical trials.
These agents were initially developed with the premise that sole targeting of thrombin
may be the most important step in the development of anticoagulants and antithrombotic
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drugs to treat thrombotic and cardiovascular disorders (Lefkovits and Topol 1994,
Verstraete and Zoldhelyi 1995). It is nearly five years that these agents have undergone
clinical trials. Hirudin and hirulog have completed several phase II trials, whereas the
peptide D-MePhe-Pro-Arg-H, marketed under the generic name efegatran sulfate, has
recently entered a phase II trial.

The primary focus of these trials has been in

cardiovascular areas such as pretreatment of ischemic heart disorders, anticoagulation
during coronary angioplasty, treatment of post-interventional abrupt closure and late
reocclusion (restenosis) and adjunct usage during thrombolysis. It is too early to suggest
that these agents have a definitive advantage over heparin.

However, in heparin

compromised patients, these new anticoagulants may be useful on a compassionate basis.
The cost of hirudin therapy is relatively higher than heparin. The relative cost for the
synthetic antithrombin agents may be lower than hirudin, however, the true cost analysis
can only be valid after a comprehensive pharmacoeconomic analysis for specific
prophylactic and therapeutic indications.
Several peptidomimetic antithrombin agents are also currently in clinical
development for both cardiovascular and therapeutic indications.

These include

argatroban (Mitsubishi, Japan), inogatran (Astra, Sweden) and napsagatran (Roche),
Switzerland). The results of some of these clinical trials are expected later this year.
In addition, many other antithrombin agents are now in active preclinical development.
Of the various peptide derived antithrombin agents, efegatran is the only agent
which is currently developed for cardiovascular indications.

Many other agents

developed by different companies were initially developed in various preclinicaLstudies,

Table 30 -- Developmental Status of Site-Directed Thrombin Inhibitors
Chemical Nature
Hirudin and its analogues

Recombinant protein

Developmental Status

Developed for both arterial and venous
thrombosis
Hirulogs
Synthetic bifunctional oligopeptides
Several clinical studies are completed; additional
studies are planned in various indications
Peptidomimetics
Synthetic heterocyclic derivatives
Phase II clinical development in the USA; used
(argatroban, inogatran, napsagatran)
in Japan
Peptides and their derivatives
Peptide arginals (efegatran)
Phase II clinical development
Aptamers
DNA and RNA derived oligonucleotides with Preclinical stage; limited animal data available
thrombin-binding domains (defibrotide)
Natural proteins and their recombinant
Plasma derived antithrombin
Antithrombin (AT-III) is currently used. HC-II
equivalent products
is still in developmental status
Transition state peptide analogues Oligopeptides and synthetic organic agents
Preclinical screening is being completed
(boronic acid derivatives)
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but due to problematic developmental issues, their clinical development was discontinued.
Aptamers represent both DNA and RNA derived oligonucleotides with weaker
anticoagulant effects.

As such, these agents are not developed for the purpose of

anticoagulation. However, some of these agents show antithrombin actions in the in vitro
settings. A mammalian DNA derived product, defibrotide (Crinos, Italy), has been used
as an anti-ischemic drug, however, its actions are not solely attributed to the inhibition
of thrombin.

This agent, like heparin, produces multiple pharmacologic effects on

platelets, endothelial cells and also release of TFPI (Fareed et al. 1995).
Despite the isolation and characterization of various antithrombin proteins from
human plasma and development of their recombinant equivalent, antithrombin obtained
by the fractionation of human plasma remains the only thrombin inhibitor for clinical use
(Menache 1991, Fourrier et al. 1993). Several products are currently available for the
treatment of congenital thrombophilia and acquired hypercoagulable state including DIC.
HC-11 has also become available but is not currently used.
Many other synthetic and recombinant approaches have been used to develop
antithrombin agents at this time.

Of these, the development of the transition state

analogues has been pursued. Despite developing very potent antithrombin agents using
this approach, these agents have not been clinically developed due to toxic effects.
From the studies reported in this dissertation and the published data, it is clear
that the currently available thrombin inhibitors are not solely specific for thrombin. With
the exception of hirudin, most of the other thrombin inhibitors are capable of producing
several additional effects including inhibition of non-thrombin serine proteases,
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interacting with vascular sites and modulating various regulatory processes. Some of
these effects are depicted in Fig. 61.
Most antithrombin agents have been designed and developed as specific inhibitors
of thrombin. However, these agents exhibit variable interactions with the serine protease
network, including the fibrinolytic, kallikrein and complement system. Since thrombin
belongs to the serine protease family of enzymes, as do most of the coagulation factors
and the fibrinolytic enzymes, developing an inhibitor with strong affinity for thrombin
and none for the other enzymes remains a challenge to the pharmaceutical industry.
While aptamers, hirudin and hirulog have inhibitory activities only towards thrombin due
to their unique mode of action (they recognize and inhibit sites on thrombin other than
the catalytic site, which are unique for thrombin), the other thrombin inhibitors, which
are designed to bind to the catalytic site of thrombin have weaker inhibitory activities
against other enzymes as well. Thus, at high doses, these agents may interfere with the
fibrinolytic system and with APC. This interaction may have some safety compromise
in patients who are treated with these drugs, especially at high dosages (Theroux 1995).
Another important issue is the inhibition of thrombomodulin-bound thrombin by
the low molecular weight thrombin inhibitors. While thrombomodulin-bound thrombin
is devoid of procoagulant effects, it retains its anticoagulant effects since it is still capable
of activating protein C (which functions both as an anticoagulant by inactivating factor
Va and factor VIIIa and as a pro-fibrinolytic by inactivating PAI-1 and PAI-3). The
importance of thrombomodulin-bound thrombin inhibition remains to be clarified.
However, as reported in clinical trial results with hirudin, the lack of dose-dependency

330

Inhibition of
fibrinolytic pathwa

Feedback

NO·
Activated Protein
C Inhibition

Fig. 61. Sites of Actions of Thrombin Inhibitors. Beside the inhibition of thrombin,
these agents are also capable of inhibiting some of the regulatory actions of thrombin,
such as the activation of protein C through thrombomodulin bound thrombin, stabilization
of clot through factor XIIIa and primary hemostatic activation of platelets. The nonthrombin mediated activities of these agents include the inhibition of fibrinolytic and
kallikrein related enzymes, feedback amplification of proteases (thrombin and nonthrombin), modulation of complement esteroproteases and potential modulation of nitric
oxide pathways.
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after a threshold dose of hirudin, indicate that thrombomodulin-bound thrombin plays an
significant role in the overall anticoagulant response (Theroux 1995).
Some of the thrombin inhibitors also possess direct vasodilatory effects,
independent of their activity on thrombin. These effects are believed to be mediated
through metabolic products containing guanidino groups which result in the increase of
nitric oxide generation (Fareed and Callas 1995). Depending on the specific indication
for which the thrombin inhibitor is developed, this vascular effect may be desirable.
Nevertheless, this type of effect should be investigated and considered.
The pathophysiologic role of thrombin extends beyond coagulation and platelet
activation. Thrombin also has direct effects on other cell types and functions, ranging
from mitogenesis and contraction of smooth muscle cells to adhesion and metastasis of
tumor cells to neurite growth regulation to endothelial cell stimulation (Tapparelli et al.
1993). Although the functions of thrombin in such processes as atherogenesis and cancer
metastasis have not been fully characterized, a thrombin inhibitor will interfere with all
of thrombin's bioregulatory functions. These observations may have some impact on the
development of thrombin inhibitors in cancer and cardiovascular indications.
Ever since their introduction, most of the clinical indications for these new
anticoagulants have been in the interventional cardiovascular areas (Herrman and Serruys
1994).

Initial focus has been on the prevention of abrupt closure during coronary

angioplasty (Topol et al. 1993, Topol 1995). These agents have also been tried for the
post-PTCA prevention of both the early and late reocclusion (Suzuki et al. 1995). In
addition, some of the thrombin inhibitors have been used for the treatment of unstable
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angina (Topol 1995). More recently, some of these agents have been tested for their
efficacy in stenting (Sternberger et al. 1996, van Beusekom et al. 1994, Buchwald et al.
1993). Although several reports on the experimental use of these antithrombin agents
have been made available on their use in cardiovascular surgery in animal models, only
isolated reports in human studies are available (Riess et al. 1995).

Since a known

antagonist to neutralize the effects of antithrombin agents is not available, concerns over
the use of these agents have been expressed (Edmunds 1995).

Currently, no

pharmacologic antagonists exist for hirudin or any of the other direct thrombin inhibitors,
making the managing of precipitated hemorrhagic effects problematic. Current hirudin
reversal strategies employed include prothrombin complex concentrate to neutralize the
circulating antithrombin agents (Irani et al. 1995) or dialysis to remove an antithrombin
agent from the blood (Fareed et al. 1991). Strategies that are under development of
effective neutralizing agents are production of mutant thrombin molecules that are devoid
of clotting activity but for which antithrombin agents retain a high affinity, thus
saturating circulating levels of these agents (Fischer et al. 1996).
Thrombin inhibitors are attractive to both clinicians and surgeons as substitute
anticoagulants in heparin compromised patients in particular. For patients exhibiting
heparin induced thrombocytopenia and requiring anticoagulation, several trials are
currently in progress to test the efficacy of new antithrombin agents (Edmunds 1995,
Chamberlin et al. 1995).
Although thrombin inhibitors are potent anticoagulants and unlike heparin do not
require any endogenous cofactors for their actions, their development as· surgical
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anticoagulants has been rather slow due to the non-availability of a pharmacologic
antagonist. Only when such an antagonist is available and clinically validated, these
agents may find their way into surgical applications.
There is a growing interest in the use of these agents in the prevention and
treatment of DVT (Bridey et al. 1995). A recent study (Eriksson et al. 1996) reported
on the successful use of recombinant hirudin in the prophylaxis of post-orthopaedic
surgery. In this study unfractionated heparin (5000 IU s.c. t.i.d.) was compared with
hirudin (15 mg s.c. b.i.d.), which was found to be superior. Several additional trials are
currently being conducted on different antithrombin agents.
Current clinical trends also point to polypharmacologic approaches for the
treatment and management of cardiovascular disorders.

Combination modalities of

anticoagulants with other drug classes such as antiplatelet and fibrinolytic drugs has been
employed (Theroux et al. 1995, Lee 1995, Cannon and Braunwald 1995).

While

clinically developed thrombin inhibitors are reportedly specific for thrombin inhibition,
these agents exhibit interactions with other drugs. Antiplatelet drugs such as aspirin and
ticlopidine have additive or synergistic actions when used in conjunction with thrombin
inhibitors (O'Donnell et al. 1995).

Similar interactions would be expected when

thrombin inhibitors would be used with heparin and low molecular weight heparins or
antithrombin III concentrates (Biemond et al. 1994). On the other hand, adjunct usage
of thrombin inhibitors with thrombolytic agents, at an optimized dose, could result in the
facilitation of thrombolysis or, if the thrombin inhibitor dose is not adjusted, in
thrombolytic compromise.

Some of these agents may also directly inhibit activated
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protein C, or inhibit activated protein C formation by neutralizing thrombomodulin-bound
thrombin (Theroux et al. 1995, Callas et al 1995, Callas and Fareed 1995). Furthermore,
thrombin inhibitors may neutralize the coagulant actions of factor VIia and prothrombin
complex concentrates (Biemond et al. 1994).

Therefore, it is desirable that the

interactions of thrombin inhibitors are well studied and considered when designing drug
combination protocols for clinical applications, as such interactions may have both safety
and efficacy implications.
The development of thrombin inhibitors has added a new dimension in the
management of thrombotic and vascular disorders. While the major clinical indications
for these agents include interventional cardiovascular procedures and DVT prophylaxis,
little is known for their use in the area of surgical and therapeutic anticoagulation. It is
projected that many of the newer thrombin inhibitors, such as hirulog and hirudin, will
be developed as anticoagulants and may be substituted for heparin. Synthetic tripeptides
with broader serine protease inhibitory spectrum offer unique tools to control thrombogenesis at different levels and may prove to be more useful in chronic indications,
including prophylactic usage. The usefulness of various thrombin inhibitors in a given
medical or surgical indication can be proven only in properly designed clinical trials.

CHAPTER VI
SUMMARY

A. In Vitro Studies
1. The molecular profile was investigated in the case of the peptide arginals, Ac(D)Phe-Pro-boroArg-OH and unfractionated heparin. The specifications on hirudin and
argatroban indicated these agents to be > 903 pure and homogeneous. The peptide
arginals and Ac-(D)Phe-Pro-boroArg-OH exhibited hydrate form transformations. As
expected, heparin was determined to be polycomponent and exhibited similar molecular
weight profile in both the UV and RI analyses.
2.

The relative antithrombin potency (ATU) for each thrombin inhibitor as

measured by an amidolytic method was found to widely vary in the range of 2,000200,000 ATU/mg (1,000-156,000 ATU/nmol).

These unit potency values were not

consistent with the published Ki and IC50 values. This may be due to differences in the
experimental methods, the choice of thrombin preparations and the mathematical analyses
of the generated data.

3.

When the thrombin titration was carried out on the natural substrate of

thrombin, fibrinogen, against the commercially available human thrombin preparation,
all of the thrombin inhibitors exhibited different degrees of antithrombin potency.
However, heparin did not exhibit any antithrombin potency in these assays. The rank
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order for the relative antithrombin actions of these agents is given as follows: hirudin>
Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > argatroban > D-Phe-Pro-Arg-H >
Boc-D-Phe-Pro-Arg-H.
4. The amidolytic antithrombin potencies were also measured for heparin and
various antithrombin agents in normal human plasma and normal rabbit plasma based
assays. In these assays, heparin was found to be the strongest inhibitor (IC50 of 6.1-9.6
nM). Species dependent variations were noted. The various thrombin inhibitors exhibited
the following rank order of potency: heparin> hirudin > Ac-(D)Phe-Pro-boroArg-OH >
D-Phe-Pro-Arg-H > D-MePhe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban.
5. In the amidolytic anti-Xa assays performed in the normal human plasma and
normal rabbit plasma assays, except for heparin and Ac-(D)Phe-Pro-boroArg-OH, none
of the other thrombin inhibitors produced any anti-Xa effects. Heparin in both systems
was found to be an efficient inhibitor of factor Xa.
6.

The antiprotease profile for each of the individual thrombin inhibitors and

heparin/antithrombin complex was investigated utilizing chymotrypsin, trypsin, activated
protein C, glandular kallikrein, tPA, urokinase and plasmin. Aprotinin was also included
as a reference inhibitor. None of the thrombin inhibitors produced any inhibition of
chymotrypsin.

With the exception of hirudin and argatroban, all of the thrombin

inhibitors produced varying degrees of inhibition of these stated enzymes with IC50 values
in the µM range. These studies clearly indicate that different thrombin inhibitors are
capable of producing measurable inhibition of non-thrombin serine proteases of the
fibrinolytic and kallikrein system, at concentrations which are least one .order of
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magnitude greater than those observed for the inhibition of thrombin.
7. The thrombin and factor Xa generation studies were carried out in fibrinogen
deficient plasma to compare the relative ability of heparin and these thrombin inhibitors
on the generation of these enzymes after extrinsic and intrinsic activation. All agents
produced varying degrees of the inhibition of thrombin and factor Xa generation,
following the order of hirudin > heparin> Ac-(D) Phe-Pro-boroArg-OH > D-MePhe-ProArg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban for extrinsic and
intrinsic thrombin generation and with the following order for extrinsic factor Xa
generation: heparin> Ac-(D)Phe-Pro-boroArg-OH > D-Phe-Pro-Arg-H, D-MePhe-ProArg-H and Boc-D-Phe-Pro-Arg-H.
8. The influence of these agents on the generation of factor Xa and thrombin was
also carried out in activated and native prothrombin complex concentrates.

After

extrinsic activation, varying degrees of inhibition of both of these enzymes was noted.
Activation and system variations were evident and each inhibitor showed an individual
profile. In comparison to heparin, thrombin inhibitors produced relatively stronger antiXa than antithrombin effects. Ac-(D)Phe-Pro-boroArg-OH was found to be the strongest
inhibitor in most of these assays.
9.

Each of the thrombin inhibitors and heparin exhibited a distinct inhibitory

profile in the norman human plasma based clotting assays, such as the PT, APTT, TT,
Heptest and ECT. The relative anticoagulant potency was also both agent and assay
dependent. In each test, the following potency rank orders were observed:
PT: hirudin, Ac-(D)Phe-Pro-boroArg-OH > argatroban > D-MePhe-Pro-Arg-H > D-Phe-
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Pro-Arg-H > Boc-D-Phe-Pro-Arg-H
APTT: heparin> Ac-(D)Phe-Pro-boroArg-OH > hirudin > argatroban > Boc-D-Phe-ProArg-H > D-MePhe-Pro-Arg-H > D-Phe-Pro-Arg-H
TT: hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H> D-PhePro-Arg-H > Boc-D-Phe-Pro-Arg-H > argatroban
Heptest: heparin> hirudin> Ac-(D)Phe-Pro-boroArg-OH > argatroban> D-MePhe-ProArg-H > D-Phe-Pro-Arg-H > Boc-D-Phe-Pro-Arg-H
ECT: hirudin> Ac-(D)Phe-Pro-boroArg-OH > D-Phe-Pro-Arg-H > D-MePhe-Pro-ArgH > argatroban > Boc-D-Phe-Pro-Arg-H
10. The relative anticoagulant effects of heparin and various inhibitors were also
investigated in the whole blood ACT and TEG assays. In both assays, a concentrationdependent anticoagulant effect was evident in the ACT (rank order: hirudin, heparin, Ac(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H, argatroban) and the TEG (rank order:
hirudin, heparin, Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H > argatroban).
11. For the comparative anticoagulant effects in the normal rabbit plasma based PT,
APTT, TT and Heptest, heparin, hirudin, D-MePhe-Pro-Arg-H and Ac-(D)Phe-ProboroArg-OH exhibited distinct profiles. The relative anticoagulant potency was also both
agent and assay dependent. In each test, the following rank orders were observed:
PT: hirudin, Ac-(D)Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H
APTT: heparin> Ac-(D)Phe-Pro-boroArg-OH> hirudin> D-MePhe-Pro-Arg-H
TT: hirudin> heparin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H
Heptest: heparin> hirudin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H
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12.

Heparin and various thrombin inhibitors also produced varying degrees of

anticoagulant actions in the ACT and TEG assays performed in the native rabbit whole
blood. The relative anticoagulant effects were both assay and agent dependent. Thus,
each method provided a different degree of anticoagulant potency.

B. In Vivo Studies
1. Recombinant TF was found to produce dose-dependent thrombogenic effects
in a rabbit jugular vein stasis thrombosis model. The apparent ED50 for producing the
thrombogenic response at 10 min was determined to be 0.34 pmol/kg. At 20 min, the
ED 50 was about 4 pmol/kg. The relative thrombogenic response of rTF at 10 and 20 min
did not appear to be significantly different.

At dosages of up to 1 pmol/kg I. V.

administration, rTF did not produce any alterations in the clot based tests such as the PT,
APTT, TT and Heptest. However, in the ACT and TEG tests, at doses ranging from
0 .1-1 pmol/kg, a dose-dependent anticoagulant effect was noted. The mechanism for this
rTF produced effect on ACT and TEG was not explored.
2.

Heparin, hirudin, D-MePhe-Pro-Arg-H and Ac-(D)Phe-Pro-boroArg-OH

produced dose-dependent antithrombotic effects at both the 10 and 20 min end points.
The order of potency for these agents was found to be hirudin > heparin> Ac-(D)PhePro-boroArg-OH > D-MePhe-Pro-Arg-H at the 10 min end point and heparin>
hirudin> Ac-(D)Phe-Pro-boroArg-OH> D-MePhe-Pro-Arg-H at the 20 min endpoint.
The ex vivo analyses of the blood revealed sizeable antithrombin activities. However,
the relative anti-Xa activities were markedly lower. The ACT and TEG test also showed
individual anticoagulant profiles for each of these agents. In the plasmatic clotting tests,
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while the PT remained unaffected, agent specific anticoagulant effects were noted in the
APTT, TT and Heptest.

Ac-(D)Phe-Pro-boroArg-OH produced the strongest

anticoagulant effects.
3. In the S.C. studies, a dose-dependent and agent specific antithrombotic action
was noted with all four agents. The order of potency was found to be hirudin > Ac(D)Phe-Pro-boroArg-OH > heparin> D-MePhe-Pro-Arg-H and hirudin > heparin> Ac(D )Phe-Pro-boroArg-OH > D-MePhe-Pro-Arg-H at both the 10 and 20 min end points
respectively. Dose-dependent antithrombin effects were also evident with all four agents.
However, relatively weaker anti-Xa activities were observed. The ex vivo ACT and TEG
analyses also revealed agent and dose-dependent effects. The ex vivo analyses of plasma
revealed a dose-dependent prolongation of the APTT, TT and Heptest. However, no
effects were observed in the PT assay. On a molar basis, hirudin was found to be the
strongest antithrombotic agent in these studies.
4.

At a fixed I.V. dosage, each of these agents produced a time-dependent

antithrombotic action. Regardless of the anti thrombotic potency, each of these agents
showed varying duration of the antithrombotic and ex vivo effects as measured by various
tests. The duration of action followed the order of hirudin> D-MePhe-Pro-Arg-H >
heparin> Ac-(D)Phe-Pro-boroArg-OH. With the exception of the PT, the other ex vivo
tests showed time-dependent agent specific effects.
5. In the S.C. studies, fixed doses of each of these inhibitors also produced timedependent antithrombotic and assay-dependent ex vivo effects on various parameters. In
contrast to the I.V. studies, the subcutaneously administered agents produced sustained
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antithrombotic actions.

Heparin and hirudin exhibited relatively longer duration of

actions in contrast to the peptides used.
6. Heparin and antithrombin agents also produced dose-dependent antithrombotic
actions in a rat model of laser-induced arterial thrombosis. The antithrombotic potency
in this model was determined to be heparin> Ac-(D)Phe-Pro-boroArg-OH> hirudin>
D-MePhe-Pro-Arg-H.
7. The hemorrhagic actions of heparin and thrombin inhibitors were investigated
in a rabbit model of ear blood loss at 5 and 20 min post agent administration. Each of
these agents produced a dose-dependent hemorrhagic effect. The hemorrhagic potential
for these agents is graded in the following order: hirudin> Ac-(D)Phe-Pro-boroArgOH > D-MePhe-Pro-Arg-H > heparin. The duration of the hemorrhagic action for each
of these agents was also investigated at a fixed dosage. The hemorrhagic actions of these
agents followed different time courses and were cleared within 60 min.
8. Subcutaneously administered heparin and antithrombin agents were also found
to produce hemorrhagic effects in the rabbit ear blood loss model at 45 and 60 min
circulation times. Hirudin and Ac-(D)Phe-Pro-boroArg-OH produced a dose-dependent
effect. However, heparin and D-MePhe-Pro-Arg-H produced relatively weaker effects.
At a fixed dosage, the time course of the hemorrhagic actions of D-MePhe-Pro-Arg-H
decreased with time, whereas hirudin and Ac-(D)Phe-Pro-boroArg-OH showed biphasic
responses. The hemorrhagic actions of these agents peaked at 45 min. While the effect
produced by hirudin reverted to baseline, the action of Ac-(D)Phe-Pro-boroArg-OH
remained elevated at 90 min.

CHAPTER VII
CONCLUSIONS

Antithrombin agents represent a chemically and functionally diverse variety of
pharmacologic agents with different degrees of specificity for the inhibition of thrombin.
As a class, these agents have been found to be distinct from heparin in terms of their
mechanism of action and pharmacodynamic effects. Independent of the antithrombin
potency for each of the individual agents as measured by either the Ki or the IC50 based
titration of the antithrombin actions, these agents exhibit several endogenous effects
which are not completely attributable to their relative inhibitory action on thrombin.
Furthermore, each of the thrombin inhibitors exhibits a distinct anti-serine protease and
protease generation inhibitory profile which also contributes to its biochemical and
pharmacologic identity. This research also provided experimental evidence that sole
targeting of thrombin is not enough in the control of thrombogenesis and additional
endogenous factors which contribute to these processes. Furthermore, indiscriminate
inhibition of thrombin may compromise the regulatory roles of thrombin, such as the
activation of protein C, clot stabilization through factor Xllla, hemostatic process
mediated through platelets and other cellular functions.

It is concluded that beside

distinct differences amongst various thrombin inhibitors, these agents also exhibit nonthrombin mediated biochemical and pharmacologic actions which may not be related to
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their actions on thrombin. Even in the case of highly specific thrombin inhibitors such
as hirudin, several distinct actions of this agent are responsible for some of the additional
biochemical and pharmacologic effects which can contribute to its therapeutic index.
Thus, a comprehensive profile for each agent is a prerequisite for an objective
development of these new anticoagulant and antithrombotic drugs. Furthermore, for the
clinical development in specific vascular and thrombotic indications, these drugs should
not be developed mimicking the approaches which have been used for heparin, rather
each agent should be considered as a distinct pharmacologic agent with its own profile
and be developed as such. Biochemical and pharmacologic modelling approaches can be
used to mimic specific thrombotic and cardiovascular disorders where each of these new
antithrombin agents can be profiled.
projections can be made.

On the basis of these investigations, some

Such an approach may be more cost-effective and will

minimize the necessity for large scale, costly and time consuming clinical trials where
the safety issues are not always clear.

APPENDIX I
PRODUCT SPECIFICATION SHEETS
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-PENTAPHARM AG

Analysen-Zertifikat Certificat d'Analyse
Produkt, Produit, Product:

Let

BASEL

Certificate of Analysis

A P R 0 T I N I N

6120 KIU/mg

5388/074

Pl'Ufungs-Resultate. ResuJtars de !'examen, Examination Results:

Aspect:

white, solid lyophilisate

Solubilit-J in water at 20 mg/ml

clearly soluble

pH of the aqueous solut:.on (0,2%)

7,35

Ac':i vi t-/

6,8 TIU/mg

ltlater content

(K.Fischer)

= 6'120

7,79"
none

Preservative
.- .._~.!

Protein content (UV)
SDS - PAG - Elect::-ophoresis
H"eparin neutralizing activity

0,88 mg/mg
on single band

< 3

U/90'000 KIU

' , .'.·J'

..

Befur.d,Conclusion,Condusion:

Basel/ Schweiz,
Bale/Suisse,
Basle/Switzerland, November 22, 1989

A 29772

FUr die verantwortliche Abteilung:
Pour le seM:e responsab!e:
· On behalf of the responsible department

KIU/~g
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LOYOLA UN IVERS IT'f MEJ [CAL CEilTER
MAYWOOD, IL!..IilO!S
SPECIAL HEMATOLOGY (PATHOLOGY)
HEMOSTASIS RESEARCCI (PATHOLOG'I)
INFORMED COilSEili

Patient's Name:

Date:

Project Title:

-----

Consent Form for Volunteer 31ood Donors

VOLUNTEER INFORMATION
A sample of your blood is to be drawn from a vein for tne puroose of being
used as a contra 1 for procedures perfor:ned in the Her:ia. '.:J ~ og:1 /He~·os :as is Research
Labora:ories. The amount of blood dra1·m frc::i you, the ty~e of test performed
on this sample (as a control) is marked on the following lists:
TE37

A>~CUi:T

OF BLOOD RE'.:;U IREJ

_Platelet Aggregation Study

9 mi citrate~ bleed
(Butterfly Syringe method)

_Osmotic Fragility Studies

5 m; blood (Plas:ic syringe)

_

Autohemolysis

5 ml blood (syringe method)

-

NBT Test (White cell
function test)

10 ml heparinized blood
(Vacutainer method}

_

Leucocyte Chemotaxis

10 ml heoarinizec blood
(Syringe' method)

_

Who 1e Bl cod Vi seas i ty Studies

10 ml heoarinizec blood
{Syringe' method)

-

For the Preparation of Nonnal
Human Pool Plasma and other
Blood Components

10 ml citrated blood
{Syringe method}

For these tests there is no commercially available control at this time.
For the proper interpretation of these tests, fresh normal human blood is
needed. The drawing of your blood from the vein is a well established
procedure which has very little risk. Slight pain and a small amount of
bleeding may occur. Occasionally, a blood clot may fonn in the vein, but
this is rare and seldom produces permanent damage.

{over)
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VOLUNTEER INFORMATION (continued)
No direct benefit is expected to any one individua1, but it may eventua11y
improve the quality of tests done on blood in the future, and may identify
certain diseases more accurate1y. There is no a1ternative procedure at this
time which would pennit us to obtain the a~ount of human blood we need for
the· test.
CONSENT
I have fully exp1ained t o - - - - - - - - - - - - - - - - - - - - - Name: Volunteer
the nat:Jre and purpose of the above described procedure and the risks that
are involved in its perfor:nance. I have ans'..iered and 't1il 1 ans;·1er a11 questions
to the best of my abi 1i ty.
(Si gna ::Jre:

Spec i a1 r:ema to 1ogy Personnel)

I have been fully infor:ned of the abo•1e described proc:~dure l'lith its possible
benefits and risks. I give permission for my participation in this study. I
know that
or his/her associates wi11 be
avai1able to ans1-1er any questions r may ha·1e. If, at any time, I fee1 my
questions have not been adequately answered, I may request to speak with a
member of the ~'1edica1 Center Institutiona~ Revie'..i Soard. I understand that
I am free to withdraw this consent and discontinue participation in this
project at any time without prejudice to my care. I have received a copy of
this informed consent document.

(Signature:

Signature:

Witness to Signatures)

Volunteer)

APPENDIX ill
LETTERS OF PERMISSION
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#A.

,.,
Wadsworth Center

STATE OF NEW YORK
DEPARTMENT OF HEALTH

The Governor Nelson A. Rockefeller Empire State Plaza

P.O. Box 509

Barbara A. DeBuono, M.D .• M.P.H.
Commissioner

Albany, New York 12201·0509
Karen Schimke
Executive Deputy Commissioner

February 5, 1996

Ms. Demetra Callas
Department of Pathology
Loyola University Medical Center
2160 South First Ave.
Maywood, IL 60153
Fax: 708-216-6660
Dear Ms. Callas:
As far as I am concerned, I have no objections to you using figures from a previous
publication by D.H. Bing and myself(Thromb. Hemost. 14: 234-240, 1988). However, I do not
know if the publisher of the journal require written permission for reproduction of such materials.

' .)
A

.·
_
/
{< - ;~At VyL£-

~incerely,

/J1.Y,l ~,

J
I

.

-;-i'----

ohn W. Fenton, II, Ph.D., FACB
Phone: 518-486-256212119
Fax: 518-474-7992

JWF/lrnj
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1~:

'.3

Pc.Gi::

2160 So..th l'inr A..:nuc:
!llmois 60153

~od,

!tki>hc.nc:: (:-OS) 215-JUI
Fa: (708)

2l6~396

February 13, 1996

Mr. Chris Hall
Thi=: M:dical Publisb.m
381 Park Ave

New York, NY

Dear Mr. Hail.

i

I

i

Thank: you fer your wi3tm:= rCprdmg my ~ about ;;:pr~ a tiguI'l! publliht!d in
Se::ninarl in Thrombolis and H::moswi3. I am a graduati: smdci:tt in die Ph.:0. prog:-am of the
Oeparm:.elll: of Ph.arma.c:ology at Loyola Univer3ity Chicago, in t.h.e fii:al. stages of my ~.
under the guidance af Dr. J~wied. Fareed.. The figore r would Im lD get ~ion to r~roduce
is Fig. l ("A 3..Cimc:nsinaal model ofliuman a-tbrombin") published in Se:ni..n.m in inro.cibosis
mi Hemostasi3, 14(3):m, 1988, in the article at.'.tllorcd by Dr. Femcu.. My imenrlon is ta
reproduce this ~in my~ in tile lln:ratu;e r=vicw section. fur visual apreseritation
and claf.fication of the !truame 'or thrombin. If there is my ocher in.~on that you ·:leed.
do llOt hesiuu: to ccm:act me. ·
Sincerely

rflernef.~~
Demetra Callas

Phone: 708-216-5587
Fax= 708-216-6660 .

I

E-mail: dctllas@wpo.iLlm;.ad'G :

01
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Table 8a -- Antithrombin Activity of Antithrombin Agents, as
Studied in the Thrombin Titration Assay.
D-Phe-Pro-Arg-H
% Residual
ng/ml
nM
Thrombin Activity*
21.28 4.25
7.7 ± 0.9
15.96 3.19
9.6 ± 1.8
13.83
2.76
11.0±3.6
12.77 2.55
11.9±3.0
11.70 2.34
13.9 ± 2.9
10.64 2.13
15.4 ± 0.9
10.11
2.02
16.5 ± 4.4
9.57
1.91
17.8 ± 6.9
9.31
1.86
18.8 ± 2.4
9.04
1.81
20.2 ± 4.9
8.78
1.75
21.4 ± 2.9
8.51
1.70
22.7 ± 4.5
8.24
1.65
23.3 ± 4.5
7.98
1.59
25.6 ± 3.4
7.71
1.54
25.8 ± 3.8
6.91
1.38
26.1 ± 3.7
6.38
1.28
31.3 ± 3.6
5.85
1.17
33.8 ± 5.4
5.59
1.12
35.0± 3.3
5.32
1.06
39.1 ± 1.2
5.05
1.01
41.4 ± 5.0
4.79 0.96
46.5 ± 6.7
4.52
0.90
51.3 ± 5.6
3.99 0.80
53.3 ± 5.2
3.72 0.74
57.3 ± 5.7
3.46 0.69
61.9 ± 3.9
3.19 0.64
64.6± 3.5
2.66 0.53
66.5 ± 5.7
2.39 0.48
72.2 ± 6.4
2.13
0.43
72.9 ± 3.0
1.86 0.37
77.3 ± 6.1
1.60 0.32
85.0 ± 3.3
1.06 0.21
89.2 ± 2.3
0.80 0.16
91.8 ± 5.4
0.53
0.11
94.7 ± 6.8
0.27 0.05
98.8±6.1
0.00 0.00
100.0± 0.0
* Each value represents the mean

± SD of three independent determinations.
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Table 8b -- Antithrombin Activity of Antithrombin Agents,
as Studied in the Thrombin Titration Assay.
D-MePhe-Pro-Arg-H
% Residual
ng/ml
nM
Thrombin Activity*
21.28
41.35
10.4 ± 0.5
19.15
37.21
10.9 ± 0.8
17.02
33.08
11.8± 1.1
15.96
31.01
12.8 ± 1.2
14.89
28.94
13.2 ± 2.5
13.83
26.87
15.7 ± 0.6
12.77
24.81
18.9 ± 3.8
11.70
22.74
17.7 ± 0.8
11.17
21.71
18.2 ± 2.2
10.64
20.67
19.7 ± 3.3
10.11
19.64
22.7 ± 1.9
9.57
18.61
23.5 ± 1.7
9.04
17.57
26.4 ± 2.7
8.51
16.54
26.1 ± 5.2
7.98
15.50
29.1 ± 3.1
7.45
14.47
30.7 ± 3.9
6.91
13.44
30.3 ± 4.5
6.38
12.40
37.7 ± 3.0
5.85
11.37
43.1 ± 4.2
10.34
5.32
46.0 ± 1.3
4.79
9.30
51.7± 8.5
4.26
8.27
57.6 ± 0.7
3.72
7.24
63.2 ± 10.4
3.19
6.20
69.1 ± 7.9
2.66
5.17
73.4 ± 2.0
2.13
4.13
76.6 ± 5.8
3.10
1.60
81.2 ± 1.9
1.06
2.07
88.3 ± 6.3
1.86
0.96
89.8 ± 5.2
1.65
89.6 ± 5.0
0.85
0.74
1.45
90.8 ± 3.1
1.24
0.64
91.6 ± 2.7
1.03
95.4 ± 1.8
0.53
0.83
95.7 ± 3.5
0.43
0.21
0.41
98.7 ± 4.3
0.11
0.21
98.0 ± 0.7
0.00
0.00
100.0± 0.0
* Each value represents the mean

± SD of three independent determinations.
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Table 8c -- Antithrombin Activity of Antithrombin Agents,
as Studied in the Thrombin Titration Assay.
Boc-D-Phe-Pro-Arg-H
% Residual
ng/ml
nM
Thrombin Activity*
1063.83
1928.63
12.5 ± 1.4
957.45
1735.76
12.9 ± 1.8
851.06
1542.90
14.2 ± 1.0
744.68
1350.04
14.2± 1.0
638.30
1157.18
16.2 ± 2.5
531.91
964.31
17.1±1.2
425.53
771.45
18.2 ± 4.8
319.15
578.59
19.2 ± 4.2
212.77
385.73
24.4 ± 6.0
106.38
192.86
30.8 ± 3.4
95.74
173.58
32.8 ± 0.5
85.11
154.29
31.7 ± 2.5
74.47
135.00
32.9 ± 2.6
63.83
115.72
35.2 ± 3.8
53.19
96.43
36.2 ± 3.5
47.87
86.79
38.1±4.3
42.55
77.15
35.7 ± 2.5
37.23
67.50
37.1±0.9
31.91
57.86
38.5 ± 2.0
29.26
53.04
36.6 ± 0.4
48.22
26.60
39.2 ± 5.6
23.94
43.39
40.3 ± 5.7
21.28
38.57
40.3 ± 2.3
18.62
33.75
43.9 ± 7.8
15.96
28.93
44.2 ± 4.3
13.30
24.11
52.7 ± 3.0
10.64
19.29
55.2 ± 1.8
17.36
9.57
56.5 ± 2.2
8.51
15.43
64.4 ± 4.8
7.45
13.50
68.1 ± 1.9
6.38
11.57
72.4 ± 6.4
9.64
77.0 ± 1.4
5.32
7.71
4.26
80.7 ± 3.0
5.79
86.5 ± 4.7
3.19
2.13
3.86
88.5 ± 5.1
1.06
1.93
97.0± 6.1
0.00
100.0 ± 0.0
0.00
* Each value represents the mean

± SD of three independent determinations.
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Table 8d -- Antithrombin Activity of Antithrombin Agents,
as Studied in the Thrombin Titration Assay.
Ac-(D)Phe-Pro-boroArg-OH
% Residual
ng/ml
nM
Thrombin Activity*
6.38
12.85
8.4± 4.2
5.85
11.78
9.1 ± 4.8
10.71
5.32
15.8 ± 4.4
5.05
10.17
20.0 ± 16.8
4.79
9.64
18.7 ± 5.8
4.52
9.10
17.9± 4.2
4.26
8.57
19.8 ± 2.0
3.99
8.03
23.4± 3.4
3.72
7.49
32.8± 0.9
3.46
6.96
39.8± 2.9
3.19
6.42
39.5± 3.3
2.93
5.89
44.4± 1.6
2.66
5.35
49.0± 3.3
2.39
4.82
53.2± 5.0
2.13
4.28
59.0± 3.7
3.75
1.86
60.8± 3.7
3.21
1.60
65.9± 3.0
1.33
2.68
74.4± 1.3
2.14
1.06
77.2± 1.4
0.96
1.93
78.1 ± 1.3
1.71
0.85
81.5 ± 1.3
0.74
1.50
86.2± 3.4
0.64
1.28
91.3 ± 4.8
0.53
1.07
88.3± 1.4
0.43
0.86
94.9± 5.1
0.64
0.32
94.8± 5.3
0.21
0.43
97.3± 4.8
0.21
0.11
97.0± 5.0
0.00
0.00
100.0 ± 0.0
* Each value represents the mean ± SD of three
independent determinations.
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Table 8e -- Antithrombin Activity of Antithrombin Agents,
as Studied in the Thrombin Titration Assay.
Argatroban
% Residual
ng/ml
nM
Thrombin Activity*

2127.66
1861.70
1489.36
1276.60
1063.83
957.45
851.06
744.68
638.30
531.91
478.72
425.53
372.34
319.15
265.96
212.77
159.57
106.38
101.06
95.74
85.11
74.47
63.83
58.51
53.19
47.87
42.55
37.23
31.91
26.60
21.28
15.96
10.64
5.32
0.00

3999.36
3499.44
2799.55
2399.62
1999.68
1799.71
1599.74
1399.78
1199.81
999.84
899.86
799.87
699.89
599.90
499.92
399.94
299.95
199.97
189.97
179.97
159.97
139.98
119.98
109.98
99.98
89.99
79.99
69.99
59.99
49.99
39.99
30.00
20.00
10.00
0.00

* Each value represents the mean
independent determinations.

9.3 ± 0.7
10.7 ± 0.7
12.8 ± 1.0
14.2 ± 1.0
17.3 ± 0.9
19.2±1.1
20.6 ± 1.0
22.6 ± 2.7
24.3 ± 1.0
27.5 ± 1.0
28.9 ± 1.6
32.0 ± 2.4
35.1 ± 2.2
38.6 ± 2.8
40.2 ± 2.5
47.6 ± 3.7
51.2 ± 3.2
61.3±3.1
65.2 ± 4.2
69.2 ± 3.1
71.9 ± 0.8
73.1 ± 2.8
74.3 ± 4.6
77.5 ± 4.7
81.7± 1.1
84.8 ± 2.5
85.0 ± 1.6
85.2± 2.0
89.0 ± 1.6
91.4 ± 4.1
91.9 ± 1.7
95.3 ± 5.8
97.6 ± 3.9
98.7 ± 2.3
100.0 ± 0.0

±

SD of three
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Table Sf -- Antithrombin Activity of Antithrombin Agents,
as Studied in the Thrombin Titration Assay.
Hirudin
% Residual
ng/ml
nM
Thrombin Activity*

58.51
50.53
47.87
45.21
42.55
41.49
40.43
39.36
38.30
37.23
36.17
35.11
34.04
32.98
31.91
30.85
29.79
28.72
27.66
26.60
24.47
22.34
21.28
20.21
19.15
18.09
17.02
15.96
14.89
13.83

11.70
9.57
8.51
6.38
5.32
4.26
3.19
1.06
0.00

8.40
7.26
6.88
6.49
6.11
5.96
5.81
5.65
5.50
5.35
5.19
5.04
4.89
4.74
4.58
4.43
4.28
4.13

3.97
3.82
3.51
3.21
3.06
2.90
2.75
2.60
2.44
2.29
2.14
1.99
1.68
1.38
1.22
0.92
0.76
0.61
0.46
0.15
0.00

* Each value represents the mean

5.5 ± 0.2
7.2 ± 1.4
8.4 ± 1.0
12.0 ± 3.5
14.5 ± 0.1
16.6±2.1
17.7 ± 2.5
20.0 ± 2.0
21.8 ± 2.9
26.1±3.4
25.8 ± 3.6
26.0 ± 1.1
31.8 ± 4.7
35.1±7.8
34.8 ± 1.9
37.0 ± 1.3
39.0± 2.6
41.7±2.3
46.9 ± 6.9
48.0 ± 3.9
48.5 ± 4.4
50.9 ± 1.4
49.8 ± 0.9
51.5 ± 1.4
58.6 ± 2.4
58.2 ± 0.7
63.6 ± 3.4
67.9 ± 4.1
74.3 ± 1.0
75.0± 4.6
76.5 ± 0.8
80.9 ± 2.5
84.3 ± 0.3
86.9 ± 1.3
87.7 ± 1.1
91.2 ± 1.0
93.1±3.2
98.9 ± 5.9
100.0± 0.0

± SD of three independent determinations.
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Table 9a -- 10 U TT of Various Thrombin Inhibitors in the Human Fibrinogen Based
System.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
ng/ml
nM
sec*
nM
sec*
nM
sec*
1450.3 > 300.0
800.000
400.000
725.2 124.8 ± 76.9
200.000 399.5 > 300.0
362.6
388.7 > 300.0
59.0±32.5
194.3 210.0 ± 75.7
181.3
36.5 ±26.1
100.000 199.8 115.8 ± 1.3
97.2
90.6
50.000
99.9
27.9 ± 7.2
20.7 ± 7.2
33.9± 19.0
25.000
49.9
45.3
18.1 ± 5.4
48.6
18.6± 6.1
28.7± 19.6
22.7
12.500
25.0
24.3
18.2 ± 4.5
17.9 ± 5.3
24.6± 15.8
6.250
12.5
17.2 ± 4.7
12.1
16.6± 4.1
3.125
6.2
6.1
19.3 ± 7.1
17.8 ± 4.3
0.0
0.000
0.0
18.7 ± 1.7
0.0
18.7 ± 1.7
18.7 ± 1.7
* Each value represents the mean ± SD of three independent determinations.

Table 9b -- 10 UTT of Various Thrombin Inhibitors in the
Human Fibrinogen Based System.
Ac-(D)Phe-Pro-boroArg-OH
ng/ml
nM
sec*
40.000
80.5 > 300.0
20.000
40.3
44.0 ± 10.0
10.000
20.1
25.1 ± 5.9
5.000
10.1
17.5± 3.1
2.500
22.3 ± 10.5
5.0
1.250
2.5
18.7 ± 4.6
0.000
0.0
18.7 ± 1.7
* Each value represents the mean ± SD of three
independent determinations.
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Table 9c -- 10 U TT of Various
Fibrinogen Based System.
Argatroban
ng/ml
nM
sec*
500.000
939.8 > 300.0
250.000
469.9 294.9 ±
125.000
235.0 165.6 ±
62.500
117.5
83.1 ±
31.250
58.7
40.0±
15.625
29.4
30.8 ±
7.813
14.7
21.3 ±
3.906
7.3
17.5 ±
1.953
3.7
19.4 ±
0.000
0.0
18.7 ±

Thrombin Inhibitors in the Human

8.8
39.0
18.7
15.4
13.4
5.1
2.5
2.2
1.7

Hirudin
nM
sec*
71.8 >300.0
35.9
42.9 ± 34.0
18.0
24.8± 5.8
9.0
24.6 ± 12.1
4.5
21.7 ± 8.4
2.2
17.1 ± 3.4

0.0

18.7 ±

1.7

* Each value represents the mean ± SD of three independent
determinations.

Table 9d -- 10 UTT of Various Thrombin Inhibitors in the
Human Fibrinogen Based System.
Heparin
ng/ml
nM
sec*
100000
9090.9 32.6 ± 12.1
4545.5 27.0± 0.9
50000
10000
909.1 22.8± 5.5
0
0.0 18.7 ± 1.7
* Each value represents the mean ± SD of three
independent determinations.
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Table 9e -- 10 U Ca++TT of Various Thrombin Inhibitors in the Human Fibrinogen
Based System.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-OH Boc-D-Phe-Pro-Arg-H
nM
nM
nM
ng/ml
sec*
sec*
sec*
2900.7 242.3 ± 71.8
1600.00
1554.6 >300.0
1450.3 72.7± 3.6
800.000
777.3
725.2 29.3± 5.4
799.0 >300.0
174.1 ± 54.8
400.000
399.5
388.7
362.6 13.2 ± 3.1
200.000
21.5 ± 3.5
16.6± 7.7
199.8
194.3
0.5
181.3
100.000
12.2 ± 1.7
10.6±
9.3 ± 0.1
50.000
99.9
97.2
90.6
10.4 ± 3.0
7.7± 1.1
8.4 ± 0.4
45.3
49.9
48.6
25.000
8.7 ± 1.5
8.2± 0.5
9.5 ± 2.0
22.7
12.500
25.0
24.3
8.4 ± 0.7
8.1 ± 0.3
8.1 ± 0.6
12.1
6.250
12.5
8.5 ± 0.4
7.6± 0.5
6.1
3.125
6.2
8.5 ± 0.4
7.7± 0.3
0.0
0.000
0.0
0.0
7.6±0.1
7.6± 0.1
7.6± 0.1
* Each value represents the mean ± SD of three independent determinations.

Table 9f -- 10 U Ca++TT of Various Thrombin Inhibitors
in the Human Fibrinogen Based System.
Ac-(D)Phe-Pro-boroArg-OH
ng/ml
nM
sec*
80.000
161.0 > 300.0
40.000
80.5
34.8 ± 22.0
20.000
40.3
25.4 ± 25.2
20.1
10.000
9.0± 0.3
10.1
5.000
8.5± 0.6
2.500
5.0
8.3± 0.1
2.5
1.250
8.1 ± 0.6
0.0
0.000
7.6± 0.1
* Each value represents the mean ± SD of three
independent determinations.
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Table 9g -- 10 U ca++TT of Various Thrombin Inhibitors in the
Fibrinogen Based System.
Argatroban
Hirudin
ng/ml
nM
sec*
nM
sec*
1000.000
1879.7 > 300.0
143.6 > 300.0
500.000
939.8 221.7 ± 34.3
71.8 169.9 ±
250.000
469.9 109.3 ± 22.7
35.9
15.3 ±
125.000
235.0
18.0
59.2 ± 22.6
19.4 ±
62.500
117.5
9.0
33.8 ± 17.3
16.9±
31.250
58.7
4.5
21.6 ± 15.0
15.1 ±
15.625
29.4
2.2
3.5
7.7±
8.7±
14.7
7.813
6.2 ± 3.1
3.906
7.3
7.5 ± 0.7
1.953
3.7
8.1 ± 0.3
0.000
0.0
0.0
7.6± 0.1
7.6±

Human

123.3
7.9
18.0
14.1
12.1
0.7

0.1

* Each value represents the mean ± SD of three independent
determinations.

Table 9h -- 10 U Ca+ +TT of Various Thrombin Inhibitors
in the Human Fibrinogen Based System.
Heparin
ng/ml
nM
sec*
100000
9090.9
15.9± 11.2
4545.5
50000
9.6± 0.9
10000
909.1
8.7± 0.6
0.0
0
7.6± 0.1
* Each value represents the mean ± SD of three
independent determinations.
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Table lOa -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in
NHP.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
ng/ml
nM
% Inhibition*
% Inhibition*
nM
nM
% Inhibition*
6666.67 13317.35 97.3± 0.3 12955.05 96.4± 0.2 12086.05 93.3 ± 0.0
6477.52 94.5± 0.9 6043.03 89.5±0.1
3333.33 6658.68 96.0± 0.4
1666.67 3329.34 94.5± 0.5
3238.76 92.3± 0.5 3021.51
83.1±0.3
666.67 1331.74 92.4 ± 0.7
1295.50 89.4 ± 1.3 1208.61 75.4 ± 3.1
333.33
665.87 90.1 ± 0.9
647.75 85.6± 1.4
604.30 67.8 ± 3.3
166.67
302.15 61.0 ± 2.5
332.93 87.1 ± 1.3
323.88 82.6± 1.2
83.33
166.47 85.5 ± 1.5
161.94 79.6± 1.3
151.08 54.0 ± 2.9
75.54 42.3 ± 6.7
41.67
83.23 82.0± 2.0
80.97 75.2± 2.6
37.77 25.8 ± 7.4
20.83
41.62 67.3± 10.2
40.48 58.7± 9.5
20.24 31.3 ± 10.2
10.42
20.81 36.3 ± 10.7
18.88 11.4 ± 4.5
10.12 13.9± 3.4
9.44
5.21
10.40 16.6± 2.8
5.5 ± 1.2
4.72
2.60
5.20
5.06 7.1 ± 1.3
2.9±1.1
8.8± 1.8
2.36
2.53 4.5 ± 0.6
1.30
2.60 5.9± 1.9
2.6 ± 0.8
0.00
0.0
0.00
0.0
0.00
0.0
± 0.0
0.00
0.0±
0.0±
* Each value represents the mean ± SD of three independent determinations.

Table 1Ob -- Inhibition of the Amidolytic Activity of
Thrombin by Various Agents in NHP.
Ac-D-Phe-Pro-boroArg-OH
ng/ml
nM
% Inhibition*
666.67
1341.92
97.1 ± 0.4
333.33
670.96
96.5 ± 0.2
166.67
335.48
95.4 ± 0.2
66.67
134.19
94.6 ± 0.4
67.10
33.33
90.7 ± 1.1
16.67
33.55
63.1 ± 9.5
16.77
8.33
28.3 ± 3.4
4.17
8.39
11.9± 1.4
2.08
4.19
3.6± 0.5
0.00
0.00
0.0± 0.0
* Each value represents the mean ± SD of three
independent determinations.
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Table 1Oc -- Inhibition of the Amidolytic Activity of Thrombin by Various
Agents in NHP.
Hirudin
Argatroban
% Inhibition*
nM
% Inhibition*
ng/ml
nM
12531.33
957.44 90.7± 1.2
6666.67
84.8± 2.9
478.72 90.6± 1.1
3333.33
6265.66
79.1 ± 3.9
1666.67
3132.83
239.36 90.5± 1.3
67.9± 5.5
1253.13
95.74 89.9± 1.0
666.67
49.6± 10.6
333.33
626.57
47.87 86.0± 1.9
26.3± 6.4
23.94 57.8 ± 16.7
166.67
313.28
8.4± 4.6
156.64
11.97 22.8± 5.2
83.33
0.0± 0.5
41.67
5.98
8.3± 0.8
20.83
2.99
2.5± 1.1
0.00
0.00
0.00
0.0
0.0± 0.0
0.0±
* Each value represents the mean ± SD of three independent
determinations.

Table lOd -- Inhibition of the Amidolytic Activity of
Thrombin by Various Agents in NHP.
Heparin
% Inhibition*
ng/ml
nM
66666.67
6060.61
70.1 ± 1.9
33333.33
3030.30
68.6 ± 1.3
16666.67
1515.15
68.9± 2.7
606.06
71.0 ± 2.2
6666.67
303.03
70.9 ± 1.5
3333.33
1666.67
151.52
72.3 ± 1.0
666.67
60.61
78.4 ± 1.6
30.30
79.9 ± 1.7
333.33
166.67
15.15
68.5 ± 2.3
7.58
40.4 ± 2.3
83.33
3.79
17.4±0.8
41.67
20.83
1.89
5.5 ± 0.6
0.95
2.6 ± 1.6
10.42
0.00
0.0± 0.0
0.00
* Each value represents the mean

± SD of three

independent determinations.

Table lOe -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in NRP.
Ac-(D )Phe-Pro-boroArg-OH
Hirudin
D-MePhe-Pro-Arg-H
nM % Inhibition*
nM % Inhibition*
nM % Inhibition*
ng/ml
6666.1
2666.7
5182.0 95.4 ± 0.4
383.0 93.1 ± 0.5
2591.0 93.6± 0.7
191.5 92.6 ± 0.7
1333.3
1295.5 91.1 ± 0.8
1342.0 98.9 ± 0.0
666.7
95.7 91.1 ± 0.9
4.7
647.8
671.0
333.3
98.3 ± 0.5
47.9 81.9 ± 4.9
86.4 ±
166.7
323.9 86.7 ± 0.9
335.0 97.8 ± 0.1
23.9 47.4 ± 7.3
83.3
161.9 85.1 ± 0.7
168.0 97.1 ± 0.0
12.0 23.3 ± 5.9
41.3
80.3 82.3 ± 0.5
83.9 95.6 ± 0.6
5.9 13.5 ± 5.6
20.7
40.2 75.8 ± 3.9
41.9 85.5 ± 2.7
3.0
7.2 ± 1.9
10.7
20.7 53.7±10.8
21.0 47.3 ± 4.0
1.5
4.7± 2.5
5.3
10.4 22.3±19.4
10.5 21.4 ± 2.4
0.8
3.5 ± 2.1
2.7
5.2 17.7 ± 6.8
5.2 11.9 ± 0.9
0.4
4.7± 2.7
1.3
2.6
6.3 ± 1.4
0.7
1.3
5.4 ± 0.8
0.0
0.0
0.0± 0.0
0.0
0.0 ± 0.0
0.0 0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.

Heparin
nM % Inhibition*
606.l 77.l ± 6.3
242.4 75.8 ± 2.5
121.2 77.2 ± 2.5
60.6 79.6 ± 0.9
30.3 78.6± 4.0
15.2 70.5 ± 6.6
7.6 57.9± 6.3
3.8 31.5 ± 8.0
1.9 17.1 ± 2.0
1.0
9.2 ± 2.0

0.0

0.0 ± 0.0
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Table 1la -- Inhibition of the Amidolytic Activity of
Factor Xa by Various Agents in NHP.
Ac-D-Phe-Pro-boroArg-OH
ng/ml
nM
3 Inhibition*
540.54
1088.04
72.1 ± 2.5
270.27
544.02
58.3 ± 2.8
135.14
272.01
40.6 ± 5.0
54.05
108.80
26.3 ± 3.6
27.03
54.40
12.9 ± 1.2
13.51
27.20
8.4 ± 2.1
6.76
13.60
2.5 ± 0.4
3.38
6.80
0.0± 0.7
0.00
0.00
0.0 ± 0.0
* Each value represents the mean
independent determinations.

± SD of three

Table llb -- Inhibition of the Amidolytic Activity
of Factor Xa by Various Agents in NHP.
Heparin
ng/ml
nM
3 Inhibition*
54054.05
4914.00
45.6 ± 9.5
27027.03
2457.00
49.4±10.3
13513.51
1228.50
56.7± 9.3
5405.41
491.40
66.5 ± 5.3
2702.70
245.70
75.2± 3.2
1351.35
122.85
87.6± 2.2
540.54
49.14
89.1 ± 1.2
270.27
24.57
90.4 ± 0.7
135.14
12.29
81.4 ± 4.1
67.57
6.14
55.8 ± 7.4
33.78
3.07
26.6± 2.5
16.89
1.54
10.9± 0.9
8.45
0.77
5.0± 1.3
4.22
0.38
0.0± 2.7
0.00
0.00
0.0± 0.0
* Each value represents the mean

± SD of three

independent determinations.

Table 11 c -- Inhibition of the Amidolytic Activity of Thrombin by Various Agents in NRP.
Ac-(D)Phe-Pro-boroArg-OH
Hirudin
D-MePhe-Pro-Arg-H
nM 3 Inhibition*
nM 3 Inhibition*
nM 3 Inhibition*
ng/ml
6666.7
383.0
93.1±0.5
2666.7
5182.0
95.4 ± 0.4
191.5
92.6 ± 0.7
2591.0
1333.3
93.6 ± 0.7
1341.9
95.7
91.1±0.9
1295.5
98.9 ± 0.0
666.7
91.1 ± 0.8
47.9
671.0
647.8
98.3 ± 0.5
81.9 ± 4.9
333.3
86.4 ± 4.7
23.9
335.5
47.4 ± 7.3
323.9
97.8 ± 0.1
166.7
86.7 ± 0.9
167.7
12.0
97.1 ± 0.0
23.3 ± 5.9
161.9
83.3
85.1 ± 0.7
5.9
83.9
95.6 ± 0.6
13.5 ± 5.6
80.3
41.7
82.3 ± 0.5
41.9
3.0
40.2
85.5 ± 2.7
7.2 ± 1.9
20.8
75.8 ± 3.9
21.0
1.5
20.7
47.3 ± 4.0
4.7 ±2.5
10.4
53.7± 10.8
0.8
10.5
21.4 ± 2.4
3.5±2.1
5.2
10.4
22.3 ± 19.4
5.2
0.4
4.7 ± 2.7
5.2
11.9 ± 0.9
2.6
17.7 ± 6.8
2.6
6.3 ± 1.4
1.3
1.3
5.4 ± 0.8
0.7
0.0
0.0
0.0
0.0 ±0.0
0.0
0.0
0.0 ± 0.0
0.0±
* Each value represents the mean ± SD of three independent determinations.

Heparin
nM 3 Inhibition*
606.1
77.1 ± 6.3
242.4
75.8 ± 2.5
121.2
77.2 ± 2.5
60.6
79.6 ± 0.9
30.3
78.6 ± 4.0
15.2
70.5 ± 6.6
7.6
57.9 ± 6.3
3.8
31.5 ± 8.0
1.9
17.1 ± 2.0
1.1
9.2 ± 2.0

0.0

0.0 ± 0.0
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Table 12a -- Inhibition of the Amidolytic
Activity of Chymotrypsin by Various
Inhibitors.
Aprotinin
µglml
µM
% Inhibition*
30.71
4.72
87.6 ± 0.5
15.36
2.36
82.1 ± 0.4
7.68
1.18
71.4 ± 1.2
3.84
0.59
34.3 ± 3.5
1.92
0.29
28.6 ± 0.7
0.96
0.15
11.6 ± 0.5
0.48
0.07
5.0 ± 0.4
0.24
0.04
3.9 ± 0.3
0.12
0.02
0.9 ± 0.6
0.00
0.00
0.0 ± 0.0
* Each value represents the mean ± SD of
three independent determinations.

Table 12b -- Inhibition of the Amidolytic Activity of Trypsin by Thrombin Inhibitors.
D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H
Ac-(D) Phe-ProD-Phe-Pro-Arg-H
boroArg-OH
µM % Inhibition*
µM % Inhibition*
µM % Inhibition*
µM % Inhibition*
µglml
25.910 97.7 ± 0.1 24.172 99.1 ± 0.2 26.838 99.4 ± 0.3
13.333 26.635 95.3 ± 1.1
12.955 95.9 ± 0.1 12.086 98.8 ± 0.2 13.419 99.4 ± 0.2
6.667
13.317 93.8 ± 1.0
6.478 93.1 ± 1.5
6.043 97.7 ± 0.1 6.710 99.2 ± 0.1
6.659 91.8 ± 1.2
3.333
3.239 88.6 ± 0.1
3.022 97.0± 0.6 3.355 99.4 ± 0.2
1.667
3.329 88.6 ± 0.6
1.619 86.5 ± 1.3
1.511 94.2 ± 3.5 1.677 99.1 ± 0.2
0.833
1.665 86.1 ± 3.0
0.810 86.3 ± 3.8
0.755 95.7± 0.7 0.839 99.0± 0.3
0.417
0.832 79.8 ± 0.4
0.378 81.9 ± 6.1 0.419 98.6 ± 0.9
0.416 44.0±12.5
0.405 79.1 ± 9.7
0.208
0.202 54.1 ±22.8
0.189 38.0 ± 3.8 0.210 82.9 ±22.6
0.104
0.208 26.3 ± 3.0
0.101 28.6 ± 21.1
0.094 26.9± 6.3 0.105 54.1±53.1
0.104 17.5 ± 9.8
0.052
0.051
17.9±17.8
0.047
0.052
16.4
±
12.2
19.2 ± 9.4 0.052 27.6±15.1
0.026
0.025
0.024 19.2 ± 0.1 0.026 20.9 ± 22.1
0.026 12.9 ± 10.4
9.9 ± 5.9
0.013
0.013 16.3 ± 7.5
0.012 18.0 ± 5.7 0.013 11.9±17.4
0.007
0.013
7.7 ± 14.8
0.006
0.006 15.3 ± 6.6 0.007 14.4 ± 7.8
0.007
8.7 ± 4.0
0.003
7.4 ± 3.5
0.003
0.003
0.003
7.1±15.6
4.0± 5.1
0.002
6.8 ± 1.3 0.003 12.1 ±26.3
0.002
0.001
0.002 14.1± 2.8
6.5 ± 15.6
0.001
9.7 ± 4.5 0.002 15.7±11.4
4.7
0.001
0.001
0.001
13.4 ± 0.5
0.000
12.4 ± 2.5 0.001
9.3 ± 14.4
3.3 ±
0.0
0.000
0.000
0.0
0.000
0.000
0.0
±
0.0
0.000
0.0±
0.0 ±
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.

Aprotinin
µM % Inhibition*
2.048 98.7 ± 0.9
1.024 92.2 ± 10.0
0.512 66.8 ± 27.5
0.256 29.5 ± 12.6
0.128 30.9 ± 17.3
0.064 24.4 ± 6.9
0.032 19.9 ± 1.5
0.016 20.1 ± 6.6

0.000

0.0 ±

0.0

Table 12c -- Inhibition of the Amidolytic Activity of APC by Thrombin Inhibitors.
D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H
D-Phe-Pro-Arg-H
µg/ml
125.000
62.500
31.250
15.625
7.813
3.906
1.953
0.977
0.488
0.244
0.000

µM
124.850
62.425
31.213
15.606
7.803
3.902
1.951
0.975
0.488
0.000

% Inh*
96.4 ±
93.9 ±
89.2 ±
80.2 ±
66.8 ±
48.1 ±
28.9 ±
15.2 ±
5.5 ±
0.0 ±

0.6
0.6
0.7
1.5
3.2
3.4
4.1
4.6
4.9
0.0

µM
121.454
60.727
30.363
15.182
7.591
3.795
1.898
0.949
0.474
0.000

% Inh*
93.3 ±
86.4 ±
76.4 ±
63.1 ±
47.4 ±
31.3 ±
17.4 ±
10.4 ±
6.8 ±
0.0 ±

0.8
1.5
4.3
3.4
4.5
2.9
2.5
1.1
3.2
0.0

µM
113.307
56.653
28.327
14.163
7.082
3.541
1.770
0.885
0.443
0.000

% Inh*
86.4 ±
72.0 ±
58.4 ±
49.6 ±
32.5 ±
16.7 ±
9.3 ±
4.2 ±
3.9 ±
0.0 ±

* Each value represents the mean ± SD of three independent determinations.

1.3
7.2
9.3
5.3
4.7
2.9
1.4
2.8
1.7
0.0

Ac-(D)Phe-ProboroArg-OH
µM % Inh*
125.805
62.903
31.451
15. 726
7.863
3.931
1.966
0.983
0.491
0.000

97.9 ±
96.1 ±
92.6 ±
86.4 ±
73.6 ±
53.0 ±
30.0 ±
12.9 ±
5.5 ±
0.0±

0.3
0.2
1.1
0.2
1.3
0.9
2.7
2.4
1.5
0.0

Aprotinin

µM
19.195
9.598
4.799
2.399
1.200
0.600
0.300

% Inh*
55.0 ± 1.2
36.6 ± 1.4
25.8 ± 1.9
13.8 ± 1.4
10.1 ± 0.3
3.7 ± 0.4
1.9 ± 0.9

0.000 0.0 ± 0.0
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Table 12d -- Inhibition of the Amidolytic Activity of Glandular Kallikrein
by Thrombin Inhibitors.
Ac-(D)Phe-Pro-boroArg-OH
Aprotinin
µg/ml
µM % Inhibition*
µM % Inhibition*
66.667
5.119 95.0 ± 4.5
33.333
67.096
79.8 ±4.6
2.559 96.8 ± 3.8
16.667
33.548
1.280 87.7 ± 8.4
68.8 ±7.5
16.774
8.333
0.640 72.5 ± 2.9
49.2 ± 6.9
4.167
8.387
0.320 42.0 ± 2.8
34.9 ± 9.5
2.083
4.194
0.160 21.0 ± 4.6
20.6 ±2.3
1.042
2.097
0.080
11.4 ± 3.2
8.3 ± 3.3
0.521
1.048
0.040
1.6 ± 4.3
3.0 ± 3.5
0.260
0.524
0.020
2.1 ± 6.2
4.3 ± 1.6
0.000
0.000
0.010
0.0 ± 2.3
0.5 ± 2.8
* Each value represents the mean ± SD of three independent
determinations.

Table 12e -- Inhibition of the Amidolytic
Activity of Glandular Kallikrein by
Thrombin Inhibitors.
Heparin
µg/ml
µM % Inhibition*
66.667
6.231 44.6 ± 27.8
33.333
3.115 38.6 ± 30.9
16.667
1.558 28.7 ± 33.6
8.333
0.779 13.7 ± 22.3
4.167
0.389
6.1 ± 14.4
2.083
0.195
1.3 ± 8.0
1.042
0.097
0.0 ± 7.7
0.000 0.0 ± 1.0
0.000
* Each value represents the mean ± SD of
three independent determinations.

Table 12f -- Inhibition of the Amidolytic Activity oft-PA by Thrombin Inhibitors.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H Ac-(D)Phe-Pro-boroArg-OH
µg/ml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
64.775 64.2 ± 2.1
60.430 94.1±1.0
33.333
66.587 56.2 ± 2.9
67.096
99.5 ± 0.8
30.215 86.8 ± 1.8
16.667
33.293 39.7 ± 1.2
32.388 50.0 ± 4.0
33.548
99.5 ± 0.8
16.647 25.2 ± 2.0
16.194 30.7 ± 2.7
15.108 68.4 ± 2.5
16.774
8.333
98.8 ± 0.7
8.323 13.3 ± 3.2
8.097 17.7 ± 4.8
7.554 44.8 ± 7.0
4.167
8.387
48.9±7.1
4.162
4.048 10.8 ± 0.9
3.777 22.6 ± 5.5
4.194
2.083
9.4 ± 4.6
20.3 ± 3.4
2.081
2.024
1.888 12.2 ± 5.5
1.042
2.5 ± 5.7
6.7 ± 1.8
2.097
6.8 ± 1.7
1.040
1.012
0.944
1.048
0.521
3.3 ± 7.4
4.6 ± 1.3
5.9 ± 2.7
5.4 ± 4.4
0.472
0.520
2.6± 4.1
0.506
0.524
0.260
3.3 ± 4.1
5.9 ± 2.3
1.2 ± 5.2
0.253
0.260
2.1 ± 3.6
0.236
0.262
0.130
3.2± 3.8
2.4 ± 3.6
0.4 ± 5.2
0.127
0.118
0.065
0.130
0.131
1.9 ± 5.6
1.5 ± 2.9
0.0± 4.0
0.0± 7.9
* Each value represents the mean ± SD of three independent determinations.
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Table 12g -- Inhibition of the Amidolytic Activity of Urokinase by Thrombin
Inhibitors.
Boc-D-Phe-Pro-Arg-H
Ac-(D )Phe-Pro-boroArg-OH
µg/ml
µM %Inhibition*
µM %Inhibition*
33.333
60.430
67.096
76.9 ± 1.2
98.6± 1.3
16.667
30.215
33.548
61.8 ± 3.2
97.8± 1.2
8.333
15.108
16.774
47.1 ± 0.9
95.6± 1.2
4.167
7.554
8.387
35.4 ± 2.8
92.0± 0.6
2.083
3.777
4.194
23.6 ± 5.6
83.4 + 2.6
1.042
1.888
15.2 ± 4.6
2.097
62.9± 4.1
0.521
0.944
1.048
8.0± 2.2
31.1 ± 1.8
0.472
0.524
0.260
5.7 ± 4.0
14.8 ± 1.8
0.236
0.262
0.130
2.5 ± 9.0
6.5 ± 1.1
0.118
0.131
0.065
5.2 ± 4.5
4.0± 1.6
0.033
0.059
0.066
2.6 ± 3.4
3.3 ± 3.2
0.016
0.030
0.033
1.6 ± 2.9
3.1 ± 2.0
* Each value represents the mean ± SD of three independent determinations.
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Table 12h -- Inhibition of the Amidolytic Activity of Plasmin by Thrombin Inhibitors.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H
µg/ml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
66.587 93.6± 4.3
64.775 96.6 ± 4.1
33.333
60.430 99.4 ± 1.0
16.667
33.293 88.8 ± 4.6
32.388 94.3 ± 3.7
30.215 99.2 ± 1.3
8.333
16.647 80.2 ± 2.1
16.194 88.3 ± 4.6
15.108 97.9 ± 1.7
4.167
8.323 66.3 ± 3.0
8.097 79.0 ± 6.4
7.554 95.9 ± 1.4
2.083
4.162 52.1 ± 2.2
4.048 68.0 ± 4.6
3.777 90.8 ± 1.3
1.042
2.081 35.2 ± 2.2
2.024 50.7 ± 4.0
1.888 82.8 ± 1.6
0.521
1.040 22.1±1.7
1.012 34.1±2.0
0.944 71.4 ± 2.8
0.260
0.520 11.7±2.9
0.506 22.0 ± 2.8
0.472 55.3 ± 5.5
0.260
0.130
0.253 13.1 ± 2.3
0.236 35.7±6.1
7.2 ± 0.4
0.065
0.130
0.127
0.118 19.6 ± 3.3
3.5 ± 1.6
6.2 ± 0.6
0.065
0.033
1.7 ± 0.7
0.063
2.6 ± 1.2
0.059 12.0 ± 2.1
0.016
0.032
0.033
0.1 ± 2.4
0.030
0.0 ± 1.8
3.3 ± 3.0
* Each value represents the mean ± SD of three independent determinations.

Table 12i -- Inhibition of the Amidolytic
Ac-(D)Phe-Pro-boroArg-OH
µM
µg/ml
%Inhibition*
66.667
67.096
33.333
100.0 ± 0.0
16.667
33.548
100.0 ± 0.0
16.774
8.333
100.0± 0.0
8.387
4.167
100.0± 0.0
2.083
4.194
100.0± 0.0
1.042
2.097
99.8 ± 0.4
1.048
0.521
97.2 ± 0.3
0.260
0.524
92.5 ± 0.9
0.130
0.262
78.9± 3.1
0.131
53.8 ± 2.6
0.065
0.033
0.066
30.2 ± 2.2
0.016
0.033
15.3 ± 1.0
0.016
0.008
7.4 ± 1.0
0.004
0.008
1.4 ± 1.0

Activity of Plasmin by Thrombin Inhibitors.
Aprotinin
Heparin
µM %Inhibition*
µM %Inhibition*
6.231 22.2± 10.2
3.115 21.3 ± 9.6
5.119 99.0 ± 8.4
2.559
14.9
99.0 ± 1.4
1.558 20.2±
0.779 17.2± 16.8
1.280 99.1 ± 1.4
0.640 99.3 ± 1.5
0.389 18.0± 16.8
0.320 98.9 ± 1.1
0.195 19.3 ± 17.8
0.160 85.8 ± 1.9
0.097
4.1 ± 7.2
0.080 58.4 ± 4.5
0.049
8.1 ± 5.4
0.040 26.1 ± 3.8
0.024
6.2± 2.1
2.5
0.020 13.8 ± 4.4
0.012
1.8 ±
0.010
3.4± 3.8
0.006
2.0± 2.0
1.4 ± 3.4
0.005
0.003
2.3 ± 0.9
0.002
0.002
1.9 ± 1.3
0.5 ± 1.9
0.001
1.7 ± 2.7
0.001
1.1 ± 1.3
0.001
0.2 ± 1.7
0.000
1.4 ± 0.0

* Each value represents the mean ± SD of three independent determinations.

378
Table 13a -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen
Lysed by Streptokinase.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
µg/ml
15.606 71.7 ± 3.0
14.163 80.4 ± 2.0
7.813
15.182 73.9 ± 3.0
7.082 65.2 ± 2.0
7.803 47.8 ± 2.0
7.591 54.3 ± 2.0
3.906
3.541 52.2 ± 1.5
1.953
3.902 41.3 ± 2.0
3.795 47.8 ± 2.0
1.770 39.1 ± 1.5
0.977
1.951 15.2 ± 1.5
1.898 17.4±1.5
0.000 0.0 ± 0.0
0.000 0.0 ± 0.0
0.000 0.0± 0.0
0.000
* Each value represents the mean ± SD of three independent determinations.

Table 13b -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen
Lysed by Streptokinase.
Ac-(D)Phe-Pro-boroArg-OH
Hirudin
Heparin
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
µg/ml
15.726 91.3 ± 1.0
0.730 47.8 ± 1.0
7.813
1.122 28.3 ± 1.0
7.863 87.0 ± 1.5
0.561 19.6 ± 1.5
0.365 34.8 + 0.5
3.906
3.931 78.3 ± 2.0
0.281 19.6 ± 1.0
0.183 34.8 ± 0.5
1.953
0.140 8.7± 0.5
0.091 26.1 ± 1.0
0.977
1.966 63.0 ± 1.5
0.000 0.0± 0.0
0.000
0.000
0.000 0.0± 0.0
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.

Table 13c -- Inhibition of Plasminogenolysis by Thrombin
Inhibitors: Pure Plasminogen Lysed by Streptokinase.
Aprotinin
µg/ml
µM %Inhibition*
25.000
3.839 47.8 ± 1.0
12.500
1.920 37.0 ± 2.0
6.250
0.960 23.9 ± 1.5
3.125
0.480 21.7 ± 1.0
0.000
0.000
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.
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Table 13d -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen
Lysed by t-PA.
D-Phe-Pro-Arg-H D-MePhe-Pro-Arg-HBoc-D-Phe-Pro-Arg-H
µg/ml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
0.781
1.561 68.2 ± 2.0
1.518 72.7 ± 2.0 1.416 90.9± 0.5
0.391
0.780 45.5 ± 1.5
0.759 59.1 ± 1.5 0.708 90.9± 2.0
0.195
0.390 45.5 ± 2.0
0.380 45.5 ± 2.0 0.354 81.8 ± 1.0
0.098
0.195 45.5 ± 1.0
0.190 45.5 ± 1.0 0.177 72.7 ± 1.5
0.049
0.098 45.5 ± 1.0
0.095 22.7 ± 1.0 0.089 63.6 ± 1.0
0.024
0.049 0.0± 0.0
0.047 0.0± 0.0 0.044 0.0± 0.0
* Each value represents the mean ± SD of three independent determinations.

Table 13e -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: Pure Plasminogen
Lysed by t-PA.
Ac-(D)Phe-Pro-boroArg-OH
Hirudin
Heparin
µM %Inhibition*
µg/ml
µM % Inhibition*
µM % Inhibition*
0.781
1.573 90.9 ± 0.5
0.112 18.2 ± 2.0
0.073 36.4 ± 1.0
0.037 36.4 ± 1.5
0.391
0.786 90.9± 0.0
0.056 18.2 ± 1.0
0.393 90.9± 1.0
0.018 36.4 ± 1.0
0.195
0.028 18.2 ± 1.5
0.098
0.197 81.8 ± 1.0
0.014 18.2 ± 1.0
0.009 31.8 ± 2.0
0.049
0.098 68.2 ± 1.5
0.007
0.005 9.1 ± 0.5
9.1 ± 0.5
0.002 0.0± 0.0
0.024
0.049
0.004
0.0± 0.0
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.

Table 13f -- Inhibition of Plasminogenolysis by Thrombin
Inhibitors: Pure Plasminogen Lysed by t-PA.
Aprotinin
µg/ml
µM
%Inhibition*
25.000
3.839
54.5 ± 2.0
1.920
12.500
36.4 ± 1.0
6.250
0.960
31.8 ± 1.0
3.125
0.480
31.8 ± 1.5
0.240
1.563
18.2 ± 1.5
0.781
0.120
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.
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Table 13g -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived
Plasminogen Lysed by Streptokinase.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Boc-D-Phe-Pro-Arg-H
µglml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
7.813
15.606 68.9 ± 4.0
15.182 81.1 ± 4.0
14.163 85.1 ± 3.0
7.803 58.1 ± 3.0
7.082 73.0± 3.0
3.906
7.591 64.9 ± 4.0
3.541 51.4 ± 2.5
1.953
3.902 41.9 ± 3.0
3.795 48.6 ± 3.0
1.951 27.0± 2.0
1.770 27.0 ± 2.0
0.977
1.898 33.8 ± 2.0
0.000
0.000
0.000 0.0± 0.0
0.000 0.0 ± 0.0
0.0± 0.0
* Each value represents the mean ± SD of three independent determinations.

Table 13h -- Inhibition of Plasminogenolysis by Thrombin Inhibitors:
Plasminogen Lysed by Streptokinase.
Hirudin
Ac-(D )Phe-Pro-boroArg-OH
µM
µM %Inhibition*
µglml
µM %Inhibition*
15.726 98.6 ± 1.0
1.122 24.3 ± 1.0
0.730
7.813
0.561 16.2 ± 1.5
0.365
7.863 97.3 ± 1.0
3.906
0.183
3.931 89.2 ± 2.0
0.281 8.1 ± 1.0
1.953
0.091
0.140 5.4 ± 1.0
0.977
1.966 82.4 ± 2.0
0.000
0.000 0.0 ± 0.0
0.000 0.0± 0.0
0.000

NHP-Derived
Heparin
%Inhibition*
25.7 ± 2.0
21.6 ± 1.0
16.2 ± 1.5
8.1 ± 1.0
0.0 ± 0.0

* Each value represents the mean ± SD of three independent determinations.

Table 13i -- Inhibition of Plasminogenolysis by Thrombin Inhibitors:
NHP-Derived Plasminogen Lysed by Streptokinase.
Aprotinin
µM %Inhibition*
25.000
3.839 48.6± 1.5
1.920 27.0± 1.0
12.500
0.960 18.9 ± 0.5
6.250
3.125
0.480 16.2 ± 0.5
0.000
0.000
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.
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Table 13j -- Inhibition of Plasminogenolysis by Thrombin Inhibitors: NHP-Derived
Plasminogen Lysed by t-PA.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H Boc-D-Phe-Pro-Arg-H
µg/ml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
7.813
15.606 83.3 ± 2.0
15.182 79.2 ± 3.0
3.906
7.803 66.7 ± 2.0
7.591 66.7 ± 2.5
3.902 58.3 ± 2.5
1.953
3.795 58.3 ± 3.0
0.977
1.951 50.0± 2.0
1.898 41.7 ± 2.0
1.770 79.2 ± 2.0
0.000
0.000 0.0 ± 0.0
0.000 0.0± 0.0
0.000 0.0 ± 0.0
* Each value represents the mean

± SD of three

independent determinations.

Table 13k -- Inhibition of Plasminogenolysis by Thrombin
Inhibitors: NHP-Derived Plasminogen Lysed by t-PA.
Ac-(D)Phe-Pro-boroArg-OH
Hirudin
µglml
µM %Inhibition*
µM %Inhibition*
7.813
1.122 33.3 ± 1.0
3.906
0.561 25.0 ± 1.5
1.953
3.931 87.5 ± 2.0
0.281 25.0 ± 1.5
0.977
1.966 87.5 ± 2.0
0.140 16.7 ± 1.0
0.000
0.000 0.0 ± 0.0
0.000
0.0 ± 0.0
* Each value represents the mean ± SD of three independent determinations.

Table 131 -- Inhibition of Plasminogenolysis by Thrombin
Inhibitors: NHP-Derived Plasminogen Lysed by t-PA.
Aprotinin
µM
%Inhibition*
µg/ml
25.000
3.839
75.0± 2.0
12.500
1.920
50.0± 2.0
6.250
0.960
41.7 ± 1.5
3.125
0.480
25.0± 1.0
0.000
0.000
0.0± 0.0
* Each value represents the mean ± SD of three independent determinations.
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Table 14a -- Inhibition of Thrombin Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Argatroban
µM %Inhibition*
µg/ml
µM %Inhibition*
µM %Inhibition*
66.587 97.4 ± 1.5
64.775 97.5 ± 1.0
62.657 79.4 ± 5.4
33.333
53.269 96.7± 1.6
50.125 75.3 ± 8.9
26.667
51.820 96.9 ± 1.3
20.000
39.952 95.3 ± 1.1
38.865 95.7± 1.6
37.594 71.4 ± 12.1
26.635 93.9± 2.3
25.910 93.7± 2.4
25.063 63.9 ± 19.8
13.333
18.797 59.6 ± 21.7
10.000
19.976 92.1 ± 2.0
19.433 91.9± 2.9
16.647 90.8± 2.2
16.194 90.5 ± 3.1
15.664 51.9 ± 26.2
8.333
12.531 46.4 ± 31.3
13.317
2.7
12.955
3.5
6.667
88.9±
88.4 ±
11.278 43.1±31.4
6.000
11.986 88.1 ± 2.5
11.660 86.4 ± 4.3
10.025 40.7 ± 30.3
10.364 85.5 ± 2.9
5.333
10.654 85.4 ± 3.6
8.772 38.6 ± 28.4
9.069 82.9± 2.8
4.667
9.322 83.8± 4.4
7.519 36.9 ± 26.8
7.773 75.5 ± 2.5
7.990 81.1 ± 5.5
4.000
6.266 29.3 ± 24.4
6.478 53.1 ± 10.8
3.333
6.659 72.1 ± 9.0
5.639 20.2 ± 20.8
5.830 50.8± 2.4
3.000
5.993 56.9 ± 11.6
5.013 14.5 ± 14.5
5.182 42.9± 4.5
5.327 49.1 ± 14.2
2.667
4.386 12.0 ± 14.9
4.661 43.7± 9.8
4.534 33.9± 3.8
2.333
3.759 10.9 ± 15.4
3.887 23.5 ± 11.6
3.995 38.1 ± 12.8
2.000
3.446
8.9 ± 12.9
3.563 22.9± 5.8
3.662 33.7± 10.1
1.833
3.133 18.3 ± 14.7
3.239 28.8 ± 2.7
3.329 33.2± 8.1
1.667
2.820 11.0 ± 13.4
2.2
2.915 25.0±
2.996 34.2± 9.0
1.500
2.506 10.0 ± 12.5
2.591 18.9± 4.1
1.333
2.663 24.0 ± 13.5
2.193
8.1 ± 12.4
2.267 15.3 ± 2.2
1.167
2.331 21.2± 12.1
1.880 6.1 ± 12.1
1.943 9.9± 1.8
1.000
1.998 18.0± 7.6
1.566 5.6± 11.7
1.619 4.7± 3.3
1.665 10.9± 6.8
0.833
1.253
4.7± 11.2
1.296 2.2± 1.8
0.667
1.332 6.3± 4.9
* All values represent the mean ± SD of three independent determinations.
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Table 14b -- Inhibition of Thrombin
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Boc-D-Phe-Pro-Arg-H
µg/ml
µM %Inhibition*
16.667
30.215 95.9 ± 2.5
13.333
24.172 95.5 ± 2.3
10.000
18.129 95.0± 2.4
6.667
12.086 92.7± 2.2
5.000
9.065 89.4± 2.0
4.167
7.554 83.5 ± 4.5
3.333
6.043 70.9± 9.6
2.667
4.834 17.1 ± 12.4
2.000
3.626
2.4 ± 5.0
* All values represent the mean ± SD of
three independent determinations.

Table 14c -- Inhibition of Thrombin
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Ac-(D )Phe-Pro-boroArg-OH
µg/ml
µM
%Inhibition*
3333.330
6709.610
98.3 ± 2.1
2500.000
5032.210
98.3 ± 2.2
1666.670
3354.800
98.3± 2.3
1677.400
833.330
97.8± 2.5
333.330
670.960
93.3± 3.3
250.000
503.220
90.2± 4.5
166.670
335.480
48.0± 23.8
167.740
83.330
0.1 ± 0.7
* All values represent the mean ± SD of
three independent determinations.
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Table 14d -- Inhibition of Thrombin
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Hirudin
µg/ml
µM
%Inhibition*
33.333
4787.210
80.3 ± 8.3
26.667
3829.770
80.5 ± 8.1
20.000
2872.330
80.3 ± 8.3
13.333
1914.880
80.7 ± 8.1
10.000
1436.160
80.5 ± 8.0
6.667
957.440
80.3 ± 8.3
718.080
5.000
80.1 ± 8.3
4.167
598.400
80.2 ± 8.2
478.720
3.333
80.1 ± 8.3
2.500
359.040
79.8 ± 8.4
1.667
239.360
79.7 ± 8.7
0.833
119.680
79.5 ± 8.5
47.870
0.333
78.5 ± 9.4
0.250
35.900
76.3 ± 12.1
0.167
23.940
54.2 ± 46.7
11.970
0.083
0.6 ± 3.6
* All values represent the mean
three independent determinations.

± SD of
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Table 14e -- Inhibition of Thrombin
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Heparin
µg/ml
µM %lnhib ition *
333.333
30303.000
96.7 ± 2.9
250.000
22727.300
96.5 ± 3.0
166.667
15151.500
98.0 ± 1.9
133.333
12121.200
98.4± 1.7
100.000
9090.900
97.8 ± 2.5
66.667
6060.600
98.8 ± 1.3
33.333
3030.300
98.6 ± 1.6
26.667
2424.200
99.0 ± 1.8
1818.200
20.000
99.1 ± 1.2
1212.100
13.333
98.8 ± 1.8
10.000
909.100
98.0 ± 1.9
6.667
606.100
94.7 ± 1.4
5.000
454.500
90.1 ± 3.1
4.167
378.800
81.8 ± 9.3
3.333
303.000
72.5 ± 14.2
242.400
2.667
54.7 ± 25.5
2.000
181.800
20.0± 7.8
1.667
151.500
5.7 ± 8.5
121.200
1.333
4.0± 7.1
1.000
90.900
3.0 ± 5.6

* All values represent the mean
three independent determinations.

± SD of
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Table 14f -- Inhibition of Factor
Fibrinogen-Deficient Human Plasma.
D-Phe-Pro-Arg-H
µg/ml
µM %Inhibition*
33.333
66.587 88.2± 6.1
26.667
53.269 86.7± 7.0
20.000
39.952 81.0± 9.4
13.333
26.635 76.4 ± 8.0
19.976 69.8 ± 10.8
10.000
8.333
16.647 64.9± 12.4
6.667
13.317 58.0± 12.9
6.000
11.986 57.9± 9.0
5.333
10.654 50.2± 12.4
4.667
9.322 49.1 ± 13.8
4.000
7.990 46.8± 13.4
3.333
6.659 29.0± 29.3
3.000
5.993 38.6± 13.4
5.327 36.5 ± 16.7
2.667
4.661 32.0± 12.3
2.333
2.000
3.995 30.9± 12.6
3.662 21.2 ± 19.5
1.833
3.329 31.6 ± 5.6
1.667
2.996 30.8± 5.1
1.500
1.333
2.663 29.2± 7.7
2.331 27.5 ± 6.1
1.167
1.998 25.5 ± 5.7
1.000
1.665 23.6± 6.8
0.833
1.332 21.5 ± 5.7
0.667
0.500
0.999 19.3 ± 4.6
0.333
0.666 17.0± 3.9
0.499 16.7 ± 4.4
0.250
0.167
0.333 15.1 ± 4.5
0.166 14.1 ± 3.1
0.083
0.067
0.033
6.8± 3.0

Xa Generation After Extrinsic Stimulation of
D-MePhe-Pro-Arg-H
µM %Inhibition*
64.775 91.0± 4.5
51.820 88.4± 6.2
38.865 84.4 ± 8.3
25.910 76.4 ± 13.3
19.433 71.2± 13.7
16.194 66.6± 13.2
12.955 61.9± 15.4
11.660 59.6± 14.9
10.364 57.4± 15.0
9.069 53.0± 18.8
7.773 51.6± 16.7
6.478 44.3± 20.6
5.830 46.9± 16.2
5.182 45.3 ± 16.2
4.534 43.1 ± 16.5
3.887 41.4 ± 16.0
3.563 40.2± 15.9
3.239 32.2± 7.4
2.915 31.0± 6.9
2.591 30.6± 6.4
2.267 29.0± 6.6
1.943 26.0± 6.2
1.619 24.7± 5.2
1.296 23.2± 5.6
0.972 21.0± 4.1
0.648 19.8 ± 4.2
0.486 17.5 ± 4.0
0.324 16.1 ± 4.3
0.162
8.4 ± 3.0
0.065
0.6± 1.8

µM
62.657
50.125
37.594
25.063
18.797
15.664
12.531
11.278
10.025
8.772
7.519
6.266
5.639
5.013
4.386
3.759
3.446
3.133
2.820
2.506
2.193
1.880
1.566
1.253
0.940
0.627
0.470
0.313
0.157
0.063

Argatroban
%Inhibition*
36.1 ± 6.0
33.6 ± 6.2
31.8 ± 6.5
28.2± 5.1
27.2 ± 6.8
26.4 ± 7.1
24.8 ± 7.0
23.8 ± 7.0
23.9 ± 7.4
22.6 ± 7.2
21.8 ± 7.6
21.5 ± 7.5
21.0±8.1
20.9 ± 6.6
20.0 ± 7.7
19.6± 7.7
21.4 ± 7.7
16.5 ± 7.3
16.0 ± 6.5
15.4 ± 7.0
15.5 ± 6.7
15.4 ± 6.5
15.1 ± 6.1
14.7 ± 5.7
13.6 ± 5.5
11.6± 5.6
10.4 ± 4.6
7.9± 3.0
4.3 ± 1.7
0.4 ± 0.9

*All values represent the mean ± SD of three independent determinations.
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Table 14g -- Inhibition of Factor Xa
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Boc-D-Phe-Pro-Arg-H
µg/ml
µM
%Inhibition*
16.667
30.215
96.7 ± 0.2
13.333
24.172
95.6 ± 0.5
10.000
18.129
94.0 ± 0.6
6.667
12.086
89.5 ± 2.4
5.000
9.065
86.1± 4.0
4.167
7.554
82.0 ± 6.2
3.333
6.043
78.5 ± 4.8
2.667
4.834
68.5 ± 5.3
2.000
3.626
61.8 ± 5.3
2.417
1.333
51.9 ± 7.6
1.813
1.000
44.5 ± 6.0
0.833
1.511
42.4 ± 5.7
0.667
1.209
35.1± 6.4
0.583
1.058
36.2 ± 7.0
0.500
0.906
32.3 ± 7.3
0.417
0.755
28.1 ± 5.2
0.333
0.604
22.3 ± 6.9
0.250
0.453
18.3 ± 8.7
0.167
0.302
12.7 ± 8.7
0.151
0.083
4.5 ± 5.0
* All values represent the mean
three independent determinations.

± SD of
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Table 14h -- Inhibition of Factor Xa
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Ac-(D)Phe-Pro-boroArg-OH
µg/ml
µM
%Inhibition*
3333.330
6709.610
99.6 ± 0.4
2500.000
5032.210
99.4 ± 0.5
1666.670
3354.800
99.1 ± 0.8
833.330
1677.400
96.1 ± 0. 7
333.330
670.960
79.3 ± 1.1
250.000
503.220
71.2 ± 6.3
166.670
335.480
60.4 ± 8.5
83.330
167. 740
40.0 ± 12.0
33.330
67.100
17.8 ± 7.0
26.670
53.680
9.2 ± 4.2
20.000
40.260
1.5 ± 2.5
* All values represent the mean
three independent determinations.

± SD of

Table 14i -- Inhibition of Factor Xa
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Hirudin
µg/ml
µM %Inhibition*
33.333
4787.210
24.9± 5.5
26.667
3829.770
26.2 ± 8.0
20.000
2872.330
26.7 ± 8.6
13.333
1914.880
26.9± 8.6
10.000
1436.160
26.7 ± 9.0
957.440
6.667
26.8 ± 9.0
718.080
5.000
25.6 ± 7.0
4.167
598.400
26.8 ± 9.8
3.333
478.720
27.0 ± 9.6
2.500
359.040
25.3 ± 7.5
1.667
239.360
24.8 ± 7.8
119.680
23.7± 8.1
0.833
0.333
47.870
4.4 ± 8.6
* All values represent the mean
three independent determinations.

±

SD of
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Table 14j -- Inhibition of Factor Xa
Generation After Extrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Heparin
µM %Inhibition*
µglml
333.333
30303.000
91.5 ± 7.0
250.000
22727.300
94.8 ± 3.2
166.667
15151.500
95.2 ± 2.9
12121.200
133.333
95.2 ± 2.3
100.000
9090.900
94.7 ± 1.9
66.667
6060.600
95.4 ± 2.1
33.333
3030.300
95.3 ± 2.4
26.667
2424.200
95.4 ± 2.0
20.000
1818.200
95.5 ± 2.1
13.333
1212.100
95.5 ± 2.3
10.000
909.100
95.6 ± 2.8
6.667
606.100
95.0 ± 2.2
454.500
5.000
94.8 ± 2.2
4.167
378.800
94.0 ± 1.4
3.333
303.000
93.0 ± 2.2
242.400
2.667
90.4 ± 2.3
2.000
181.800
87.0 ± 4.8
1.667
151.500
27.2 ± 47.1
1.333
121.200
52.8 ±46.2
1.000
90.900
48.5 ±42.7
0.667
60.600
42.1 ±38.3
0.583
53.000
35.8 ± 31.8
0.500
45.500
32.9 ± 29.1
0.417
37.900
29.5 ±26.3
0.333
30.300
25.4 ±22.8
22.700
0.250
17.7±15.7
15.200
0.167
7.8 ± 6.9
* All values represent the mean
three independent determinations.

±

SD of
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Table 14k -- Inhibition of Thrombin Generation After Intrinsic Stimulation of FibrinogenDeficient Human Plasma.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Argatroban
µglml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
33.333
62.657 64.2 ± 11.0
26.667
51.820 100.0 ± 0.0
50.125 64.6 ± 13.7
20.000
38.865 99.9± 0.2
37.594 54.9 ± 16.5
13.333
25.910 99.1 ± 1.6
25.063 60.8 ± 15.9
10.000
19.976 100.0 ± 0.0
19.433 98.6± 2.4
18.797 57.4 ± 12.4
8.333
16.647 99.3 ± 1.3
16.194 97.7± 4.0
15.664 55.5 ± 17.0
6.667
13.317 98.4 ± 2.8
12.955 96.8 ± 5.5
12.531 51.6 ± 20.7
11.278 50.9 ± 23.5
6.000
11.986 98.5 ± 2.6
11.660 96.8± 5.5
4.1
10.364
7.0
10.025 47.3 ± 20.0
5.333
10.654 97.6±
95.9±
9.069 91.4 ± 15.0
8.772 50.1 ± 19.9
4.667
9.322 97.0± 5.2
7.773 92.5 ± 13.0
7.519 50.1 ± 18.1
4.000
7.990 96.1 ± 6.8
6.266 40.3 ± 13.2
3.333
6.659 94.0± 10.3
6.478 90.8± 15.2
5.830 89.6± 16.9
5.639 36.1 ± 22.4
3.000
5.993 92.2± 13.5
5.327 90.5 ± 16.4
5.182 84.1 ± 25.8
5.013 31.8 ± 18.9
2.667
4.386 25.3 ± 17.7
2.333
4.661 87.3 ± 21.9
4.534 79.3 ± 32.6
3.887 77.2± 34.6
3.759 22.0 ± 17.3
2.000
3.995 82.2± 30.0
3.662 80.0 ± 32.7
3.563 75.7 ± 35.1
3.446 20.6 ± 16.5
1.833
3.133 13.3 ± 6.9
3.239 74.6 ± 37.2
1.667
3.329 80.0 ± 32.2
2.820 11.1 ± 3.9
1.500
2.996 76.8± 33.5
2.915 71.9± 39.5
2.506 7.7± 2.6
2.591 64.3 ± 38.6
1.333
2.663 75.1 ± 36.3
2.193 6.1 ± 2.1
1.167
2.331 69.3± 36.2
2.267 61.3 ± 42.4
1.880 2.1 ± 0.6
1.000
1.998 57.8± 33.6
1.943 50.8 ± 40.4
1.566 1.0 ± 1.2
0.833
1.665 52.9 ± 35.0
1.619 42.5 ± 40.3
1.253 0.3 ± 0.7
1.296 27.5 ± 27.4
0.667
1.332 35.9 ± 24.3
0.500
0.999 20.3± 12.4
0.972 16.2 ± 18.8
0.648
0.333
0.666
5.9± 6.6
2.7 ± 5.0
0.250
0.499
2.8± 3.9
* All values represent the mean ± SD of three independent determinations.
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Table 141 -- Inhibition of Thrombin
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Boc-D-Phe-Pro-Arg-H
µglml
µM
%Inhibition*
13.333
24.172 100.0 ± 0.0
18.129
10.000
99.1 ± 1.5
6.667
12.086
97.8 ± 3.8
5.000
9.065
97.2 ± 4.8
4.167
7.554
95.7 + 7.1
6.043
3.333
92.7 ± 11.3
2.667
4.834
85.5 ± 19.9
2.000
3.626
67.2 ± 48.1
2.417
1.333
61.6 ± 50.8
1.813
58.0 ± 49.2
1.000
0.833
1.511
50.2 ± 43.0
0.667
1.209
13.4 ± 11.0
0.583
1.058
13.8 ± 10.7
0.500
0.906
1.9 ± 2.0
* All values represent the mean
three independent determinations.

±

SD of

Table 14m -- Inhibition of Thrombin
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Ac-(D)Phe-Pro-boroArg-OH
µM
%Inhibition*
µglml
166.670
335.480
100.0 ± 0.1
167. 740
83.4 ± 12.5
83.330
33.330
67.100
0.0 ± 0.4
* All values represent the mean
three independent determinations.

±

SD of
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Table 14n -- Inhibition of Thrombin
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Hirudin
µg/ml
µM
%Inhibition*
33.333
4787.210
79.6 ± 3.7
26.667
3829.770
79.2± 4.1
20.000
2872.330
79.6 ± 3.9
13.333
1914.880
79.5 ± 3.7
10.000
1436.160
79.6 ± 3.9
6.667
957.440
79.4 ± 3.9
5.000
718.080
79.3 ± 3.8
4.167
598.400
79.3 ± 4.0
3.333
478.720
79.3 ± 3.8
2.500
359.040
78.9± 4.2
1.667
239.360
79.1 ± 4.3
0.833
119.680
78.9± 3.9
0.333
47.870
45.4 ± 41.0
0.250
35.900
20.5 ± 31.4
0.167
23.940
0.0 ± 0.8
* All values represent the mean
three independent determinations.

± SD of
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Table 140 -- Inhibition of Thrombin
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Heparin
µg/ml
µM %Inhibition*
333.333
30303.000
75.1±16.5
250.000
22727.300
73.8±16.4
166.667
15151.500
73.2±16.2
133.333
12121.200
73.0±17.8
100.000
9090.900
74.3±17.8
66.667
6060.600
74.0±15.3
33.333
3030.300
71.8 ± 7.5
26.667
2424.200
71.6± 2.7
20.000
1818.200
71.4 ± 2.6
13.333
1212.100
69.9± 6.1
10.000
909.100
71.0 ± 7.2
6.667
606.100
73.2 ± 4.8
5.000
454.500
76.5± 1.7
4.167
378.800
77.1 ± 1.9
3.333
303.000
78.3 ± 4.2
2.667
242.400
77.9 ± 5.6
2.000
181.800
78.0 ± 4.9
1.667
151.500
51.8 ±45.7
1.333
121.200
52.2 ±45.3
1.000
90.900
51.9 ±44.9
0.667
60.600
51.4 ±44.3
0.583
53.000
50.8 ±44.8
0.500
45.500
50.6 ±44.4
0.417
37.900
47.3 ±42.9
0.333
30.300
29.1 ±34.2
22.700
0.250
18.0 ±35.8
15.200
0.167
0.0± 2.0
* All values represent the mean
three independent determinations.

±

SD of
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Table 14p -- Inhibition of Factor Xa Generation After Intrinsic Stimulation of FibrinogenDeficient Human Plasma.
D-Phe-Pro-Arg-H
D-MePhe-Pro-Arg-H
Argatroban
µg/ml
µM %Inhibition*
µM %Inhibition*
µM %Inhibition*
33.333
66.587 99.2± 1.4
62.657 97.0± 4.0
26.667
53.269 99.2± 1.4
50.125 98.0± 2.1
20.000
39.952 99.2± 1.4
37.594 94.4 ± 5.0
13.333
26.635 99.1 ± 1.5
25.063 95.6± 4.9
19.976 99.1 ± 1.5
10.000
18. 797 96.8± 5.6
8.333
16.647 99.1 ± 1.6
15.664 97.1 ± 5.1
6.667
13.317 99.0± 1.7
12.531 95.9± 7.1
11.986 99.0± 1.7
11.278 97.7± 4.0
6.000
10.654 98.9± 1.9
10.025 95.3 ± 8.1
5.333
8.772 97.1 ± 5.0
4.667
9.322 98.9± 1.9
4.000
7.519 94.3 ± 9.8
7.990 98.8± 2.0
6.659
2.1
6.266 96.2± 6.6
3.333
98.8 ±
5.993 98.7± 2.2
5.639 96.0± 7.0
3.000
2.667
5.327 98.7± 2.3
5.013 96.1 ± 6.7
2.333
4.661 98.5 ± 2.7
4.386 96.1 ± 6.7
2.000
3.995 98.3 ± 2.9
3.887 100.0 ± 0.0
3.759 95.7± 7.5
3.662 97.9± 3.2
3.563 99.9± 0.1
3.446 95.5 ± 7.8
1.833
3.239 100.0± 0.0
3.133 86.6 ± 15.0
1.667
3.329 98.0± 3.5
2.915
2.820
86.4± 14.7
2.996
3.8
99.8
±
0.3
1.500
97.8±
2.506 84.8± 14.5
2.663 96.7± 3.9
2.591 99.5 ± 0.5
1.333
2.267 99.2 ± 0.8
2.193 84.9± 14.7
1.167
2.331 96.1 ± 3.9
1.943 98.7± 1.1
1.880 84.6± 15.0
1.998 96.6± 4.7
1.000
1.566 84.1 ± 14.7
1.619 97.9± 1.7
1.665 95.1 ± 4.7
0.833
1.253 83.4 ± 14.2
1.296 97.2± 1.4
0.667
1.332 94.1 ± 5.6
0.940 81.1 ± 13.0
0.972 96.0± 1.6
0.999 93.4 ± 5.4
0.500
0.648 93.8± 1.7
0.627 78.2± 13.3
0.666 92.3 ± 5.9
0.333
0.470 73.9± 13.7
0.486 91.5± 1.1
0.250
0.499 91.2 ± 5.6
0.313 66.0± 12.6
0.324 86.4 ± 0.8
0.167
0.333 89.1 ± 5.5
0.157 47.4 ± 15.0
0.162 69.3 ± 5.5
0.166 81.1± 5.2
0.083
0.063 17.5 ± 13.7
0.065 28.2± 3.1
0.067 43.2± 12.7
0.033
0.047 11.4 ± 12.5
0.049 17.5 ± 2.4
0.050 25.1 ± 13.9
0.025
0.031
0.032
5.2± 6.8
5.5 ± 1.1
0.017
0.033 10.7± 7.5
0.016
0.016
0.1 ± 0.3
0.4 ± 2.1
0.017
0.008
1.8 ± 2.5
*All values represent the mean ± SD of three independent determinations.
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Table 14q -- Inhibition of Factor Xa
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Boc-D-Phe-Pro-Arg-H
µglml
µM
%Inhibition*
2.000
3.626
100.0 ± 0.0
1.333
2.417
99.8 ± 0.3
1.000
1.813
99.2 ± 1.5
0.833
1.511
98.6 ± 2.5
0.667
1.209
97.7 ± 4.0
0.583
1.058
97.7 ± 4.0
0.500
0.906
96.7 ± 4.6
0.417
0.755
94.4 ± 7.7
0.333
0.604
91.8 ± 7.3
0.250
0.453
85.4 ± 5.1
0.167
0.302
73.1 ± 4.8
0.083
0.151
46.8 ± 5.9
0.033
0.060
11.9± 6.1
0.025
0.045
2.8 ± 1.5
0.017
0.030
0.6 ± 1.2
* All values represent the mean
three independent determinations.

±

SD of

Table 14r -- Inhibition of Factor Xa
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Ac-(D)Phe-Pro-boroArg-OH
µglml
µM
%Inhibition*
83.330
167.740
100.0 ± 0.0
67.100
33.330
89.0± 8.5
26.670
53.680
77.7± 25.6
20.000
40.260
60.7± 27.6
26.840
13.330
22.1 ± 11.3
6.670
13.420
1.0 ± 1.5

* All

values represent the mean
three independent determinations.

±

SD of
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Table 14s -- Inhibition of Factor Xa
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Hirudin
µg/ml
µM
%Inhibition*
0.833
119.680
100.0± 0.0
0.333
47.870
97.1 ± 2.0
0.250
35.900
80.7± 9.6
0.167
23.940
56.9± 21.1
0.083
11.970
5.9± 5.4
0.033
4.790
0.9± 1.1
* All values represent the mean ± SD of
three independent determinations.
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Table 14t -- Inhibition of Factor Xa
Generation After Intrinsic Stimulation of
Fibrinogen-Deficient Human Plasma.
Heparin
µg!ml
µM
%Inhibition*
333.333
30303.000
93.6± 4.4
250.000
22727.300
93.7± 3.9
166.667
15151.500
93.6± 4.1
12121.200
133.333
93.5± 4.0
100.000
9090.900
93.8± 3.8
66.667
6060.600
93.8± 3.9
33.333
3030.300
93.7± 3.9
26.667
2424.200
93.9± 3.8
20.000
1818.200
93.8± 3.9
13.333
1212.100
94.2± 4.0
10.000
909.100
94.2± 4.1
6.667
606.100
94.6± 3.9
454.500
5.000
94.5± 4.4
4.167
378.800
94.9± 4.4
303.000
3.333
94.8± 4.5
242.400
2.667
95.2± 4.3
2.000
181.800
95.0± 4.3
1.667
151.500
96.1 ± 5.6
121.200
1.333
95.3 ± 4.1
90.900
1.000
95.6± 3.9
0.667
60.600
96.3± 3.4
53.000
0.583
97.0± 2.9
45.500
0.500
97.4± 2.9
0.417
37.900
97.4 ± 3.2
30.300
0.333
96.5± 4.5
22.700
93.6 ± 7.8
0.250
0.167
15.200
86.0 ± 14.1
55.3 ± 25.3
7.600
0.083
3.000
19.3 ± 13.2
0.033
2.300
0.025
7.4± 7.4
1.500
0.017
1.7 ± 1.9
0.800
0.1 ± 0.2
0.008
* All values represent the mean ± SD of
three independent determinations.
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Table 15a -- Inhibition of Thrombin Generation
Inhibitors.
D-PheD-MePhePro-Arg-H
Pro-Arg-H
µM %In
µg/ml
µM %In
2.915 53.6
1.500
1.000
1.943 49.8
1.998 44.8
0.500
0.972 38.2
0.999 29.5
0.250
0.499 15.9
0.486 24.2
0.125
0.250
2.3
0.243 14.5
0.063
0.125
2.9
0.121
8.7
0.031
0.062
0.0
0.061
1.6
0.016
0.031
1.6
0.030
1.8
0.0
0.000
0.000 0.0
0.000

from KONYNE® by Thrombin
Boc-D-PhePro-Arg-H
µM %In
2.719 59.8
1.813 53.3
0.906 35.5
0.453 18.7
0.227
8.0
0.113
5.6
0.057
5.2
0.028
1.3
0.000
0.0

Table 15b -- Inhibition of Thrombin
Generation from KONYNE® by Thrombin
Inhibitors.
Argatroban
µg/ml
µM
%In
62.6
5.000
9.398
2.500
4.699
42.0
1.250
2.350
38.0
1.175
35.0
0.625
0.587
0.313
23.0
0.294
0.156
14.0
0.078
0.147
11.0
0.073
0.039
8.0
0.037
8.0
0.020
0.018
1.0
0.010
0.0
0.000
0.000

Ac-(D)Phe-ProboroArg-OH
µM %In
2.013
0.999
0.499
0.250
0.125
0.062
0.031
0.000

80.5
68.3
57.7
50.2
39.6
28.3
19.2
0.0
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Table 15c -- Inhibition of Thrombin
KONYNE® by Thrombin Inhibitors.
Hirudin
µglml
µM
%In
20.000
36.7
2.872
15.000
10.000
1.436
35.1
5.000
2.500
44.6
0.359
43.4
1.000
0.144
0.500
0.072
40.2
0.250
0.036
28.2
0.125
19.7
0.018
6.1
0.063
0.009
0.031
0.004
2.9
0.000
0.000
0.0

Generation from
Heparin
µM
%In
1.402
0.935
0.467
0.234
0.093

43.2
39.1
25.3
9.8
0.0

0.000

0.0

Table 15d -- Inhibition of Factor Xa Generation from KONYNE® by Thrombin
Inhibitors.
D-PheD-MePheBoc-D-Phe- Ac-(D) Phe-ProPro-Arg-H
Pro-Arg-H
Pro-Arg-H
boroArg-OH
µM % In
µg/ml
µM % In
µM % In
µM % In
2.719 75.3
1.500
2.996 50.6
1.943 58.6
1.813 70.7
2.013 99.3
1.000
1.998 48.0
0.999 98.1
0.500
0.999 34.3
0.906 49.8
0.499 94.1
0.250
0.453 21.7
0.499 0.0
0.486 58.3
0.227
0.250 89.3
0.125
0.250 0.0
0.243 14.5
1.6
0.125 74.7
0.113
0.125 0.0
0.121
0.0
0.9
0.063
0.062 8.5
0.0
0.057
0.031
0.062 0.0
0.061
1.6
0.031 0.0
0.028
1.4
0.030
0.0
0.016
0.031 0.0
0.000 0.0
0.000
0.0
0.000
0.0
0.000 0.0
0.000
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Table 15e -- Inhibition of Factor Xa
Generation from KONYNE® by Thrombin
Inhibitors.
Argatroban
µg/ml
µM
%In
10.000
18.797
56.0
5.000
9.398
52.0
2.500
4.699
50.0
1.250
2.350
49.0
0.625
1.175
49.0
0.313
0.587
45.0
0.156
0.294
39.0
0.078
0.147
33.0
0.039
0.073
22.0
0.020
0.037
13.0
0.010
0.018
0.0

Table 15f -- Inhibition of Factor Xa Generation from
KONYNE® by Thrombin Inhibitors.
Hirudin
Heparin
µg/ml
µM %In
µM
%In
20.000
2.872 51.7
15.000
2.154 52.8
1.402 69.1
1.436 53.1
10.000
0.935 60.1
0.467 28.1
5.000
2.500
0.234 14.1
0.359 48.7
0.144 46.5
1.000
0.093
0.0
0.072 19.6
0.047
0.500
0.9
0.250
0.036
0.0
0.023
0.0
0.125
0.018
5.9
0.009
6.2
0.063
0.031
0.004
2.3
0.016
0.002
0.0
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Table 15g -- Inhibition of Thrombin Generation from FEIBA®by Thrombin Inhibitors.
D-PheD-MePheBoc-D-PheAc-(D)Phe-ProPro-Arg-H
Pro-Arg-H
Pro-Arg-H
boroArg-OH
µg/ml
µM %In
µM %In
µM %In
µM %In
1.1
1.500
2.996 69.4
2.915
2.719 0.2
1.998 10.9
1.943
3.1
1.000
1.813 0.0
96.8 99.3
7.6
0.500
0.999
0.972 16.2
0.906 1.9
81.7 98.1
0.250
5.1
0.499
0.486
0.0
0.453 0.0
28.0 94.1
0.125
0.250
7.0
0.243
4.9
0.227 0.0
13.9 89.3
5.1
2.1
10.3 74.7
0.063
0.125
0.121
0.113 0.0
0.031
0.062
0.061
4.0
0.057 0.0
11.3 8.5
5.0
0.016
0.031
3.2
0.028 5.3
13.2 0.0
6.6
0.030

Table 15h -- Inhibition of Thrombin
Generation from FEIBA® by Thrombin
Inhibitors.
Argatroban
µg/ml
µM
%In
18.797
10.000
49.0
14.0
5.000
9.398
2.500
4.699
11.0
1.250
2.350
8.0
1.175
0.625
3.0
0.587
0.0
0.313
0.156
0.294
1.0
0.147
0.078
0.0
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Table 15i -- Inhibition of Thrombin Generation from
FEIBA® by Thrombin Inhibitors.
Hirudin
Heparin
µg/ml
µM
%In
µM %In
20.000
2.872
93.8
1.869 56.9
15.000
2.154
91.7
1.402 34.2
10.000
1.436
90.4
0.935
5.2
5.000
0.718
83.7
0.467
0.0
2.500
0.359
0.0
1.000
2.4
0.144
0.500
0.072
5.5
0.250
2.9
0.036
0.125
4.2
0.018
0.063
0.009
10.6
0.031
0.004
4.7
0.016
0.002
0.0

Table 15j -- Inhibition of Factor
D-PhePro-Arg-H
µg/ml
µM %In
1.500
2.996 66.4
1.000
1.998
0.0
0.500
0.999
0.0
0.250
0.499
0.0
0.125
0.250
0.0

Xa Generation from FEIBA®by Thrombin Inhibitors.
D-MePheBoc-D-PheAc-(D) Phe-ProPro-Arg-H
Pro-Arg-H
boroArg-OH
µM %In
µM %In
µM %In
2.915 85.4
2.719 73.3
1.943 65.7
2.013 99.8
1.813 33.2
1.006 99.1
0.972
0.5
0.906
2.6
0.486
0.0
0.453
0.503 94.4
0.0
2.8
0.243
1.5
0.227
0.252
0.0
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Table 15k -- Inhibition of Factor Xa
Generation from FEIBA ® by Thrombin
Inhibitors.
Argatroban
µglml
µM
%In
10.000
18. 797
91.0
5.000
9.398
90.0
2.500
4.699
85.0
1.250
2.350
78.0
0.625
1.175
66.0
0.313
0.587
33.0
0.156
0.294
1.0
0.078
0.147
1.0
0.039
0.073
2.0
0.037
0.020
0.0

Table 151 -- Inhibition of Factor Xa Generation from
FEIBA ®by Thrombin Inhibitors.
Heparin
Hirudin
µM
%In
µglml
µM
%In
20.000
2.872
1.869
0.0
88.4
15.000
2.154
82.5
1.402
2.3
0.935
2.6
10.000
1.436
87.8
0.718
84.7
0.467
0.0
5.000
0.0
2.500
0.359
0.0
0.234

Table 16a -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based PT assay.
D-Phe-Pro-Arg-H
µg/ml
100.00

µM

Clotting
Time (sec)

D-MePhe-Pro-Arg-H

µM

Boc-D-Phe-Pro-Arg-H

µM

Clotting
Time (sec)

199.76 >300.0

50.00

99.88

186.5± 2.0

25.00

49.94

10.00

Clotting
Time (sec)

Ac-(D)Phe-Pro-boroArg-OH

µM

Clotting
Time (sec)

181.29 > 300.0
97.16 > 300.0

90.65

74.5± 4.7

75.9± 2.2

48.58

162.1± 36.3

45.32

26.8± 0.2

19.98

26.1± 0.6

19.43

49.4±

1.4

18.13

30.4± 0.8

5.00

9.99

17.5± 0.3

9.72

23.4±

0.5

9.06

18.8± 0.3

2.50

4.99

14.8± 0.5

4.86

17.1±

0.8

4.53

14.8± 0.3

5.03

39.9± 2.1

1.25

2.50

13.0± 0.6

2.43

14.4±

0.5

2.27

12.3± 1.2

2.52

22.0± 1.5

0.63

1.25

13.3± 0.5

1.21

13.2±

0.3

1.13

12.6± 0.2

1.26

16.7± 1.4

0.31

0.62

12.6± 0.3

0.61

12.6±

0.3

0.57

12.6± 0.2

0.63

15.2± 1.7

0.16

0.31

12.0± 1.8

0.30

12.4±

1.0

0.28

12.5± 0.9

0.31

13.3± 1.3

0.00

0.00

12.0± 1.8

0.00

12.0±

1.8

0.00

12.0± 1.8

0.00

12.0± 1.8

Each clotting time value represents the mean ± SD of three independent determinations.

10.06 > 300.0
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Table 16b -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based PT assay.

µg/ml
100.00

Argatroban

Heparin

µM

µM

Clotting
Time (sec)

Clotting
Time (sec)

187.97 > 300.0

50.00

93.98

219.9± 4.0

25.00

46.99

139.9± 3.0

10.00

18.80

89.3± 3.0

0.93 20.5± 3.6

5.00

9.40

58.3± 2.0

0.47 13.8± 0.6

2.50

4.70

37.9± 1.0

0.23 12.3± 0.3

1.25

2.35

26.4± 0.7

0.12 12.1± 0.3

0.63

1.17

20.4± 0.5

0.06 11.8± 0.3

0.31

0.59

15.9± 0.3

0.03 12.3± 0.9

0.16

0.29

13.7± 0.3

0.01 12.2± 1.2

0.00

0.00

11.6± 0.3

0.00 12.0± 1.8

Each clotting time value represents the mean ± SD of
three independent determinations.
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Table 16c -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based PT assay.
Hirudin
µg/ml

µM

Clotting
Time (sec)

25.00

3.59 >300.0

12.50

1.80

18.4± 1.0

6.25

0.90

15.7± 1.0

3.13

0.45

13.9± 1.0

1.56

0.22

12.9± 0.5

0.78

0.11

12.4± 0.5

0.39

0.06

12.3± 0.5

0.20

0.03

11.9± 0.3

0.00

0.00

11.4± 0.3

Each clotting time value represents the mean ± SD of
three independent determinations.

Table l 6d -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based APTT assay.
D-Phe-Pro-Arg-H
µglml

µM

Clotting
Time (sec)

D-MePhe-Pro-Arg-H
µM

Clotting
Time (sec)

Boc-D-Phe-Pro-Arg-H
µM

Ac-(D )Phe-Pro-boroArg-OH

Clotting
Time (sec)

µM

Clotting
Time (sec)

90.65 > 300.0

50.00
25.00

49.94 > 300.0

48.58 > 300.0

45.32

191.2± 9.8

10.00

19.98

145.8± 1.6

19.43

186.0± 3.0

18.13

198.1 ± 4.7

5.00

9.99

88.4± 1.0

9.72

110.7± 1.1

9.06

112.0± 3.8

2.50

4.99

64.7± 1.8

4.86

75.5± 0.6

4.53

70.1± 3.3

1.25

2.50

49.5± 0.7

2.43

59.5± 3.5

2.27

51.4± 0.5

2.52

0.63

1.25

40.7± 1.5

1.21

45.7± 0.3

1.13

42.4± 1.0

1.26

0.31

0.62

38.3± 1.3

0.61

40.3± 0.6

0.57

37.7± 0.3

0.63

90.1±

8.0

0.16

0.31

34.7± 0.3

0.30

36.2± 0.6

0.28

35.0± 0.3

0.31

68.3±

1.8

0.00

0.00

34.7± 0.3

0.00

34.7± 0.3

0.00

34.7± 0.3

0.00

34.7±

0.3

Each clotting time value represents the mean ± SD of three independent determinations.

>300.0
218.0± 14.0
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Table 16e -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based APTT assay.
Argatroban
µg/ml

µM

Clotting
Time (sec)

Heparin
µM

Clotting
Time (sec)

50.00

93.98 > 300.0

25.00

46.99

216.6± 5.0

10.00

18.80

157.9± 4.0

5.00

9.40

123.2± 4.0

2.50

4.70

94.4± 3.0

0.23

98.0±

3.9

1.25

2.35

79.0± 3.0

0.12

51.0±

1.3

0.63

1.17

63.4± 2.0

0.06

35.7±

0.3

0.31

0.59

53.4± 2.0

0.03

36.4±

4.6

0.16

0.29

46.8± 1.0

0.01

32.7±

0.6

0.00

0.00

29.4± 0.5

0.00

34.7±

0.3

0.47 >300.0

Each clotting time value represents the mean ± SD of
three independent determinations.
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Table 16f -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based APTT assay.
Hirudin
µg/ml

µM

Clotting
Time (sec)

25.00

3.59 >300.0

12.50

1.80

105.9± 3.0

6.25

0.90

89.3± 3.0

3.13

0.45

74.9± 3.0

1.56

0.22

63.0± 2.0

0.78

0.11

56.0± 2.0

0.39

0.06

48.5± 1.0

0.20

0.03

42.7± 1.0

0.00

0.00

29.4± 0.5

Each clotting time value represents the mean ± SD of
three independent determinations.

Table 16g -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based TT assay.
D-Phe-Pro-Arg-H
µg/ml
10.00

µM

Clotting
Time (sec)

D-MePhe-Pro-Arg-H

µM

Clotting
Time (sec)

19.98 > 300.0

Boc-D-Phe-Pro-Arg-H

µM

Ac-(D)Phe-Pro-boroArg-OH

Clotting
Time (sec)

µM

Clotting
Time (sec)

18.13 > 300.0
9.72 >300.0

9.06

190.5± 37.6

96.5± 2.0

4.86

161.3± 20.4

4.53

75.2± 2.0

2.50

32.5± 2.3

2.43

91.4± 4.8

2.27

23.2± 2.0

0.63

1.25

8.7± 3.0

1.21

48.0± 6.0

1.13

10.2± 0.8

0.31

0.62

9.3± 0.5

0.61

16.0± 0.7

0.57

7.0± 0.3

0.63

106.9± 4.7

0.16

0.31

7.2± 0.4

0.30

8.0± 1.5

0.28

6.5± 0.3

0.31

20.2± 3.3

5.00

9.99

207.4± 41.7

2.50

4.99

1.25

Each clotting time value represents the mean ± SD of three independent determinations.

1.26 >300.0
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Table 16h -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based TT assay.
Hirudin
µg/ml

µM

Clotting
Time (sec)

Heparin
µM

Clotting
Time (sec)

5.00

0.72 >300.0

0.47 >300.0

2.50

0.36

288.4± 16.3

0.23

137.0± 2.0

1.25

0.18

204.1± 24.0

0.12

78.0± 0.2

0.63

0.09

93.2± 4.7

0.06

6.7± 0.4

0.31

0.04

54.8± 1.0

0.03

6.0± 0.3

0.16

0.02

8.2± 2.3

0.01

5.4± 0.6

Each clotting time value represents the mean ± SD of
three independent determinations.
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Table 16i -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based TT assay.
Argatroban
Clotting
Time (sec)

µglml

µM

50.00

93.98

25.00

46.99

239.9±

5.0

12.50

23.50

181.9±

3.0

6.25

11.75

118.2±

3.0

3.13

5.87

79.5±

2.0

1.56

2.94

64.9±

2.0

0.78

1.47

44.6±

1.0

0.39

0.73

33.7±

1.0

0.20

0.37

24.2±

1.0

0.10

0.18

12.2±

1.0

>300.0

Each clotting time value represents the mean ± SD of
three independent determinations.

Table 16j -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based ECT assay.
D-Phe-Pro-Arg-H
µg/ml

µM

Clotting
Time (sec)

D-MePhe-Pro-Arg-H
µg/ml

µM

Boc-D-Phe-Pro-Arg-H

Clotting
Time (sec)

µg/ml

µM

Clotting
Time (sec)

0.00 0.00

43.1 ± 0.0

0.00 0.00

41.5 ±

1.5

0.00

0.00

40.9 ±

2.7

0.01 0.02

51.7 ± 1.3

0.01 0.02

46.9±

4.0

0.05

0.09

50.7 ±

1.3

0.05 0.10

75.4 ± 6.6

0.05 0.10

64.6±

6.3

0.10

0.18

57.0 ±

2.2

0.10 0.20 114.0 ± 9.7

0.10 0.19

92.5 ± 13.4

0.50

0.91 100.7 ±

7.4

0.25 0.50 233.4 ± 18.6

0.25 0.49 178.0 ± 33.3

1.00

1.81 149.1 ± 15.8

0.50 1.00 361.0 ± 75.1

0.50 0.97 306.7 ± 81.3

2.00

3.63 225.1 ± 27.0

0.75 1.50 587.7 ±34.6

0.75 1.46 437.0 ± 100.4

3.00

5.44 295.8 ± 29.0

1.00 2.00 768.9 ± 71.7

1.00 1.94 553.5 ± 121.1

4.00

7.25 356.0 ± 37.3

1.25 2.50 887.2 ±24.8

1.25 2.43 694.1 ± 161.6

5.00

9.06 406.6 ± 51.5

1.50 2.91 719.0 ± 102.8

6.00 10.88 585.5 ± ERR

1.75 3.40 798.4 ± 124.9

7.50 13.60 575.1 ± 120.2
10.00 18.13 663.7 ± 194.7
12.50 22.66 742.8 ± 104.2

Each clotting time value represents the mean ± SD of three independent determinations.

Table 16k -- Comparative anticoagulant effects of thrombin inhibitors in the
Ac-(D)Phe-Pro-boroArg-OH
Argatroban
Clotting
µg/ml
µM
Clotting
µg/ml µM
µg/ml
Time (sec)
Time (sec)
0.00 0.00 42.1 ± 3.8
0.00 0.00 43.7 ± 2.4
0.00
0.01 0.02 48.8 ± 2.7
0.01 0.02 71.6 ± 30.9
0.10
0.01 0.02 52.6 ± 2.9
0.05 0.09 73.5 ± 1.0
0.25
14.8
0.10
0.19
3.6
0.05 0.10 104.5 ±
96.0 ±
0.50
0.25 0.47 147.6 ± 9.4
0.10 0.20 188.7 ± 19.9
1.00
0.20 0.40 378.1 ± 29.4
0.50 0.94 213.7 ± 13.3
2.00
0.75 1.41 282.4 ± 12.0
0.30 0.60 577.9 ± 42.5
3.00
0.40 0.81 755.3 ± 50.9
1.00 1.88 329.0 ± 9.3
4.00
1.25 2.35 373.7 ± 4.0
5.00
1.50 2.82 420.2 ± 2.5
6.00
1.75 3.29 454.5 ± 6.7
2.00 3.76 475.9 ± 39.1
3.00 5.64 600.8 ± 9.4
4.00 7.52 694.3 ± 11.5
5.00 9.40 793.6 ± 0.0
Each clotting time value represents the mean

± SD of three

NHP based ECT assay.
Hirudin
µM
Clotting
Time (sec)
0.00 43.1 ± 3.5
0.01 59.3 ± 4.0
0.04 73.8 ± 9.2
0.07 105.5 ± 21.0
0.14 173.5 ± 38.9
0.29 325.5 ± 70.5
0.43 457.3 ± 148.4
0.57 632.4 ± 183. 7
0.72 698.1 ± 96.0
0.86 796.4 ± 143.0

independent determinations.

Table 161 -- Comparative anticoagulant effects of thrombin inhibitors in the NHP based Heptest assay.
D-Phe-Pro-Arg-H
µg/ml

µM

Clotting
Time (sec)

D-MePhe-Pro-Arg-H
µM

50.00

99.88 > 300.0

25.00

49.94

240.5± 6.2

10.00

19.98

90.5± 5.1

5.00

9.99

34.8± 3.2

9.72

2.50

4.99

25.5± 0.7

1.25

2.50

0.63

Clotting
Time (sec)

Boc-D-Phe-Pro-Arg-H
µM

Ac-(D)Phe-Pro-boroArg-OH

Clotting
Time (sec)

µM

Clotting
Time (sec)

45.32 >300.0
19.43 > 300.0

18.13

44.2± 7.3

65.4± 7.2

9.06

75.1± 0.7

4.86

38.7± 2.9

4.53

33.0± 0.8

5.03

21.8± 2.1

2.43

28.4± 0.7

2.27

24.8± 1.0

2.52

125.4± 0.8

1.25

19.1± 1.2

1.21

22.2± 0.3

1.13

20.1± 0.7

1.26

59.0± 0.3

0.31

0.62

17.8± 0.5

0.61

19.2± 0.3

0.57

17.4± 0.5

0.63

37.3± 2.0

0.16

0.31

16.6± 0.6

0.30

16.9± 0.5

0.28

17.1± 0.8

0.31

24.3± 0.5

0.00

0.00

16.6± 0.6

0.00

16.6± 0.6

0.00

15.6± 0.3

0.00

16.6± 0.6

Each clotting time value represents the mean ± SD of three independent determinations.

>300.0
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Table 16m -- Comparative anticoagulant effects of
thrombin inhibitors in the NHP based Heptest assay.
Argatroban
µg/ml

µM

Clotting
Time (sec)

25.0
12.5

Hirudin
µM

Clotting
Time (sec)

3.59 >300.0
23.50 > 300.0

1.80

127.4± 3.0

6.3

11.75

221.7± 4.0

0.90

77.3± 2.0

3.1

5.87

131.7± 3.0

0.45

30.7± 2.0

1.6

2.94

89.9± 3.0

0.22

26.1± 1.0

0.8

1.47

63.3± 2.0

0.11

21.8± 0.7

0.4

0.73

44.8± 2.0

0.06

21.4± 0.5

0.2

0.37

34.7± 1.0

0.03

20.8± 0.5

0.0

0.00

20.7± 0.5

0.00

20.7± 0.3

Each clotting time value represents the mean ± SD of
three independent determinations.
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Table 16n -- Comparative anticoagulant effects of thrombin
inhibitors in the NHP based Heptest assay.
Heparin
µglml

10.00

µM

Clotting
Time (sec)

2.34 >300.0

5.00

0.93

274.5±

14.2

2.50

0.47

123.7±

0.7

1.25

0.23

84.0±

0.2

0.63

0.12

57.0±

2.3

0.31

0.06

28.9±

0.9

0.16

0.03

19.5±

1.0

0.08

0.01

17.0±

0.0

0.00

0.00

16.3±

0.3

Each clotting time value represents the mean ± SD of
three independent determinations.

Table l 60 -- Comparative anticoagulant effects of thrombin inhibitors after supplementation into normal human whole blood, in the
ACT assay.
D-MePhe-Pro-Arg-H

µM

Ac-(D) Phe-ProboroArg-OH

Argatroban

Heparin

Clotting
Time (sec)

ng/ml

Clotting
Time (sec)

1.00

514.6 156.0 ± 27.9

496.8

307 ±23.8

532 183.3 ± 25.0

6963 366.0 ± 19.7

10700 326.3 ± 21.0

0.10

51.46 134.3 ± 2.5

49.68139.7±11.6

53.2 145.7 ± 65.0

696.3 184.3 ± 10.6

1070 160.7 ± 32.8

0.01

5.146 128.7 ± 2.1

4.968 132.3 ± 6.7

5.32 139.0 ± 2.8

69.63 136.0 ± 5.7

0.00

0 130.0 ± 4.2

ng/ml

Each clotting time value represents the mean

µg/ml

Hirudin

± SD of three

Clotting
Time (sec)

µg/ml

independent determinations.

Clotting
Time (sec)

µg/ml

Clotting
Time (sec)

107 127.3 ±

7.4

Table 16p -- Comparative anticoagulant effects of thrombin inhibitors after supplementation into normal human whole blood, in the
TEG assay.
D-MePhe-Pro-Arg-H

µM

ng/ml TEG R Value
(mm)

Ac-(D)Phe-ProboroArg-OH
ng/ml

TEGR
Value (mm)

1.00

Argatroban
µg/ml TEG R Value
(mm)
532

31.2 ± 1.6

Hirudin
µg/ml TEG R Value
(mm)

Heparin
µg/ml TEG R Value
(mm)

0.10

51.46

38

49.68 43.3 ± 17.7

53.2

25.2± 2.5

696.3

42.8 ± 3.9

1070

46.5 ±

3.0

0.01

5.146

22

4.968 26.3 ± 2.5

5.32

25.7 ± 1.0

69.63

27.0 ± 4.2

107

26. 7 ±

3.3

Each TEG R value represents the mean ± SD of three independent determinations.

Table 17a -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based PT assay.
D-MePhe-Pro-Arg-H
µg/ml
100.00
40.00
20.00
10.00
5.00
2.50
1.25
0.62
0.31
0.16
0.08
0.04
0.02
0.01
0.00

µM

Clotting
Time (sec)

194.33 > 300.0
77.73
32.2 ± 4.1
38.87
15.9 ± 2.0
19.43
11.0 ± 1.4
9.72
8.8 ± 0.3
4.86
7.9 ± 0.4
2.43
7.4 ± 0.1
1.21
6.7 ± 0.1
0.60
6.6 ± 0.7
0.31
6.9 ± 0.2
0.16
6.8 ± 0.3
0.08
6.5 ± 0.6

0.00

6.9 ± 0.3

Ac-(D)Phe-Pro-boroArg-OH
µM

20.13
10.06
5.03
2.52
1.26
0.63
0.32
0.16
0.08
0.04
0.02
0.00

Clotting
Time (sec)

23.7 ±
13.8 ±
10.3 ±
8.3 ±
7.5 ±
7.0 ±
6.6 ±
6.8 ±
6.5 ±
7.0 ±
6.7 ±
6.8 ±

5.5
3.2
0.6
0.3
0.5
0.2
0.3
0.2
0.3
0.1
0.4
0.4

Hirudin
µM

Heparin

Clotting
Time (sec)

µM

5.745 >300.0
2.872
48.3 ± 25.6
1.436
14.1 ± 1.2
0.718
10.3 ± 2.9
0.359
8.7 ± 0.5
0.180
8.3 ± 0.6
0.089
7.4 ± 0.5
0.045
7.3 ± 0.2
0.023
6.8 ± 0.2
0.011
6.9± 0.4
0.006
7.1 ± 0.2

0.000

Each clotting time value represents the mean ± SD of three independent determinations.

7.3 ±

0.1

Clotting
Time (sec)

9.35
3.74
1.87
0.94
0.47
0.23
0.12
0.06
0.03
0.02

16.5 ± 0.7
10.7 ± 1.4
8.8 ± 1.0
7.4 ± 0.9
7.1±0.4
7.0 ± 0.5
6.6 ± 0.3
6.8 ± 0.6
6.8 ± 0.3
6.7± 0.1

0.00

7.0 ± 0.3

Table 17b -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based APTT assay.
D-MePhe-Pro-Arg-H
µg/ml
40.00
20.00
10.00
5.00
2.50
1.25
0.62
0.31
0.16
0.08
0.04
0.02
0.01
0.00

µM

Clotting
Time (sec)

38.87 > 300.0
19.43 273.2 ±46.4
9.72 195.7 ± 35.5
4.86 101.5 ± 6.1
2.43
74.9 ± 7.7
1.21
54.6 ± 1.8
0.60
52.8 ± 7.6
0.31
42.2± 2.9
0.16
39.8 ± 3.1
0.08
36.9± 5.7

0.00

39.4 ± 5.8

Ac-(D)Phe-Pro-boroArg-OH
µM

2.52
1.26
0.63
0.32
0.16
0.08
0.04
0.02
0.00

Clotting
Time (sec)

>300.0
263.5 ± 63.3
124.7 ± 7.9
82.1±14.1
63.6 ± 7.7
50.2 ± 8.6
44.0 ± 8.9
37.4 ± 4.7
37.5 ± 4.3

Hirudin
µM

Clotting
Time (sec)

5.745 >300.0
2.872 167.2 ± 21.1
1.436 130.6 ± 45.8
0.718 101.6 ±40.5
0.359
72.7 ± 19.3
0.180
64.0 ± 21.9
0.089
56.2 ± 15.3
0.045
45.7 ± 5.7
0.023
39.2± 4.7
0.011
39.8 ± 3.9
0.006
34.9 ± 3.6

0.000

36.1 ± 6.0

Each clotting time value represents the mean ± SD of three independent determinations.

Heparin
µM

Clotting
Time (sec)

0.94 >300.0
0.47 132.7 ± 36.2
0.23
76.8 ± 16.7
0.12
57.7 ± 11.3
0.06
52.2 ± 8.6
0.03
44.4 ± 8.9
0.02
37.7 ± 6.0

0.00

38.2 ± 4.3

Table 17c -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based TT assay.
Ac-(D)Phe-Pro-boroArg-OH

D-MePhe-Pro-Arg-H
µg/ml
20.00
10.00
5.00
2.50
1.25
0.62
0.31
0.16
0.08
0.04
0.02
0.01
0.00

µM

Clotting
Time (sec)

µM

38.87 > 300.0
19.43 298.6 ± 2.4
9.72 176.8 ± 29.3
4.86 106.8 ± 19.9
2.43
59.0 ± 10.5
1.21
44.7 ± 4.9
0.60
29.2 ± 9.1
0.31
17.9 ± 6.2
0.16
13.6 ± 6.3
0.08
11.5 ± 3.2

0.00

12.3 ±

3.2

Clotting
Time (sec)

2.52 >300.0
1.26 131.7 ± 7.0
0.63
71.6 ± 3.8
0.32
37.5 ± 6.5
0.16
20.7 ± 4.5
0.08
16.2 ± 7.5
0.04
12.8 ± 4.6
0.02
11.0 ± 2.0
0.00
10.9 ± 3.0

Hirudin
µM

Clotting
Time (sec)

Heparin
µM

Clotting
Time (sec)

0.718 > 300.0
0.359 172.1 ±26.0
0.180 100.7 ± 4.4
0.089
66.7 ± 2.5
0.045
41.0 ± 8.7
0.023
23.6 ± 6.1
0.011
13.8 ± 5.5
0.006
11.3 ± 3.1

0.47 >300.0
0.23
59.3 ± 14.9
0.12
26.3 ± 10.0
0.06
18.3 ± 2.6
0.03
13.7 ± 0.6
0.02
11.8 ± 2.5

0.000

0.00

11.9 ± 3.2

11.9 ± 3.0

Each clotting time value represents the mean ± SD of three independent determinations.
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Table 17d -- Comparative anticoagulant effects of thrombin inhibitors in the NRP based Heptest assay.
D-MePhe-Pro-Arg-H
µg/ml
10.00
5.00
2.50
1.25
0.62
0.31
0.16
0.08
0.04
0.02
0.01
0.00

µM

Clotting
Time (sec)

19.43 > 300.0
9.72 215.3 ± 32.0
4.86 133.9 ± 44.2
2.43
83.7 ± 4.5
1.21
56.6 ±20.5
0.60
38.4 ± 9.0
0.31
29.6 ± 4.9
0.16
25.5 ± 5.0
0.08
21.8 ± 6.2

0.00

22.0 ± 2.5

Ac-(D)Phe-Pro-boroArg-OH
µM

Clotting
Time (sec)

5.03 >300.0
2.52 290.6±16.3
1.26 133.4 ± 17.6
0.63
64.6 ± 2.8
0.32
43.3 ± 5.9
0.16
29.0±10.3
0.08
22.6 ± 8.0
0.04
18.7 ± 6.6
0.02
17.6 ± 7.1
0.00
17.9 ± 7.3

Hirudin
µM

Clotting
Time (sec)

0.718
0.359
0.180
0.089
0.045
0.023
0.011
0.006

>300.0
169.8 ± 8.0
76.9 ± 9.9
54.1±16.5
38.0±14.9
30.3 ± 3.8
26.7 ± 2.7
21.4 ± 2.2

0.000

23.0 ± 2.3

Each clotting time value represents the mean ± SD of three independent determinations.

Heparin
µM

Clotting
Time (sec)

0.47 >300.0
0.23
80.5 ± 55.6
0.12
45.5 ± 7.1
0.06
31.3 ± 2.7
0.03
26.0± 1.6
0.02
22.6 ± 2.5

0.00

21.3 ±

2.1
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Table 17e -- Comparative anticoagulant effects of thrombin inhibitors after
supplementation into normal whole rabbit blood, as assessed by the ACT assay.
µg/ml

nM

Clotting Time
Difference from
Baseline (sec)

D-MePhe-Pro-Arg-H

0.2

389

92 ± 28

Ac-(D)Phe-Pro-boroArg-OH

0.1

201

179 ± 58

Hirudin

1.0

144

215 ± 32

Heparin

2.0

187

235 ±

4

Each clotting time value represents the mean ± SD of three independent determinations.

Table 17f -- Comparative anticoagulant effects of thrombin inhibitors after
supplementation into normal whole rabbit blood, as assessed by the TEG assay.
µg/ml

nM

R Value Difference
from Baseline (mm)

D-MePhe-Pro-Arg-H

0.2

389

32.0±

Ac-(D )Phe-Pro-boroArg-OH

0.1

201

40.3 ± 23.6

Hirudin

1.0

144

30.0 ± 13.0

Heparin

2.0

187

8.0

>200

Each TEG R value represents the mean ± SD of three independent determinations.
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Table 19a -- Comparative dose-dependent antithrombotic
effects of thrombin inhibitors as studied in the rabbit model
of jugular vein stasis thrombosis, after I. V. injection, 5
min prior to r-TF injection, after 10 and 20 min stasis.
D-Me-Phe-Pro-Arg-H
Dose
Dose
Clot Score After Clot Score After
20 min Stasis*
10 min Stasis*
µg/kg µmol!kg
0
0.00
3.2±0.2
3.6±0.3
50
0.10
3.6±0.3
3.0±0.4
100
0.19
2.8±0.2
2.4±0.3
250
0.49
0.6±0.4
2.2±0.4
0.97
2.3±0.4
500
0.8±0.3
1000
1.94
0.2±0.2
0.8±0.4
*Each value represents the mean± SEM of 6 independent
determinations.

Table 19b -- Comparative dose-dependent antithrombotic
effects of thrombin inhibitors as studied in the rabbit model
of jugular vein stasis thrombosis, after I.V. injection, 5
min prior to r-TF injection, after 10 and 20 min stasis.
Ac-D-Phe-Pro-boroArg-OH
Clot Score After Clot Score After
Dose
Dose
10 min Stasis*
20 min Stasis*
µglkg µmol!kg
3.6±0.3
0
0.00
3.2±0.2
0.01
3.6±0.3
3.4±0.3
5
2.8±0.2
12.5
0.03
2.8±0.2
25
0.05
1.8±0.4
0.6±0.3
0.2±0.2
0.10
0.0±0.0
50
*Each value represents the mean± SEM of 6 independent
determinations.
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Table 19c -- Comparative dose-dependent antithrombotic
effects of thrombin inhibitors as studied in the rabbit model
of jugular vein stasis thrombosis, after I. V. injection, 5
min prior to r-TF injection, after 10 and 20 min stasis.
Hirudin
Dose
Dose
Clot Score After Clot Score After
µg/kg µmo I/kg
10 min Stasis*
20 min Stasis*
0
0.000
3.2±0.2
3.6±0.3
10
0.001
3.0±0.4
3.4±0.3
25
0.004
1.3±0.4
2.7±0.2
50
0.007
1.6±0.3
2.2±0.2
100
0.014
0.6±0.3
1.4±0.3
250
0.036
0.2±0.2
0.0±0.0
*Each value represents the mean± SEM of 6 independent
determinations.

Table l 9d -- Comparative dose-dependent antithrombotic
effects of thrombin inhibitors as studied in the rabbit model
of jugular vein stasis thrombosis, after I. V. injection, 5
min prior to r-TF injection, after 10 and 20 min stasis.
Heparin
Dose
Dose
Clot Score After
Clot Score After
µg/kg
µmol/kg
10 min Stasis*
20 min Stasis*
0
0.000
3.2±0.2
3.6±0.3
25
0.002
4.0±0.0
3.8±0.3
50
0.005
2.5±0.3
2.8±0.3
0.009
100
1.8±0.3
2.0±0.3
0.023
250
0.0±0.0
0.6±0.4
* Each value represents the mean ± SEM of 6 independent
determinations.
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Table 19e -- Time dependance of antithrombotic effects of thrombin inhibitors in the
rabbit model of jugular vein stasis thrombosis, after I.V. injection and 10 minutes stasis.
Clot Scores After 10 min Stasis*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

5

0.2±0.2

0.0±0.0

0.2±0.2

0.0±0.0

30

0.2±0.2

2.6±0.3

60

2.0±0.0

3.0±0.3

90

3.3±0.5

1.5±0.4
1.3±0.2

3.8±0.2

3.0±0.4

D-MePhe-Pro-Arg-H was injected at 1.94 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.10
µmol/kg, hirudin at 0.04 µmol/kg and heparin at 0.02 µmol/kg. *Each value represents
the mean ± SEM of 6 independent determinations.

Table 19f -- Time dependance of antithrombotic effects of thrombin inhibitors in the
rabbit model of jugular vein stasis thrombosis, after I.V. injection and 20 minutes stasis.
Clot Score After 20 min Stasis*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

5

0.8±0.4

0.2±0.2

0.0±0.0

0.6±0.4

30

1.0±0.5

2.6±0.3

60

2.8±0.2

3.3±0.4

90

3.0±0.4

2.2±0.6
1.8±0.3

3.2±0.4

3.2±0.4

D-MePhe-Pro-Arg-H was injected at 1.94 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.10
µmol/kg, hirudin at 0.04 µmol/kg and heparin at 0.02 µmol/kg. *Each value represents
the mean ± SEM of 6 independent determinations.
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Table 20a -- Comparative dose-dependent antithrombotic effects of
thrombin inhibitors as studied in the rabbit model of jugular vein stasis
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after
10 and 20 min stasis.
D-Me-Phe-Pro-Arg-H
Dose
µg/kg

Dose
µmol/kg

Clot Score After
10 min Stasis*

Clot Score After
20 min Stasis*

0

0.00

3.2±0.2

3.6±0.3

100

0.19

3.6±0.3

3.8±0.2

250

0.49

2.8±0.2

3.6±0.3

500

0.97

2.4±0.3

2.8±0.2

1000

1.94

1.2±0.4

2.3±0.5

2500

4.85

0.0±0.0

1.2±0.4

* Each value represents the mean ±
determinations.

SEM of 6 independent

Table 20b -- Comparative dose-dependent antithrombotic effects of
thrombin inhibitors as studied in the rabbit model of jugular vein stasis
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after
10 and 20 min stasis.
Ac-D-Phe-Pro-boroArg-OH
µglkg

Dose
µmol/kg

Clot Score After
10 min Stasis*

Clot Score After
20 min Stasis*

0

0.00

3.2±0.2

3.6±0.3

25

0.05

3.1±0.1

3.4±0.2

50

0.10

2.4±0.3

3.2±0.4

100

0.20

1.7±0.4

2.5±0.4

250

0.50

0.0±0.0

0.8±0.4

Dose

* Each value represents the mean ±
determinations.

SEM of 6 independent
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Table 20c -- Comparative dose-dependent antithrombotic effects of
thrombin inhibitors as studied in the rabbit model of jugular vein stasis
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after
10 and 20 min stasis.
Hirudin
Dose
µg/kg

Dose
µmol/kg

Clot Score After
10 min Stasis*

Clot Score After
20 min Stasis*

0

0.000

3.2±0.2

3.6±0.3

25

0.004

4.0±0.0

3.8±0.2

50

0.007

2.8±0.2

3.2±0.2

100

0.014

2.5±0.2

2.7±0.2

250

0.036

2.0±0.3

2.3±0.5

500

0.072

1.3±0.5

2.0±0.4

1000

0.144

0.4±0.3

1.0±0.6

* Each value represents the mean ± SEM of 6 independent determinations.

Table 20d -- Comparative dose-dependent antithrombotic effects of
thrombin inhibitors as studied in the rabbit model of jugular vein stasis
thrombosis, after S.C. injection, 45 min prior to r-TF injection and after
10 and 20 min stasis.
Heparin
Dose
µg/kg

Dose
µmol/kg

Clot Score After
10 min Stasis*

Clot Score After
20 min Stasis*

0

0.000

3.2±0.2

3.6±0.3

500

0.046

3.6±0.2

3.8±0.2

1000

0.091

3.3±0.2

3.1 ±0.2

2750

0.250

1.3±0.5

2.0±0.6

5000

0.455

0.7±0.2

0.8±0.3

* Each value represents the mean ± SEM of 6 independent determinations.
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Table 20e -- Time dependance of antithrombotic effects of thrombin inhibitors in the
rabbit model of jugular vein stasis thrombosis, after S.C. injection and 10 minutes stasis.
Clot Scores After 10 min Stasis*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

15

0.0±0.0

0.0±0.0

0.4±0.3

1.2±0.2

45

0.0±0.0

0.3±0.4

0.4±0.3

0.7±0.2

90

0.6±0.4

0.2±0.2

0.7±0.5

0.3±0.2

D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50
µmol/kg, hirudin at 0.14 µmol/kg and heparin at 0.47 µmol/kg. *Each value represents
the mean ± SEM of 6 independent determinations.

Table 20f -- Time dependance of antithrombotic effects of thrombin inhibitors in the
rabbit model of jugular vein stasis thrombosis, after S.C. injection and 20 minutes stasis.
Clot Scores After 20 min Stasis*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

15

0.2±0.2

1.4±0.3

0.8±0.4

1.8±0.3

45

1.2±0.4

1.2±0.5

1.0±0.6

0.8±0.3

90

1.7±0.5

1.7±0.6

0.9±0.4

1.2±0.3

D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50
µmol/kg, hirudin at 0.14 µmol/kg and heparin at 0.47 µmol/kg. *Each value represents
the mean ± SEM of 6 independent determinations.
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Table 21a -- Comparative dose-dependent
antithrombotic effects of thrombin inhibitors
as studied in the rat model of laser induced
thrombosis, after I. V. injection, 5 min prior
to initiation of the laser injuries.
D-Me-Phe-Pro-Arg-H
Dose

Dose

µglkg

µmo I/kg

#Laser
Exposures*

500

0.97

4.3±0.8

1000

1.94

6.3±1.5

1750

3.40

6.0± 1.1

2500

4.85

4.5±1.2

0

0.00

2.9±0.1

* Each value represents the mean ± SEM of
6 independent determinations.

Table 2lb -- Comparative dose-dependent
antithrombotic effects of thrombin inhibitors
as studied in the rat model of laser induced
thrombosis, after I. V. injection, 5 min prior
to initiation of the laser injuries.
Ac-D-Phe-Pro-boroArg-OH
Dose

Dose

µglkg

µmol/kg

#Laser
Exposures*

50

0.10

3.5±0.2

75

0.15

5.7±0.6

100

0.20

10.2±0.4

0

0.00

2.9±0.1

* Each value represents the mean ± SEM of
6 independent determinations.
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Table 2 lc -- Comparative dose-dependent
antithrombotic effects of thrombin inhibitors
as studied in the rat model of laser induced
thrombosis, after I.V. injection, 5 min prior
to initiation of the laser injuries.
Hirudin
Dose
µglkg

Dose
µmol/kg

#Laser
Exposures*

50

0.007

3.8±0.5

100

0.014

5.3±0.5

500

0.072

8.2±0.7

0

0.000

2.9±0.1

*Each value represents the mean ± SEM of
6 independent determinations.

Table 21d -- Comparative dose-dependent
antithrombotic effects of thrombin inhibitors
as studied in the rat model of laser induced
thrombosis, after I. V. injection, 5 min prior
to initiation of the laser injuries.
Heparin
Dose
µglkg

Dose
µmol/kg

#Laser
Exposures*

500

0.047

4.5±0.5

1000

0.093

6.5±0.5

5000

0.467

8.0±1.0

0

0.000

2.9±0.l

* Each value represents the mean ± SEM of
6 independent determinations.
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Table 22a -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after I.V. injection, 5 and 20 min prior to
initiation of the bleeding procedure.
D-Me-Phe-Pro-Arg-H
Dose
µglkg

Dose
µmol!kg

RBC (109 /L)
After 5 min*

RBC (109 /L)
After 20 min*

0

0.00

0.100±0.075

0.100±0.075

500

0.97

0.155 ±0.055

0.165 ±0.110

1000

1.94

0.990±0.525

0.445 ±0.300

2500

4.85

4.445±0.730

1.715±0.475

* Each value represents the mean ± SEM of 6 independent
determinations.

Table 22b -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after I.V. injection, 5 and 20 min prior to
initiation of the bleeding procedure.
Ac-D-Phe-Pro-boroArg-OH
Dose
µg!kg

Dose
µmollkg

RBC (109/L)
After 5 min*

RBC (109 /L)
After 20 min*

0

0.00

0.100±0.075

0.100±0.075

50

0.10

0.215±0.075

0.065 ±0.035

125

0.25

2.24±1.065

0. 515 ±0. 220

250

0.50

1.520±0.54

1.395±0.465

500

1.00

3.245±1.080

11. 790±7.295

* Each value represents the mean ± SEM of 6 independent
determinations.
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Table 22c -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after I.V. injection, 5 and 20 min prior to
initiation of the bleeding procedure.
Hirudin
µglkg

Dose
µmol/kg

RBC (109 /L)
After 5 min*

RBC (109 /L)
After 20 min*

0

0.000

0.100±0.075

0.100±0.075

500

0.046

0.470±0.245

0.100±0.060

1000

0.144

3.880± 1.075

0.140±0.050

2500

0.359

4.910± 1.485

3.025±1.015

Dose

*Each value represents the mean± SEM of 6 independent
determinations.

Table 22d -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after I.V. injection, 5 and 20 min prior to
initiation of the bleeding procedure.
Heparin
µglkg

Dose
µmol/kg

RBC (109/L)
After 5 min*

RBC(l0 9/L)
After 20 min*

0

0.000

0.100±0.075

0.100±0.075

500

0.046

0.975 ±0.370

0.420±0.275

1000

0.091

0.870±0.530

0.465 ±0.250

2500

0.227

0. 745 ±0.270

0.920±0.480

5000

0.455

1.115 ±0.630

0.370±0.130

Dose

*Each value represents the mean ± SEM of 6 independent
determinations.
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Table 22e -- Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit
ear bleeding model, after I. V. injection.
RBC (109/L)*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

5

8.655 ±2.865

9.830±5.830

4.910±2.130

1.115 ±0.630

20

1.865 ±0.425

4.680±2.380

3.025±1.590

0.370±0.130

30

1.090±0.580

6.650±4.455

0.590±0.275

1.835±0.540

45

0.210±0.080

1.245 ±0.425

0.130±0.035

1.180±0.415

60

0.135 ±0.025

0.440±0.265

0.140±0.050

90

0.150±0.155

0.065 ±0.045

0.165±0.090

D-MePhe-Pro-Arg-H was injected at 4.86 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 0.50
µmollkg, hirudin at 0.36 µmol/kg and heparin at 0.47 µmollkg. *Each value represents
the mean ± SEM of 6 independent determinations.
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Table 23a -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after S.C. injection, 45 and 60 min prior
to initiation of the bleeding procedure.
D-Me-Phe-Pro-Arg-H
Dose
µg/ml

Dose
µmol/kg

RBC (109/L)
After 45 min*

RBC (109/L)
After 60 min*

0

0.00

0.100±0.075

0.100±0.075

1000

1.94

0.125±0.080

0.080±0.055

2500

4.85

0.855 ±0.280

0.225 ±0.105

5000

9.71

0.680±0.190

0.375 ±0.280

* Each value represents the mean ± SEM of 6 independent
determinations.

Table 23b -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after S.C. injection, 45 and 60 min prior
to initiation of the bleeding procedure.
Ac-D-Phe-Pro-boroArg-OH
µglkg

Dose
µmo I/kg

RBC (109/L)
After 45 min*

RBC (109/L)
After 60 min*

0

0.00

0.100±0.075

0.100±0.075

100

0.20

0.235 ±0.075

0.030±0.020

250

0.50

0. 730±0.265

0.465±0.180

500

1.00

1.405 ±0.945

1.150±0.934

1000

2.01

7.190±3.151

2.645 ±0.655

Dose

*Each value represents the mean ± SEM of 6 independent
determinations.
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Table 23c -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after S.C. injection, 45 and 60 min prior
to initiation of the bleeding procedure.
Hirudin
µglkg

Dose
µmol/kg

RBC (109/L)
After 45 min*

RBC (109/L)
After 60 min*

0

0.000

0.100±0.075

0.100±0.075

500

0.046

0.135 ±0.070

0.040±0.035

1000

0.144

0.315 ±0.285

0.215 ±0.170

2500

0.359

0.225 ±0.140

0.140±0.075

5000

0.718

1.865±0.715

0.350±0.140

Dose

* Each value represents the mean ± SEM of 6 independent
determinations.

Table 23d -- Comparative dose-dependent hemorrhagic
effects of thrombin inhibitors as studied in the rabbit ear
bleeding model, after S.C. injection, 45 and 60 min prior
to initiation of the bleeding procedure.
Heparin
µglkg

Dose
µmo I/kg

RBC (109/L)
After 45 min*

RBC (109 /L)
After 60 min*

0

0.000

0.100±0.075

0.100±0.075

5000

0.455

0.095 ±0.060

0.100±0.055

10,000

0.909

0.395±0.215

0.160±0.065

Dose

* Each value represents the mean ± SEM of 6 independent
determinations.
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Table 23e -- Time dependance of hemorrhagic effects of thrombin inhibitors in the rabbit
ear bleeding model after S.C. injection.
RBC (109/L)*
Time
(min)

D-Me-Phe-Pro-Arg-H

Ac-D-Phe-ProboroArg-OH

Hirudin

Heparin

15

1.445±0.620

2.445 ±0. 700

0.160±0.150

0.100

30

0.520±0.325

1.245 ±0.529

0.020±0.010

0.150

45

0.680±0.190

7.190±3.151

1.865 ±0.715

0.395 ±0.215

60

0.375 ±0.280

2.646±0. 732

0.350±0.140

0.160±0.065

90

0.140±0.110

1.438±0.412

0.045 ±0.025

0.035 ±0.025

120

0. 755 ±0.290

1.663±0.443

0.220±0.125

0.055 ±0.020

D-MePhe-Pro-Arg-H was injected at 9.72 µmol/kg, Ac-(D)Phe-Pro-Arg-OH at 2.01
µmol/kg, hirudin at 0.72 µmol/kg and heparin at 0.93 µmol/kg. *Each value represents
the mean ± SEM of 6 independent determinations.
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